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Abstract 
Mounting evidence suggests the pathogenesis of Crohn’s disease (CD) involves an 
impaired acute inflammatory response. Monocyte-derived macrophages from CD 
patients release deficient levels of pro-inflammatory cytokines in response to 
Escherichia coli, arising from post-translational trafficking abnormalities. In this thesis, 
the macrophage responses to microbial stimuli were further characterised, and the 
underlying molecular lesions investigated. 
Macrophage TNF release was attenuated in response to Escherichia coli, 
Candida albicans and Toll-like receptor (TLR) stimulation in CD. This deficit was 
unrelated to use of medication, age, gender and smoking status. Patients with stricturing 
and colonic disease demonstrated the most profound defects in response to TLR2 and 
TLR4 stimulation respectively. Genotyping for 34 known CD susceptibility 
polymorphisms revealed no detectable association between any individual variant and 
impaired TNF release. However in CD, TNF secretion in response to Escherichia coli 
was weakly correlated with overall genetic risk score. 
Macrophage sphingolipid and phospholipid compositions were subsequently 
investigated, given the prominent role of these molecules in vesicle trafficking. Mass 
spectrometric analysis revealed no gross abnormalities in CD macrophages, although a 
reduced percentage of phosphatidylinositol 16:0/18:1 was synthesised over 3 hours; the 
same species was also present at reduced levels in ileal biopsies. 
Given the heterogeneity of CD, a microarray outlier analysis strategy was 
developed to identify specific gene expression abnormalities in individual patients. A 
subset of patients had deficient expression of optineurin, a molecule implicated in 
vesicle trafficking and autophagy. These individuals shared a number of allelic variants, 
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which were associated with optineurin expression levels. Macrophages from these 
patients had attenuated TNF secretion downstream of TLR2. Concordantly, depletion of 
optineurin in THP-1 cells impaired TNF release after TLR2 activation. 
This study supports a role for immune deficiency in the pathogenesis of CD and 
identifies abnormal optineurin expression as a relevant molecular abnormality in a 
subset of patients. 
 
4
  
Table of contents 
Acknowledgements........................................................................................................ 14 
Statement of Collaborative Work ................................................................................ 16 
List of abbreviations ..................................................................................................... 18 
Chapter 1: Introduction ............................................................................................... 23 
1.1 Clinical and epidemiological aspects of Inflammatory Bowel Disease ................ 23 
1.1.1 Clinical presentation and management of Crohn’s disease ................................ 23 
1.1.2 Ulcerative colitis and other inflammatory bowel diseases ............................. 28 
1.1.3 Inflammatory bowel disease is associated with genetic and environmental 
factors ...................................................................................................................... 29 
1.2 Theories of Crohn’s disease pathogenesis ............................................................. 30 
1.2.1 Abnormal mucosal barrier function in Crohn’s disease ................................ 31 
1.2.2. Infectious aetiology, ‘Dysbiosis’ and Crohn’s disease pathogenesis ............ 34 
1.2.3 Autoimmunity .................................................................................................. 42 
1.2.4 Immunodeficiency ........................................................................................... 43 
1.2.5 Integrated models of Crohn’s disease pathogenesis....................................... 47 
1.3 Impaired acute inflammation in Crohn’s disease .................................................. 48 
1.3.1 Acute inflammation and the role of macrophages .......................................... 48 
1.3.2 Mechanism of impaired neutrophil recruitment in Crohn’s disease .............. 52 
1.3.3 Mechanism of defective macrophage cytokine secretion in Crohn’s disease . 54 
1.3.4 Pathways of cytokine secretion and relevance to CD ..................................... 55 
1.3.5 Other macrophage defects in Crohn’s disease ............................................... 59 
1.3.6 Macrophage function in ulcerative colitis ...................................................... 60 
1.4 Genetic factors in Crohn’s disease and their relationship to impaired acute 
inflammation ............................................................................................................... 61 
1.4.1 NOD2 .............................................................................................................. 61 
1.4.2 IBD5 ................................................................................................................ 63 
1.4.3 ATG16L1, IRGM and autophagy .................................................................... 64 
1.4.4 Other CD-susceptibility loci ........................................................................... 67 
1.4.5 Limitations of GWAS and ‘Missing heritability’ ............................................ 69 
5
  
1.4.6 The missing heritability of CD remains unexplained ..................................... 70 
1.5 Outline of Thesis ................................................................................................... 71 
1.5.1 Summary of background information ............................................................. 71 
1.5.2 Summary of investigations conducted and hypotheses ................................... 73 
Chapter 2: Materials and Methods ............................................................................. 75 
2.1 Subject recruitment and selection .......................................................................... 75 
2.2 Cell culture and assays .......................................................................................... 76 
2.2.1 Preparation of stimuli for cell culture assays ................................................. 76 
2.1.2 Primary macrophage isolation, culture and stimulation ................................ 77 
2.1.3 THP-1 cell culture and stimulation ................................................................ 78 
2.1.4 THP-1 cell transfection and siRNA knockdown ............................................. 78 
2.1.5 TNF Bioassay .................................................................................................. 79 
2.1.6 Multiplex cytokine measurement .................................................................... 80 
2.1.7 MTT cell viability assay to estimate cell number ........................................... 81 
2.1.8 Propidium iodide staining and flow cytometry ............................................... 82 
2.1.9 SDS-PAGE and Western blotting ................................................................... 82 
2.3 Genomic DNA preparation and analysis ............................................................... 84 
2.3.1 Genomic DNA extraction ................................................................................ 84 
2.3.2 Genotyping of Crohn’s disease associated polymorphisms ........................... 84 
2.3.3 Calculation of genetic risk scores ................................................................... 86 
2.3.4 Sequencing of OPTN region ........................................................................... 87 
2.4 Lipid extraction and analysis ................................................................................. 89 
2.4.1 Sphingolipid analysis of cultured macrophages ............................................. 89 
2.4.2 BCA assay ....................................................................................................... 90 
2.4.3 Preparation of samples for phospholipid analysis and stable isotope 
incubation ................................................................................................................ 91 
2.4.4 Phospholipid extraction and analysis by electrospray ionisation mass 
spectrometry............................................................................................................. 92 
2.5 RNA preparation and analysis ............................................................................... 94 
2.5.1 RNA extraction from HC, CD and UC macrophages ..................................... 94 
2.5.2 Microarray hybridisation ............................................................................... 95 
6
  
2.5.3 Microarray data analysis................................................................................ 95 
2.5.4 cDNA conversion and Quantitative PCR........................................................ 98 
2.6 Statistical analysis ................................................................................................. 99 
2.6.1 Analysis of cytokine secretion measurements, and relationships to phenotypes 
and genotypes (chapter 3)........................................................................................ 99 
2.6.2 Analysis of macrophage lipids in CD (chapter 4) .......................................... 99 
2.6.3 Analysis of transcriptomic abnormalities in CD (chapter 5) ......................... 99 
Chapter 3: The macrophage response to microbial stimuli in Crohn’s disease, and 
genotype-phenotype correlations ............................................................................... 101 
3.1 Introduction ......................................................................................................... 101 
3.2 Results ................................................................................................................. 103 
3.2.1 Optimisation of stimuli for cytokine secretion assays .................................. 103 
3.2.2 Pro-inflammatory cytokine secretion from CD macrophages after HkEc 
stimulation is defective........................................................................................... 103 
3.2.3 Release of TNF is impaired in response to other microbial stimuli ............. 107 
3.2.4 Impaired TNF release is not dependent on treatment regimes, age, gender 
and smoking status ................................................................................................. 113 
3.2.5 Association between aberrant TNF release and disease phenotype ............. 115 
3.2.6 Relationship of impaired TNF secretion to GWAS susceptibility loci .......... 119 
3.2.7 Relationship of attenuated TNF release to overall genetic risk score .......... 123 
3.3 Discussion ........................................................................................................... 128 
Chapter 4: Investigation of macrophage lipids in Crohn’s disease ........................ 137 
4.1 Introduction ......................................................................................................... 137 
4.1.1 Introduction to sphingolipids and their functions ........................................ 137 
4.1.2 Phospholipids: structure, synthesis and biological functions ...................... 141 
4.1.3 Previous investigations of lipids in Crohn’s disease and hypothesis ........... 146 
4.2 Results ................................................................................................................. 148 
4.2.1 Sphingolipid composition of unstimulated HC and CD macrophages ......... 148 
4.2.2 Sphingolipid composition of HkEc stimulated macrophages ....................... 151 
4.2.3 Investigation of phospholipid dynamics in CD and HC macrophages ......... 154 
4.2.4 Analysis of PC in HC and CD macrophages ................................................ 156 
4.2.5 Analysis of PS in HC and CD macrophages ................................................ 161 
7
  
4.2.6 Analysis of PI in HC and CD macrophages ................................................. 164 
4.2.7 Shotgun lipidomics analysis of ileal biopsies ............................................... 171 
4.3 Discussion ........................................................................................................... 173 
Chapter 5: Analysis of macrophage transcriptomic abnormalities in Crohn’s 
disease ........................................................................................................................... 180 
5.1 Introduction ......................................................................................................... 180 
5.2 Results ................................................................................................................. 183 
5.2.1 Differentially expressed genes between CD, HC and UC macrophages ...... 183 
5.2.2 Principal component analysis of CD, HC and UC macrophage gene 
expression .............................................................................................................. 190 
5.2.3 Identification of outlier probes in CD, HC and UC subjects and their 
biological function ................................................................................................. 192 
5.2.4 Overlap between macrophage gene expression outliers and GWAS 
susceptibility loci ................................................................................................... 199 
5.2.5 Outlier probes common between CD patients .............................................. 202 
5.2.6 Identification of optineurin gene expression outlier patients in other array 
datasets .................................................................................................................. 206 
5.2.7 Validation of abnormal optineurin expression in a subset of CD patients ... 208 
5.2.8 Phenotype and genotypes of optineurin outlier patients .............................. 210 
5.2.9 Functional relevance of abnormal optineurin expression in TNF release ... 212 
5.2.10 DNA sequence variants associated with abnormal optineurin expression 215 
5.3 Discussion ........................................................................................................ 220 
Chapter 6: General Discussion .................................................................................. 231 
6.1 Summary of investigations conducted and novel findings .................................. 231 
6.2 Discussion of novel findings, implications and study limitations ....................... 233 
6.2.1 Impaired macrophage function in Crohn’s disease ...................................... 233 
6.2.2 Molecular mechanisms underlying impaired cytokine release and 
macrophage function ............................................................................................. 239 
6.2.3 Implications for CD pathogenesis and therapeutic strategies...................... 244 
6.3 Future directions .................................................................................................. 246 
6.3.1 Macrophage cytokine secretion and genotype correlations ......................... 246 
6.3.2 Lipid investigations in CD ............................................................................ 250 
8
  
6.3.3 Macrophage transcriptomic abnormalities in CD........................................ 250 
6.4 Conclusion ........................................................................................................... 253 
 
References .................................................................................................................... 254 
Appendix 1: Demographics of patients ........................................................................ 289 
Appendix 2: Publications and poster presentations...................................................... 293 
 
 
9
  
Figures and Tables 
Chapter 1 
Figure 1.1: Clinicopathological features of Crohn’s disease ......................................... 26 
Figure 1.2: Microorganisms postulated to have a role in CD pathogenesis .................. 36 
Figure 1.3: Three stage model for the pathogenesis of Crohn’s disease........................ 49 
 
Chapter 2 
Table 2.1: Details of the 34 SNPs genotyped and used to determine overall genetic risk 
score. ............................................................................................................................... 85 
Figure 2.1: PCR amplification of OPTN gene for sequencing ...................................... 88 
 
Chapter 3 
Figure 3.1: Dose response curves of TNF release with increasing doses of C. albicans 
and E. coli ..................................................................................................................... 105 
Figure 3.2: Pro-inflammatory cytokine release from CD macrophages after HkEc 
stimulation is deficient .................................................................................................. 106 
Figure 3.3: Correlation of TNF secretion with IFN-γ, IL-6 and IL-10 release from HC 
and CD macrophages .................................................................................................... 108 
Figure 3.4: Macrophages from CD patients release attenuated levels of TNF in response 
to multiple stimuli ......................................................................................................... 109 
Figure 3.5: Correlation of  attenuated TNF release from CD macrophages between 
microbial stimuli ........................................................................................................... 111 
Figure 3.6: Impaired TNF secretion from CD macrophages is not related to treatment 
regimes .......................................................................................................................... 112 
Figure 3.7: Defective TNF release is  not releated to age, gender or smoking status .. 114 
Figure 3.8: TNF release from CD macrophages in response to TLR2 stimulation, with 
CD patients subdivided by Montreal phenotypic classification  ................................... 116 
Figure 3.9: TNF release from CD macrophages in response to TLR4 stimulation, with 
CD patients subdivided by Montreal phenotypic classification .................................... 117 
Figure 3.10: TNF release from CD macrophages in response to HkEc stimulation, with 
CD patients subdivided by Montreal phenotypic classification .................................... 118 
Figure 3.11: Relationship bêtween TNF secretion after TLR2 stimulation and NOD2, 
ATG16L1 and IRGM genotypes  ................................................................................... 120 
Figure 3.12: Relationship between TNF secretion after HkEc stimulation and NOD2, 
ATG16L1 and IRGM  genotypes ................................................................................... 122 
10
  
Figure 3.13: Genetic risk scores for developing CD in the total UCLH and study 
cohorts ........................................................................................................................... 125 
Figure 3.14: HC and CD individuals separated into risk of developing CD (Genetic risk 
score, GRS) and relationship to the TLR2 and HkEc response .................................... 126 
Figure 3.15 Correlation between TNF release from CD macrophages after HkEc 
stimulation and genetic risk score ................................................................................. 127 
 
Chapter 4 
Figure 4.1: Diagrams of ceramide structure and sphingolipid metabolism pathway ... 139 
Figure 4.2: Structure and biosynthesis of phospholipids ............................................. 143 
Figure 4.3: Ceramide and sphingoid base composition of unstimulated HC and CD 
macrophages .................................................................................................................. 150 
Figure 4.4: Alterations in the amounts of ceramide and sphingoid bases in HC and CD 
macrophages .................................................................................................................. 152 
Figure 4.5: Ceramide and sphingoid base composition of HkEc stimulated HC and CD 
macrophages .................................................................................................................. 153 
Figure 4.6: Electrospray ionisation mass spectrometric analysis of endogenous and 
newly synthesised PC .................................................................................................... 157 
Figure 4.7: Composition of endogenous and newly synthesised PC species in HC and 
CD macrophages ........................................................................................................... 158 
Figure 4.8: Incorporation of methyl-d9-choline into HC and CD macrophage PC ...... 160 
Figure 4.9: Electrospray ionisation mass spectrometric analysis of endogenous and 
newly synthesised PS .................................................................................................... 162 
Figure 4.10: Composition of endogenous and newly synthesised PS species in HC and 
CD macrophages ........................................................................................................... 163 
Figure 4.11: Incorporation of serine-d3 into HC and CD macrophage PS ................... 165 
Figure 4.12 Electrospray ionisation mass spectrometric analysis of endogenous and 
newly synthesised PI species in macrophages .............................................................. 166 
Figure 4.13: Composition of endogenous and newly synthesised PI species in HC and 
CD macrophages ........................................................................................................... 168 
Figure 4.14: Alterations in the molar % of PI 16:0/18:1 in CD macrophages ............. 169 
Figure 4.15 Incorporation of myo-d6-inositol into HC and CD macrophage PI .......... 170 
Figure 4.16 Shotgun lipidomics analysis of ileal biopsies ........................................... 172 
 
 
11
  
Chapter 5 
Table 5.1: Differentially expressed genes in unstimulated CD macrophages..............185 
Table 5.2: Over-expressed genes in HkEc stimulated CD macrophages in comparison 
to HC.......................................................................................................................... ...186 
Table 5.3: Under-expressed genes in CD macrophages after HkEc stimulation ......... 187 
Table 5.4: Differentially expressed genes in CD compared to UC macrophages after 
HkEc stimulation ........................................................................................................... 189 
Table 5.5: Functional annotation of differentially expressed genes between CD and HC 
macrophage groups ....................................................................................................... 191 
Figure 5.1: Principal component analysis of unstimulated macrophage gene expression 
profiles from CD, UC and HC patients ......................................................................... 193 
Figure 5.2: Principal component analysis of unstimulated and HkEc stimulated 
macrophages .................................................................................................................. 194 
Table 5.6: Differentially expressed probes between male and female individuals ...... 196 
Figure 5.3: Macrophage gene expression outliers in a representative CD patient ....... 197 
Figure 5.4: Numbers of outlier probes in unstimulated macrophages from CD, UC and 
HC individuals .............................................................................................................. 198 
Table 5.7: Functional analysis of CD and HC gene expression outliers by gene 
ontology (GO) annotation ............................................................................................. 200 
Figure 5.5: Abnormal macrophage expression of genes located in CD GWAS 
susceptibility loci in CD, UC and HC individuals ........................................................ 201 
Figure 5.6: Outlier probes common between CD patients ........................................... 203 
Figure 5.7: Abnormal optineurin (ILMN_2381899) expression in unstimulated 
macrophages from patients with CD ............................................................................. 204 
Figure 5.8: Abnormal optineurin expression in individual patients in two distinct array 
datasets .......................................................................................................................... 205 
Figure 5.9: Validation of abnormal optineurin expression in a subset of CD patients 209 
Figure 5.10: Phenotypes of optineurin outlier patients ................................................ 211 
Figure 5.11: Knockdown of optineurin in THP-1 cells using siRNA .......................... 213 
Figure 5.12: Impaired TNF release from optineurin depleted THP-1 cells after TLR2, 
but not HkEc stimulation .............................................................................................. 214 
Figure 5.13: Single nucleotide polymorphisms identified in the OPTN region in outlier 
patients .......................................................................................................................... 216 
Figure 5.14: Linkage disequilibrium between single nucleotide polymorphisms 
identified in optineurin outlier patients. ........................................................................ 218 
12
  
Figure 5.15: Association of single nucleotide polymorphisms in the OPTN region with 
optineurin expression .................................................................................................... 219 
 
Chapter 6 
Figure 6.1: Defective macrophage function in Crohn's disease: a proposed pathogenic 
schema ........................................................................................................................... 247 
 
Appendix 1 
Table I: Demographics and Montreal classification of patients included in cytokine 
secretion assays ............................................................................................................. 290 
Table II: Demographics of patients included in lipid studies (chapter 4)  ................... 291 
Table III: Demographics and Montreal classification of patients included in microarray 
study .............................................................................................................................. 292 
 
 
13
  
Acknowledgements 
This work was supported by the Wellcome Trust, Medical Research Council and 
National Association for Colitis and Crohn’s disease. I would like to thank the 
following people for their support with various aspects of this project: 
 Dr Andrew Smith – for helpful discussions, support and guidance throughout the 
project. 
 Dr Farooq Rahman and Dr Daniel Marks – for valuable discussions and help 
with sample collection (see statement of collaborative work). 
 Mr Adam Levine, Mr Luke Jostins and Dr Jeffrey Barrett – for helpful 
discussions and calculation of genetic risk scores. 
 Dr Roser Vega – for biopsy sample collection. 
 Professor Tony Postle, Dr Grielof Koster, Dr Vikki Ledger, Dr Jonathan 
Townsend, Dr Yusuf Hannun, Dr Jacek Bielawski, Dr Xianlin Han and 
Professor Tony Futerman – for all their help with the lipidomics aspects of 
project (see statement of collaborative work). 
 Dr Philip Smith, Dr Bu’ Hussain Hayee and Dr Nuala O’Shea - for help with 
blood sample collection and patient phenotyping. 
 Dr Josh Chew and Dr Christine Palmer – for help with tissue culture. 
 Dr Daniel Roden and Dr Anna Lobley – for developing the software for 
customised outlier analysis of microarray data. 
 Dr Carol McDonald, Ms Penelope Harrison, Ms Jane Tempero and Ms Rebecca 
Marnane - for excellent technical support and assistance throughout. 
 Dr Stuart Bloom, Dr Sara McCartney and Dr Louise Langmead – for allowing 
study of patients under their care, and help with patient recruitment to the study. 
14
  
 Ms Belinda Theis – for help with patient recruitment and useful discussions, 
especially regarding ethics applications. 
 Mrs Sophia Joyce - for administrative support. 
I would especially like to thank my two supervisors, Professor Tony Segal and Dr Ann 
Walker for their continued support and encouragement throughout the project. I would 
also like to thank all patients and volunteers who participated in these studies, the UCL 
MB PhD programme for organising funding, and finally my friends and family for all 
the help and support they have offered in the past 3 years. 
15
  
Statement of Collaborative Work 
A number of aspects of the work presented in this thesis were conducted as 
collaborative projects. These included 
 Macrophage cytokine secretion assays in response to TLR agonist stimulation.  
L929 bioassays investigating TNF-α release to TLR agonists were performed 
jointly with Dr Farooq Rahman (FR). Initial optimisation studies were 
performed by FR. Data presented comparing HC with CD are the combined 
results for assays performed by FR (~70% of total) and GS (~30%), with the 
exception of TLR5, which were performed by FR and are presented here for 
completeness. Subsequent analysis of phenotype and genotype correlations was 
performed by GS. All assays investigating HkEc and HkCa stimulation in this 
study were performed by GS. 
 Sequenom genotyping and determination of genetic risk scores for the UCLH 
cohort of CD patients and HC individuals was performed as a collaborative 
project with Dr Jeffrey Barrett and Mr Luke Jostins at the Wellcome Trust 
Sanger centre, and Mr Adam Levine. 
 Analysis of macrophage lipids in Crohn’s disease.  
Macrophage ceramide content was investigated as a collaborative project with 
the Medical University of South Carolina. All samples were collected and 
prepared by GS; lipid extractions were performed by GS and Professor Jacek 
Bielawski (JB). Mass spectrometry was performed by JB with technical support. 
Subsequent analysis was performed by GS.  
Macrophage phospholipid dynamics were investigated in a collaborative study 
with the University of Southampton. Samples were prepared by GS; lipid 
extractions were performed by GS under kind supervision of Dr Vikki Ledger 
16
  
(VL). Mass spectrometry was performed by Dr Grielof Koster and VL. Spectra 
and data generated by the in house macro were analysed by GS with helpful 
advice from members of the University of Southampton lipidomics group. 
Shotgun lipidomics experiments were performed as a collaborative project with 
Dr Xianlin Han (XL) (Washington University, St Louis). Sample preparation 
was performed by GS and XL. Mass spectrometry was performed by XL. Data 
were analysed by XL and GS. 
 Transcriptomic abnormalities in Crohn’s disease 
Sample preparation and RNA extraction was performed by GS (with technical 
assistance of Dr Carol McDonald). Array hybridisation was performed at the 
Wellcome Trust Sanger Centre. Analysis and subsequent experiments were 
performed by GS. The software for customised outlier analysis was developed in 
collaboration with Dr Daniel Roden and Dr Anna Lobley, Department of 
Computer Sciences, UCL. 
17
  
List of abbreviations 
5-ASA: 5-aminosalicylate 
ADAMDEC1: ADAM-like decysin 1 
AIEC: Adherent, invasive Escherichia coli 
ALS: Amyotrophic lateral sclerosis 
ANOVA: Analysis of variance 
ASCA: Anti-Saccharomyces cerevisiae antibodies 
ATG16L1: Autophagy-related 16-like 1 
BCA: Bicinchoninic acid 
BMI: Body mass index 
BSA: Bovine serum albumin 
C. albicans: Candida albicans 
CARD: caspase recruitment domain-containing protein 
CCT: CTP: phosphocholine cytidylyltransferase 
CD:  Crohn’s disease 
CDAI: Crohn’s disease Activity Index 
CGD: Chronic granulomatous disease 
CL: Cardiolipin 
COPA: Cancer outlier profile analysis 
DAG: Diacylglycerol 
DMEM: Dulbecco’s Modified Eagle medium 
DSS: Dextran sodium sulphate 
E. coli: Escherichia coli 
18
  
EDTA: Ethylenediaminetetraacetic acid 
eQTL: expression quantitative trait locus 
ER: Endoplasmic reticulum 
ESI-MS: Electrospray ionisation tandem mass spectrometry 
FBS: Foetal Bovine Serum 
FDR: False discovery rate 
GAPDH: Glyceraldehyde-3-phosphate dehydrogenase 
GM-CSF: Granulocyte macrophage-colony stimulating factor 
GO: Gene ontology 
GRS: Genetic risk score 
GWAS: Genome-wide association study 
HC: Healthy control 
HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV: Human Immunodeficiency virus 
HkCa: Heat-killed Candida albicans 
HkEc: Heat-killed Escherichia coli 
HLA: Human leukocyte antigen 
HPLC: High performance liquid chromatography 
HPLC-MS: High performance liquid chromatography tandem mass spectrometry 
IBD: Inflammatory bowel disease 
IFN: Interferon 
Ig: Immunoglobulin 
IL: Interleukin 
19
  
IL-23R: Interleukin-23 receptor 
IRGM: immunity-related GTPase family, M 
LB: Luria-Bertani 
LC3: microtubule –associated protein 1 light chain 3 
LPS: Lipopolysaccharide 
M cell: Microfold cell 
MAP: Mycobacterium avium subspecies paratuberculosis 
MDP: Muramyl dipeptide 
MS: Mass spectrometry 
MSD: MesoScale Discovery 
MTT: 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide 
NEMO: NF-κB essential modulator 
NLR: Nod-like receptor 
NOD: Nucleotide oligomerisation binding domain 
OPTN: Optineurin 
PA: Phosphatidic acid 
Pam3CSK4: N-palmitoyl-S-[2,3-bis(palmitoyloxy)-propyl]-(R)-cysteinyl-(lysyl)3-
lysine 
PAMP: Pathogen-associated molecular pattern 
PBMC: Peripheral blood mononuclear cell 
PBS: Phosphate buffered saline 
PC: Phosphatidylcholine 
PCA: Principal component analysis 
PCR: Polymerase chain reaction 
20
  
PE: Phosphatidylethanolamine 
PEMT: Phosphatidylethanolamine N-methyltransferase 
PG: Phosphoglycerol 
PI: Phosphatidylinositol 
PLA2: Phospholipase A2 
PMA: Phorbol-12-myristate-13-acetate 
PRR: Pathogen pattern recognition receptor 
PS: Phosphatidylserine 
S. cerevisiae: Saccharomyces cerevisiae 
SAMP: SAMP1/ Yit 
SAP: Shrimp alkaline phosphatase 
SDS: Sodium dodecyl sulphate 
siRNA: Small interfering RNA 
SNAP: SNP annotation and proxy search 
SNARE: Soluble NSF attachment protein receptor 
SNP: Single nucleotide polymorphism 
TACE: TNF converting enzyme 
TBK: TANK-binding kinase 
TGF-β: Transforming growth factor-β 
TGN: Trans-Golgi network 
Th: T-helper 
TIM: T-cell immunoglobulin mucin 
TIR: Toll / IL-1 receptor 
21
  
TIRF: Total internal reflection fluorescence microscopy 
TLR: Toll-like receptor 
TNF:  Tumour necrosis factor 
UC: Ulcerative colitis 
UCL: University College London 
UCLH: University College London Hospitals NHS Foundation Trust 
UK: United Kingdom 
USA: United States of America 
UTS: Urotensin 
VAMP: Vesicle-associated membrane protein 
WTCCC: Wellcome Trust Case Control Consortium 
YPD: Yeast peptone dextrose 
22
  
Chapter 1: Introduction 
1.1 Clinical and epidemiological aspects of Inflammatory Bowel Disease 
1.1.1 Clinical presentation and management of Crohn’s disease 
Crohn’s disease (CD) is a common inflammatory bowel disease (IBD) associated with 
considerable lifelong morbidity. The first descriptions of the disorder may date back to 
the 18
th
 century, when Giovanni Battista Morgagni described ‘erosion’ and ‘ulceration’ 
of the internal surface of the terminal ileum and caecum in a 20 year old patient with 
abdominal pain and diarrhoea. There were a number of subsequent descriptions of a 
CD-like disorder, and notably in 1913 T. Kennedy Dalziel published a case series 
describing 13 patients with thickening of the terminal ileum and transmural 
inflammation, some of whom also had colonic involvement and intestinal obstruction. 
Dalziel also recognised that the disorder strikingly resembled Johne’s disease in cattle 
and human intestinal tuberculosis, but without demonstrable acid-fast bacilli. From 
1932 onwards, the disorder became known as Crohn’s disease after Burrill B. Crohn, 
Leon Ginzburg and Gordon Oppenheimer published a case series of patients with 
‘regional ileitis’ (1). 
CD currently affects approximately 100 individuals per 100,000 in developed 
populations, incidence having increased dramatically in the second half of the twentieth 
century. The majority of cases occur in Western populations, including Europe and 
North America. Caucasians are more frequently affected than other ethnic groups, and 
females are slightly more frequently affected than males. The age of onset of CD 
follows a bimodal distribution, with a first peak of onset in the second and third decade, 
followed by a second peak in patients 60-79 years of age. The underlying reasons 
behind the trends in incidence and onset remain incompletely understood (2). 
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Clinical features of CD include chronic abdominal pain and diarrhoea, weight 
loss, gastrointestinal bleeding and malnutrition. There are often associated constitutional 
symptoms, which may include low grade fever, malaise and lethargy. The onset is 
typically insidious, although some patients may present acutely, either with fulminant 
symptoms or with complications such as toxic megacolon. Over 25% of patients also 
experience extra-intestinal manifestations of CD, which typically affect the eyes, joints 
and skin. Cutaneous manifestations include erythema nodosum and pyoderma 
gangrenosum; inflammatory ocular manifestations include uveitis, episcleritis and 
conjunctivitis, and in the joints patients may develop seronegative arthritis, ankylosing 
spondylitis and sacroiliitis. There is also an association with primary sclerosing 
cholangitis, a chronic condition affecting the bile ducts, characterised by progressive 
inflammation and fibrosis. Furthermore, the malabsorptive state experienced by some 
CD patients may lead to sequelae such as anaemia, metabolic bone disease, 
cholelithiasis, nephrolithiasis, and in children, failure to grow appropriately. Patients 
with colonic CD are also at increased risk of colorectal cancer. In most patients, the 
disease is relapsing and remitting, with flares of active inflammation interspersed with 
periods of remission (‘quiescent disease’). At any one time, approximately half of all 
CD patients will have quiescent disease (3). 
Considerable heterogeneity exists in the clinical presentation of CD between 
individual patients. Nevertheless, there are definable patterns of disease location, 
behaviour and age of onset. Although CD may affect any part of the gastrointestinal 
tract from mouth to anus, typically the terminal ileum (~40% of patients) and colon 
(~30% of patients) are affected. In approximately one third of patients, lesions occur in 
both large and small bowel (‘ileocolonic disease’). Upper gastrointestinal tract 
involvement is relatively uncommon, occurring in less than 10% of patients. The region 
of the bowel affected is a major determinant of the predominant clinical symptoms 
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experienced by the patient. Patients may also be subdivided as having either pure 
inflammatory disease, stricturing, or penetrating disease (where abnormal connections 
between epithelial surfaces, termed ‘fistulas’ develop). In a small proportion of patients, 
a mixed picture of stenotic and fistulating disease is observed. The Montreal system has 
been developed for classification of CD phenotypes, incorporating age of onset, disease 
location and behaviour (Figure 1.1A) (4). However, it is also recognised that both 
disease location and behaviour are dynamic over time; for example, patients with 
inflammatory disease are at risk of developing stricturing and fistulating complications 
(5). 
The lesions that characterise CD have a number of distinctive features, which 
help distinguish CD from other intestinal diseases. Typical macroscopic features include 
mucosal oedema and erythema, aphthous ulceration and discontinuous skip lesions 
(discrete patches of inflammation separated by normal mucosa). Together these give 
rise to a characteristic cobblestone appearance of the mucosa. Fistulas and strictures 
may also be observed in some patients. Additional macroscopic features identifiable 
from surgical resection specimens include changes in the vasculature (6) and fat 
wrapping (where the intestinal circumference becomes covered with adipose tissue and 
there is associated loss of the bowel-mesentery angle), the latter being strongly 
correlated with the presence of transmural inflammation (7). Histological features of 
actively inflamed bowel include transmural inflammation with leukocytic infiltration 
and lymphoid hyperplasia, often with non-caseating granulomata (aggregates of 
activated macrophages surrounded by a mantle of lymphocytes) (Figure 1.1B, C) (8). 
The early lesions observed in CD also have a characteristic distribution, tending to 
overlie Peyer’s patches in the small intestine and lymphoid follicles in the colon (9). 
Peyer’s patches are aggregates of lymphoid follicles covered by a dome-shaped ‘follicle  
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Age at diagnosis
A1 16 years or younger
A2 17-40 years
A3 Over 40 years
Anatomical location
L1 Ileal
L2 Colonic
L3 Ileocolonic
L4 Isolated upper GI disease
Disease behaviour
B1 Inflammatory
B2 Stricturing
B3 Penetrating
p Perianal disease modifier
Figure 1.1 Clinicopathological features of Crohn’s disease.
(A) Montreal classification of CD phenotypes, based on age at diagnosis,
anatomical location and disease behaviour. Adapted from (4). (B) Colon
from patient with CD, showing areas of ulceration separated by areas of
normal mucosa (from http://www.pathology.washington.edu). (C) Ileal
biopsy from a patient with active disease. The arrow indicates a
granuloma. Image was obtained from (8).
A
B
C
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associated epithelium’ which may have important roles in the control of the immune 
response to luminal bacteria and antigens. 
Currently, no curative treatments exist for CD. Management of CD involves 
induction of remission from an active flare, and the prevention of recurrence once a 
patient has entered the quiescent phase of the disease. Immunosuppressants form the 
basis of current medical management for inducing remission. These include 
corticosteroids, thiopurines such as azathioprine and its metabolite 6-mercaptopurine, 5-
aminosalicylates (5-ASA) and biological therapies such as the anti-tumour necrosis 
factor (anti-TNF) agents infliximab and adalimumab. Surgical management may be 
required for patients with disease that is refractory to medical treatment, or in patients 
who experience complications such as intractable haemorrhage, perforation, recurrent 
obstruction or cancer (3). Furthermore, an important aspect of CD management is 
ensuring patients receive adequate nutritional support when indicated. This can be 
delivered as food or prepared formula feeds (enteral nutrition), and administered orally 
or via enteral feeding tubes and devices. Poor nutritional status is associated with an 
increased risk of complications after surgery, and growth retardation in paediatric 
patients. Nutritional therapy is also helpful in inducing remission from an active flare of 
CD. Indeed, evidence from randomised trials suggests that enteral nutrition might be as 
effective as corticosteroids in inducing remission in paediatric CD patients (10).  
There is currently no ‘ideal’ maintenance therapy for preventing recurrence of 
CD. Systemic corticosteroids are not effective (11) and are associated with significant 
toxicity, and similarly 5-ASA compounds are poorly efficacious after medically-
induced remission. Immunosuppressive agents such as azathioprine and methotrexate, 
and biological therapies are beneficial, but not without side effects. Azathioprine may 
cause pancreatitis, bone marrow suppression (12) and is associated with a small 
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increased risk of lymphoma (13). Potential adverse effects of biological therapies 
include infusion reactions, deterioration of heart failure (14) and increased susceptibility 
to infection, including reactivation of latent tuberculosis (15). Neither current medical 
treatments nor surgical resection of affected bowel can be considered ‘curative’. The 
evaluation of novel therapeutic strategies for induction of remission and prevention of 
CD recurrence therefore remains a major area of investigation. Notably, in recent years, 
trials of pre- and pro-biotics, nutritional supplements such as omega-3 fatty acids (16), 
and immune stimulants such as granulocyte macrophage-colony stimulating factor 
(GM-CSF) (17;18) have been conducted in CD, some of which have shown promise.  
1.1.2 Ulcerative colitis and other inflammatory bowel diseases 
‘Inflammatory bowel disease’ encompasses several other distinct clinical entities 
besides CD, including ulcerative colitis (UC), eosinophilic colitis, lymphocytic colitis 
and collagenous colitis. Each has distinctive pathological features and is thought to have 
a different underlying aetiology. Of these, by far the most common is UC, which affects 
approximately 100 individuals per 100,000 in the United Kingdom (UK). The cardinal 
clinical symptoms of UC include diarrhoea, typically with blood and mucus, tenesmus 
and lower abdominal cramps. Malaise and low grade fever may also be present. As in 
CD, UC is a systemic disorder, and a sizeable proportion of patients experience extra-
intestinal manifestations. The most common include arthritis, ankylosing spondylitis, 
iritis and uveitis, primary sclerosing cholangitis, erythema nodosum and pyoderma 
gangrenosum. Although there is overlap in the clinical presentation of UC and CD, 
there are a number of features which distinguish the two conditions and suggest that 
they are in fact distinct disease entities, each with a different underlying 
aetiopathogenesis. 
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UC typically affects the rectum and large bowel only (although in a small 
proportion of patients a ‘backwash ileitis’ occurs), in contrast to CD where the rectum is 
usually spared. 55% of patients have rectal inflammation only (proctitis), 30% have ‘left 
sided’ ulcerative colitis that does not extend beyond the splenic flexure, and 15% have 
inflammation that extends throughout the entire large bowel (pancolitis). Secondly, the 
inflammation in UC is typically continuous and superficial in nature, being 
characteristically restricted to the mucosa, in contrast to the transmural inflammation of 
CD. Other histopathological features of UC include crypt abcess formation and goblet 
cell depletion, which is much less conspicuous in CD. Granulomata are also not 
observed in UC (19). 
1.1.3 Inflammatory bowel disease is associated with genetic and environmental factors 
Epidemiological studies have indicated roles for both genes and environment in the 
pathogenesis of CD. Environmental factors associated with CD include smoking 
tobacco, which confers both increased risk of developing CD and also influences the 
clinical phenotype (2); smokers being more likely to have ileal disease as opposed to 
colonic or ileocolonic involvement (20). Dietary factors may also be important in the 
development of CD – in particular, associations have been reported between CD and 
intake of dietary fat (21;22) and refined carbohydrates such as sucrose (23;24). 
It is also well established that CD has a genetic component, which has been 
confirmed by twin and family studies. Up to one third of patients have a positive family 
history of CD, numerous multiplex pedigrees have been reported (25-27), and 
furthermore, twin studies have consistently demonstrated a greater concordance in 
monozygotic than dizygotic twins (28;29). In addition, genome-wide association studies 
(GWAS) have identified genetic loci associated with CD susceptibility, which are 
discussed in detail in section 1.4. 
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UC is also associated with genetic and environmental factors. However, in 
contrast to CD, smoking appears to confer protection against the development of UC 
(30-32). Genetic factors also play a less prominent role, with reported concordance rates 
in monozygotic twins significantly lower than for CD (28). This further indicates likely 
differences in the aetiopathogenesis of the two conditions. 
1.2 Theories of Crohn’s disease pathogenesis 
Numerous hypotheses have been proposed as to the underlying cause of CD. These 
include an infectious aetiology, a dysfunctional mucosal barrier, and an aberrant 
immunological response to antigens – including autoimmunity and immunodeficiency. 
Whilst each theory has some supportive evidence, no single hypothesis has been 
unequivocally proven. It is likely that CD has a complex aetiology, where multiple 
factors interact to give rise to a CD phenotype. This is supported by the wide range of 
environmental and genetic susceptibility factors that are associated with the 
development of CD. Another important consideration is that CD is a heterogeneous 
syndrome, as illustrated by the variability in clinical presentation and phenotype 
discussed in section 1.1.1. It is therefore plausible that the underlying pathological 
mechanisms differ between different patients, but give rise to the same overall outcome 
in the development of CD. 
A fundamental area of contention is whether the immune response is generally 
over- or under- active in CD, and the relative contribution of both the intestinal barrier 
and microbiota in disease initiation and progression. Intuitively, a chronic inflammatory 
disorder such as CD would be expected to arise from a hyper-active immune response; 
this however assumes that the chronic inflammatory response is in itself the primary 
defect. In investigating complex syndromes such as CD, a considerable challenge is the 
30
  
distinction of ‘primary’ or ‘initiating’ factors from phenomena that could be secondary 
or compensatory to other defects. 
Another problem in defining the aetiology of CD is a lack of a clear animal 
model that accurately reproduces all the features of human CD. Numerous animal 
models of inflammatory bowel disease have been described, including chemically 
induced colitides, inbred animal strains, knockout or transgenic animals and adoptive 
transfer models (33;34). These are very useful tools to investigate the physiology of 
bowel inflammation, and potential pathological influences. However, the direct 
applicability of most to human CD is often unclear. There are striking differences in 
pathological features, with relatively few models demonstrating granuloma formation, 
discontinuous transmural inflammation and extra-intestinal manifestations. 
1.2.1 Abnormal mucosal barrier function in Crohn’s disease 
The intestinal mucosa is made up of a number of different cellular components, 
including a layer of simple columnar epithelial cells, and an underlying lamina propria 
and muscularis mucosa. Within the epithelial layer, a number of other cell types are 
present, including intraepithelial lymphocytes and goblet cells. In the crypts of 
Lieberkühn within the small bowel, Paneth cells are also found, which may have a role 
in secretion and in host defense. The gastrointestinal epithelial cells normally form a 
relatively impermeable physical barrier to luminal contents, a function that is facilitated 
by tight junctions. Tight junctions are multi-protein complexes composed of 
transmembrane proteins (such as occludins, claudins and junctional adhesion 
molecules), scaffolding proteins and regulatory molecules such as kinases, and act to 
impede the flux of solutes along the paracellular pathway (35). Tight junction function 
is thought to be a key determinant of intestinal permeability. 
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Mucosal surfaces are also covered by a thick layer of mucus, largely composed 
of mucin glycoproteins. Mucus acts as a physical and chemical barrier to microbes, 
provides lubrication for the flow of luminal contents, and concentrates antimicrobial 
molecules close to the intestinal epithelium. Antimicrobial compounds contained within 
the mucus layer include defensins, lectins, immunoglobulins (such as sIgA, IgG and 
IgM) and protease inhibitors. In addition, the mucus mixture also contains trefoil 
peptides, which may confer structure to the mucus layer and influence wound healing 
and apoptosis, and phospholipids, the precise role of which remain to be fully elucidated 
(36). 
Several studies have reported increased bowel permeability in CD patients (37-
39). The underlying mechanism remains debated, as does whether it represents a 
primary phenomenon or a consequence of chronic inflammation. Although many 
studies investigated active patients, and pro-inflammatory cytokines such as tumour 
necrosis factor (TNF), interferon (IFN)-γ and interleukin (IL)-1β are known to influence 
tight junction permeability (40;41), abnormal intestinal permeability has also been 
reported in macroscopically normal small bowel of CD patients (42), which may be 
predictive of disease recurrence (43). Increased permeability has also been found in a 
proportion of healthy first-degree relatives (44) and spouses (45) of patients with CD. 
Taken together, these observations suggest that abnormal permeability may be a 
primary defect, with both genetic and environmental influences. Alterations in tight 
junction proteins, including dislocation of Rab13, vasodilator-stimulated 
phosphoprotein and zonula-occludin 1 has been reported in the mucosa of patients with 
inactive CD, which indicate a possible molecular basis for the abnormal intestinal 
permeability via the paracellular pathway (46). 
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Aberrant transcellular permeability may also occur in CD. The early lesions of 
CD are characteristically distributed overlying Peyer’s patches, the site of the follicle-
associated epithelium where microfold (M) cells are located (47). M cells are 
specialised epithelial cells that are capable of transporting macromolecules and 
microorganisms from the intestinal lumen to the underlying lymphoid tissues within the 
mucosa (48-50). Interestingly, a recent study demonstrated that Escherichia coli (E. 
coli) could be readily translocated across M cells, particularly strains of E. coli 
associated with the CD mucosa. This was found to be modified by a variety of 
substances found in foodstuffs, including the emulsifier polysorbate-80 (a common 
component of processed foods), which increased the bacterial translocation. This may 
indicate a mechanistic link between dietary factors and abnormal intestinal 
permeability, and could partly account for the increasing incidence of CD in Western 
populations (51). 
A number of animal studies underscore the importance of mucosal barrier 
dysfunction in the induction of bowel inflammation. Transgenic mice manipulated to 
express a dominant negative N-cadherin, a junctional adhesion protein, develop 
spontaneous bowel inflammation (52). Furthermore, the introduction of mutations in the 
mucin encoding gene MUC2 also results in spontaneous colitis, although the 
histopathological features are more reminiscent of UC (53). Relatively few animal 
models demonstrate isolated small bowel inflammation, although the few that have been 
described highlight a likely role for intestinal permeability in the development of ileitis. 
These include the inbred SAMP1/ Yit (Samp) mouse strain, which displays increased 
ileal permeability, preceeding the onset of a spontaneous ileitis. In this model, the 
inflammation described is not dissimilar to human CD, with discontinuous, transmural 
leukocytic infiltrates and coalescence of macrophages into aggregates (54;55). In 
addition, cyclooxygenase-2 deficient mice fed an atherogenic diet containing cholate (a 
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primary bile acid) develop transmural inflammation predominantely affecting the ileum 
and caecum (56). A plausible explanation for this observation is the strong emulsifying 
action of bile acids, which could be damaging to the mucosa. Indeed, bile acids have 
been shown to increase permeability in CaCo2 monolayers (57) and bacterial 
translocation in human intestinal biopsy samples (58). This process could also be 
influenced by species of intestinal bacteria, some of which can deconjugate and convert 
primary bile acids to secondary bile acids such as deoxycholate, which may represent 
the more toxic species (59). 
The increased mucosal permeability observed in CD could contribute to the 
disease pathogenesis by directly facilitating increased translocation of bacteria and other 
antigenic material from the lumen to the bowel wall. Alternatively it may be an 
indicator of reduced mucosal resistance, which could increase its susceptibility to the 
effects of exogenous agents, bacterial infection, bile acids and other emulsifiers, intra-
luminal pressure and non-steroidal anti-inflammatory drugs. It is apparent that mucosal 
barrier dysfunction may in itself not be sufficient to cause CD, as illustrated by the 
demonstration of abnormal permeability in a proportion of healthy relatives and spouses 
of patients with CD, and furthermore in patients with other gastrointestinal disorders, 
such as irritable bowel syndrome (60;61) and coeliac disease (62). However, clearly if 
ingress of luminal contents into the underlying tissues is followed by an abnormal 
immune response to this material, the development of a chronic inflammatory state 
could be promoted. 
1.2.2. Infectious aetiology, ‘Dysbiosis’ and Crohn’s disease pathogenesis 
The human gastrointestinal tract is in continuous contact with prokaryotes from birth 
onwards; it is estimated that over 10
14
 microorganisms are present in the human gut, 
including 1,000-1,150 different species (63). The number of prokaryotes varies 
34
  
significantly with anatomical location. The highest concentrations of bacteria are found 
in the colon, which contains approximately 10
11
 cells/g, whereas the terminal ileum 
contains in the region of 10
7
-10
8
 bacteria/g, and the proximal small bowel 10
2
-10
3
/g 
(64). Although the human ‘microbiome’ varies greatly between individuals (65), it is 
thought to be relatively stable over time in health. It has long been postulated that the 
intestinal microbiota could have a key role in the pathogenesis of inflammatory bowel 
disease. There is a clear requirement for bowel luminal contents in the pathogenesis of 
CD, as demonstrated by experiments where the faecal stream was diverted in CD 
patients, which resulted in resolution of CD lesions (66;67). Re-introduction of small 
bowel effluent into the excluded ileum resulted in disease recurrence. 
Over the years, numerous specific microorganisms have been postulated as 
causative of CD (Figure 1.2). The diversity and lack of unifying characteristics between 
these organisms is noteworthy – the list includes bacteria, yeasts and viruses, Gram 
positive and Gram negative bacteria, and aerobic and anaerobic species. Polymerase 
chain reaction (PCR) and immunocytochemistry reveal a multitude of organisms can be 
detected in CD tissue samples, including Mycobacterium avium subspecies 
paratuberculosis (MAP) (68), E. coli, Listeria, Streptococcus (69), Helicobacter pylori 
(70), Klebsiella, Pseudomonas aeruginosa (71), and viruses such as Epstein Barr virus 
(72). In recent years, considerable research has been directed towards several particular 
species, including MAP, Candida albicans (C. albicans) and E. coli. 
MAP has been suspected to play a causative role in CD since Dalziel initially 
recognised similarities between CD and Johne’s disease, a granulomatous ileitis in 
cattle caused by Mycobacterium paratuberculosis. In support of a role for MAP in CD 
pathogenesis, mycobacterial ‘spheroplasts’ (cells which contain mycobacterial DNA but 
lack a complete cell wall) have been isolated from intestinal resection tissue (68;73).  
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Organism Illustrative references
Bacteria
Gram positive
Streptococcus sp Liu et al. (1995) Gastroenterology 108(5):1396–1404
Listeria monocytogenes Liu et al. (1995) Gastroenterology 108(5):1396–1404
Clostridium sp Bolton (1980) Lancet 1(8165):383–384
Gram negative
Escherichia coli Darfeuille-Michaud et al. (1998) Gastroenterology 115(6):1405–1413
Yersinia enterocolitica Lamps et al. (2003) Am J Surg Pathol 27(2):220–227
Helicobacter sp Puspok et al. (1999) Am J Gastroenterol 94(11):3239–3244
Bacteroides fragilis Prindiville et al. (2000) Emerg Infect Dis 6(2):171–174
Pseudomonas sp Wei et al. (2002) Infect Immum 70(12):6567–6576
Chlamydia trachomatis Schuller et al. (1979) Lancet 1(8106):19–20
Coxiella burnetti Kangro et al. (1990) Gastroenterology 98(3):549–553
Klebsiella pneumoniae Tiwana (2001) Rheumatology 40(1):15–23
Mycobacteria
Mycobacterium paratuberculosis Chiodini et al. (1984) J Clin Microbiol 20(5):966–971
Mycobacterium kansasii
Atypical
Mycoplasma pneumoniae Kangro et al. (1990) Gastroenterology 98(3):549–553
L-forms Belsheim et al. (1983) Gastroenterology 85(2):364–369
Viruses
Paramyxomavirus
Measles Wakefield et al. (1993) J Med Virol 39(4):345–354
Herpersvirus
Epstein-Barr Yanai et al.(1999) Am J Gastroenterol 94(6):1582–1586
Cytomegalovirus Dimitroulia et al. (2006) Inflamm Bowel Dis 12(9):879–884
Yeasts
Candida albicans Standaert-Vitse et al. (2006) Gastroenterology 130(6):1764–1775
Saccharomyces cerevisiae Main et al. (1988) BMJ 297(6656):1105–110
Figure 1.2 Micro-organisms postulated to have a role in CD pathogenesis. Adapted
from (80).
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These can transform into acid-fast mycobacterial species after long term culture. A 
subsequent study reported that MAP could also be cultured from blood samples of 
patients with CD (74). Furthermore, serological studies have demonstrated the presence 
of antibodies against MAP-specific proteins in a proportion of individuals with CD (75), 
and PCR (76) and Fluorescent in situ hybridisation-based methods (77) have confirmed 
the presence of MAP DNA in granuloma isolated from CD patients. A recent meta-
analysis of 28 studies revealed that MAP positivity, as detected by PCR based 
techniques, occurred at a significantly higher frequency in CD than controls (odds ratio 
7.01, 95% confidence interval 3.95-12.4) (78).  
However, the hypothesis that MAP infection causes CD remains controversial. 
Firstly, there are a number of epidemiological, clinical and pathological differences 
between Johne’s disease and CD (79;80). Secondly, a number of studies have not 
replicated a convincing association between MAP and CD. In one study of 130 CD 
patients, all blood cultures were found to be negative for MAP (81). Furthermore, other 
studies have failed to detect MAP in intestinal biopsy samples (82) and microdissected 
granulomas (83) from CD patients, raising the possibility that the reported MAP 
detection could be an artefact of contamination, or due to underlying geographic 
differences between CD patients. A recent trial of MAP eradication therapy in CD 
revealed equivalent relapse rates between control and placebo arms after 2 years 
therapy, in spite of demonstrating some short term benefit (84). Finally, the efficacy of 
anti-TNF agents in CD, which can trigger reactivation of mycobacterial infections as a 
side effect (15), seems incompatible with the notion that MAP infection is the 
underlying cause of CD. However a contributory role of MAP, in combination with 
other genetic and immunological factors cannot be excluded. 
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E. coli is a Gram negative coliform that is an important component of the normal 
intestinal flora. Many subspecies of E. coli exist without causing human disease, and 
indeed some strains may be beneficial, providing that the mucosa is not damaged. 
However, many strains have acquired specific virulence factors that give them an 
advantage in certain environments; these have been implicated in a number of different 
diseases (85). E. coli antigens were initially demonstrated in a proportion of CD tissues 
by immunocytochemistry (69). Furthermore, E. coli have been cultured from lymph 
nodes of patients with CD (86), and a small-scale study revealed that the majority of 
granulomas from CD patients have detectable E. coli DNA by PCR (87), suggesting a 
possible pathogenic role.  
In the past decade, adherent, invasive strains of E. coli (AIEC) have been the 
focus of considerable attention. These subspecies, reported to be increased in faeces 
(88) and ileal mucosa (89;90) of patients with CD, display increased adherence to 
epithelial cell layers in vitro. These interactions may be facilitated by interaction of type 
I pili with carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) 
expressed on the apical surface of epithelial cells (91). Transgenic mice expressing 
human CEACAM6 develop a severe colitis after infection with a virulent strain of 
AIEC (92), supporting a potential role for these interactions in the development of 
bowel inflammation. However, CEACAMs are known to be upregulated by pro-
inflammatory cytokines (91), and the presence of AIEC in epithelial cells is not readily 
demonstrable in vivo. As discussed in section 1.2.1, interactions with other specialised 
cell types such as M cells (51) could be a critical determinant in determining whether 
these species penetrate from the lumen into the bowel wall, which is likely be modified 
by exogenous agents and/or inherent mucosal barrier defects.  
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Once AIEC reach the underlying tissues of the bowel wall, they interact with 
cells of the immune system. In particular, they are understood to be capable of infecting 
macrophages, where they can survive and replicate without causing death of the host 
cell (93). High levels of the pro-inflammatory cytokine TNF are released by 
macrophage cell lines on infection with the bacteria. Furthermore, interactions of AIEC 
with macrophages may trigger granuloma formation, as demonstrated by studies in 
human peripheral blood mononuclear cells (PBMCs) (94). These findings point towards 
a potential role for E. coli and AIEC in CD pathogenesis, most likely via interactions 
with the mucosal barrier and the innate immune system. 
C. albicans is a fungal organism present in the gastrointestinal tract commensal 
flora of a substantial proportion of the human population (95); the degree and frequency 
of colonisation has been reported to be increased in CD patients and their healthy 
relatives compared to controls (96). C. albicans typically colonises mucosal surfaces 
without causing disease. However, in immunocompromised individuals, the organism 
can cause opportunistic infections, some of which can be life threatening. The organism 
has a multilayered cell wall, consisting of an outer layer largely composed of mannans 
and mannoproteins and an inner ‘skeleton’ of β-glucans and chitin (97).  The cell wall 
of C. albicans contains a mannan with a specific mannose α1-3 mannose terminal 
disaccharide. This is also present in other microbes, including Saccharomyces 
cerevisiae (S. cerevisiae) and some mycobacterial subspecies (98), and has been 
identified as an epitope for the generation of anti-S. cerevisiae antibodies (ASCA) 
(99;100). ASCA have been demonstrated in 50-60% of CD patients (101;102), are 
stable over time and do not correlate with clinical disease activity (103), and they may 
predict the development of inflammatory bowel disease in control individuals (104). 
The presence of ASCA may also be of diagnostic importance, as the prevalence is 
significantly greater in CD patients than in those with UC (102;105). ASCA are 
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detectable in 20-25% of healthy relatives of CD patients (106). ASCA titres correlate 
with C. albicans colonisation in healthy relatives of CD patients, although surprisingly, 
not in CD patients themselves (96). Together these observations may be indicative of a 
primary role for aberrant C. albicans-immune system interactions in the development of 
CD, which could be determined by a combination of genetic and environmental factors. 
Recently, the concept of ‘dysbiosis’ has been a major subject of investigation in 
CD. This refers to ‘qualitative or quantitative changes in the intestinal microflora 
profile, their metabolic activity and local distribution’ (107). CD is characterised by a 
reduced diversity of faecal microbiota (108). Reduced numbers have been reported for 
the Firmicutes phylum, Clostridium cluster IV, Clostridium cluster XI and subcluster 
XIVa and higher numbers for Bacteroides species (108-110). Whilst interesting, caution 
should be taken when inferring whether these alterations represent primary phenomena 
in CD pathogenesis. CD is characterised by persistent diarrhoea, and many patients 
require immunosuppressant medication, which may have effects on the profile of 
intestinal microbiota (111). Some of the changes, particularly in the Firmicutes phylum, 
have also been observed in patients with infectious colitis (112;113). Dysbiosis has been 
reported in healthy relatives of patients with CD, although the alterations were not the 
same as those observed in the patients (114). This indicates that some of the changes 
that occur in CD could be secondary to the disease state, although further studies should 
be conducted to determine whether the alterations observed in the healthy relatives 
represent primary abnormalities. 
Whilst numerous studies have demonstrated alterations in the intestinal 
microbiota in CD, and suggested roles for these organisms in the disease pathogenesis, 
to date no single infectious agent has unequivocally been shown to be sufficient to 
cause CD. MAP, AIEC and C. albicans are all detectable in a proportion of unaffected 
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individuals (78;90;96). Furthermore, CD is not regarded as a contagious disease. The 
disorder has a clear hereditary component, as demonstrated by recent genetic studies 
(115;116). Its pathogenesis also clearly involves an abnormal immune response, given 
the observation of leukocytic infiltrates and granuloma in CD lesions, and the efficacy 
of immunosuppressive medication in CD.  In the light of this, it seems unlikely that the 
pathogenesis of CD can be wholly explained by an infectious agent.  
However, given the clear role of luminal contents in the development of CD 
lesions, it is very likely that CD arises from abnormal host interactions with the 
intestinal microflora in susceptible individuals. In addition, alterations of the microflora 
could influence disease pathogenesis via effects on intestinal barrier integrity and 
immune system function. Indeed, there are indications that such effects could be 
diverse, and in part dependent on the species of microbe. On one hand, 
Faecalibacterium prausnitzii, a member of the Firmicutes phylum, is reduced in CD, 
and low levels within ileal mucosa are associated with endoscopic recurrence. This 
bacterium exhibits anti-inflammatory effects both in vitro and in vivo (117).  On the 
other hand, there is evidence that bacteria such as bifidobacteria (which are also reduced 
in patients with CD (118)) are important for stimulation of immune function, including 
enhancement of phagocytic activity, as well as macrophage TNF and IL-6 production 
(119;120). Furthermore, the probiotic mixture VSL#3 was shown to prevent the onset of 
inflammation in Samp mice, which was related to stimulation of TNF release by 
epithelial cells (121). These apparently paradoxical observations may support the notion 
that the pathogenesis CD involves temporally distinct phases, each with different 
molecular mediators. 
41
  
1.2.3 Autoimmunity 
The case for CD arising from an autoimmune aetiology or hyper-reactive adaptive 
immune response stems from the observation of pathological leukocytic infiltrates and 
elevated levels of pro-inflammatory cytokines in CD lesions, when compared to normal 
healthy tissue. The infiltrating CD4+ lymphocytes in CD lesions appear to be 
characterised by high production of IL-2 and IFN-γ, giving rise to a Th1 type 
immunological response (122). Furthermore, immunosuppressive regulatory T cells are 
decreased in actively inflamed CD tissue in comparison to normal mucosa (123), and 
Th17 cells (pro-inflammatory T lymphocytes with a potential role in autoimmunity) are 
present (124). In support of the autoimmunity hypothesis, a number of autoantibodies 
have been detected in subsets of CD patients, mostly against antigens produced in 
exocrine pancreas, neutrophils and intestinal goblet cells (125;126).[Furthermore, 
immunosuppressive drugs such as corticosteroids are effective in inducing remission. 
Finally, GWAS have highlighted potential associations with genes involved in the IL-23 
axis, which may relate to abnormal Th17 cell regulation, although these are not specific 
for CD (116). 
However, a number of observations argue against autoimmunity being a primary 
aetiological factor in CD. Firstly, CD does not fulfil Witebsky’s postulates for an 
autoimmune condition and there is no animal model that reproduces all of the 
clinicopathological features of the human disease (127). The mechanistic significance of 
the auto-reactive lymphocytes and autoantibodies to the disease pathogenesis remains 
unproven. In addition, many genetic studies have failed to show significant associations 
between CD and a particular human leukocyte antigen (HLA) haplotype, with the 
possible exception of HLA DRB1*0103, which has been associated with colonic CD in 
several studies (128;129). The lack of strong HLA association is in contrast to well-
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established autoimmune diseases such as type 1 diabetes, where HLA associations can 
be readily identified by linkage and GWAS analysis, and are understood to account for 
a significant portion of the genetic risk (130;131). Indeed, recent genetic variation 
‘profiling’ using data collected in the Wellcome Trust Case Control Consortium 
(WTCCC) study revealed minimal clustering of CD with five autoimmune conditions, 
including multiple sclerosis, ankylosing spondylitis, autoimmune thyroid disease, 
rheumatoid arthritis and type 1 diabetes (132). Furthermore, whilst there are clearly 
associations with CD to the IL-23 axis, there are indications that the functions of this 
cytokine axis are diverse and not restricted to Th17 regulation. Indeed, studies in mice 
have revealed an important role for IL-23 in protection against infection, including 
ensuring optimal neutrophil recruitment and bacterial clearance in response to infection 
with Listeria monocytogenes (133). 
1.2.4 Immunodeficiency 
It was first recognised in the 1970s that CD may arise from an immune deficiency state, 
characterised by an impaired acute inflammatory response.  Early studies demonstrated 
this phenomenon using ‘skin windows’: small dermal abrasions that permit in vivo 
assessment of acute inflammation. Neutrophil accumulation into skin windows was 
found to be dramatically impaired in CD patients (134). More recently, the impaired 
neutrophil recruitment was also shown to occur in the bowel, using a novel ‘serial 
biopsy’ technique, where paired samples were taken from same area of normal rectal or 
ileal mucosa at baseline (to initiate an acute inflammatory response) and 6 hours 
subsequently (135). Although a deficient immune response may at first seem 
incompatible with the chronic inflammatory state that characterises CD, it was 
postulated that a sub-optimal acute inflammatory response would lead to impaired 
clearance of bacteria from the bowel wall. The persistence of this material could trigger 
43
  
an adaptive immunological response, which would ultimately result in the development 
of chronic inflammation, and constitutional symptoms.  
Recently, this hypothesis was investigated experimentally by subcutaneous 
injection of killed E. coli into the forearms of patients with CD and controls. In healthy 
control subjects, a dramatic increase in local blood flow at inoculation sites was 
observed, as determined using laser Doppler scanning. This response was grossly 
attenuated in CD patients, indicating an underlying weak acute inflammatory response. 
Accumulation of 
111
indium labelled neutrophils to these sites was also impaired in CD, 
in concordance with the previous findings in skin windows. To determine whether this 
affected bacterial clearance, an additional set of experiments were performed, in which 
the bacteria were labelled with 
32
P, and the rate of disappearance of radioactivity from 
the injection sites determined. Clearance was found to be dramatically slower in CD 
patients compared to controls. Extrapolation of clearance curves to a point where 99% 
of the inoculated material would be cleared predicted total clearance times of 44.3 days 
in CD patients, compared to 10.2 days in healthy control individuals (136). 
Importantly, the defects in neutrophil accumulation and bacterial clearance were 
demonstrated in patients with inactive CD, and were not apparent in patients with other 
chronic inflammatory conditions, such as inactive UC, indicating that the phenomenon 
is not simply a consequence of a chronic inflammatory state (134-136). Although one 
study demonstrated the presence of serum chemotaxis inhibitors in CD that were 
purported to explain the observation of impaired neutrophil recruitment (137), active 
patients were investigated in this study, and inhibitors were also found in patients with 
UC, suggesting that this is not likely to be the underlying mechanism, at least in patients 
with quiescent CD. 
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In support of the immunodeficiency hypothesis, patients with congenital, 
monogenic disorders of phagocyte function frequently develop non-infectious bowel 
inflammation that is markedly similar to CD. Chronic granulomatous disease (CGD) is 
one such disorder, which is characterised by defective killing and digestion of bacteria 
by neutrophils, as a result of mutations in NADPH oxidase (138). Approximately half of 
these patients develop bowel inflammation in the absence of a demonstrable microbial 
infection, which is clinically and histopathologically indistinguishable from the 
inflammation that occurs in CD (139). In addition, strong associations between other 
monogenic disorders of neutrophil function and CD-like enteritis have been highlighted 
in recent reviews. Mutations in single genes can result in failure of neutrophil 
production and accumulation (congenital neutropenias and leukocyte adhesion 
deficiency), impaired digestion (glycogen storage disease 1b) and aberrant vesicle 
trafficking and phagolysosomal fusion (Chediak-Higashi and Hermansky-Pudlak 
syndrome), all of which result in a grossly impaired innate immune response to bacteria. 
The observation of non-infectious bowel inflammation in a substantial proportion of 
these patients bolsters support for a model of CD pathogenesis in which innate 
immunodeficiency and defective clearance of bacteria plays a critical role (140). In 
contrast, primary and secondary adaptive immunodeficiency disorders do not appear to 
be strongly associated with CD, with the possible exceptions of common variable 
immunodeficiency syndrome and Bruton’s agammaglobulinaemia, where B cell and 
antibody dysfunction predominate (141). 
The concept that CD involves an attenuated initial innate immune response is in 
also in keeping with the histopathological features of CD, especially the observation of 
granulomatous inflammation. Granulomata are frequently observed in CD lesions; a 
recent meta-analysis of 21 studies reported that 47.0% of CD patients have 
demonstrable granulomata (142). In fact, the true proportion of patients may well be 
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even greater than this, as illustrated by a comprehensive step sectioning study of 
surgically resected intestines from CD patients, which demonstrated the presence of 
granulomata in all individuals (143).  
Granulomatous inflammation is a characteristic immunological response 
following exposure to antigens that are inadequately cleared by innate immune cells, 
such as the bacterium Mycobacterium tuberculosis, and functions to contain the 
material and prevent further dissemination (144). Whilst certain stimuli may inevitably 
trigger granulomata formation in a host, in other cases defective phagocyte function 
may be the critical precipitant, such as in patients with CGD. These individuals develop 
granulomatous inflammation in response to relatively non-pathogenic stimuli such as 
coagulase negative staphylococci (145;146) It is conceivable that in CD, inadequate 
neutrophil influx to sites of bacterial ingress in the bowel, and defective clearance of 
this material, could be followed by granuloma formation as a subsequent compensatory 
response. 
Although there are few animal models that convincingly describe colitis 
occurring in conjunction with innate immunodeficiency, a number of mouse models 
support a role for defective phagocyte function in the generation of intestinal 
inflammation and merit discussion here. Mice with targeted deletions of STAT3 are one 
such example, where impaired innate immune function, including reduced NADPH 
oxidase activity, was demonstrated. Interestingly, these mice had histopathological 
features reminiscent of CD, with transmural inflammation and granuloma formation 
(147). Additionally, mice with certain innate immune defects may have a more severe 
phenotype in dextran sodium sulphate (DSS) induced models of colitis. Of particular 
note, mice deficient in Toll-like receptor 4 (TLR4), a key pathogen pattern recognition 
receptor (PRR) of the innate immune system, have earlier and more pronounced 
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gastrointestinal bleeding than wild type mice after administration of DSS. Interestingly, 
this coincides with increased bacterial translocation and impaired neutrophil recruitment 
(148). 
Recent GWAS have highlighted associations with variants in genes with roles in 
innate immune function, including NOD2, ATG16L1 and IRGM (116). These 
associations add credence to the concept that CD involves impaired innate immunity, 
and are discussed in more detail in section 1.4. 
If CD arises from a systemic defect in innate immunity, one might expect 
patients to manifest increased susceptibility to infection. This may well be the case, and 
several studies have reported higher incidences of acute gastroenteritis (149) and 
urinary tract infection (150) in patients with CD. However, larger scale studies are 
required to confirm this finding, which must take into account important confounding 
factors such as surgery, malnutrition and use of immunosuppressant medication 
(80;136). Another important consideration is bacterial load – most acute infections arise 
from the multiplication of a small number of initial inoculating organisms, which even 
the partially attenuated immune response in CD may be able to control. In contrast, the 
terminal ileum and colon contain a large number of bacteria (approximately 10
8
/g and 
10
11/g respectively, which could potentially ‘overwhelm’ the impaired clearance 
mechanisms. Interestingly, subcutaneous injection studies revealed that the defective 
clearance of 
32
P labelled E. coli was dose-dependent. At lower doses of bacteria (10
6
 or 
less), clearance of bacteria was normal in CD, whereas at larger doses, grossly delayed 
clearance was observed (136). 
1.2.5 Integrated models of Crohn’s disease pathogenesis 
Given the various strands of supportive evidence for each theory, it is possible that 
mucosal barrier dysfunction, the balance of the intestinal microflora, innate 
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immunodeficiency and chronic inflammation act together in CD pathogenesis to 
generate lesions and constitutional symptoms. Our laboratory has recently proposed a ‘3 
stage model’ of the disease pathogenesis, whereby CD occurs in three temporally 
distinct stages. The first of these is ingress of bacteria and/or antigenic material into the 
bowel wall, potentially enhanced by an underlying abnormality in the mucosal barrier. 
In stage 2, innate immunodeficiency results in impaired clearance of this material. 
Chronic granulomatous inflammation and adaptive immune responses are subsequently 
provoked in stage 3, culminating in the development of CD (Figure 1.3) (151).  
1.3 Impaired acute inflammation in Crohn’s disease 
1.3.1 Acute inflammation and the role of macrophages 
Acute inflammation is a generic mechanism by which the body responds to infection, 
trauma and other potentially harmful stimuli, and is associated with the cardinal signs of 
heat, redness, swelling, pain and loss of function. The acute inflammatory process is 
associated with various cellular events, the most striking of which is recruitment and 
infiltration of neutrophils and monocytes to the inflammatory site, which enables killing 
and clearance of microorganisms and removal of harmful material. Initially, neutrophils 
are recruited to sites of inflammation, which peak between 4 and 6 hours after an insult. 
Subsequently, the number of infiltrating mononuclear cells rises, reaching a peak at 18 
to 24 hours (152). 
Acute inflammation may be initiated by a number of mechanisms, including 
triggering of the complement cascade by microbial components or antibody, and by 
recognition of stimuli by resident cells such as macrophages. Subsequently various 
important mediators of inflammation, including pro-inflammatory cytokines, 
chemokines, nitric oxide, histamine and lipids such as leukotrienes and prostaglandins 
act to promote and propagate the acute inflammatory response (153). A number of these  
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Figure 1.3 Three stage model for the pathogenesis of Crohn's disease. Penetration of 
luminal contents occurs in stage 1, via paracellular and transcellular pathways, 
facilitated by an abnormal mucosal barrier. In stage 2, healthy indviduals mount a 
strong acute inflammatory response, characterised by neutrophil accumulation and 
clearance of material. In CD patients, neutrophil influx is defective as a consequence 
of impaired macrophage function, resulting in impaired bacterial clearance. This acts 
as a trigger for stage 3 (compensatory adaptive responses), which leads to chronic pro-
inflammatory cytokine secretion and the development of the CD lesion.
Adapted from (151).
Increased gut permeability
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trigger changes in the vasculature, including vasodilatation, alterations in permeability 
and upregulation of adhesion molecules, which facilitate the recruitment of leukocytes 
to the inflammatory site. Recruitment of leukocytes such as neutrophils is a tightly 
regulated, multistep process that involves successive interactions between leukocytes 
and endothelium (154). Initially, neutrophils interact loosely with endothelial cells via 
selectins (155). Subsequently, activation of neutrophils enables integrin-dependent, 
stable interactions to occur with the endothelium, allowing extravastation through the 
endothelium to sites of acute inflammation, down a chemoattractant gradient (155;156).  
In the subsequent days and weeks, the inflammation may resolve in a co-
ordinated fashion, in a process that involves apoptosis of neutrophils and their clearance 
by macrophages (157;158). This may trigger an alteration in macrophage cytokine 
production, whereby release of IL-1β, IL-8 and IL-10 is inhibited and production of 
transforming growth factor-β (TGF-β), a critical cytokine in wound healing, is increased 
(159;160). Various lipid mediators such as lipoxins have a pivotal role at this stage of 
inflammation (161). Alternatively, the inflammation may not resolve and progress to a 
chronic inflammatory state. Clearly, whether or not inflammation persists could well be 
dependent on both the adequacy of the acute inflammatory response to clear material, as 
illustrated by granulomatous conditions such as tuberculosis, CGD and CD, and on the 
resolving mechanisms, as illustrated by UC, where bacterial clearance is normal but 
persistent, non-resolving inflammation is observed (162;163). 
Phagocytic cells, including neutrophils and macrophages, play a pivotal role in 
acute inflammation. Macrophages differentiate from circulating peripheral blood 
mononuclear cells (PBMCs), which migrate into tissues in both the steady state and in 
response to inflammatory stimuli (164;165). Their key functions include sensing of 
microbial stimuli, phagocytosis, antigen presentation and pro-inflammatory cytokine 
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secretion. In later stages, macrophages also have a critical role in resolution of the 
inflammatory response, maintenance of tissue homeostasis and promotion of wound 
healing.  
Macrophages express a rich array of receptors that enable microbe detection. 
These receptors are located in the plasma membrane, cytosol and vacuolar 
compartments, thereby facilitating recognition of both extracellular and intracellular 
pathogens. Toll-like receptors (TLRs), Nod-like receptors (NLRs) and C-type lectin 
receptors, termed pattern-recognition receptors (PRRs) because of their ability to sense 
pathogen-associated molecular patterns (PAMPs), are critically important in the sensing 
of microbial components and induction of innate immunity (166). TLRs are type I 
transmembrane receptors that contain an extracellular leucine-rich repeat domain and an 
intracellular Toll / IL-1 receptor (TIR) domain (167;168). Their role in innate immunity 
was originally discovered in Drosophila (169), and following this human homologs of 
Drosophila Toll were identified (170), which have similarly important immunological 
functions. 
Mammalian species have at least 10 different TLRs; each recognising specific 
microbial components. Key TLRs involved in the recognition of bacterial stimuli 
include TLR2, TLR4, TLR5 and TLR9. TLR2 recognises a range of ligands including 
lipoteichoic acid, peptidoglycan and a synthetic tripalmitoylated lipopeptide (N-
palmitoyl-S-[2,3-bis(palmitoyloxy)-propyl]-(R)-cysteinyl-(lysyl)3-lysine (Pam3CSK4)). 
This broadness in specificity may be partly enabled by the ability of TLR2 to form 
heterodimeric complexes with both TLR1 and TLR6 (166;171). TLR4 functions as the 
receptor for lipopolysaccharide (LPS) (172), a component of Gram negative bacteria, 
and TLR5 is involved in recognition of flagellin, a protein found in bacterial flagella 
(173). In contrast, TLR9 recognises unmethylated CpG motifs in bacterial DNA (174). 
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Engagement of ligand with TLR results in activation of downstream signalling 
transduction pathways. Depending on the specific TLR, these may involve the myeloid 
differentiation primary response protein 88 (MyD88) adaptor (MyD88-dependent 
signalling), or other adaptors such as TIR domain-containing adaptor inducing IFN-β 
(TRIF) (175). Activation of downstream signalling cascades leads to induction of pro-
inflammatory cytokines and chemokines, which are critical in the initiation of an acute 
inflammatory response and leukocyte recruitment (170).  
Whilst macrophages clearly have a generalised role in orchestration of acute 
inflammatory responses, it is well recognised that the phenotype and function of both 
monocytes and macrophages is heterogeneous and dependent on the stimuli received 
from the surrounding environment. Treatment of macrophages with IFN-γ increases 
their microbicidal activity, and the levels of secreted pro-inflammatory cytokines such 
as IL-12, TNF and IL-23 (176;177). On the other hand, exposure of macrophages to 
cytokines such as IL-4 and IL-13 results in ‘alternative activation’. Alternatively 
activated macrophages are characterised by high release of IL-10 and IL-1 receptor 
antagonist, and expression of distinctive markers such as CD163 and scavenger 
receptors; they may have roles in tuning inflammatory responses, wound healing and 
angiogenesis (177;178). They may also be involved in the response to helminths. This 
distinction has led to the concept of M1 (classically activated) and M2 (alternatively 
activated) macrophages, although it is increasingly recognised that the macrophage 
phenotype may be more of a ‘continuum’, with M1 and M2 representing extremes of 
phenotype and opposite ends of a spectrum (178). 
1.3.2 Mechanism of impaired neutrophil recruitment in Crohn’s disease 
Although neutrophil accumulation to sites of acute inflammation is defective in CD, in 
the majority of patients, various parameters of neutrophil function appear normal. No 
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differences were observed in the chemotactic response of CD neutrophils ex vivo (179), 
and random motility of CD neutrophils was found to be normal in another study (180). 
Investigations of the neutrophil respiratory burst in CD yielded somewhat 
conflicting results, with some studies demonstrating increased or normal respiratory 
burst while others showed a reduction (181-184). A more recent study conducted in our 
laboratory using a large cohort (n=100) of quiescent patients demonstrated a modest 
(but statistically significant) reduction in superoxide generation in response to 
stimulation with phorbol-12-myristate-13-acetate (PMA) in the CD cohort compared to 
controls. However, as digestion of 
35
S-methionine-labelled E. coli was shown to be 
normal in the majority of patients, the biological or pathogenic significance of the 
decreased respiratory burst may be minimal. In spite of this, the study did highlight 
three patients with congenital disorders of neutrophil function and concurrent CD, in 
whom both the respiratory burst and bacterial digestion were shown to be defective 
(185). In one of these patients, a mutation in glucose-6-phosphatase catabolic-3 
(G6PC3) was demonstrated, with concurrent effects on N- and O- linked glycan 
synthesis and glycosylation of gp91 phox, a component of NADPH oxidase (186). 
 If the majority of patients with CD do not have an inherent defect in neutrophil 
function, why is neutrophil recruitment to sites of inflammation so dramatically 
impaired? It was postulated that an underlying defect in macrophages could be 
responsible for the impairment in acute inflammation. Macrophages cultured from 
quiescent CD patients showed decreased production of interleukin-8 (IL-8) in response 
to stimulation with C5a, wound fluid and TNF (135). Furthermore, in response to 
stimulation with heat-killed E. coli (HkEc), CD macrophages released deficient levels 
of a range of pro-inflammatory cytokines in comparison to healthy control (HC) cells, 
including TNF, IL-4, IL-5, IL-13, IL-15 and IFN-γ. In response to HkEc, no difference 
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was observed in the secreted levels of the chemokines IL-8, IP-10 and RANTES, or in 
the release of the anti-inflammatory cytokines IL-10 and IL-1Ra (136). The release of 
TNF from CD macrophages was compared with HC macrophages at 4 hours, 6 hours 
and 24 hours after stimulation with HkEc. TNF reached maximal secretion within 6 
hours in HC and CD cells. Depressed levels of TNF release from CD macrophages were 
observed all time points, suggesting that the impairment in pro-inflammatory cytokine 
release is absolute and not the result of delayed kinetics. The finding of impaired TNF 
release from CD macrophages was also replicated in a recent study that used live E. coli 
and MAP as stimuli. However, diminished IL-10 release and increased IL-23 secretion 
were also found. It is possible that this could be an effect of disease activity, as no 
reference was made as to whether patients included in this study were in remission or 
had active disease (187). 
1.3.3 Mechanism of defective macrophage cytokine secretion in Crohn’s disease 
Interestingly, the defect in pro-inflammatory cytokine release did not appear to arise 
from abnormal control of cytokine gene transcription. Microarray analysis of the gene 
transcription profiles of HC and CD macrophages revealed equivalent levels of pro-
inflammatory cytokine mRNA after stimulation with HkEc; a finding that was 
confirmed by quantitative PCR. Furthermore, in spite of the impaired release, no 
difference in TNF mRNA stability was observed between HC and CD macrophages. 
The defect also did not appear to relate to a difference in M1/ M2 macrophage 
populations. Initial M1 (CD14
+
CD16
-
) and M2 (CD14
+
CD16
+
) monocyte populations 
were similar between HC, CD and UC patients, and mRNA levels of maturation 
markers F4/80, L-selectin and ICAM-1 were similar after in vitro differentiation (136). 
 However, the impaired release in pro-inflammatory molecules from CD 
macrophages appeared to be due to an underlying defect in vesicle trafficking. The 
54
  
amounts of intracellular cytokines, including TNF were investigated by western 
blotting. Reduced amounts of intracellular cytokines were found in CD macrophages 
compared to HC; however incubation with brefeldin-A, an inhibitor of protein 
translocation from the endoplasmic reticulum (ER) to the Golgi apparatus, resulted in 
normalisation to equivalent levels between HC and CD cells. This suggested that there 
was no abnormality in cytokine gene translation; rather the defect must lie in the post-
translational trafficking of cytokines for secretion (136). 
 The role of the lysosome in intracellular cytokine trafficking was investigated by 
inclusion of monensin and chloroquine during macrophage HkEc stimulation. 
Chloroquine is a weak base that partitions into acidic compartments and elevates the 
pH, whereas monensin acts as a sodium-proton ionophore; both however have the 
consequence of inhibiting lysosomal function. In CD macrophages, incubation with the 
lysosomal inhibitors significantly increased the levels of intracellular cytokines, which 
did not occur in HC cells. Overall, these observations suggest that in CD macrophages, 
a trafficking defect results in mistargeting of pro-inflammatory cytokines to lysosomal 
compartments, where they are degraded rather than released through the normal 
secretory pathway. Interestingly, lysosomal, rather than proteasomal degradation of 
proteins appeared to be the central to the impairment in cytokine secretion, as 
incubation of cells with MG132 (a proteasomal inhibitor) was without effect (136). 
However, the molecular basis of this abnormality remains uncharacterised. 
1.3.4 Pathways of cytokine secretion and relevance to CD 
The process of cytokine secretion is highly regulated and is thought to proceed through 
a number of distinct pathways. The pathways utilised differ for individual cytokines and 
vary between cell types. Certain cytokines are thought to be secreted primarily via the 
classical ‘canonical’ secretory pathway, whereas others (such as IL-1β) are secreted by 
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alternative, unconventional pathways. In some situations, cytokines are also packaged 
into granules following processing in the Golgi complex, where they are stored until 
appropriate signals for release are received (188;189). 
 The canonical secretion pathway commences with protein synthesis in the ER, 
where proteins are appropriately folded and quality checked. Proteins are subsequently 
loaded onto vesicles for transport to the Golgi apparatus. In the Golgi apparatus, 
proteins are further modified and glycosylated before reaching the Trans-Golgi network 
(TGN), the last station in the Golgi complex. After the TGN, a diverse range of vesicles, 
carrier proteins and organelles transport proteins to the cell surface membrane, where 
they are released from the cell by exocytosis (188;189). In specialised cells such as 
macrophages, components of these pathways can be upregulated upon cell activation to 
increase the trafficking of proteins such as cytokines, thereby promoting their release. 
Many studies directed towards characterising the molecular mechanisms of 
cytokine secretion have focused on the control of TNF secretion from cell lines such as 
RAW cells (a murine macrophage cell line). TNF is synthesised as a 26kDa precursor 
molecule in the endoplasmic reticulum and in most situations is released via the 
canonical pathway. TNF is delivered via recycling endosomes to the cell surface, where 
the transmembrane precursor is cleaved by TNF converting enzyme (TACE), to release 
from the cell a 17 kDa protein, which acts in a paracrine manner (190). It is generally 
accepted that the majority of cells are not able to pre-store TNF in granules to any 
significant degree, with the exception of mast cells, which are able to direct TNF 
towards granules in a mannose-6-phosphate receptor dependent (MPR) pathway, and 
release it upon mast cell degranulation (191;192). 
TNF trafficking from the TGN to the plasma membrane in macrophages is 
dependent on a number of molecules. At the TGN, p230, a trans-Golgi network golgin 
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that labels a subset of tubulovesicular structures, is required in the first steps of TNF 
secretion (193). TNF is transported from the TGN to recycling endosomes through a 
complex of Soluble NSF Attachment protein receptor (SNARE) proteins, which 
includes syntaxin 6 and Vti1b (194) . Recycling endosomes appear to have a critical 
role for subsequent delivery of TNF to the plasma membrane, as demonstrated by recent 
studies. TNF was shown to colocalise with the transferrin receptor and the SNARE 
protein vesicle-associated membrane protein 3 (VAMP3), both of which are markers of 
the recycling endosome, and expression of a dominant negative Rab11 protein (another 
recycling endosomal marker) resulted in impaired delivery of TNF to the cell surface 
(194). TNF is subsequently delivered to cholesterol-dependent lipid rafts on the plasma 
membrane, especially concentrated around phagocytic cups (195). 
In addition to the vesicle trafficking proteins, a number of other intracellular 
components are essential for efficient post-Golgi trafficking of TNF. The first is an 
intact cytoskeleton, as agents such as nocodazole and cytochalasin D, which disrupt 
microtubules and F-actin filaments respectively, inhibit TNF secretion in RAW 
macrophages (196). The second is appropriate membrane lipid composition, which will 
be governed by the rate of synthesis of lipid species, relative to how rapidly they are 
broken down. The balance of sphingolipids, phospholipids and cholesterol within a 
membrane can affect its ability to fuse (‘fusogenicity’), as well as membrane budding 
and fission, thereby exerting a strong influence on intracellular vesicle trafficking. This 
is discussed in more detail in chapter 4. Of particular note, one study recently 
demonstrated the importance of phosphatidylcholine, an abundant phospholipid in 
eukaryotic membranes, in the secretion of TNF. Cells that are deficient in CTP: 
phosphocholine cytidylyltransferase (CCT), an enzyme that catalyses the rate limiting 
step in phosphatidylcholine biosynthesis, show an interesting parallel to CD 
macrophages in that they secrete deficient levels of TNF compared to wild type cells 
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upon activation. Although the synthesis of TNF appeared to be unaffected in these cells, 
confocal microscopy revealed retention of TNF within the Golgi apparatus, explaining 
the impaired release into the medium. This phenomenon was found to be relevant in 
vivo, as CCT knockout mice developed a more diffuse pneumonia after inoculation with 
Streptococcus pneumoniae, and a higher mortality rate compared to wild type mice 
(197). 
The intracellular trafficking of other cytokines is generally less well 
characterised than for TNF, however it is appreciated that other cytokines may be 
secreted by distinct mechanisms. IL-6, another important pro-inflammatory cytokine, 
also requires recycling endosomes for its secretion, but distinct subcompartments from 
those utilised by TNF  (198). Other cytokines such as IL-1β are thought to be released 
through alternative, non-canonical pathways. IL-1β is released independently of the ER 
and the Golgi apparatus, in a process that may depend on membrane-derived 
microvesicles. At some point between the synthesis of IL-1β on free ribosomes and its 
release, cleavage of pro-IL-1β by caspase-1 occurs, enabling the mature form of IL-1β 
to be released (188). This processing is in turn dependent on inflammasome assembly 
and activation. Inflammasomes are multiprotein complexes, activated upon infection or 
cellular stress, that mediate caspase-1 dependent processing of pro-inflammatory 
cytokines (199). Genetic variation in NLR family, pyrin domain-containing 3 (NLRP3), 
a component of the NLRP3 inflammasome, has been associated with CD (200), 
suggesting a possible relevance to the disease pathogenesis. However, the associations 
have not been universally replicated in other cohorts (201). 
Certain cytokines may be released by multiple mechanisms, for example in the 
case of IL-15, which is primarily understood to traffic via the canonical pathway in 
complex with its high affinity receptor subunit, IL-15Rα (202). However, monocytes 
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express IL-15 at the cell surface independently of the IL-15Rα, suggesting contributions 
from non-canonical pathways in IL-15 release in these cells (203). 
An unanswered question is the degree to which these pathways overlap between 
different immune cell types, for example macrophages and lymphocytes. In addition, as 
many studies of cytokine trafficking have utilised cell lines and animal models, the 
relevance to primary human macrophages is unclear. Nevertheless, given the prominent 
defect in pro-inflammatory cytokine secretion observed in CD macrophages, which 
appears to relate to an underlying defect in vesicle trafficking, such studies may point to 
interesting candidate molecules that warrant further investigation. The contribution of 
any of these molecules to the impairment in cytokine secretion observed in CD is as yet 
undetermined. Of note, a number of lines of evidence suggest abnormal fatty acid and 
lipid compositions in CD, which could exert strong effects on vesicle trafficking in 
macrophages, as discussed in chapter 4. In addition, GWAS have indicated associations 
with a number of genes that have roles in autophagy and intracellular trafficking, 
including ATG16L1 and IRGM (discussed in detail in section 1.4). It is also possible 
that polymorphisms in these genes influence disease pathogenesis by interfering with 
intracellular trafficking and secretion of pro-inflammatory cytokines in macrophages. 
1.3.5 Other macrophage defects in Crohn’s disease 
The macrophage defects in CD may not be restricted to abnormal pro-inflammatory 
cytokine secretion alone. A recent study conducted in our laboratory demonstrated 
defective apoptosis of macrophages in CD after stimulation with the phorbol ester 
PMA. This was shown to relate to impaired mitochondrial depolarisation and 
cytochrome c release on stimulation with PMA. Given the prominent role for both 
neutrophil and macrophage apoptosis in the resolution of inflammation (204), it is 
plausible that the increased resistance of CD macrophages to apoptosis leads to their 
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persistence in inflamed bowel tissue. This would prolong cytokine secretion and result 
in persistent, non-resolving inflammation and thus promote the development of CD 
lesions. The same study also demonstrated diminished generation of H2O2 in 
macrophages upon activation with PMA, although this did not appear to mechanistically 
relate to the impairment in apoptosis (205). It is likely that defective apoptosis could 
represent a more general phenomenon in CD, as neutrophils (206) and lamina propria T 
cells (207) also display abnormalities in this process. 
Interestingly, the monoclonal antibody infliximab, a widely utilised drug in the 
management of CD, has been proposed to exert its beneficial effects by cross-linking of 
membrane bound forms of TNF and stimulation of leukocyte apoptosis within the 
lamina propria (208). This substantiates a possible role for abnormal apoptosis in CD 
pathogenesis, and furthermore indicates that the mechanism of action of the anti-TNF 
agents may be indirect, rather than inhibition of TNF per se. 
1.3.6 Macrophage function in ulcerative colitis 
In contrast to CD, monocyte-derived macrophages from UC patients were found to 
release normal levels of TNF and IFN-γ after stimulation with HkEc. After stimulation 
with HkEc and LPS, UC macrophages were shown to release increased amounts of 
CXCL10, RANTES and IL-12p70. After TLR4 stimulation, secreted levels of IFN-β 
were also found to be significantly increased, relating to overactivation of the TLR4-
TRIF signalling pathway (163). 
The elevation in pro-inflammatory cytokine release may account for the 
impaired resolution of inflammation in UC patients observed after subcutaneous 
injection of HkEc (135;162;163). These findings further highlight the fact that UC and 
CD are distinct disease entities, with different underlying immunological abnormalities 
and pathogenetic mechanisms. Interestingly, specific ‘probiotic’ bacteria (Lactobacillus 
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casei) have been shown to inhibit CXCL10 secretion by inhibiting vesicular pathways 
involved in its release, which may explain the protective effect of VSL#3 in murine 
models of bowel inflammation (209). This could indicate that certain probiotics may be 
of clinical benefit in patients with UC. 
1.4 Genetic factors in Crohn’s disease and their relationship to impaired acute 
inflammation 
If CD arises from a systemic defect in acute inflammation, one would predict certain 
sequence variants in genes with roles in innate immune function to confer susceptibility 
to CD. Recently, considerable advances have been made in understanding genetic loci 
that are associated with CD, and a number of these contain genes with known or 
predicted roles in innate immunity. Initially, linkage analysis in familial cases of CD 
and positional cloning strategies identified a number of important susceptibility loci. 
More recently, the advent of the Human Genome and International HapMap projects, 
coupled with recent technological advances have enabled GWAS to be conducted in CD 
and other complex disorders. In such studies, genotyping of up to one million selected 
SNPs is performed in thousands of cases and controls in a high throughput manner 
using whole genome microarrays. For each SNP, the allele frequency in cases and 
controls is compared to identify disease­associated polymorphisms. Whilst GWAS are 
regarded as ‘hypothesis-generating’, it should be noted that they are conducted under a 
‘common disease, common variant’ hypothesis, in which much of the genetic variation 
of a common complex disease is assumed to be due to relatively few common variants 
(210). 
1.4.1 NOD2 
NOD2 was the first gene to be discovered that confers susceptibility to CD. The IBD1 
susceptibility locus, containing several genes including NOD2, was first discovered in 
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1996 by two point sib-pair linkage analysis in families affected with CD (25). It was not 
until five years later that NOD2 was identified as the relevant gene, using positional 
cloning strategies, DNA sequencing and case-control analysis. Three CD-associated 
single nucleotide polymorphisms (SNPs) were identified in NOD2 (SNP8, SNP12 and 
SNP13), two of which result in substitutions of single amino acids (R702W and G908R) 
in the leucine-rich repeat domain of the protein. The other polymorphism (SNP13) is a 
frameshift alteration (1007fs) that generates a premature stop codon, predicted to result 
in a truncated protein (211;212). Individuals that are heterozygous for one of the 
polymorphisms have a 2-4 fold increased risk of developing CD, and those that are 
homozygous or compound heterozygous a 20-40 fold elevated risk (213). 
The NOD2 protein is a PRR that is expressed in mononuclear phagocytes, 
epithelial cells and Paneth cells. Although LPS was originally thought to be the ligand 
for NOD2, it was subsequently shown that muramyl dipeptide (MDP), a component of 
bacterial peptidoglycan, is the specific agonist (214). Sensing of MDP by NOD2 results 
in activation of downstream signalling pathways, including NF-κB activation and 
ultimately pro-inflammatory cytokine gene transcription. The three CD-associated SNPs 
result in loss of function and impaired induction of pro-inflammatory cytokines 
(including IL-8, TNF and IL-1β) in response to MDP (135;215). Such a finding is 
consistent with an immunodeficiency model of CD, where defective macrophage 
function results in delayed neutrophil recruitment and impaired clearance of material. 
Although the deficit in acute inflammation in CD did not appear to relate to the 
presence of NOD2 polymorphisms, addition of exogenous MDP to skin windows 
increased levels of pro-inflammatory mediators. This did not occur in patients 
homozygous for polymorphisms in NOD2, in whom MDP was without effect. It was 
therefore postulated that NOD2 may play a compensatory role in boosting the acute 
62
  
inflammatory response to bacteria in vivo, an ability that is abolished in a subset of CD 
patients in whom NOD2 polymorphisms are present (135). 
In spite of this, the overall impact of NOD2 polymorphisms on inflammation 
remains an area of contention. NOD2 has been suggested to downregulate TLR2 
responses in mice, thereby exerting anti-inflammatory effects (216). Defective release 
of the anti-inflammatory cytokine IL-10 has been demonstrated in CD patients with 
NOD2 variants, and a recent study suggested that the frameshift mutation may in fact 
exert a ‘gain of function’, inhibiting phosphorylation of the nuclear riboprotein hnRNP-
A1 and actively suppressing IL-10 transcription. This effect was not observed for wild 
type NOD2 (217). There is also evidence to suggest that NOD2 could have a role in 
maintenance of mucosal barrier function. NOD2 variants have been associated with 
increased ileal permeability (218). Furthermore, abnormalities in the NOD2 pathway 
may also result in to abnormal expression of human β-defensin, an important 
antimicrobial component of the mucosal barrier (219). NOD2 may also have a role in 
autophagy, as discussed in section 1.4.3. Therefore, the precise role of NOD2 in the 
pathogenesis of CD may well be complex. 
1.4.2 IBD5 
The IBD5 locus was originally discovered in a genome-wide scan of 158 Canadian sib-
pair families with early-onset disease (220). It is located in the chromosome 5q31-q33 
region, and it appears that the presence of a specific haplotype confers susceptibility to 
CD. The underlying pathogenic variant in this region remains much debated, and strong 
linkage disequilibrium exists with a cytokine cluster (221). However, a putative 
candidate is the OCTN gene, which is involved in carnitine transport (222). L-carnitine 
in turn contributes to the transport of long chain fatty acids into mitochondria for β-
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oxidation. OCTN variants associated with CD may act to impair L-carnitine transport 
(222), and thus potentially β-oxidation of fatty acids. 
1.4.3 ATG16L1, IRGM and autophagy 
In 2007, three independent GWAS identified a polymorphism in the autophagy-related 
16-like 1 (ATG16L1) gene that is strongly associated with CD (116;223;224). The 
associated variant in ATG16L1 was reported to be a nonsynonymous SNP, resulting in a 
threonine to alanine substitution (T300A) in the ATG16L1 protein. Individuals 
homozygous for the risk allele have an approximately 1.65 fold increased risk of CD, 
and 2.2 fold increased risk of ileal disease (225). The WTCCC study also reported two 
other CD-associated SNPs in the chromosomal region 5q33.1, located in close 
proximity to the immunity-related GTPase family, M (IRGM) gene (130). The 
association was subsequently replicated in a number of independent cohorts (226;227). 
The polymorphisms identified were not located within the coding region of the IRGM 
gene itself, and resequencing of IRGM in 248 individuals revealed only three coding 
sequence variants, one of which was a synonymous SNP and the remaining two were 
not associated with CD (226). It was therefore postulated that the SNPs might influence 
the expression of IRGM. In a subsequent study, a deletion haplotype was discovered to 
be in perfect linkage disequilibrium (r
2
=1.0) with rs13361189, one of the original SNPs 
identified, which was shown to give rise to differential IRGM expression (228). More 
recently, a potential effect of the synonymous SNP on gene expression was also 
demonstrated. This exonic variant is a target for a family of microRNAs (miR-196), 
which are capable of downregulating IRGM expression. Under inflammatory 
conditions, downregulation of risk variant IRGM by miR-196 was reported to be 
impaired in comparison to wild type IRGM (229). 
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 ATG16L1 and IRGM are understood to have functional roles in autophagy. 
Autophagy refers to any intracellular degradative pathway that involves delivery of 
cytoplasmic cargo to lysosomal compartments. Three forms of autophagy are 
recognised – macroautophagy, microautophagy and chaperone-mediated autophagy 
(230). Macroautophagy has a role in the degradation of intracellular organelles and 
cytosolic proteins, involving the formation of a double membrane structure (‘the 
autophagosome’) to initially sequester this material. Subsequently, the autophagosome 
fuses with lysosomes which results in degradation of material. Microautophagy, in 
contrast, does not require autophagosome formation; instead material is initially 
engulfed and sequestered by the lysosomal membrane itself. Chaperone-mediated 
autophagy is involved in selective degradation of cytosolic proteins and occurs 
independently of vesicle trafficking (231). Autophagy is a tightly regulated process, and 
upregulation occurs upon starvation, ER stress and cellular activation. 
 Of potentially greater relevance to CD, autophagy may also have a role in 
bacterial clearance and the immune response to bacteria (232). Activation of PRRs such 
as TLRs and NLRs and their downstream signalling cascades induces autophagy. 
Furthermore, induction of autophagy pathways via TLR signalling during phagocytosis 
results in enhanced phagolysosomal fusion and destruction of intracellular microbes in 
macrophages (233). Autophagy has also been shown to be important for antigen 
processing and major histocompatibility complex (MHC) class II presentation in 
dendritic cells, thereby influencing CD4
+
 T lymphocyte responses (234). In addition, 
autophagy may have roles in autophagosome-independent destruction of parasite-
derived membranes (such as from Toxoplasma gondii), (235;236) and in pro-
inflammatory cytokine production by PBMCs (237). 
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 At a molecular level, ATG16L1 forms an oligomeric complex with ATG5 and 
ATG12, which is necessary for autophagosome formation. The complex is understood 
to function in elongation of the isolation membrane (a small ‘crescent like’ membrane 
precursor of the autophagosome), possibly by conjugation of microtubule-associated 
protein 1 light chain 3 (LC3) to the phospholipid phosphatidylethanolamine (238). Cells 
deficient in ATG16L1 demonstrate defective autophagy induction in response to a range 
of stimuli, including serum starvation, rapamycin treatment and intracellular Salmonella 
typhimurium (S. typhimurium) infection (223). In cell lines expressing the CD-
associated variant ATG16L1 protein, basal autophagy is equivalent compared to wild 
type cells; however mutant cells were reported to have a reduced efficiency of anti-
bacterial autophagy, as demonstrated by decreased capture of S. typhimurium within 
autophagosomes (239). These findings are in keeping with the concept that clearance of 
foreign material is important in the development of bowel inflammation. 
 Chimaeric mice with a targeted deletion of ATG16L1 in haematopoietic cells 
display defective autophagy, and increased macrophage production of IL-1β in response 
to LPS and E. coli, which was proposed to explain the more severe phenotype in the 
mutant mice after DSS induced colitis. This may result from impaired regulation of 
inflammasome activity (240). The relevance of ATG16L1 and autophagy to CD 
pathogenesis may also extend beyond phagocytes – a recent study investigating mice 
hypomorphic for ATG16L1 expression identified abnormalities in the granule 
exocytosis pathway in Paneth cells – an interesting parallel with the finding of defective 
post-translational trafficking of pro-inflammatory molecules in CD. This study also 
raises the possibility that the product of the ATG16L1 gene could have a more 
generalised role in vesicle trafficking. Transcriptional profiling of ATG16L1 deficient 
Paneth cells revealed abnormal gene expression in a number of pathways that could 
underlie the observed defects in granule exocytosis, including PPAR signalling and 
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lipid metabolism, which may be consequential or compensatory changes in response to 
alterations in ATG16L1 expression or vesicle trafficking (241). 
 Recent investigations have suggested that NOD2 and ATG16L1 may function in 
overlapping pathways. Firstly, MDP has been shown to induce autophagy in a NOD2 
dependent manner in innate immune cells. The MDP-induced autophagy was shown be 
important for bacterial handling and NOD2-mediated antigen presentation, by 
influencing intracellular trafficking and surface expression of MHC class II molecules. 
CD patients with NOD2 or ATG16L1 polymorphisms were shown to have defective 
autophagy in response to MDP, and impaired antigen presentation and CD4+ T cell 
responses after exposure to Salmonella enterica (242). Secondly, ATG16L1 has been 
shown to modulate pro-inflammatory cytokine secretion in response to MDP. Although 
abnormal IL-1β release in response to MDP was not originally observed in ATG16L1 
deficient mice (240), PBMCs from healthy individuals and CD patients carrying the 
T300A polymorphism were shown to secrete increased levels of the pro-inflammatory 
cytokine IL-1β after stimulation with MDP (243). Although interesting, the effect of 
autophagy, and thus possibly ATG16L1 polymorphisms, on cytokine release is likely to 
be complex. Contrasting effects may be observed for different stimuli, cytokines and 
cell types. A recent study revealed that autophagy inhibition in PBMCs using 3-
methyladenine was associated with enhanced IL-1β release, but impaired TNF secretion 
downstream of TLR stimulation (237). It is unknown whether impaired autophagy or 
the presence of ATG16L1 variants could contribute to the defective secretion of pro-
inflammatory cytokines observed in response to HkEc in CD macrophages. 
1.4.4 Other CD-susceptibility loci 
In addition to NOD2, IBD5, ATG16L1 and IRGM, numerous other important 
susceptibility loci have been identified in CD. In 2006, a relatively uncommon coding 
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variant was identified in the IL-23 receptor (IL-23R) gene, which confers strong 
protection against CD (244). Furthermore, a meta-analysis of three GWAS published in 
2008 demonstrated over 30 different CD-susceptibility loci. As well as verifying the 
associations with ATG16L1, IRGM and IL-23R, various novel loci were also identified. 
Some of these contain genes involved in immune system function, and especially the 
Th17 pathway (116). For example, IL-12B, JAK2 and STAT3, all appear to be involved 
in the IL-23 axis, and the regulation of CD4+ T cells that produce high levels of IL-17 
(Th17 cells). Of note, polymorphisms in these genes have also been associated with UC 
(245;246), suggesting possible roles as modifiers of a chronic inflammatory state. A 
more recent meta-analysis has increased the number of CD-susceptibility loci to 71 
(115), again highlighting associations with genes implicated in innate and adaptive 
immunity. 
In addition to the susceptibility loci identified in the GWAS meta-analyses, a 
number of other variants have been associated with CD in smaller scale studies. These 
include a non-synonymous SNP in TLR4 (247), and promoter polymorphisms in the 
TLR9 (248) and CD14 (249) genes, further suggesting that innate immune dysfunction 
could be an important aspect of CD pathogenesis. Additionally, associations have been 
identified with polymorphisms in mucin-encoding genes such as MUC3A (250), and the 
HLA haplotype DRB1*0103 (128;129). The reasons why some of these associations 
have not been convincingly replicated in the GWAS meta-analysis, and various other 
studies, are unclear. It is very possible that some represent false positive discoveries. 
However, another important consideration is the heterogeneity in disease expression 
between patients. Notably, both the TLR4 polymorphism and HLA DRB1*0103 
haplotype have been most strongly associated with colonic disease in some studies 
(251;252). It is possible that the stringent statistical thresholds applied in GWAS could 
preclude identification of subtle differences in the frequencies of variants in certain 
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disease subtypes. Therefore, whilst some of these associations should be interpreted 
with caution, their potential relevance to CD cannot be disregarded. Interestingly, a 
recent GWAS that specifically investigated patients with early-onset IBD identified 
associated variants in loci containing the ZMIZ1, IL27 and HORMAD2 genes (253). 
1.4.5 Limitations of GWAS and ‘Missing heritability’ 
It is incontestable that GWAS have shed considerable light on the genetic architecture 
associated with CD, and have provided some important insights into the mechanisms of 
CD pathogenesis. However, the functional relevance of many of the associated variants 
remains relatively uncharacterised. In addition, it is unclear whether the some of the 
polymorphisms identified indeed represent the true pathogenic variants, or whether they 
are simply ‘proxy markers’ in linkage disequilibrium with a pathogenic variant. As 
discussed, the IRGM variant originally identified was shown to be in linkage 
disequilibrium with an upstream deletion polymorphism, which more likely represents 
the causal variant in this case. Further fine mapping and resequencing of these regions 
may help clarify this issue. 
 It should also be emphasised that the associated variants have a low penetrance 
and a comparatively high frequency in the general population, even in the case of 
NOD2. Considering a random sample of 100,000 individuals, approximately 15,000 
would be heterozygous for one of the three CD-associated polymorphisms in NOD2, 
with around 500 compound heterozygous or homozygous (254). Approximately 100 
individuals in the sample would be predicted to develop CD; 28 of whom would carry at 
least one NOD2 variant. Only 8 of the 100 patients would be predicted to be compound 
heterozygous or homozygous for one of the three variants (255). A similar situation 
exists for ATG16L1, but with even weaker effects. 
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It is increasingly clear that the individual and cumulative effects of 
polymorphisms identified by GWAS are small, and explain only a proportion of the 
disease heritability (the portion of phenotypic variance attributable to additive genetic 
factors) for complex disorders. This has led to the concept of ‘missing heritability’ - that 
much of the variation underlying genetic risk is yet to be discovered (256). Considering 
CD specifically, the 32 susceptibility loci identified in the original GWAS meta-
analysis were estimated to account for less than 20% of the heritability (116). Adding 
the 39 new loci identified in the more recent meta-analysis increased the proportion of 
heritability explained to only 23.2%, in spite of the greatly increased study population 
size (6,333 and 15,056 cases and controls respectively compared to 3,230 and 4,829 in 
the original) (115). This suggests that the majority of the unexplained heritability is 
unlikely to be discovered simply by conducting larger scale GWAS in their current 
form. 
1.4.6 The missing heritability of CD remains unexplained 
The nature of the undiscovered ‘missing heritability’, and the strategies for finding it, 
are at present contentious. It has been postulated that rare or low frequency variants 
(where minor allele frequency is less than 5% of the population) could be important 
contributors, especially as these are poorly detected by current GWA genotyping arrays 
(257). Although common SNPs can, in some cases facilitate the discovery of rarer, 
pathogenic variants by association, the overall capacity of common variants to tag rare 
variants may well be limited (258). Rare mutations or variants can clearly be critical in 
the development of bowel inflammation. Up to 50% of patients with certain rare, 
monogenic disorders of phagocyte function develop bowel inflammation that is 
histologically identical to that of CD (139;140), as discussed in section 1.2.4. 
Furthermore, a recent study of two families with early-onset inflammatory bowel 
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disease revealed the presence of point mutations in the IL-10 receptor, which resulted in 
impaired IL-10 signalling. Although the phenotype observed in these patients was 
somewhat different from that of sporadic CD patients, and the mutations were not found 
in 90 patients with adult onset CD, the cases did highlight how rare mutations can be 
important determinants of susceptibility to bowel inflammation (259). 
Structural variation, including copy number variants such as duplications and 
deletions, inversions and translocations are also incompletely assessed by GWAS and 
could further account for some of the unexplained heritability (257). Interestingly, it has 
been estimated that 8% of the population carry deletions or duplications greater than 
500kb with an allele frequency of less than 5% (260). It is unlikely that a disease 
association of these large structural alterations would have been detected by GWAS. 
Finally, epigenetic effects such as DNA methylation and histone modification may 
warrant further investigation (261), given the role of these modifications in the 
regulation of gene expression. Clearly, a combination of strategies could well be 
required to identify the missing heritability. Whilst additional data from GWAS and 
large scale sequencing projects could be powerful, the results must be interpreted in the 
light of differences in gene expression and functional investigations. 
1.5 Outline of Thesis 
1.5.1 Summary of background information 
The aetiopathogenesis of CD remains unproven, although it is understood to be highly 
complex and heterogeneous. It is likely that a combination of genetic and environmental 
factors result in abnormal immune system-microbiota interactions, which are central to 
the development of CD lesions. GWAS have identified polymorphisms in over 70 genes 
that are associated with CD, which include the pathogen pattern recognition receptor 
NOD2, two genes involved in autophagy (ATG16L1 and IRGM), and various others 
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including IL-23R. Whilst providing important clues into the underlying genetic 
susceptibility and pathogenesis of CD, the polymorphisms have a comparatively high 
frequency in the general population; the penetrance of CD in individuals carrying any 
single polymorphism is generally very low. In addition, the functional mechanisms by 
which both the genes and CD-associated polymorphisms influence disease pathogenesis 
are likely to be subtle and in many cases remain incompletely understood. Finally, it is 
clear that only a small proportion of the total genetic risk has been explained by GWAS, 
which has led to the concept of ‘missing heritability’.  
Mounting evidence suggests a role for defective acute inflammation in the 
pathogenesis of CD. Acute inflammation is the mechanism by which the body responds 
to noxious stimuli such as bacteria; cells of the innate immune system such as 
macrophages and neutrophils have a vital role in this process. Patients with CD have a 
grossly impaired acute inflammatory response to bacteria, as demonstrated by skin 
window studies and subcutaneous injection of killed E. coli. Neutrophil accumulation at 
sites of acute inflammation is impaired in CD, which results in defective clearance of 
bacteria. The persistence of microbial material may act as a trigger for the development 
of a chronic inflammatory state in the bowel wall. Although neutrophil function is 
normal in the majority of CD patients, a number of immunological abnormalities in 
macrophages have been identified that could underlie the impotent acute inflammatory 
response. Monocyte-derived macrophages from CD patients release sub-optimal levels 
of pro-inflammatory cytokines such as TNF in response to HkEc, due to abnormal post-
translational targeting of these molecules to lysosomal compartments. However, the 
molecular mechanisms responsible for this defect remain uncharacterised. 
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1.5.2 Summary of investigations conducted and hypotheses 
In this thesis, the macrophage response to microbial stimuli is further characterised. 
Furthermore, molecular defects underlying the impaired pro-inflammatory cytokine 
release in CD are investigated using several different approaches. Firstly, a ‘hypothesis 
based’ approach is employed. Molecular defects previously associated with CD, and 
molecules with prominent roles in vesicle trafficking, are investigated as candidates for 
the impaired secretion of pro-inflammatory cytokines. Specifically, polymorphisms 
identified as associated with CD by GWAS, and lipid species (including sphingolipids 
and phospholipids) are investigated.  
Secondly, a ‘hypothesis-generating’ approach is taken, using transcriptomic data 
from cultured macrophages. Alterations in gene expression in CD macrophages are 
analysed by classical methods and a novel ‘outlier analysis’ strategy, enabling detection 
of gross defects in gene expression in individual CD patients. The functional relevance 
of a candidate molecule identified by this strategy is subsequently investigated in vitro. 
The key hypotheses investigated in this thesis include: 
1. Macrophage pro-inflammatory cytokine secretion, especially TNF, is impaired 
in response to a range of microbial stimuli in CD (chapter 3). 
2. CD-susceptibility polymorphisms identified by GWAS influence TNF release 
from CD macrophages (chapter 3). 
3. Alterations in macrophage lipids such as sphingolipids and phospholipids 
underlie the defective pro-inflammatory cytokine release and disordered 
macrophage function in CD (chapter 4). 
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4. Abnormalities in gene expression identified by transcriptomic profiling 
strategies indicate heterogeneous molecular defects of relevance to the impaired 
acute inflammatory response in CD (chapter 5). 
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Chapter 2: Materials and Methods 
2.1 Subject recruitment and selection 
Patients with CD and UC were recruited from the Gastroenterology outpatient clinic at 
University College London Hospitals Foundation NHS Trust (UCLH). Patients included 
in the study fulfilled internationally accepted criteria for the diagnosis of either CD or 
UC (262). Patients were excluded from the study if only non-specific features of 
inflammatory bowel disease were present, if the diagnosis had been made less than one 
year previously, or if the histological and clinical diagnoses were inconsistent. All 
patients were between 18 and 75 years of age and had quiescent disease, as determined 
by the Harvey-Bradshaw disease activity index (263) or partial Mayo activity index 
(264) for CD and UC respectively. Only CD patients with a Harvey-Bradshaw score of 
less than three, or UC patients with a partial Mayo score of two or less were included in 
the study (with the exception of shotgun lipidomics analysis of bowel biopsies). Unless 
indicated, all patients were receiving either no treatment or a stable dose (for the 
preceding 3 months) of 5-aminosalicylates alone. None of the patients included in the 
study had infections with either Human Immunodeficiency virus (HIV), Hepatitis B or 
Hepatitis C. 
Healthy volunteers were recruited from the Department of Medicine, UCL. All 
healthy volunteers were between 18 and 75 years of age, had no previous or family 
history of inflammatory bowel disease, and were not receiving immunosuppressant 
medication. For shotgun lipidomics analysis of bowel biopsies, control individuals were 
recruited that were undergoing colonoscopy for diagnostic or screening purposes. None 
of these individuals had any evidence or family history of inflammatory bowel disease. 
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Ethical approval for all studies was obtained from the Joint UCL/UCLH 
Committees on the Ethics of Human Research (project number 02/0324). Written 
informed consent was obtained from all patients and healthy volunteers. No subject was 
studied more than once in each of the different sets of experiments. 
Clinical information of patients and volunteers was recorded in an encrypted and 
password-protected database, registered and covered by the Data Protection Act 1998. 
Clinical details that were recorded included date of birth, current medication, previous 
medication, previous surgery, Montreal classification (site of disease, age at diagnosis, 
disease behaviour), Harvey-Bradshaw or partial Mayo score, smoking status, family 
history, SNP genotype information and co-morbidities. 
2.2 Cell culture and assays 
2.2.1 Preparation of stimuli for cell culture assays 
Heat-killed E. coli 
A fully antibiotic sensitive, laboratory adapted strain of E. coli (NCTC 10418) was 
obtained and grown overnight at 37
o
C in Luria-Bertani (LB) medium. The following 
day, E. coli were harvested and washed repeatedly with phosphate buffered saline (PBS) 
(GIBCO, Paisley, UK). Bacteria were killed by heat treatment at 60
o
C for 1 hour. 
Bacterial concentrations were determined by optical density (OD600 = 0.365 equates to 
10
8
 E. coli/ ml (265)). Sterility of the final sample was confirmed by multiple cultures 
on LB agar plates. 
Heat-killed C. albicans 
A standard strain of Candida albicans (ATCC 10231) was cultured overnight at 30°C in 
Yeast peptone dextrose (YPD) medium. The following day, C. albicans were harvested 
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and washed three times with PBS. The concentration of cells was determined by optical 
density (OD520=0.38 is equivalent to 10
7
 C. albicans /ml (266)) and resuspended in PBS 
to a dilution of 5x10
6
. C. albicans were killed by heat treatment at 60°C for 1 hour. 
Sterility of the final sample was confirmed by multiple cultures on YPD agar plates. 
2.1.2 Primary macrophage isolation, culture and stimulation 
Peripheral venous blood samples were collected from HC, CD and UC patients into 50 
ml syringes (Terumo Medical) containing 5 U/ml heparin (LEO laboratories, Princes 
Risborough, UK.). PBMCs were isolated by differential centrifugation (2,000 rpm, 30 
minutes, 20°C) over Lymphoprep (Axis-Shield, Oslo, Norway). Subsequently, cells 
were washed twice in sterile PBS (GIBCO, Paisley, UK), first at 1,400 rpm (5 minutes, 
20°C) and subsequently at 1,200 rpm (5 minutes, 20°C). Monocytic cells were prepared 
from PBMCs by adherence (136). To achieve this, mononuclear cells were resuspended 
in serum free RPMI-1640 medium (Invitrogen, Paisley, UK), supplemented with 100 
U/ml penicillin (GIBCO), 100 µg/ml streptomycin (GIBCO) and 20 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer pH 7.4 (Sigma-
Aldrich), and plated at approximately 5x10
6
 cells onto 20 cm
2
 Nunclon
TM
 Surface tissue 
culture dishes (Nunc, Roskilde, Denmark). Cells were incubated at 37°C in an 
atmosphere containing 5% CO2, to allow monocytic cells to adhere. After 2 hours, the 
serum free medium containing non-adherent cells was removed and cultures were 
washed once with 10 ml sterile PBS. 10 ml of RPMI-1640 medium supplemented with 
10% Foetal Bovine Serum (FBS) (Sigma-Aldrich), 100 U/ml penicillin (GIBCO), 100 
µg/ml streptomycin (GIBCO) and 20 mM HEPES buffer pH 7.4 (Sigma-Aldrich) was 
then added. Cells were then incubated for 5 days at 37°C, 5% CO2, enabling maturation 
of monocytic cells into macrophages. On day 2, cultures were supplemented with a 
further 10 ml of RPMI-1640 with 10% FBS. 
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 After 5 days of culture, cells were harvested by scraping into 10 ml PBS. A 
pellet of cells was obtained by centrifugation at 1,200 rpm (5 minutes, 20°C). Cells 
were resuspended in X-Vivo-15 medium (Cambrex, MD, USA) at a density of 10
6
 
cells/ml. Cells were then plated into BD Falcon
TM
 96 well tissue culture plates at a 
density of 10
5
 cells/well or 8 cm
2
 Nunclon
TM
 Surface tissue culture dishes at 10
6
 
cells/dish, depending on the experiment. After overnight incubation, 10
5
 cells were 
stimulated for up to 24 hours with 2 µg/ml Pam3CSK4 (Alexis Biochemicals, San 
Diego, USA), 200 ng/ml lipopolysaccharide (LPS) (Alexis), 500 ng/ml Flagellin 
(Alexis), 2.5 HkEc/ macrophage or 5 heat-killed C. albicans/ macrophage, depending 
on the experiment. 
2.1.3 THP-1 cell culture and stimulation 
THP-1 cells (a human pro-monocytic cell line) were cultured in RPMI-1640 medium 
(Invitrogen), supplemented with 10% FBS (Sigma-Aldrich), 20 mM HEPES (Sigma-
Aldrich), 100 U/ml penicillin, 100 µg/ml streptomycin (GIBCO) and 50 µM 2-
mercaptoethanol (Invitrogen).  For cytokine assays, 10
5
 cells were resuspended in 100 
µl medium and stimulated for 6 hours with 2 µg/ml Pam3CSK4 (Alexis) or 2.5 HkEc/ 
cell.  
2.1.4 THP-1 cell transfection and siRNA knockdown 
Optineurin expression in THP-1 cells was depleted by transfection of small interfering 
RNAs (siRNAs) targeted against optineurin, using the Amaxa Cell line Nucleofector® 
kit V (Amaxa/Lonza, Basel, Switzerland). THP-1 cells were harvested by centrifugation 
and washed with PBS to completely remove medium. Cells were resuspended in 
Nucleofector® solution V, to obtain a concentration of 10
6
 cells/ 100 µl. For each 
transfection, 100 µl of cell suspension was mixed with 60 pmol of appropriate siRNAs. 
Silencer® pre-designed and validated siRNA directed against optineurin was used to 
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deplete expression (ID # 4392420, Ambion, Austin, TX, USA). Non-targeting Accell
TM
 
siRNA was also used as a negative control for off-target effects (catalog # D-001910-
01-05, Dharmacon, Thermo Scientific). Transfection was performed by means of 
electroporation using an Amaxa Nucleofector® device, using programme U-01. 
Following transfection, cells were resuspended in RPMI-1640 medium (Invitrogen), 
supplemented with 10% FBS (Sigma-Aldrich), 20 mM HEPES (Sigma-Aldrich), 100 
U/ml penicillin, 100 µg/ml streptomycin (GIBCO) and 50 µM 2-mercaptoethanol 
(Invitrogen) and cultured at 37°C in an atmosphere of 5% CO2. Subsequent assays were 
performed 24 hours after transfection. 
2.1.5 TNF Bioassay 
Release of TNF was determined using the L929 cytotoxicity bioassay, a sensitive 
technique for the detection of biologically active TNF in tissue culture supernatants 
(267). A TNF sensitive clone of murine L929 fibroblast cells was kindly provided by 
Professor B. Beutler (The Scripps Institute, La Jolla, CA, USA). Cells were cultured in 
Dulbecco’s modified Eagle medium (DMEM) (Invitrogen) supplemented with 10% 
FBS (Sigma-Aldrich), 100 U/ml pencillin-streptomycin (Invitrogen) and 100 μg/ml 
streptomycin (Invitrogen) at 37°C in 5% CO2. A confluent monolayer of cells was 
trypsinised and resuspended in DMEM at 2 X 10
5
 cells/ml in DMEM. L929 cells were 
plated into 96-well flat bottomed tissue culture plates at a density of 2 X 10
4
 cells/ well, 
and incubated overnight at 37°C in 5% CO2. After overnight culture, the medium was 
removed and replaced with 50 μl DMEM containing 0.04 mg/ml cycloheximide 
(Sigma-Aldrich), and incubated at 37°C in 5% CO2. After 30 minutes incubation, 50 μl 
of cell free supernatant (collected from primary macrophages or THP-1 cells as 
previously described) was added to individual wells, at a dilution of 1:10-1:250, 
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depending on the experiment. Serially diluted recombinant human TNF (100–0 pg/ml; 
R&D Systems) was used to determine the standard curve for the assay. 
After 18 hours, 25 μl of 2.5 ng/ml MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl tetrazolium bromide, tetrazolium salt) was added to each well and incubated 
for 4 hours at 37°C in 5% CO2. Supernatants were then discarded and 100 μl/well of 
lysis solution (90% isopropanol, 0.5% SDS, 0.04 M HCl, and 10% H2O) added to each 
well. After 1 hour incubation at room temperature, absorbance in each well at 570 nm 
was determined using a FLUOstar OMEGA plate reader and software (BMG 
LABTECH Ltd., Aylesbury, UK). Data were exported into Microsoft Excel for 
subsequent analysis. TNF and multiplex cytokine measurements were normalised to 
correct for cell number using the MTT assay (primary macrophages) or propidium 
iodide DNA fragmentation assay (THP-1 cells). 
2.1.6 Multiplex cytokine measurement 
Cultured macrophages from HC individuals, CD and UC patients were stimulated for 24 
hours with HkEc (2.5/ macrophage).  After 24 hours, supernatants were removed and 
stored at -70°C until the cytokine assay was performed. Supernatants were replaced 
with X-Vivo-15 medium containing MTT, and an MTT assay was performed (see 
below) to correct for cell number. GM-CSF, IFN-γ, IL-1β, IL-2, IL-6, IL-8, IL-10, IL-
12p70 and TNF concentrations in the supernatants were determined using the Meso 
Scale Discovery
TM
 (MSD) Human Pro-inflammatory 9-plex cytokine assay (Meso Scale 
discovery, Gaithersburg, MD, USA). This 96 well multi-spot assay permits 
simultaneous detection of cytokines by electrochemoluminescence, enabling profiling 
of multiple cytokines in a single sample of supernatant. Each well in this assay has 10 
carbon electrodes, 9 of which are pre-coated with appropriate anti-cytokine antibodies; 
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the 10
th
 is coated with BSA and gives a blank reading. Cytokine measurements were 
determined as per manufacturer’s instructions. 
In brief, supernatants were diluted 1:8 in tissue culture medium supplied with 
the assay (diluent 1). Calibrators were serially diluted in diluent 1, to obtain standards 
ranging from 10000 to 2.4 pg/ml. 200 µl of blocking solution containing 1% Blocker B 
in PBS was added to each well, and the plate shaken (500 rpm) for 1 hour at room 
temperature. Subsequently, plates were washed once using 200 µl/ well PBS + 0.05% 
Tween-20. 25 µl of diluted standards and samples were then added to the appropriate 
wells, and the plate was incubated for 1.5 hours at room temperature with shaking (500 
rpm). The plate was washed three times with 200 µl PBS + 0.05% Tween-20, and 25 µl 
of detection antibody solution (prepared in diluent 100) was added. After shaking the 
plate (500 rpm) for 1 hour at room temperature, the detection antibody solution was 
removed and the plate washed three times with 200 µl PBS + 0.05% Tween-20. 150 µl 
2X Read buffer was added to each well and electrochemoluminescence measured using 
a MSD Sector Imager 2400 plate reader. Raw electrochemoluminescence data were 
automatically converted into cytokine concentrations with reference to the standards, 
using Discovery Workbench 3.0 software (MSD). This calculated data were exported 
into Microsoft Excel for further data analysis. 
2.1.7 MTT cell viability assay to estimate cell number 
Cell viability of primary macrophages was ascertained using the MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide, tetrazolium salt) assay. 25 µl 
of 2.5 ng/ml MTT was added to each well and incubated at 37
o
C, 5% CO2. After 24 
hours, supernatants were removed and 100 µl/well of lysis solution (90% isopropanol, 
0.5% sodium dodecyl sulphate, 0.05 M NH4Cl, 9.5% H2O) was added to each well. 
After 1 hour incubation at room temperature, the absorbance was determined at 570 nm 
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using a FLUOstar OMEGA microplate reader and software (BMG LABTECH Ltd, 
Aylesbury, UK). 
2.1.8 Propidium iodide staining and flow cytometry 
Cell viability of THP-1 cells after transfection was assessed by propidium iodide 
incorporation and flow cytometry. 24 hours after siRNA transfection, THP-1 cells were 
permeabilised in 0.1% Triton X-100/ PBS with 2 µM propidium iodide (Sigma Aldrich) 
for 1 hour in the dark. DNA fragmentation was assessed by flow cytometry using a 
FACSCalibur flow cytometer (BD Biosciences, NJ, USA), and analysis performed 
using Cellquest
TM
 software. The proportion of DNA giving fluorescence below the G1-0 
gated peak (gated as M1) was used as a measured of apoptosis. 
2.1.9 SDS-PAGE and Western blotting 
Western blotting was used to determine intracellular optineurin levels in THP-1 cells 
after siRNA knockdown, and levels of optineurin levels in primary macrophages. In the 
case of THP-1 cells, 2x10
5
 cells were harvested by centrifugation, washed once with 
PBS and lysed in Laemmli sample buffer (0.06 M Tris-HCl pH 6.8, 2% sodium dodecyl 
sulphate (SDS), 10% glycerol, 5% -mercaptoethanol (VWR), 0.04% (w/v) 
bromophenol blue (VWR, prepared as 3X concentrate). 1X sample buffer was freshly 
prepared containing a dissolved Complete protease inhibitor cocktail tablet (1 
tablet/10ml) (Roche Diagnostics GmbH, Germany), and phosphatase inhibitor cocktails 
2 and 3 (1:100) (Sigma Aldrich). In the case of primary macrophages, 2x10
5 
cells were 
cultured in 24 well tissue culture plates (Nunc), washed once with PBS and lysed in 
Laemmli sample buffer, prepared as detailed previously. Prior to electrophoresis, 
samples were heated to 95°C for 5 minutes, and subsequently centrifuged for 2 minutes 
at 15,000 g at 4°C. 
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 Proteins in the lysates were resolved by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE), using the method of Laemmli (268). 
10% resolving gels were cast by mixing 1.65 ml of ProtoGel 30% (w/v) acrylamide/ 
0.8% bisacrylamide (National Diagnostics, Atlanta, USA) with 1.25 ml of 1.5 M Tris 
pH 8.8, 50 µl 10% SDS (Sigma-Aldrich), 2 ml distilled water, 50 µl of 10% freshly 
prepared ammonium persulphate (Sigma-Aldrich), and 4 µl tetramethylethylenediamine 
(TEMED) (Sigma-Aldrich). Stacking gels were created by mixing 500 µl ProtoGel 30% 
(w/v) acrylamide/ methylene bisacrylamide (National Diagnostics) with 380 µl of 1 M 
Tris pH 6.8, 2.1 ml distilled water, 40 µl of 10% SDS (Sigma-Aldrich), 40 µl 
ammonium persulphate and 4 µl TEMED. Electrophoresis was conducted using Hoefer 
Mighty Small II SE 250 systems units (Hoefer, CA, USA) at 30 mA per gel. 
 Proteins were subsequently transferred onto Hybond P nitrocellulose membrane 
(GE Healthcare, Buckinghamshire, UK) using a semi dry transfer system (Trans-Blot 
SD semi-dry transfer cell, Bio-Rad) in transfer buffer (200 mM glycine, 0.1% SDS 
(w/v), 10% methanol (v/v), 25 mM Tris-HCl pH 8.8). In initial experiments, transfer 
was confirmed using reversible staining with Ponceau Red (Sigma-Aldrich). Membanes 
were subsequently blocked for 1 hour with 5% non-fat milk (w/v) in TBS/0.05% 
Tween-20 (v/v). Following blocking, membranes were probed overnight at 4°C with 
primary antibodies directed against optineurin (Sigma-Aldrich, 1:1000 in TBS/0.05% 
Tween-20 (v/v) containing 5% bovine serum albumin (w/v)) or β-actin (Sigma-Aldrich; 
1:1000 in TBS/0.05% Tween-20 containing 5% non-fat milk (w/v)). After overnight 
incubation, membranes were washed three times in TBS/0.05% Tween-20 for 5 
minutes. Subsequently, membranes were probed with HRP-conjugated anti-rabbit IgG 
antibody (Amersham Biosciences, 1:2000 in TBS/0.05% Tween-20 containing 5% non-
fat milk) for 1 hour at room temperature. After three further 5 minute washes in 
TBS/0.05% Tween-20, blots were developed using the Enhanced Chemiluminescence 
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method (ECL PLUS; Amersham Biosciences), and the autoradiograph processed with 
an X-Omat film developer (Kodak, Hertfordshire, UK). Densitometry analysis was 
performed using ImageJ software (National Institutes of Health, Bethesda, MD), with 
band densities normalised to β-actin loading controls. 
2.3 Genomic DNA preparation and analysis 
2.3.1 Genomic DNA extraction 
For SNP genotyping and DNA sequencing, genomic DNA was extracted from 
peripheral blood samples. 1-2 ml of peripheral venous blood was collected from 
subjects into an ethylenediaminetetraacetic acid (EDTA) tube (BD Biosciences). 
Genomic DNA was extracted using the QIAamp DNA blood Mini Kit (Qiagen GmbH, 
Hilden, Germany), in accordance with the manufacturer’s instructions. Optical density 
readings were determined for OD260/OD280 and OD260/OD230 using a NanoDrop ND-
1000 spectrophotometer (Fisher Scientific, Loughborough, UK) to assess protein and 
solvent contamination respectively.  
2.3.2 Genotyping of Crohn’s disease associated polymorphisms 
HC, CD and UC patients were genotyped for 34 single nucleotide polymorphisms that 
were previously identified as convincingly associated with CD by GWAS (116;253). 
Details of the polymorphisms are shown (Table 2.1). Genotyping was performed by the 
Sanger Centre using the iPLEX™ Gold Assay (Sequenom® Inc., San Diego, CA, 
USA). Assays for all SNPs were designed using the eXTEND suite and MassARRAY 
Assay Design software version 3.1 (Sequenom® Inc.). Amplification was performed in 
a total volume of 5 µL containing ~0.06-0.4 ng genomic DNA, 100 nM of each PCR 
primer, 500 µM of each dNTP, 1.25 x PCR buffer (Qiagen), 1.625 mM MgCl2 and 1 U 
HotStar Taq® (Qiagen). Reactions were heated to 94°C for 15 minutes followed by 45  
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dbSNP ID Chromosome Potential candidategenes
Risk
Allele
HC
Frequency
CD
Frequency
Odds
ratio
rs11209026 1p31 IL23R G 0.932 0.973 2.66
rs9286879 1q24 TNFSF18, TNFSF4,FASLG G 0.246 0.285 1.22
rs11584383 1q32 C1orf106, KIF21B T 0.710 0.733 1.12
rs3024505 1q32 IL10, IL19 A 0.156 0.179 1.18
rs10210302 2q37 ATG16L1 T 0.525 0.597 1.34
rs4613763 5p13 PTGER4 C 0.120 0.163 1.43
rs10067603 5q3 SLC22A4, SLC22A5,IRF1, IL3 A 0.789 0.821 1.23
rs13361189 5q33 IRGM C 0.086 0.114 1.37
rs10045431 5q33 IL12B C 0.757 0.792 1.22
rs6908425 6p22 CDKAL1 C 0.784 0.805 1.14
rs7746082 6q21 PRDM1 C 0.299 0.325 1.13
rs2301436 6q27 CCR6 T 0.467 0.504 1.16
rs1456893 7p12 IKZF1, ZPBP, FIGNL1 A 0.697 0.724 1.14
rs1551398 8q24 A 0.610 0.647 1.17
rs10758669 9p24 JAK2 C 0.349 0.387 1.18
rs4263839 9q32 TNFSF15, TNFSF8 G 0.681 0.721 1.21
rs17582416 10p11 CREM G 0.344 0.374 1.14
rs10995271 10p21 ZNF365 G 0.392 0.442 1.23
rs1250550 10q22 ZMIZ1 C 0.678 0.710 1.16
rs7927894 11q13 C11orf30 T 0.389 0.427 1.17
rs11175593 12q12 MUC19, LRRK2 T 0.023 0.037 1.64
rs3764147 13q14 C13orf31 G 0.245 0.275 1.17
rs8049439 16p11 IL27, SH2B1, EIF3C,LAT, CD19 C 0.378 0.409 1.14
rs2066844 16q12 NOD2 (R702W, SNP8) T 0.036 0.081 2.36
rs2066845 16q12 NOD2 (G908R,SNP12) C 0.017 0.041 2.50
rs2066847 16q12 NOD2 (L1007finsC,SNP13) C 0.022 0.087 4.24
rs2872507 17q21 GSMDL, ZPBP2,ORMDL3, IKZF3 A 0.458 0.491 1.14
rs744166 17q21 MLX, STAT3 A 0.583 0.612 1.13
rs2542151 18p11 PTPN2 G 0.153 0.183 1.24
rs10500264 19q13 G 0.807 0.829 1.16
rs1736135 21q21 T 0.577 0.613 1.16
rs762421 21q22 ICOSLG G 0.383 0.423 1.18
rs2412973 22q12 MTMR3 A 0.457 0.487 1.13
rs4821544 22q12 NCF4 C 0.330 0.351 1.10
Table 2.1 Details of the 34 SNPs genotyped and used to determine overall genetic risk score
for CD. SNPs were selected based on the results of two GWAS (116;253). The potential
candidate genes of interest for each locus are those reported in (115).
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cycles at 94°C for 20 seconds, 56°C for 30 seconds and 72°C for 1 minute, then a final 
extension at 72°C for 3 minutes. Unincorporated dNTPs were digested with shrimp 
alkaline phosphatase (SAP) prior to iPLEX™ Gold allele specific extension with mass-
modified ddNTPs using an iPLEX Gold reagent kit (Sequenom® Inc.). SAP digestion 
and extension were performed according to the manufacturer’s instructions with 
reaction extension primer concentrations adjusted to between 0.7-1.8 µM, dependent 
upon primer mass. Extension products were desalted and dispensed onto a SpectroCHIP 
using a MassARRAY Nanodispenser prior to MALDI-TOF analysis with a 
MassARRAY Analyzer Compact mass spectrometer. Genotypes were automatically 
assigned and manually confirmed using MassARRAY TyperAnalyzer software version 
4.0 (Sequenom® Inc.).  
2.3.3 Calculation of genetic risk scores 
Weighted genetic risk scores (GRS) for CD, given the 34-SNP genotype, relative to 
mean population risk were calculated for each individual using a logistic regression 
model, with allele counts as predictors of disease status as outcome, assuming additivity 
within and between loci. The model intercept was set based on the allele frequencies, 
and regression co-efficients were derived from odds ratio, both taken from a recent 
meta-analysis (115). For those SNPs that were not directly assessed in the meta-
analysis, the best proxy SNP was used. The allele frequencies and odds ratio for the 
three NOD2 SNPs were taken from a NOD2 specific meta-analysis (269). Only those 
individuals where >95% of the SNPs could be reliably determined were included in the 
analysis. Potential genotyping errors were assessed via deviations from Hardy Weinberg 
equilibrium. 
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2.3.4 Sequencing of OPTN region  
Sequencing of the OPTN region in outlier individuals, including all exons and flanking 
sequences, was conducted by PCR amplification and automated Sanger chemistry. The 
reference sequence of the OPTN gene was obtained from the University of California 
Santa Cruz (UCSC) genome browser. Forward and reverse primers were designed for 
specific amplification of OPTN exons, promoter and downstream reactions, using 
Primer3 software (270). Sequences of these primers are shown (Figure 2.1A).  
PCR was carried out in 25 µl reactions containing 12.5 µl 2X Hotstar Taq 
master mix (Qiagen GmbH), 200 pmol of the appropriate forward and reverse primers 
(Eurofins MWG operon), the equivalent of 20 ng DNA per reaction, and made up to a 
total volume 25 µl using  DNAse free water (Qiagen GmbH). PCR was conducted using 
a DNA engine Tetrad 2 Peltier Thermal cycler (Bio-Rad, Hercules, CA, USA). 
Reactions were initially heated at 95°C for 2 minutes. Subsequently, reactions were 
subjected to 35 cycles of denaturation at 95°C (30 seconds), annealing at 56-60°C, 
depending on the specific primer (30 seconds), and extension at 72°C (30 seconds). For 
products over 900 base pairs, an extension time of 1 minute was used. After 35 cycles, 
reactions were incubated at 72°C for 10 minutes. Negative control reactions containing 
no DNA template were performed in parallel to test for contamination. 
Following PCR, 5 µl of the reactions were subjected to agarose gel 
electrophoresis, stained with ethidium bromide and visualised using a Chemi-Doc
TM
 
XRS system (Bio-Rad), to assess amplification of a specific PCR product of the 
appropriate size, and absence of contamination (Figure 2.1B). Prior to DNA sequencing, 
PCR products were purified using the QIAquick PCR purification kit (Qiagen GmbH), 
in accordance with the manufacturer’s instructions. DNA was eluted in 30 µl DNAse 
free water, and the concentration measured using a NanoDrop ND-1000 
87
1 2 3 4 5 6 7 8 9 10 11 12 13
Primer 
pair 
Product size 
(base pairs) 
Exon/ Region 
coverage  Primer sequence 
1 940 Promoter F 5’-CAGCCTCTAGCCTCATCTGC-3’ 
    R 5’-CACCCTGCCCATTCCATA-3’ 
2 390 Promoter, 1 F 5’-CTTGGTCGGGTGGGGTAT-3’ 
   R 5’-GCGGGTACCGTTTTCAGG-3’ 
3 1558 2,3,4 F 5’-TCACCAAGTGTGAAGGTGGA-3’ 
   R 5’-GCCTTGCCAAATGCTAAATC-3’ 
4 656 5 F 5’-GGGCAGGACCAGTATTTGAA-3’ 
   R 5’-CTTCCAAGACCAGGCAAAAC-3’ 
5 332 6 F 5’- GTGCCCAGCCTTAGTTTGAT-3’ 
   R 5’-CTTGGCTTGTGTTGACAAGAA-3’ 
6 343 7 F 5’- TGGGTTGCATGTCACAAAAA-3’ 
   R 5’-CCAGTTTGAGCTGCAACATTA-3’ 
7 593 8 F 5’-GCATTGTAAGCTGGCCTCTC-3’ 
   R 5’-CAGAAAGCACATTGCTTGGA-3’ 
8 268 9 F 5’- TTTTGAAAACCCCTGATCCTT-3’ 
   R 5’-GTGTGTGGGTGTGGTAGTGG-3’ 
9 371 10 F 5’-TGGTTCAGCCTGTTTTCTCC-3’ 
   R 5’-TCATGCTCACACATTAACTGGA-3’ 
10 734 11,12 F 5’-ACTGCGACGTAAAGGAGCAT-3’ 
   R 5’-AACGTTCAACAGTTTCTGTTCATT-3’ 
11 329 13 F 5’-CGGCCAGAGCTGATAATTAAA-3’ 
   R 5’-TGCTTTCCAATGCGAGAATA-3’ 
12 313 14 F 5’-AGCAGGATTGTGCATCTGTG-3’ 
   R 5’-GACAGGCACCTCTTCTACGG-3’ 
13 261 15 F 5’-TGAACCTTGGCAGTGTAGTTTG-3’ 
   R 5’-TGAAGTGGAATTTTTCTTCAAGC-3’ 
14 1762 16 F 5’-AACTGCCTGCAAAATGGAAC-3’ 
   R 5’-TGAGGTGTGGTAGGGGACTC-3’ 
15 749 Downstream F 5’-TTGCCAAGAGTAAATAACACTGGA-3’ 
   R 5’-TCGTAAACCTGTTAAGAGTGCAA-3’ 
16 957 Downstream F 5’-GAAGGCCATTTCACGTAGTCA-3’ 
   R 5’-AAGGGATTCCTCTCACACCA-3’ 
17 975 Downstream F 5’-CAGGGACACCACAGGCTATT-3’ 
   R 5’-GGATCCCGACACAAAATCAC-3’ 
18 890 Downstream F 5’-GCCTCTTTGGGCCATATTTT-3’ 
   R 5’-GAGCCTGAATCCAATTTCCA-3’ 
 
Figure 2.1 PCR Amplification of OPTN gene for sequencing. (A) Primer sets used for 
PCR amplification of OPTN gene, showing product sizes, region coverage and 
sequences for the forward (F) and reverse (R) reactions. (B) Representative gel 
showing PCR amplification of a fragment using primer pair 8, and subsequent agarose 
gel electrophoresis. In lane 1, 100 base pair ladder is shown. In lanes 2-12, specific 
amplification of a 268 base pair product is shown in outlier patients (lanes 3-9) and 
controls (lane 2 and 10-12). Lane 13 shows no DNA template control reaction, 
showing absence of contamination.
A
B
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spectrophotometer (Fisher Scientific), and resuspended to obtain a concentration of 2-10 
ng/µl, depending on the fragment length. Sequencing of the fragments was conducted at 
the Wolfson Institute for Biomedical Research, UCL by automated Sanger dideoxy 
sequencing reactions. 
DNA sequence chromatograms were viewed using FinchTV (Geospiza Inc., 
Seattle, WA, USA). The chromatogram quality and presence of heterozygous changes 
were inspected by eye. Sequences of amplified fragments were aligned with reference 
sequences using the ClustalW algorithm on the SDSC Biology workbench 3.2 website 
(http://workbench.sdsc.edu/), with default parameter settings. Sequences were searched 
for previously recognised variants in the OPTN gene, as documented in the National 
Centre for Biotechnology Information (NCBI) SNP database (dbSNP). 
 Linkage disequilibrium (the non-random association of alleles at two or more 
loci) between polymorphisms indentified in the optineurin outlier patients was 
determined using SNP annotation and proxy search (SNAP) software (271). This 
software package calculates pair-wise linkage disequilibrium between variants, using 
phased genotype data from the International HapMap and 1000 genomes projects. In 
order to assess whether any of the identified SNPs were associated with gene 
expression, data from expression quantitative trait loci (eQTL) studies was interrogated 
using Genevar (GENe Expression VARiation) software (272). 
2.4 Lipid extraction and analysis 
2.4.1 Sphingolipid analysis of cultured macrophages 
Monocyte-derived macrophages were cultured onto 8 cm
2
 dishes (Nunc) as described in 
section 2.1.2 and stimulated for 4 hours with HkEc (2.5:1). Cells were harvested in PBS 
89
  
and pellets obtained. Cell pellets were resuspended in 200 µl PBS and sonicated. 10 µl 
aliquots were obtained for protein determination. 
The ceramide content of the solution remaining was determined using high 
performance liquid chromatography tandem mass spectrometry (HPLC-MS), as 
previously described by Bielawski et al. (273). Prior to extraction, cell lysates were 
spiked with appropriate internal standards synthesised by the Lipidomics Core at the 
Medical University of South Carolina. A 50 µl volume of 1 µM internal standard 
solution containing 17-carbon (C) analogues of sphingosine, which occur at trace 
amounts in nature (17C Sphingosine-1-phosphate, 17C24:1 ceramide and 18C17:0 
ceramide), in methanol was added to all samples. Following addition of the internal 
standards, 2 ml of an iso-propanol:water:ethyl acetate mixture (30:10:60) was added, 
samples were vortexed and sonicated periodically for 30 seconds. Samples were 
centrifuged for 10 minutes at 4000 rpm, and supernatant transferred to a new vial. This 
process was repeated once. Lipid extracts were evaporated to dryness under liquid 
nitrogen. The dry residue was resuspended in 150 µl Mobile Phase A solution (1 mM 
ammonium formate dissolved in methanol containing 0.2% formic acid). 20 µl of the 
resulting solution were injected into the HPLC system. 
 HPLC-MS analysis was performed in the Lipidomics Core at the Medical 
University of South Carolina on a Thermo Finnigan TSQ 7000 triple quadrupole mass 
spectrometer operating in a Multiple Reaction Monitoring positive ionisation mode. 
Measurements of macrophage sphingolipids were normalised to total protein content. 
 
2.4.2 BCA assay 
The protein content of cell lysate aliquots was determined using the bicinchoninic acid 
(BCA) assay (Pierce/ Thermo Fisher Scientific Inc.). Appropriate dilutions of samples 
were prepared and transferred to a 96 well plate. BCA reagent (20:1 BCA reagent A: 
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BCA reagent B) was added to each well and heated at 60
o
C. After 30 minutes, the plate 
was read using a FLUOstar OMEGA plate reader (BMG LABTECH Ltd.) at 562 nm 
and the protein concentration was determined by reference to known concentrations of 
bovine serum albumin (BSA) standards. Absolute measurements of sphingolipids 
obtained using mass spectrometric analysis were normalised to the total protein content 
of the lysate. 
2.4.3 Preparation of samples for phospholipid analysis and stable isotope incubation 
Monocyte-derived macrophages from HC and CD patients were cultured onto 8 cm
2
 
dishes (Nunc) at a density of 10
6
 cells/ well. After overnight incubation, medium was 
removed and replaced with X-vivo-15 (Cambrex) supplemented with deuterated choline 
(methyl-d9-choline, 100 µg/ml (Sigma Aldrich)), deuterated inositol (myo-d6-inositol, 
100 µg/ml, (C/D/N isotopes, Quebec)) and deuterated serine (serine-d3, 100 µg/ml 
(C/D/N isotopes)), in the presence or absence of HkEc (2.5:1). Inclusion of deuterated 
(‘stable’) isotope labelled choline, inositol and serine in the culture medium enables 
mass-spectrometric distinction of newly synthesised phospholipid species from 
‘endogenous’ species, and allows assessment of metabolic flux through phospholipid 
synthesis pathways. 
Macrophages were incubated with the stable isotope labelled compounds for 3 
hours at 37
o
C in an atmosphere of 5% (v/v) CO2. Subsequently, medium was removed 
and cells were washed once with Hanks Balanced Salt Solution (Invitrogen). Cells were 
then lysed in 1 ml ice cold methanol and cell fragments were stored at -20
o
C until lipid 
extractions were performed. 
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2.4.4 Phospholipid extraction and analysis by electrospray ionisation mass 
spectrometry 
Total lipid was extracted from macrophages using chloroform and methanol as 
described previously (274). Prior to lipid extraction, cell lysates were spiked with 
appropriate internal standards, including 2 nmol dimyristolphosphatidylcholine (PC 
14:0/14:0), 0.2 nmol 17:0 lyso-phosphatidylcholine, 0.8 nmol 
dimyristoylphosphatidylethanolamine (PE 14:0/14:0), 0.4 nmol 
dimyristoylphosphatidylserine (PS 14:0/14:0), 0.4 nmol 
dimyristoylphosphatidylglycerol (PG 14:0/14:0), 0.2 nmol dimyristoylphosphatidic acid 
(PA 14:0/14:0) per sample. All of these species added as internal standards are present 
at trace amounts in nature. An 800 µl volume of 0.9% NaCl, 1 ml chloroform and 1 ml 
methanol was subsequently added, and samples were sonicated for 5 minutes. A further 
1 ml of chloroform was added followed by 1 ml HPLC-grade water. Samples were  
thoroughly mixed by vortexing, and centrifuged at 1,000 g for 10 minutes at 20
o
C. The 
lower phase was carefully aspirated into new borosilicate tubes using a glass Pasteur 
pipette. Samples were dried under nitrogen at 37
o
C for 45 minutes. When dry, 2X 500 
µl chloroform was added, the samples were transferred to 1 ml mass spectrometry vials 
(Waters, Milford MA), and dried under nitrogen again at 37
o
C for 45 minutes. 
For analysis, samples were reconstituted in 30 µl of a solution containing 20% 
butanol, 60% methanol, 16% water and 4% concentrated aqueous NH3 and introduced 
by direct infusion into a triple quadrupole mass spectrometer (Quattro Ultima, 
Micromass, Manchester, UK) equipped with a nanoflow electrospray ionisation 
interface. Phospholipid and neutral lipid species, both endogenous and with 
incorporated stable isotope-labelled substrates, were selectively detected and quantified 
from a variety of precursor (P) and neutral loss (NL) scans.  Phosphatidylcholine (PC) 
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was analysed in positive ionisation as P184+ and P193+ scans for endogenous and 
newly synthesised (D9) PC.  Phosphatidylinositol (PI) and phosphatidylserine (PS) were 
analysed in negative ionisation, as P241- and P247- scans for endogenous PI and newly 
synthesised (D6) PI respectively, and NL87- and NL90- for endogenous PS and and 
newly synthesised (D3) PS respectively. Data were processed using MassLynx software 
(Waters) and analysed using a macro developed at the University of Southampton, as 
employed in previous studies (275). The macro enabled spectra to be smoothed, 
background subtracted, converted into centroid format and exported into individual 
Excel sample files, which were imported into the analyser programme. Correction for 
the 
13
C isotope was performed prior to calculation of percentage composition and 
incorporation of labelled phospholipid head groups. The fractional incorporations of 
methyl-d9-choline, myo-d6-inositol and serine-d3 into PC, PI and PS species respectively 
were calculated relative to the total abundance. Only species of PC, PI and PS that made 
up >2% of the total molar percentage of PC, PI or PS respectively were considered 
detectable. 
2.4.5 Shotgun lipidomics analysis of ileal biopsies 
Shotgun lipidomics analysis was performed on ileal biopsies from CD patients and 
control individuals, in collaboration with Dr Xianlin Han (Washington University, St 
Louis). Shotgun lipidomics is a technique for analysing the global lipid profile 
(‘lipidome’) in biological extracts, whereby lithium adducts of lipid species are formed 
prior to extraction and mass spectrometric analysis (276). Ileal biopsies were obtained 
from non-inflamed ileum at colonoscopy. Tissue samples were snap frozen in liquid 
nitrogen and stored at -70
o
C until sample processing. Analysis of the lipidome was 
performed as described previously (277). Briefly, samples were homogenised in 1 ml 
ice-cold LiCl aqueous solution (50 mmol/L) using a Potter-Elvehjem tissue grinder. 
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Aliquots of the homogenates were obtained and protein content determined using the 
BCA assay. Internal standards, including dimyristoylphosphocholine (15 nmol/mg 
protein), dimyristoylphosphatidylserine (1 nmol/mg protein), 1,2-dipentadecanoyl-sn-
glycero-3-phosphoglycerol (4.2 nmol/mg protein), 1,2-dipentadecanoyl-sn-glycero-3-
phosphoethanolamine  (18.75 nmol/mg protein), 17C16 ceramide (40 pmol/mg protein) 
and triheptadecenoylglycerol (10 nmol/mg protein) were added at this stage. Lipid 
extraction was performed using a modified Bligh and Dyer procedure, and samples 
were dried under nitrogen gas. ESI-MS was performed as previously described using a 
triple-quadrupole mass spectrometer (ThermoElectron TSQ Quantum Ultra, San Jose, 
CA, USA) (277). 
2.5 RNA preparation and analysis 
2.5.1 RNA extraction from HC, CD and UC macrophages 
Monocyte-derived macrophages were cultured from HC, CD and UC donors as 
described above, resuspended in X-vivo-15 medium (Cambrex) and cultured onto 8 cm
2
 
tissue culture dishes (Nunc) at a density of 10
6
 cells/ dish. Total RNA was extracted 
from unstimulated and 4 hour-HkEc-stimulated macrophages using the RNeasy Mini kit 
with RNase free DNase treatment (Qiagen), in accordance with the manufacturer’s 
instructions. The RNeasy Mini kit enables up to 100 µg RNA greater than 200 bases in 
length to be extracted from homogenised cell lysates, using an RNeasy silica membrane 
and a series of high salt buffer solutions in the presence of ethanol. 
Optical density readings were determined for OD260/OD280 and OD260/OD230 using 
a NanoDrop ND-1000 spectrophotometer (Fisher Scientific, Loughborough, UK) to 
assess protein and solvent contamination respectively. Prior to microarray analysis, 
RNA integrity was analyzed by assessing ribosomal RNA band 28S/18S ratios using an 
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Agilent Technologies Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) high 
resolution electrophoresis system. All samples had an RNA integrity number above 8. 
2.5.2 Microarray hybridisation 
500 ng of total RNA for each sample was amplified and purified using the Illumina 
TotalPrep-96 RNA Amplification kit (Ambion, Huntingdon, UK), according to the 
manufacturer’s instructions. Biotin-Labelled cRNA was then normalized to a 150 ng/µl 
concentration and 750 ng was hybridised to Illumina Human-WG6 v3.0 Expression 
BeadChips (Illumina) for 16 hours at 58°C. Following hybridisation, beadarrays were 
washed and stained with streptavidin-Cy3 (GE Healthcare, UK). Beadarrays were then 
scanned using the Beadarray reader and image data were then processed using Genome 
Studio software (Illumina). 
2.5.3 Microarray data analysis 
Expression data were exported from Genome Studio software (Illumina) after log2 
transformation to stabilise the variance and cubic spline normalisation. Data were 
exported without background subtraction. Detection p-values associated with each 
probe expression value were also exported. Batch variation was minimised using 
ComBat, an established R algorithm for preventing batch effects in microarrays (278). 
Probes that reached a minimum detection p-value of p<0.01 in a single chip were 
included in the subsequent outlier and differential gene expression analysis, to enable 
detection of over-expressed outliers in individual CD patients and HC individuals. 
Probes that had associated detection p-values of p>0.01 in all chips were excluded from 
the analysis. 
 Differentially expressed genes between groups were computed using 
MultiExperiment viewer TM4 Microarray Software suite version 4.7 (279). Probes were 
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initially identified that reached an uncorrected p-value threshold of p<0.01 and a 
minimum raw fold change of 1.2 between groups. Correction for multiple testing was 
performed using an adjusted Bonferroni method. Analysis was also performed in R 
programming language using customised software developed by the Department of 
Computer Sciences, UCL, which enabled correction for multiple testing using the less 
stringent method of Benjamini and Hochberg (280). Principal component analysis 
(PCA) was conducted to determine whether global macrophage gene expression profiles 
could be separated on the basis of disease or batch of microarray analysis. PCA is a 
mathematical algorithm for reducing the dimensionality of datasets, by finding the 
principal components (directions) along which the variation is maximal. PCA was 
conducted using the PCA tool of MultiExperiment viewer TM4 Microarray Software 
suite, with default settings.  
Gene expression outlier analysis was performed using customised software 
developed in collaboration with Daniel Roden and Anna Lobley (Department of 
Computer Sciences, UCL). In brief, this software enables identification and 
visualisation of abnormally expressed genes (‘outliers’) in individual patients compared 
to a comparison cohort of healthy individuals, and utilises both the R programming 
language with Biobase package from the bioconductor platform (281), and the Java 
programming language. A configurable Graphical User Interface is provided to run the 
analysis. Two adjustable thresholds are used to identify potential probe-set outliers: (i) 
the significance level (p-value) of the standardised deviation of the expression levels 
from the test sample, when compared to the mean expression levels of the comparison 
group; and (ii) the (log2) fold-change between the expression level from the test sample 
and the average of the comparison group. 
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To assess the significance of the standardised deviation of the test sample 
expression values from the comparison group average, a Z-score is calculated, using 
equation 1, for each probe. 
                                                            (equation 1) 
Where:  is the expression level of the test sample; and  and  are the mean and 
standard deviation of the expression levels of the samples in the comparison group 
respectively. From these Z-scores, p-values are calculated by determining the likelihood 
that the standardised expression value of the probe-set, in the test sample, would be 
selected at random from a normal distribution with a mean of 0 and standard deviation 
of 1. Fold changes between expression level in the test sample and mean expression in 
the HC comparison group were also calculated. For outlier analysis, the threshold p-
value was set at p<0.005 and minimum fold change was set at 1.5 compared to mean 
expression in the HC cohort. 
MetaCore software (GeneGo, St Joseph, MI, USA) was used to determine the 
significantly enriched Gene Ontology (GO) processes and pathway networks within the 
differentially expressed and outlier gene lists. MetaCore is an integrated software suite 
that enables identification of GO processes and pathway networks that are enriched 
within datasets in an unbiased manner, based on a manually curated database. Illumina 
probe IDs, with associated fold changes and p-values where appropriate, were uploaded 
onto the MetaCore pathway analysis package. Significantly enriched GO processes and 
MetaCore pathway networks within the gene lists were identified and ranked in order of 
p-value. 
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2.5.4 cDNA conversion and Quantitative PCR 
Prior to performing quantitative PCR, 0.5 µg of RNA was converted to cDNA by oligo 
d(T) priming and reverse transcription using the Promega  (Qiagen GmbH) reverse 
transcription kit, as per manufacturer’s instructions. Real time quantitative PCR analysis 
of optineurin expression was performed using TaqMan® gene expression assay kits 
(Applied Biosystems, Warrington, UK), using glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) as an endogenous control. TaqMan gene expression assay 
identifiers were Hs01014552_m1 (optineurin) and Hs03929097_g1 (GAPDH). 
Efficiency of both primer sets was estimated to be above 95%, using serially diluted 
pooled cDNA templates. 
All quantitative PCR reactions were conducted in ABgene 96 well PCR plates 
(Abgene, Epsom, UK), in 20 µl total volumes containing 1 µl of 20X TaqMan gene 
expression assay and 10 µl of 2X TaqMan Universal Master Mix  (Applied 
Biosystems). A 4 µl volume of cDNA equivalent to 5 ng of total RNA was used for 
each quantitative PCR reaction. Real time quantitative PCR was conducted using an 
Eppendorf Mastercycler® ep realplex Thermal Cycler (Eppendorf, Hamburg, 
Germany). PCR cycling conditions utilised included an initial 10 minute hold at 95
o
C, 
followed by 40 cycles of denaturation (15 seconds at 95
o
C) and primer annealing and 
extension (1 minute at 60
o
C). All reactions were performed in triplicate. The cycle at 
which fluorescence reached an arbitrary threshold of 100 relative units (cycle threshold, 
Ct) was determined for each reaction. Data were exported from realplex software into 
Microsoft Excel for further analysis. 
Relative expression of optineurin in the CD patients of interest compared to HC 
was determined using the comparative Ct (ΔΔ Ct) method (282). Briefly, mean Ct 
values obtained for GAPDH amplification were subtracted from mean Ct values for 
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OPTN amplification for each sample.  The average difference in these values between 
HC and patient samples was determined, and the exponent to base 2 calculated to 
determine the fold difference in expression. 
2.6 Statistical analysis 
Unless otherwise indicated, all statistical calculations were performed using GraphPad 
Prism 4 software (GraphPad Software, Inc., San Diego, CA, USA). A p-value <0.05 
was considered statistically significant. The Komolgorov-Smirnov test was used to 
determine whether distributions of datasets were Gaussian. 
2.6.1 Analysis of cytokine secretion measurements, and relationships to phenotypes and 
genotypes (chapter 3) 
Statistical significance was assessed using an unpaired t-test or Mann-Whitney U test as 
appropriate. For multiple comparisons between groups, statistical significance was 
assessed by one-way analysis of variance (ANOVA) with Tukey post test, or for non-
normally distributed data, Kruskal-Wallis one-way ANOVA with Dunn’s post test.  
Correlation between cytokine measurements and GRS was ascertained using 
Spearman’s rank correlation co-efficient. A correlation was considered significant when 
p<0.05.   
2.6.2 Analysis of macrophage lipids in CD (chapter 4) 
Statistical significance of differences between groups was determined using a paired or 
unpaired t-test. A p-value was considered significant when p<0.05. 
2.6.3 Analysis of transcriptomic abnormalities in CD (chapter 5) 
Microarray data were analysed using MultiExperiment viewer TM4 Microarray 
Software suite and customised outlier analysis software, as described in section 2.5.3. 
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For all other experiments, statistical significance was assessed using a paired or 
unpaired t-test. For multiple comparisons between groups, statistical significance was 
assessed by one way ANOVA with Tukey post-test.  
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Chapter 3: The macrophage response to microbial stimuli in Crohn’s 
disease, and genotype-phenotype correlations 
3.1 Introduction 
Recent evidence strongly implicates a role for macrophages in the pathogenesis of CD. 
Macrophages are key orchestrators of an acute inflammatory response, involved in pro- 
and anti-inflammatory cytokine secretion, antigen presentation and phagocytosis. Our 
laboratory recently demonstrated that CD patients have a grossly impaired acute 
inflammatory response to killed E. coli in vivo, with associated defects in pro-
inflammatory cytokine secretion by CD macrophages in response to HkEc. The latter 
was related to abnormal post-translational trafficking of cytokines within these cells, 
resulting in mistargeting and degradation of these proteins in lysosomal compartments 
(136). 
A wide variety of microbes have been postulated as causative in CD. These 
include Gram positive and Gram negative species, mycobacteria, viruses, and yeasts 
such as C. albicans that are commonly found in the commensal microflora of patients 
and healthy individuals (85;96). Whilst direct causality has not been proven for any 
organism, there is a clear requirement for luminal contents in the development of CD 
lesions; abnormal interactions of intestinal microbiota with the innate immune system 
may be crucial in CD pathogenesis.  
Intestinal flora provides a complex and diverse range of ligands for pathogen 
pattern recognition receptors (PRRs) expressed by macrophages, including Toll-like 
receptors (TLRs) and NOD-like receptors (NLRs). TLRs are transmembrane PRRs with 
critical roles in pathogen sensing by macrophages. Each TLR recognises specific 
bacterial or viral components; key TLRs in the response to bacteria include TLR2, 
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TLR4 and TLR5. Ligand-receptor engagement results in intracellular signalling 
cascades and the induction of effector responses important for the innate immune 
defence against microbes, as discussed previously in section 1.3.1 (166). The potential 
relevance of TLRs in the response to intestinal microbiota is demonstrated by TLR4 
knockout mice (148). These mice have earlier and more pronounced gastrointestinal 
bleeding than wild type mice after administration of DSS, which coincides with 
increased bacterial translocation and impaired neutrophil recruitment. Differential 
expression of TLRs has been documented in biopsy samples from IBD patients 
(283;284). A number of studies have reported associations between TLR4 
polymorphisms and CD (247), although these were not identified in the recent large 
meta-analysis. 
Recently, GWAS have identified polymorphisms within susceptibility loci that 
are believed to account for approximately 23% of the total heritability of the disease 
(115;116). Some of the strongest associations include NOD2, which encodes a PRR, the 
IL-23 receptor IL-23R, and two genes with putative roles in autophagy (ATG16L1 and 
IRGM). Many of the CD-associated genes identified to date appear to have important 
roles in sensing, clearance and propagation of the inflammatory response to commensal 
microflora. However, although many of the loci are suspected to influence the innate 
immune system, their precise functional roles remain to be elucidated, as well as the 
mechanisms by which the associated SNPs influence disease susceptibility.   
Here the macrophage response to microbial stimuli in CD is further 
characterised. Pro-inflammatory cytokine secretion is investigated in response to 
stimulation with the Gram negative bacterium E. coli, TLR ligands and the yeast C. 
albicans. The relationship of the macrophage response to both patient phenotypic data 
and previously identified genetic susceptibility loci are interrogated.  
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3.2 Results 
3.2.1 Optimisation of stimuli for cytokine secretion assays 
The relationships of heat-killed E. coli (HkEc), heat-killed C. albicans (HkCa) and TLR 
stimulus dose to TNF release were investigated in HC macrophages, in order to 
determine the concentrations resulting in near maximal TNF release for use in 
subsequent experiments. Optimal TNF release occurred at a 5:1 ratio of HkCa: 
macrophage and a 2.5:1 ratio of HkEc: macrophage (Figure 3.1A, B). Dose-response 
relationships of TLR agonists were previously determined by Dr Farooq Rahman. The 
optimum doses of Pam3CSK4, LPS and flagellin were found to be 2 µg/ml, 200 ng/ml 
and 500 ng/ml respectively. TNF release reached maximum by 6 hours in response to 
HkEc and TLR agonists and was stable over a 24 hour period, whereas IL-8 and IL-10 
reached a maximum by 24 hours. 
3.2.2 Pro-inflammatory cytokine secretion from CD macrophages after HkEc 
stimulation is defective 
In order to validate the previous finding of impaired pro-inflammatory cytokine release 
in CD, peripheral blood monocyte-derived macrophages were cultured from a new 
cohort of quiescent CD (n=43), UC (n=25) patients and HC individuals (n=39), which 
differed from the previous study (136). The demographics of these patients are shown 
(Appendix 1 Table IA). Eight CD patients were receiving immunosuppressive therapy 
(6-mercaptopurine, azathioprine or methotrexate), 21 were receiving 5-ASA and 14 
were receiving no treatment. Macrophages were stimulated with HkEc (2.5:1) for 24 
hours. Supernatants were collected and secretion of the pro-inflammatory cytokines 
TNF, IL-2, IL-6, IFN-γ, GM-CSF, IL-1β and IL-12p70 were determined using a 
multiplex cytokine assay. Secreted levels of the chemokine IL-8 and the anti-
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inflammatory cytokine IL-10 were also determined. At the dilution used, levels of all 
cytokines were within the detectable range of the assay. 
In the CD cohort, the secreted levels of TNF after HkEc stimulation were 
significantly reduced compared to both HC individuals (p<0.05) and UC patients 
(p<0.05) (Figure 3.2A, B). Median TNF secretion from CD macrophages was 12,276 
pg/ml (interquartile range 7,645-23,871 pg/ml) compared to 21,991 pg/ml (interquartile 
range 11,080-35,059 pg/ml) in HC and 22,065 pg/ml (interquartile range 12,798-42,675 
pg/ml) in UC. Release of IFN-γ was also significantly attenuated in CD compared to 
HC (p<0.01) (Figure 3.2C). A trend towards attenuated IL-6 secretion was also 
observed in CD (median 8,117 pg/ml, interquartile range 5,239-14,746 pg/ml) 
compared to HC (median 12,179 pg/ml, interquartile range 6,319-25,276 pg/ml), 
although this did not reach statistical significance. 
Secretion of IL-2, GM-CSF, IL-1β, IL-12p70, IL-8 and IL-10 did not differ 
between HC and CD patients. These findings therefore provide confirmatory evidence 
of the selective defect in the release of a number of pro-inflammatory cytokines 
previously identified in CD macrophages. 
No significant differences in the secreted levels of cytokines between UC and 
HC macrophages were found, with the exception of IL-10, the release of which was 
significantly elevated in UC compared to HC (p<0.05) macrophages. Taken together, 
the results suggest that the defective release of pro-inflammatory cytokines observed in 
CD is likely to be specific to CD, rather than consequential to a chronic inflammatory 
state in the bowel. 
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Figure 3.1 Dose response curves of TNF release with increasing doses of C. 
albicans and E. coli. Macrophages from HC donors (n=3) were cultured and 
stimulated with (A) heat killed C. albicans and (B) E. coli at differing ratios 
of micro-organism : macrophage. TNF release was determined using the 
TNF bioassay. Ratios of micro-organism are presented on a logarithmic 
scale. Data shown are mean of 3 experiments with error bars representing 
standard error of the mean (SEM).
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Figure 3.2 Pro-inflammatory cytokine release from CD macrophages after HkEc
stimulation is deficient compared to HC and UC macrophages. Monocyte-derived
macrophages were cultured from HC (n=39), CD (n=43) and UC patients (n=25) and
stimulated with HkEc for 24 hours. Cytokine release was determined by the MSD
pro-inflammatory 9-plex assay. (A) Cytokine secretion from HC, CD and UC
macrophages. Data are expressed as median (interquartile range).* indicates p<0.05
compared to HC, **p<0.01 compared to HC. Dot plots show the impaired (B) TNF
and (C) IFN-γ secretion from CD macrophages. Data are presented on a logarithmic 
scale. * indicates p<0.05, ** p<0.01
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There was a significant positive correlation between the secreted levels of TNF 
and IFN-γ release in HC individuals (Rs=0.613, p<0.0001) and CD patients (Rs=0.302, 
p<0.05) (Figure 3.3A). Likewise, IL-6 secretion was significantly correlated with TNF 
in HC (Rs=0.617, p<0.0001) and CD (Rs=0.718, p<0.0001) (Figure 3.3B), indicating a 
relationship between the attenuated release of TNF, IFN-γ and IL-6 from CD 
macrophages. In contrast, there was no relationship between macrophage TNF release 
and IL-10 secretion in HC individuals (Rs= -0.261, p>0.05) or CD patients (Rs=0.14, 
p>0.05). 
3.2.3 Release of TNF is impaired in response to other microbial stimuli 
Having confirmed an impairment in macrophage pro-inflammatory cytokine release in 
response to HkEc stimulation, the investigation was extended to determine whether this 
was a phenomenon specific to E. coli, or whether the defect could also be seen in 
response to other microbial stimuli. Monocyte-derived macrophages were cultured from 
CD patients and HC individuals and stimulated with TLR ligands and heat-killed C. 
albicans (HkCa). Demographics of patients included in the TLR and HkCa studies 
(Appendix 1 Table IB, C) are shown. All patients had quiescent disease, and were 
receiving either no medication or 5-ASA, with the exception of two patients in the 
HkCa study who were receiving azathioprine. 
Monocyte-derived macrophages were stimulated with Pam3CSK4 (a TLR1/2 
agonist (166)), LPS (a TLR4 agonist (172)) and HkCa, for 6-24 hours and release of 
TNF quantified using the L929 bioassay, a sensitive assay for the detection of 
biologically active TNF. Data presented for Pam3CSK4 and LPS stimulation show 
combined results incorporating data obtained previously by Dr Farooq Rahman. Data 
for flagellin (TLR5 agonist (173)) were collated by Dr Farooq Rahman and are shown 
here for completeness. The previous experiments also employed the L929 bioassay, and  
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Figure 3.3 Correlation of TNF secretion with (A) IFN-γ, (B) IL-6 and (C) IL-10 release 
from HC and CD macrophages. Macrophages were cultured from HC (n=39) and CD 
(n=43) donors and stimulated for 24 hours with HkEc. Release of TNF,  IFN-γ, IL-6 and 
IL-10 were compared, as determined using the MSD pro-inflammatory 9-plex assay. All 
data are presented on a logarithmic scale. Rs is Spearman's rank correlation co-efficient.
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Figure 3.4 Macrophages from CD patients release attenuated levels TNF in response to 
multiple stimuli. Monocyte-derived macrophages were stimulated for 6-24 hours with the 
TLR agonists Pam3CSK4, LPS and flagellin, and release of TNF quantified using the 
TNF bioassay. Heat-killed C. albicans was also used as a stimulus. (A) TNF release from 
HC (n=41 donors) and CD (n=101) macrophages in response to TLR2 stimulation with 
Pam3CSK4 (PAM3). (B) TNF release from HC (n=38) and CD (n=87) macrophages in 
response to the TLR4 agonist LPS. (C) TNF release from HC (n=13) and CD (n=28) 
macrophages in response to TLR5 stimulation with flagellin. (D) TNF release from HC 
(n=16) and CD (n=18) macrophages after 24 hours stimulation with heat-killed C. 
albicans. All data are presented on a logarithmic scale. * represents p<0.05, ** p<0.01 
and ***p<0.001.
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no statistical difference was identified between the two batches of data. Secreted levels 
of TNF into tissue culture medium without stimuli were minimal over 24 hours and did 
not differ between HC and CD macrophages (p>0.05). 
 TNF release from CD (n=101) patient macrophages after TLR2 activation with 
Pam3CSK4 was significantly (p<0.001) reduced compared to HC (n=41) (Figure 3.4A). 
Median TNF release from CD macrophages in response to Pam3CSK4 was 1,270 pg/ml 
(interquartile range 650-2,155 pg/ml) compared to 2,700 pg/ml (interquartile range 
1,805-3,495 pg/ml) from HC cells, representing a 53% reduction from the HC cohort.  
 Similarly, after TLR4 stimulation using LPS, TNF release from CD 
macrophages (n=87) was significantly (p<0.001) lower than TNF release from HC 
macrophages (n=38) (Figure 3.4B). Stimulation with flagellin, a TLR5 agonist, likewise 
revealed diminished TNF release from CD macrophages compared to HC (CD n=28 
and HC n=13, p<0.001) (Figure 3.4C). 
 Differential levels of TNF release were also observed in response to HkCa 
(Figure 3.4D). HC macrophages released, on average  21,109 pg/ml TNF after 24 hours 
stimulation with HkCa (n=16). In contrast, CD macrophages released 9,304 pg/ml in 
response to HkCa (n=18); 56% less than that of the control group. The difference in 
TNF release was statistically significant (p<0.05). 
 Correlation analysis was used to determine whether there was a relationship 
between attenuated TNF release downstream of TLR2, TLR4 and HkEc stimulation in 
the CD cohort. There was a significant positive correlation between TLR2 induced TNF 
release and secreted levels of TNF after HkEc (Rs=0.521, p<0.05) (Figure 3.5A). 
Furthermore, there was a weak but significant correlation between TLR2 and TLR4 
induced TNF release in the CD group (Rs=0.281, p<0.01) (Figure 3.5B). Insufficient  
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Figure 3.5 Correlation of attenuated TNF release in CD between microbial 
stimuli. (A) Correlation between secreted levels of TNF from CD 
macrophages (n=20) in response to TLR2 stimulation with Pam3CSK4 and 
HkEc. (B) Correlation between secreted levels of TNF from CD macrophages 
(n=87) in response to TLR2 stimulation with Pam3CSK4 and TLR4 
stimulation with LPS. Rs is Spearman's rank correlation coefficient.
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Figure 3.6 Impaired TNF secretion from CD macrophages is not related to treatment 
regimes. Macrophage TNF release from HC and CD patients after (A) Pam3CSK4 
stimulation, (B) LPS stimulation and (C) HkEc stimulation, with CD patients 
subdivided on the basis of treatment regimes, including no treatment (None), 5-
aminosalicylates (5-ASA) or immunosuppressant (IS, azathioprine or methotrexate). 
Data are presented as box and whisker plots on a logarithmic scale showing median, 
interquartile range and range. Numbers for each group are shown in italics. 
*** indicates p<0.001; no other differences were statistically significant.
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overlap in the patients studied between the TLR4, HkEc and HkCa cohorts precluded 
assessment of correlation between these stimuli. 
3.2.4 Impaired TNF release is not dependent on treatment regimes, age, gender and 
smoking status 
In order to assess whether use of medication could have a confounding influence on 
TLR2 induced macrophage TNF release, the CD cohort was subdivided into those 
receiving either no medical treatment (n=25) or 5-ASA alone (n=76) at the time of 
venesection. No patients in this cohort were receiving immunosuppressants. Both 
groups displayed impaired TNF secretion after Pam3CSK4 exposure compared to HC 
(p<0.001). Furthermore, there was no significant difference in TNF release between 
patients receiving no treatment or those prescribed 5-ASA (Figure 3.6A). Similar results 
were obtained for TLR4 activation with LPS (Figure 3.6B). 
 Furthermore, levels of TNF secretion in response to HkEc were equivalent 
between patients receiving no treatment, 5-ASA or immunosuppressants (azathioprine 
or methotrexate) (Figure 3.6C), although none of the groups reached statistical 
significance against the HC cohort. Taken together, these observations suggest that the 
impaired TNF release from CD macrophages is independent of treatment regimes at the 
time of sample collection. 
 In addition, no associations were identified between TNF release and age, 
gender and smoking status after TLR2 stimulation (Figure 3.7A, B, C). Similar results 
were obtained for TLR4 and HkEc stimulation. 
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Figure 3.7 Defective release of TNF is not associated with age, gender or smoking status.  
CD patients and where applicable HC were divided by (A) age, (B) gender (M=male, 
F=female) and (C) current smoking status and TNF secretion in response to TLR2 
stimulation compared between groups. Results for TNF aganist age are shown as a scatter 
plot with corresponding Rs value. All other results are expressed as box and whisker plots 
on a logarithmic scale showing median, interquartile range and range. Numbers in each 
group are shown in italics. *** represents p<0.001, **p<0.01. All other changes were not 
significant (n.s.) 
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3.2.5 Association between aberrant TNF release and disease phenotype 
It is now recognised that CD is a heterogeneous syndrome and can be divided into 
phenotypic subtypes. Where information was available, CD patients were sub-divided 
into groups according to Montreal classification, a system that classifies patients based 
on age at diagnosis (A), anatomical location of disease (L), and disease behaviour (B) 
(4). After TLR2 stimulation, TNF release was comparable between patients diagnosed 
with CD under 16 years (A1, n=15), those diagnosed between 17 and 40 years (A2, 
n=65) and those diagnosed over 40 years of age (A3, n=21) (Figure 3.8A). Similarly, 
equivalent levels of TNF were released between patients with ileal (L1, n=32), colonic 
(L2, n=44) and ileocolonic (L3, n=24) disease (Figure 3.8B). Considering disease 
behaviour, patients with stricturing disease (B2, n=23), released significantly reduced 
levels of TNF compared to those with pure inflammatory disease (B1, n=63) and those 
with penetrating disease (B3, n=15), suggesting that an abnormality in TLR2 induced 
TNF could be particularly relevant in stricture pathogenesis. 
 Considering TLR4 stimulation with LPS, there were no significant differences in 
TNF release between patients subdivided by age of diagnosis (Figure 3.9A). 
Macrophages from patients with colonic involvement (n=41) released diminished levels 
of TNF downstream of LPS (p<0.05) compared to patients with ileal disease (n=25) 
(Figure 3.9B). Macrophages from one patient with isolated upper GI disease (L4) 
secreted TNF at levels that were ~5% of median HC levels. This patient had early-onset 
disease (A1) and stricturing behaviour (B2). In contrast to TLR2, there were no 
differences between patients when subdivided by disease behaviour (Figure 3.9C). 
Considering HkEc stimulation, there was a trend for patients diagnosed with CD 
under 16 years of age (n=11) to release less TNF than patients diagnosed over 40 years  
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Figure 3.8 TNF release from CD macrophages in response to TLR2 stimulation, with CD 
patients subdivided by Montreal phenotypic classification. Monocyte-derived macrophages 
were cultured from CD patients and stimulated with Pam3CSK4. (A) Subdivision by age at 
diagnosis, where A1, A2 and A3 represent age below 16, 17-40 and above 40 years 
respectively. (B) Subdivision by disease location, where L1, L2 and L3 are ileal, colonic and 
ileocolonic disease. (C) Subdivision by phenotype, where B1, B2 and B3 represent 
inflammatory, stricturing and penetrating disease respectively. Results are presented on a 
logarithmic scale. Numbers in each group are shown in italics. * represents p<0.05. No other 
changes were statistically significant.
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Figure 3.9 TNF release from CD macrophages in response to TLR4 stimulation, with 
CD patients subdivided by Montreal phenotypic classification. Monocyte-derived 
macrophages were cultured from CD patients and stimulated with LPS. (A) 
Subdivision by age at diagnosis, where A1, A2 and A3 represent age below 16, 17-40 
and above 40 years respectively. (B) Subdivision by disease location, where L1, L2 
and L3 are ileal, colonic and ileocolonic disease. (C) Subdivision by phenotype, where 
B1, B2 and B3 represent inflammatory, stricturing and penetrating disease 
respectively. Results are presented on a logarithmic scale. Numbers in each group are 
shown in italics. * represents p<0.05. No other changes were statistically significant.
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Figure 3.10 TNF release from CD macrophages in response to HkEc stimulation, with CD 
patients subdivided by Montreal phenotypic classification. Monocyte-derived macrophages 
were cultured from CD patients and stimulated with HkEc (A) Subdivision by age at 
diagnosis, where A1, A2 and A3 represent age below 16, 17-40 and above 40 years 
respectively. (B) Subdivision by disease location, where L1, L2 and L3 are ileal, colonic and 
ileocolonic disease. (C) Subdivision by phenotype, where B1, B2 and B3 represent 
inflammatory, stricturing and penetrating disease respectively. Results are presented on a 
logarithmic scale. Numbers in each group are shown in italics.
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of age (n=4) (p<0.05) (Figure 3.10A), although this was not statistically significant 
(p>0.05) (Figure 3.10A). Secreted levels of TNF were not significantly different 
between patients with ileal (n=12), colonic (n=16) and ileocolonic (n=9) disease (Figure 
3.10B), and levels were comparable between patients with inflammatory, stricturing and 
penetrating disease (Figure 3.10C). 
3.2.6 Relationship of impaired TNF secretion to GWAS susceptibility loci 
GWAS have identified numerous susceptibility loci associated with CD. A meta-
analysis of three genome-wide association studies in 2008 identified 32 susceptibility 
loci that were convincingly associated with CD (116). More recently, a GWAS meta-
analysis using a larger cohort of patients identified 39 additional associated variants, 
accounting for an additional 3% of the total heritability (115). A GWAS study of early-
onset IBD patients, published in 2009, identified three additional associations in patients 
with CD (253). Of the polymorphisms identified to date, the strongest association is 
with NOD2, which encodes an intracellular PRR that recognises MDP, a component of 
peptidoglycan. The three CD-associated polymorphisms in NOD2 have been shown to 
result in defective pro- and anti- inflammatory cytokine induction after MDP (215). The 
effect of NOD2 polymorphisms on TNF release downstream of TLR2 stimulation was 
investigated (Figure 3.11A). Patients homozygous or compound heterozygous for 
polymorphisms in NOD2 (n=5) secreted, on average 710 pg/ml (interquartile range 546-
1,505 pg/ml) TNF in response to TLR2, compared to 1,270 pg/ml (interquartile range 
630-2,120 pg/ml) in patients wild type for NOD2 polymorphisms (n=71), however this 
reduction was not statistically significant. There was also no detectable relationship 
between attenuated TNF release and polymorphisms in the autophagy-associated genes 
ATG16L1 and IRGM (Figure 3.11B, C). 
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 Similar findings were apparent in the HC cohort. HC carrying one NOD2 risk 
allele (n=5) released TNF at equivalent levels to individuals with two wild type alleles 
(n=29). One healthy individual was identified who was homozygous for NOD2 risk 
alleles. This 25 year old male had a history of atopic eczema but no other medical 
history of note, and no family history of IBD. Macrophage TNF release in response to 
TLR2 stimulation was attenuated from this individual (480 pg/ml, ~38% of median HC 
secretion) (Figure 3.11D). The release of TNF from HC macrophages in response to 
Pam3CSK4 did not differ significantly between wild type, heterozygous or homozygous 
individuals for ATG16L1 and IRGM CD-associated polymorphisms (Figure 3.11E, F). 
 In addition to NOD2, ATG16L1 and IRGM, none of the 28 other CD-associated 
polymorphisms tested (25 from the 2008 meta-analysis (116) and 3 from the 2009 study 
(253)) showed detectable associations with TNF release downstream of TLR2 
activation. No CD patients or HC individuals in the cohort were homozygous for the 
minor IL-23R allele, precluding assessment of how TNF release in response to TLR2 
activation could be influenced by this protective genotype. 
 The influence of GWAS susceptibility loci on HkEc-induced TNF release was 
also assessed. Although median TNF release from CD patients carrying two NOD2 risk 
alleles (n=3) was slightly reduced compared to CD patients with two wild type alleles 
(n=26), this difference was not statistically significant (Figure 3.12A). As for TLR2 
stimulation, there was no significant difference in HkEc-induced TNF release between 
CD patients carrying no, one or two ATG16L1 or IRGM risk alleles (Figure 3.12B, C). 
Similar results were obtained in the HC cohort (Figure 3.12D, E, F). TNF release in 
response to HkEc from HC individuals heterozygous for CD-associated polymorphisms 
in NOD2 (n=5) did not differ significantly from the wild type group (n=26). 
Macrophage TNF release from the HC individual homozygous for CD-associated  
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NOD2 polymorphisms in response to HkEc was in the lowest quartile for the HC cohort 
(9279 pg/ml). No HC individuals were homozygous for the IRGM risk allele.  
 Furthermore, none of the other 28 polymorphisms were significantly associated 
with TNF release in response to HkEc, in either CD or HC patients. As for TLR2, no 
patients were homozygous for the IL-23R minor allele, meaning that the contribution of 
this protective genotype to macrophage TNF release in response to HkEc could not be 
assessed. 
3.2.7 Relationship of attenuated TNF release to overall genetic risk score 
Polymorphisms in multiple genetic loci are associated with increased susceptibility to 
CD. Emerging evidence suggests that products encoded by these loci may map to 
common pathways and networks, giving rise to abnormal phenotypes relevant to CD 
pathogenesis. The overall contribution of 34 GWAS susceptibility loci (31 from the 
2008 meta-analysis, and 3 from the more recent GWAS of early-onset disease) to 
impaired macrophage TNF release was assessed by calculation of a CD ‘genetic risk 
score’ (GRS) for each individual. This risk score was based on the genotype of the 34 
CD-associated polymorphisms, weighted by odds ratio of each locus and assuming 
additive genetic effects. A risk score of 1 represents average risk for a control 
population. Only individuals where >95% of the SNPs could be reliably determined 
were included in this analysis. 
 Overall, our entire cohort of 356 CD patients displayed enrichment for the 34 
CD susceptibility alleles, as shown by the increased GRS compared to 221 HC 
individuals (p<0.001). This cohort has been collated over a 10 year period by a number 
of individuals (M. Harbord, D. Marks, F. Rahman, B. Hayee, G. Sewell, A. Walker, A. 
Smith, A. Levine, P. Smith and A. Segal). Of note, a wide variation in GRS was 
observed in both groups, ranging between 0.07 and 9.07 in the HC cohort and 0.14 to 
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37.2 in the CD cohort. GRS for patients in the TLR2 and HkEc study did not differ from 
the overall cohort, indicating a representative sample of patients (p>0.05); (Figure 
3.13A, B). 
 The HC and CD study cohort of patients was divided into two groups – those 
with an overall GRS of less than 1, and those with a GRS greater than 1. There was no 
difference in TLR2-induced TNF release between CD patients with a GRS less than 1 
(n=47), and those with a GRS greater than 1 (n=43), suggesting that the impaired TNF 
secretion in response to TLR2 is unrelated to patients’ overall genetic risk as identified 
by GWAS (Figure 3.14A). Intriguingly, macrophages from HC individuals with a GRS 
greater than 1 (n=16) released significantly (p<0.05) more TNF than those with a GRS 
less than 1 (n=18) (Figure 3.14B), suggesting that healthy individuals with a greater 
burden of GWAS risk alleles could be protected from developing CD by virtue of a 
strong, TLR2-mediated macrophage response to bacteria. 
 In contrast to the results for TLR2, after HkEc stimulation, CD patients with a 
GRS greater than 1 (n=20) released significantly (p<0.05) less TNF than patients with a 
GRS less than 1 (n=18) (Figure 3.14C). Furthermore, there was a weak but significant 
negative correlation between HkEc-induced TNF release and GRS in the CD cohort 
(Rs=-0.38, p=0.018) (Figure 3.15). This indicates a relationship between attenuated TNF 
release in response to HkEc and an increased burden of GWAS susceptibility alleles. In 
the HC cohort, patients with a GRS over 1 also secreted reduced TNF in response to 
HkEc than those with a GRS less than 1, although this did not reach statistical 
significance (Figure 3.14D). 
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Figure 3.13 Genetic risk scores for developing CD in the total UCLH and study 
cohorts. The UCLH cohort consists of CD patients (n=356) and HC individuals 
(n=221). *** represents p<0.001 for difference in genetic risk score of the entire 
UCLH cohort of CD patients compared to HC individuals. (A) TLR2 study cohort 
patients are highlighted in red. (B) HkEc study cohort are highlighted in red. The 
genetic risk scores of the HC and CD studied in the TLR2 and HkEc cohorts did not 
differ from the total UCLH HC and CD patient cohorts.
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Figure 3.14 HC and CD individuals separated into risk of developing CD (Genetic risk 
score, GRS) based on a 34 SNP genotype, and relationship to the TLR2 and HkEc 
response. Susceptibility variants of SNPs associated with the development of CD are 
common in both HC and CD individuals. The (A) CD and (B) HC cohorts were divided 
into individuals with GRS <1 and GRS >1, and  macrophage TNF response to TLR2 
(PAM3) stimulation compared. (C, D) Corresponding results for HkEc stimulation. Data 
are presented as box and whisker plots on a logarithmic scale showing median, interquartile 
range and range. Numbers in each group are shown in italics. * indicates p<0.05.
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Figure 3.15 Correlation between TNF release from CD macrophages after HkEc 
stimulation and genetic risk score. Genetic risk score for CD patients (n=38) was 
calculated from the genotype of 34 risk-associated variants and correlated with TNF 
release after HkEc stimulation. Data are presented on logarithmic scale. Rs value 
shown is Spearman's rank correlation coefficient, with corresponding p-value. 
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3.3 Discussion 
In vivo studies clearly demonstrate that the CD phenotype is characterised by an 
impaired acute inflammatory response and delayed bacterial clearance (135;136). 
Whilst neutrophil function in the majority of patients is normal, macrophages from CD 
patients were previously shown to release deficient levels of pro-inflammatory 
cytokines in response to HkEc, as a result of aberrant degradation of these molecules in 
lysosomal compartments (136). In this chapter, the abnormal release of pro-
inflammatory cytokines in response to HkEc was verified in a second cohort of CD 
patients and HC individuals. Macrophages from CD patients demonstrate attenuated 
TNF release downstream of multiple microbial stimuli, including the TLR2, TLR4 and 
TLR5 agonists, and HkCa, which stimulates a variety of TLR and non-TLR receptors 
such as the C-type lectin mannose receptor and dectin 1 (97). In addition, whilst there 
was a generalised depression in TNF release to various stimuli in the overall CD cohort, 
a number of subtle differences in the levels of TNF release were apparent between 
patient phenotypic subgroups, which were stimulus specific.  
CD is a complex syndrome, the pathogenesis of which is likely to occur in many 
temporally distinct phases. Our group recently proposed a ‘three stage’ model for CD 
pathogenesis, where mucosal damage and penetration of bacteria and other particulate 
matter into the bowel wall are followed by an inadequate acute inflammatory response 
and incomplete bacterial clearance. Subsequently, a compensatory adaptive 
immunological response develops, associated with chronic, granulomatous 
inflammation and an elevation in pro-inflammatory cytokines that is characteristic of 
the ‘active’ phase of CD (151). The finding of deficient macrophage secretion of pro-
inflammatory cytokines such as TNF in response to microbial stimuli is consistent with 
this pathogenic schema. TNF is a pleiotropic cytokine with a prominent role in the 
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initiation of an acute inflammatory response, upregulating endothelial cell adhesion 
molecules such as ICAMs necessary to ensure neutrophil influx to sites of acute 
inflammation (285). Defective macrophage TNF release may therefore provide an 
explanation for the deficient neutrophil recruitment observed at acute inflammatory sites 
in CD.  
Animal studies further support the concept that inadequate TNF production 
during an acute inflammatory response leads to impaired bacterial clearance, increasing 
susceptibility to bowel inflammation and driving chronic granulomatous pathology. 
TNF deficient mice display enhanced susceptibility to DSS-induced colitis, and a 
greater 7 day mortality in comparison to wild type mice (286). Furthermore, in zebrafish 
models infected with Mycobacterium marinum, loss of TNF signalling results in 
increased bacterial burden, which is associated with accelerated granuloma formation 
(287). 
The secreted levels of the chemoattractant IL-8 after HkEc stimulation did not 
differ between CD and HC macrophages. This may be surprising, given the previous 
demonstrations of attenuated IL-8 levels in skin windows from CD patients, and 
defective macrophage release of IL-8 in response to stimuli such as C5a and wound 
fluid (135). There are two important considerations here. Firstly, TNF is an inducer of 
NF-κB activation (288), thereby triggering IL-8 gene transcription; abnormalities in IL-
8 could therefore occur secondary to defective release of TNF, depending on the timing 
and nature of the stimulus investigated. Secondly, whilst macrophages are important 
producers of chemokines during acute inflammation, neutrophils are also recognised to 
secrete significant amounts of IL-8 upon activation (289). IL-8 levels were determined 
24 hours after skin window creation, when neutrophil influx is dramatically impaired in 
CD. It is therefore possible that the observed reduction in IL-8 in skin windows is a 
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consequence of differential neutrophil recruitment between HC and CD patients. This 
may well still be of pathogenic significance and could act to further compound an initial 
defect in the acute inflammatory response in CD. 
Attenuated TNF secretion in CD was observed in response to a variety of 
stimuli, including TLR agonists and HkCa, demonstrating that the abnormalities 
previously described are not purely a phenomenon specific to HkEc. The observation of 
impaired macrophage TNF release in response to HkCa is noteworthy, given the 
presence of ASCA in a substantial percentage of CD patients, and to a lesser extent in 
their healthy relatives, in whom ASCA titres correlate with C. albicans colonisation 
(101;290;291). Defective pro-inflammatory cytokine release from macrophages could 
lead to impaired clearance of C. albicans in vivo; the persistence of C. albicans or its 
components could then trigger the generation of ASCA. However, a primary role for C. 
albicans itself in CD remains an area of controversy, given the lack of clear microscopic 
evidence of invasive candidosis in CD, and expression of the ASCA epitope in other 
microbes, including MAP (98). Interestingly, MAP stimulation of CD macrophages 
may also be associated with attenuated TNF release (187). Therefore, the results cannot 
be extrapolated as proof of a causative role for any individual organism in the 
pathogenesis of CD. Rather, the results suggest an attenuated macrophage response to a 
variety of microbial stimuli; the nature of the critical macrophage-microbe interactions 
in the mucosa is however likely to be complex and heterogeneous between individuals. 
The observation of attenuated TNF release in response to a variety of microbial 
stimuli is consistent with an abnormality in post-translational trafficking of pro-
inflammatory cytokines in CD macrophages. Although post-translational handling of 
cytokines in response to TLR agonists and C. albicans has not been directly addressed 
here, surface expression of TLRs, levels of pro-inflammatory cytokine mRNA after 
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TLR agonist stimulation, as well as mRNA stability, were found to be unaltered in other 
studies conducted in our laboratory (Dr Farooq Rahman, unpublished findings). This 
indicates that there is no abnormality in the downstream signalling pathways of TLRs, 
and in the control of cytokine gene transcription after TLR stimulation, further 
suggesting a post-translational defect in pro-inflammatory cytokine handling in these 
cells. The correlations observed between secreted levels of TNF in response to TLR2 
and HkEc stimulation, and between TNF release after TLR2 and TLR4 stimulation, also 
indicate a likely degree of overlap in the underlying cellular and molecular mechanisms 
responsible for the attenuated pro-inflammatory cytokine release downstream of each 
stimulus. 
A strong correlation was observed between the secreted levels of TNF, IL-6 and 
IFN-γ, indicating that the impaired release of these pro-inflammatory cytokines in CD 
macrophages is related. One possible explanation is that impaired release of IL-6 and 
IFN-γ is secondary to an initial impairment in TNF secretion, given the ability of TNF 
to influence IL-6 gene transcription and release (292). However, the selective 
impairment in a number of pro-inflammatory cytokines could also relate to 
abnormalities in a specific vesicle subset. Studies conducted in RAW macrophage cell 
lines revealed that overlapping mechanisms are involved in the post-translational 
trafficking of TNF and IL-6, both of which require subcompartments of the recycling 
endosome for their release (198). It could therefore be hypothesised that abnormalities 
exist in the recycling endosomal compartment of CD macrophages, which prevent 
adequate pro-inflammatory cytokine release on exposure to microbial stimuli. This is 
currently being addressed in parallel microscopy studies on cellular vesicle trafficking 
being conducted in our laboratory. Interestingly, the release of the pro-inflammatory 
cytokine IL-1β was unaffected from CD macrophages in response to HkEc. The 
intracellular machinery necessary for IL-1β processing and trafficking is distinct from 
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that of TNF and IL-6, involving membrane-derived microvesicles and inflammasome 
activity (188). The finding of equivalent IL-1β release indicates that these alternative 
pathways of cytokine secretion are likely to function normally in CD macrophages in 
response to E. coli, and further argues in favour of specific cellular and molecular 
defects that give rise to a selective abnormality in cytokine secretion. 
Classification of patients in these studies using the Montreal system revealed a 
number of subtle differences in the macrophage TNF response between phenotypes. The 
release of TNF after TLR2 stimulation was most attenuated in patients with stricturing 
disease. Stricture formation is characterised by abnormal wound healing and excessive 
fibrosis of the bowel wall. This may relate to abnormal myofibroblast migration and 
collagen deposition in the context of chronic or relapsing inflammation (293). It is 
possible that a defective TLR2 response predisposes CD patients to stricture formation, 
either by direct influences on myofibroblast function and collagen formation, or 
indirectly by predisposing to a more severe disease course. Interestingly, 
polymorphisms in NOD2 have been associated with a stricturing phenotype in genetic 
studies (294;295), supporting the concept that a defective response to microbes 
downstream of PRRs could be an important prerequisite for the development of 
strictures. 
In contrast, macrophage TNF release downstream of TLR4 stimulation could be 
particularly pertinent in the development of colonic CD. The large bowel contains larger 
numbers of bacteria than the ileum (64), and distinct species, including high numbers of 
anaerobic, Gram negative Bacteroides species (65). Some controversy exists as to 
whether these species primarily stimulate a TLR2 or TLR4 response (296;297). 
Nevertheless, in a context of a high, complex load of bacterial ligands in the underlying 
colonic mucosal tissues (that could occur after the mucosal barrier is breached), 
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adequacy of macrophage TNF release downstream of TLR4 may be a critical factor in 
ensuring adequate neutrophil recruitment and bacterial clearance in the colon. A small 
scale genetic study revealed an association of the D299G TLR4 polymorphism with 
colonic CD (251), potentially adding credence to this hypothesis. This could exert a 
small contributory role in the impaired TNF release; most likely in concert with other, 
distinct molecular and cellular defects, however this has not yet been fully addressed. 
The stimulus specific differences in TNF release between patient subphenotypes 
add to a growing body of evidence that CD is a highly heterogeneous syndrome, with 
various patterns of disease associated with distinct genetic and functional abnormalities. 
It is therefore likely that the underlying molecular mechanisms responsible for such 
functional defects in macrophages, including pro-inflammatory cytokine secretion, are 
also highly heterogeneous. A variety of abnormalities could give rise to subtly different 
patterns of macrophage cytokine release between patients, predisposing to a particular 
disease course. 
In an attempt to identify molecular defects underlying the impaired pro-
inflammatory cytokine secretion, patients were genotyped for 34 SNPs associated with 
CD, and TNF release in response to TLR2 and HkEc compared between genotypes. No 
associations could be detected between any specific CD-associated polymorphism and 
TNF release, either in response to HkEc or TLR2 stimulation. A possible exception was 
NOD2, as CD individuals and one HC individual that were homozygous for NOD2 
variants demonstrated a trend towards attenuated TNF release compared to wild type 
individuals. Although studies conducted on macrophages from NOD2 knockout mice 
revealed normal TNF release in response to TLR2 activation with peptidoglycan (298), 
further studies may be required to clarify the role of NOD2 in the human macrophage 
response to TLR2 and HkEc. 
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Polymorphisms associated with disease through GWAS are mainly markers of 
shared genetic regions which are present at increased frequency in individuals with 
diagnosed disease. It is clear that the effects of individual genetic polymorphisms 
associated with disease by GWAS may be relatively weak, as demonstrated by the high 
frequency of disease associated SNPs in healthy populations and low penetrance, even 
in the case of NOD2. However, it is likely that the cumulative effects of multiple 
susceptibility polymorphisms may be of greater relevance to disease pathogenesis. Gene 
products may interact together in particular functional pathways, giving rise to an 
abnormal phenotype; statistical approaches (299) and functional studies (242) have 
identified a number of such pathways where interactions could occur in CD. In order to 
account for the possibility of cumulative effects of GWAS polymorphisms on 
macrophage TNF release, overall genetic risk scores were calculated for each individual 
patient. In the CD group, patients with an increased burden of GWAS risk alleles had a 
more severe impairment in TNF release in response to HkEc.  
Although correlation cannot be regarded as equating to causality, the observed 
relationship is nevertheless consistent with the notion that the products of GWAS 
susceptibility loci interact to depress the macrophage response to HkEc in CD. The 
precise mechanisms can only be speculated on at this stage, especially given that no 
single polymorphism could be identified as strongly associated with TNF release. 
Larger scale and functional studies will be required to delineate which polymorphisms 
and interactions are responsible for the relationship. It is possible that the products 
encoded by GWAS risk alleles interact to influence intracellular trafficking pathways 
relevant to pro-inflammatory cytokine release in response to HkEc. In support of this, 
the NOD2 protein may be targeted to membranes on activation (300), and its agonist 
MDP is localised to acidified vesicles upon uptake into primary macrophages; a process 
that occurs via a clathrin and dynamin-dependent endocytic pathway (301). In addition, 
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stimulation of the NOD2 receptor with MDP leads to induction of autophagy (242;302) 
and recruitment of ATG16L1 to the plasma membrane (302). Recent studies have 
implicated a role for autophagy in controlling the release of pro-inflammatory cytokines 
such as TNF and IL-1β from macrophages, and notably incubation of cells with the 
autophagy inhibitor 3-methyladenine reduces TNF release in response to TLR 
stimulation (237). Although this was proposed to relate to reduced transcription of the 
TNF gene, influences at the post-translational level cannot be ruled out.  
Whilst tempting to speculate that the products of GWAS susceptibility loci 
could interact to influence vesicle trafficking pathways, there are a number of other 
possible explanations for the relationship. Distinct abnormalities could exist in the 
cytokine trafficking pathway in CD macrophages, but the effect could be compounded 
by an increased load of GWAS polymorphisms, acting to further impair the macrophage 
response to Gram negative bacteria such as E. coli. Furthermore, the association may 
also be explained by protective alleles interacting to increase TNF release in response to 
HkEc stimulation, partially compensating for an inadequate innate immune response to 
HkEc. Regions containing IL-23R and TNFSF15 are both examples of loci where 
certain alleles can confer protection against CD (116;244), and interestingly IL-23 has 
been shown to induce inflammatory macrophages to produce TNF in murine models of 
autoimmune inflammation (303). Finally, the possibility of indirect associations 
between GRS and macrophage TNF release cannot be excluded. 
There was no association between overall GRS and macrophage TLR2 response 
in CD patients, suggesting these risk alleles have no major role in the impaired release 
of TNF downstream of TLR2 stimulation. Somewhat paradoxically, macrophages from 
HC individuals with a GRS of more than 1 produced significantly more TNF than those 
with a GRS less than 1. This could indicate a protective role of a strong TLR2 response 
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in HC individuals with a higher burden of GWAS hits, which might be able to 
compensate to prevent the development of CD. 
Overall, the lack of association of GRS with TNF release downstream of TLR2 
activation, and weak relationship with HkEc stimulation, suggests that the molecular 
basis of impaired pro-inflammatory cytokine secretion by CD macrophages remains 
incompletely understood. A number of additional loci have recently been reported as 
associated with CD, several of which contain genes encoding proteins involved in 
vesicle and protein trafficking (VAMP3, NDFIP1, SCAMP3) (115), which could have a 
role in pro-inflammatory cytokine release by macrophages. It has been estimated that 
approximately 23% of the heritability of CD can be explained by the variants identified 
to date by GWAS (115). Furthermore, it has recently been postulated that rare variants 
and structural rearrangements could account for some of the ‘missing heritability’ (257). 
It is very possible that some of these mutations, which are likely to be highly 
heterogeneous between individual patients, could be important determinants of the 
macrophage response to bacterial stimuli. 
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Chapter 4: Investigation of macrophage lipids in Crohn’s disease 
4.1 Introduction 
Mounting evidence, including data presented in the previous chapter, suggests the 
pathogenesis of CD involves a defective innate immune response to microbial material. 
Patients with CD have delayed clearance of bacteria in vivo, which is likely to relate to 
abnormal macrophage function. Cultured macrophages from CD patients release 
deficient levels of pro-inflammatory cytokines in response to HkEc. Defective TNF 
release is also observed in response to a range of stimuli, including TLR agonists and 
the yeast C. albicans, as demonstrated in chapter 3.  
The abnormality in cytokine secretion was shown to relate to post-translational 
handling of pro-inflammatory molecules, as discussed in chapter 1. Whilst the level of 
cytokine gene transcription in response to HkEc was equivalent between CD and HC 
macrophages, studies using inhibitors of protein trafficking and lysosomal function 
revealed mistargeting of pro-inflammatory cytokines to lysosomes in CD macrophages, 
where they are degraded rather than released through the normal secretory pathway 
(136). However, the molecular mechanisms responsible for this abnormality remain 
uncharacterised.   
 In this chapter, sphingolipids and phospholipids are investigated as candidates 
for the defective macrophage function observed in CD, given the prominent roles of 
these lipids in membrane trafficking, autophagy and apoptosis. 
4.1.1 Introduction to sphingolipids and their functions 
The sphingolipids and phospholipids are major constituents of eukaryotic cell 
membranes. Whilst both have long been understood to have a critical role in the 
maintenance of membrane structure, the rich array of functions of each lipid class is 
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increasingly being uncovered (304). Sphingolipids were originally named by J.L.W 
Thudichum in 1884, as a testament to their enigmatic or “sphinx-like” nature (305). All 
sphingolipids contain a sphingoid base backbone. In humans, the sphingoid base is 
typically sphingosine (an 18 carbon length base containing one double bond) or 
sphinganine (a saturated 18 carbon length base). Ceramide, the simplest sphingolipid, is 
made up of sphingosine and a fatty acid, which are linked by an amide bond (Figure 
4.1A). The fatty acid can vary in carbon chain length, ranging from 16 to 26 atoms, and 
in the number of double bonds (degree of unsaturation), giving rise to a multitude of 
different ceramide ‘species’. The precise biological roles of each individual ceramide 
species remain somewhat of an enigma. Ceramide is considered a structural backbone 
for all other complex sphingolipids, including sphingomyelin and glycosphingolipids 
(306). 
Ceramide may be generated from two distinct pathways, including ‘de novo’ 
synthesis from fatty acyl-CoA and serine, and by hydrolysis of sphingomyelin or other 
complex sphingolipids. The former involves condensation of serine and fatty acyl-CoA 
by serine palmitoyltransferase to form 3-ketosphinganine. Reduction of 3-
ketosphinganine results in sphinganine generation, which can be N-acylated to form 
dihydroceramide, and further desaturated to form ceramide (307). Serine 
palmitoyltransferase catalyses the rate limiting step of this reaction, whereas 
sphingomyelinases catalyse the breakdown of sphingomyelin to release ceramide and 
phosphocholine. Ceramide may be phosphorylated to ceramide phosphate (308); used to 
synthesise glycosphingolipids, sphingomyelin or sulphatides, or broken down by 
ceramidase enzymes to release sphingosine and free fatty acids (306;309). The pathway 
of sphingolipid metabolism is illustrated diagrammatically (Figure 4.1B). 
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Figure 4.1 Diagrams of ceramide structure and sphingolipid metabolism
pathway. (A) Structure of C16 ceramide, showing sphingosine (red box)
attached to a C16 fatty acid (green box) via an amide bond. Adapted from
http://lipidlibrary.aocs.org/lipids/ceramide/index.htm. (B) Sphingolipid
metabolism pathway. Note the central role of ceramide. Adapted from (309).
A
B
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Sphingolipids have diverse effects on cellular physiology. Firstly, the 
sphingolipid content has strong influences on the biophysical properties of cell 
membranes. Ceramide has been shown to facilitate fission and fusion of membranes, to 
increase the order of acyl chains, and permeabilise lipid bilayers (310). Importantly, 
slug-a-bed (SLAB) (ceramidase) mutant Drosophilia show impaired neurotransmitter 
release, which relates to alterations in presynaptic ceramide content and changes in 
synaptic vesicle fusion, exocytosis and trafficking (311). Furthermore, macrophages 
from acid sphingomyelinase (ASM) deficient mice have impaired phagolysosomal 
fusion, which results in grossly defective killing of Listeria monocytogenes, suggesting 
a role for sphingolipids in the regulation of ‘fusogenicity’ of membranes, with 
consequential biological effects on cell function (312). Some of the biological effects of 
ceramides may also depend on their tendency to self-associate, which can lead to the 
formation and stabilisation of ceramide-enriched microdomains (‘lipid rafts’) (313;314). 
Although their existence remains an area of controversy, a number of studies indicate 
that lipid rafts may serve to cluster receptors and signalling proteins such as CD95 and 
CD40 (315;316). 
It is increasingly apparent that sphingolipid metabolism and inflammatory 
responses are intimately connected (317). On one hand, bacterial ligands such as LPS, 
as well as pro-inflammatory cytokines such as TNF and IL-1β, have been shown to 
stimulate an increase in intracellular ceramide levels (318;319) by various mechanisms, 
including serine palmitoyltransferase activation (320). Moreover, sphingolipids are 
involved in the induction of certain cytokines, such as IL-6 (321). Ceramide and 
ceramide-1-phosphate may also depress TNF release (322), most likely via effects at the 
post-translational level and influencing TACE activity (323). 
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Sphingolipids show another parallel to the acute inflammatory defect of CD, in 
that they may also influence inflammatory responses via effects on apoptosis of immune 
cells. Ceramide is a well-established apoptotic mediator, which may exert effects via 
signalling molecules such as protein kinase C zeta (324) and ceramide-activated protein 
phosphatases (325). It may also exert effects on mitochondria directly; increasing the 
permeability of the outer membrane via formation of ‘ceramide channels’ (326). This 
facilitates the release of small proteins such as cytochrome c from mitochondria, which 
can trigger caspase activation and thereby apoptosis.  
Furthermore, ceramide has been shown to have important roles in the control of 
autophagy, a process strongly implicated in the pathogenesis of CD. Alterations in 
sphingolipid metabolism could therefore provide a mechanistic connection between the 
defective trafficking of cytokines and impaired autophagy in CD pathogenesis. Addition 
of exogenous ceramide has been shown to induce autophagy (327), which may relate to 
modulation of signalling networks or changes in the biophysical properties of 
membranes (306). 
4.1.2 Phospholipids: structure, synthesis and biological functions 
Glycerophospholipids (also known as phospholipids) are the predominant lipid 
components of eukaryotic cell membranes. Phospholipids are composed of two fatty 
acids attached to a glycerol backbone via ester, ether or vinylether bonds, and a 
headgroup comprised of phosphate and polar moieties. Various classes of phospholipids 
exist, which are defined by the structure of the headgroup. The principal phospholipid 
classes include phosphatidylcholines (PC), phosphatidylethanolamines (PE), 
phosphatidylinositols (PI) and phosphatidylserines (PS), where the headgroups are 
choline, ethanolamine, inositol and serine respectively (Figure 4.2A). As for 
sphingolipids, the nature of the two fatty acids may vary both in carbon chain length 
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(typically from 14 to 26 carbon atoms) and the number of double bonds (normally 
between 0 and 6), which gives rise to a complex repertoire of different possible 
molecular species within each phospholipid class (328;329). Fatty acids found in 
phospholipids typically include palmitic acid (C16:0), stearic acid (C18:0), oleic acid 
(C18:1), arachidonic acid (C20:4), the essential fatty acid linoleic acid (C18:2), 
eicosapentaenoic acid (C20:5) and docosahexaenoic acid (C22:6). 
 All glycerophospholipids are synthesised from the precursor phosphatidic acid 
(PA). PA may be dephosphorylated to yield diacylglycerol (DAG), which is used in the 
synthesis of PC, PE and PS. CDP-Diacylglycerol (CDP-DAG) may also be generated 
from PA by action of the CDP-diacylglycerol synthase. The CDP-DAG may be 
converted to PI, phosphoglycerol (PG) and cardiolipin (CL) in subsequent reactions 
(328) (Figure 4.2B). 
 PC is the most abundant phospholipid in eukaryotic cell membranes and 
functions as a major structural component. Synthesis of PC generally occurs via the 
CDP-choline (Kennedy) pathway (330), although certain cells such as hepatocytes are 
also capable of generating PC from PE in a series of reactions catalysed by the enzyme 
phosphatidylethanolamine N-methyltransferase (PEMT) (331). The first step in the 
Kennedy pathway is the phosphorylation of choline to produce phosphocholine, 
catalysed by choline kinase (332;333). The choline utilised in this reaction is obtained 
from the diet or from the breakdown of lipids and acetylcholine (334). Subsequently, 
the phosphocholine is converted to CDP-choline in a condensation reaction utilising 
cytidine triphosphate (CTP) and catalysed by the CTP: phosphocholine 
cytidylyltransferase enzyme (CCT). Distinct α and β isoforms of CCT exist, which are 
encoded by two separate genes. The transcripts encoded by these genes may undergo 
alternative splicing to generate multiple protein products. CCT-α isoforms predominate  
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Figure 4.2 Structure and biosynthesis of phospholipids. (A) Generic phospholipid structure,
showing a glycerol backbone to which two fatty acids (R1 and R2) are attached. A head-
group (X) is also attached to glycerol via a phosphodiester bond. The nature of the head
group determines the phospholipid class, as indicated. Adapted from (276). (B) Schematic
diagram of the phospholipid biosynthetic pathway. Enzymes catalysing each reaction are
shown in red. The major metabolites are highlighted in bold (PC, phosphatidylcholine; PS,
phosphatidylserine; PE, phosphatidylethanolamine; PA, phosphatidic acid; PI ,
phosphatidylinositol; CL, cardiolipin; PG, phosphatidylglycerol; DAG, diacylglycerol.
Adapted from (328).
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in most tissues, generally being expressed at levels 10 to 30 fold higher than CCT-β 
(335;336). The reaction catalysed by CCT is regarded as the rate limiting step in PC 
synthesis (337) and is tightly regulated. The final step in the Kennedy pathway is the 
transfer of phosphocholine from CDP-choline to DAG by a phosphotransferase enzyme, 
thereby generating PC. 
 PC is an important structural component of all cell membranes, including 
intracellular vesicles (338). A number of studies have highlighted the importance of PC 
and phospholipid composition in ensuring efficient intracellular membrane trafficking. 
In Drosophila, mutations in CCT give rise to an altered ratio of PC to PI and 
consequential alterations in endocytosis, resulting in aberrant localisation of the 
epidermal growth factor and Notch receptors (339). In yeast, the phospholipid transfer 
protein SEC14p is required for efficient export of proteins from the Golgi apparatus 
(340), and mutations in the CDP-choline pathway overcome this requirement (341). 
Together these observations indicate that SEC14p regulation of membrane phospholipid 
dynamics is important in maintaining the ‘secretory competence’ of Golgi membranes. 
 The generation of PC is understood to have a number of important roles in 
macrophage function. Differentiation of monocytes into macrophages is associated with 
an increase in PC content, and alterations in the degree of PC saturation (342). The 
same study reported that induction of fatty acid synthesis during differentiation 
influenced macrophage ultrastructure and organelle development, possibly by 
influencing the synthesis of PC and PE. Furthermore, PC biosynthesis has been shown 
to have a critical role in pro-inflammatory cytokine secretion in macrophages (197), as 
indicated in section 1.3.4. Murine macrophages deficient in CCT-α secrete reduced 
levels of TNF and IL-6 in response to LPS stimulation, whilst IL-1β and apolipoprotein 
E release are unaffected. Interestingly, although the synthesis of pro-inflammatory 
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cytokines in CCT-α deficient macrophages is normal, impaired release occurs due to 
abnormal post-translational handling and retention of these molecules in the Golgi 
apparatus. Given the parallels between the phenotype of CCT-α deficient macrophages 
and that of cultured macrophages from CD patients, it could be hypothesised that CD 
macrophages display abnormalities in PC synthesis that underlie the impairment in 
cytokine secretion. 
 In mammalian cells, PS is synthesised in a base exchange reaction from PC or 
PE, in which the headgroup is replaced by L-serine. Two distinct PS synthase enzymes 
are found in mammalian cells; PS synthase-1 (PSS-1) catalyses the synthesis of PS from 
PC (343), whereas PS synthase-2 (PSS-2) uses PE as the substrate (344). PS is 
understood to have a number of important biological functions, including as a cofactor 
for enzymes such as protein kinase C (345). PS is normally found at high concentrations 
at the plasma membrane, where it is asymmetrically distributed so that nearly all PS is 
located at the cytoplasmic face of the membrane bilayer. During apoptosis, loss of the 
phospholipid asymmetry occurs so that PS becomes distributed on the external 
membrane surface (346). PS externalisation by apoptotic cells is required for their 
uptake and clearance by macrophages (347), a process which is also dependent on the T 
cell immunoglobulin mucin (TIM) glycoproteins on the surface of macrophages and 
other phagocytic cells, which specifically bind PS (348). 
 PI is synthesised in a two step process from phosphatidic acid. Initially, CDP-
DAG is synthesised from PA and CTP, catalysed by the enzyme CDP-DAG synthase. 
Subsequently, CDP-DAG is converted to PI in a condensation reaction with myo-
inositol, which is catalysed by PI synthase (328). PI is an important structural lipid, and 
is also a substrate for various lipid kinases and phosphatases, which can generate 
phosphoinositide derivatives (phosphoinositides or PIPs). PIPs are important second 
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messenger molecules in signalling pathways involved in the control of cell growth, 
cytoskeletal re-organisation and membrane trafficking (349). Interestingly, PI 3-kinase, 
an enzyme that converts PI species to phosphatidylinositol-3,4,5-bisphosphate, was 
recently shown to be important for TNF trafficking from the Golgi apparatus to the 
plasma membrane in macrophages (350). The generation of phosphatidylinositol-3,4,5-
bisphosphate via PI 3-kinase activity has also been shown to be important for autophagy 
(351). 
4.1.3 Previous investigations of lipids in Crohn’s disease and hypothesis 
A number of studies have indicated that CD patients may have abnormalities in lipid 
metabolism, which could have a pivotal role in the disease pathogenesis. Case-control 
studies have shown positive correlations between dietary fat consumption and the 
development of CD (22), and in one small scale randomised controlled trial, a high fat 
content was found to attenuate the benefits of an elemental diet in patients with active 
disease (352). GWAS have also identified CD-associated variants in loci containing 
genes related to lipid metabolism. The recent GWAS meta-analysis identified a SNP on 
chromosome 11q12 in close proximity to FADS1 (115), which encodes the fatty acid 
desaturase 1 enzyme. Genetic variation in this gene has been associated with alterations 
in the fatty acid composition in serum phospholipids (353). The WTCCC found 
moderate evidence of association with a SNP located in the SPTLC2 gene encoding 
serine palmitoyltransferase, long chain base subunit 2 (p=2.65x10
-5
) (130), although this 
association was not replicated in the recent GWAS meta-analysis (115). Furthermore, 
whilst the exact identity of the ‘CD susceptibility gene’ within the IBD5 locus remains 
contentious, a putative candidate is the organic cation transporter 1, which functions in 
the mitochondrial transport of L-carnitine (222). 
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Studies conducted on biological samples from CD patients have demonstrated 
decreased membrane fluidity in erythrocytes from CD patients, with concomitant 
increases in sphingomyelin and reductions in phosphatidylcholine and polyunsaturated 
acyl chains of phospholipid (354). Another study demonstrated alterations in 
glycosphingolipid metabolism in patients with CD (355). Increased concentrations of 
the glycosphingolipid lactosylceramide were reported in biopsies from CD patients, 
compared to controls and patients with UC. However, as inflamed tissue was 
investigated from patients with active CD, it is possible that these changes were 
secondary to a chronic inflammatory state in the bowel. 
 There is also considerable evidence describing fatty acid abnormalities in CD, 
although the results are somewhat conflicting. Plasma phospholipids of patients with 
CD were reported to have alterations in the fatty acid profile, with reductions in the 
percentage of arachidonate (20:4), and an increased saturation index (sum of saturated 
fatty acids in relation to unsaturated fatty acids) (356). Another investigation of 
peripheral blood mononuclear cells demonstrated an altered ratio of omega-3 (n-3) to 
omega-6 (n-6) polyunsaturated fatty acids (357). In contrast, two studies investigating 
serum fatty acids in patients with CD revealed an increase in unsaturated fatty acids, 
particularly arachidonate and docosahexaenoic acid (C22:6 n-3) (358;359). The changes 
were common to patients with active and quiescent disease, and patients with UC. 
Lipids from adipose and lymphoid tissues have been reported to contain more saturated 
but fewer polyunsaturated fatty acids, with preferential depletion of n-6 polyunsaturates 
in lymphoid cells and n-3 polyunsaturates in adipose tissue (360). Whilst the evidence 
for n-3 polyunsaturated fatty acids in the treatment of CD is not yet compelling (16), the 
efficacy of enteral nutrition in CD may depend on the relative content of 
monounsaturated compared to polyunsaturated fatty acids, suggesting that the balance 
of fatty acids could influence disease pathogenesis and course (361). 
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To date, no studies have been conducted investigating macrophage phospholipid 
and sphingolipid composition in CD. Given prominent roles of sphingolipids and 
phospholipids in the maintenance of membrane structure and vesicle trafficking, it was 
hypothesised that abnormalities in the macrophage sphingolipid or phospholipid 
composition could underlie the defective cytokine secretion observed in CD. 
Sphingolipids (including ceramides, dihydroceramides and sphingoid bases) in CD 
macrophages were therefore quantified using high performance liquid chromatography 
tandem mass spectrometry (HPLC-MS). Phospholipid composition and dynamics were 
investigated using stable isotope labelling and electrospray ionisation mass 
spectrometry (ESI-MS). Lipidomics analysis of ileal biopsies from CD patients was also 
performed to determine whether any alterations were also present in the mucosa. 
4.2 Results 
4.2.1 Sphingolipid composition of unstimulated HC and CD macrophages 
The sphingolipid composition of HC and CD macrophages was quantified to determine 
any abnormalities that could explain the impairment in cytokine secretion and 
apoptosis. Macrophages were cultured, and the amounts of sphingoid bases, 
dihydroceramide and ceramide (in pmol/mg protein) were determined by HPLC-MS. 
Demographics of patients included in this study are shown (Appendix 1 Table IIA). 
Two batches of analysis were performed, the first consisting of unstimulated 
macrophages from HC (n=11) and CD (n=14) donors, and the second consisting of 
macrophages from HC (n=7) and CD (n=8) patients, with paired unstimulated and HkEc 
stimulated samples from these donors. Although similar patterns in the ceramide carbon 
chain length and degree of unsaturation were observed, the absolute values for the 
amounts of C16 and C24 ceramide differed significantly between batches (p<0.001). 
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Therefore, for simplicity only the results of the second batch are discussed below, to 
allow comparison of unstimulated and HkEc paired samples. 
Ceramide species consisting of 14-26 carbon atom length fatty acids were 
detectable in HC and CD macrophages. C16 dihydroceramide, sphingosine and 
dihydrosphingosine (sphinganine), but not sphingosine-1-phosphate, were also 
detectable. The predominant species in both HC and CD macrophages were the C16:0, 
C24:0 and C24:1 ceramides (Figure 4.3A, B). In HC macrophages, C16:0, C24:0 and 
C24:1 ceramides constituted 22.4% + 3.6%, 32.4 + 2.1% and 37.6 + 1.6% of the total 
ceramide content respectively. In CD macrophages, the C16:0, C24:0 and C24:1 
ceramides constituted 18.4 + 6.5%, 35.5 + 12.5% and 38 + 13.4% respectively.  There 
were no statistically significant differences in the mean amounts of any ceramide 
species, dihydroceramide or sphingoid base between HC and CD macrophages in the 
unstimulated state (Figure 4.3C, D). The mean total cellular ceramide content was also 
not significantly different between HC (802.3 + 82.7 pmol/mg) and CD (672.4 + 56.5 
pmol/mg) macrophages (Figure 4.3E). 
Whilst ceramides are considered to have a central role in the sphingolipid 
pathway, they may be used to synthesise more complex species such as sphingomyelin 
and glycosphingolipids. A parallel study, conducted in our laboratory by Dr Andrew 
Smith and Professor Al Merrill using HPLC-MS, also revealed no significant 
differences in the sphingomyelin and hexosylceramide content of CD macrophages, 
further evidencing the lack of a gross defect in the sphingolipid pathway in CD 
macrophages. 
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Figure 4.3 Ceramide and sphingoid base composition of unstimulated HC and CD 
macrophages. The amounts of individual ceramide species, consisting of between 14 and 26 
carbon chain length fatty acids were quantified in HC (n=7) and CD (n=8) macrophages by 
high performance liquid chromatography tandem mass spectrometry. (A, B) Pie charts 
depicting the proportion of various ceramide species (C, fatty acid carbon chain length) in 
HC and CD macrophages respectively, expressed as a percentage of the total amount of 
ceramide detected. (C) The amounts of individual ceramide species (in pmol/mg protein) in 
unstimulated HC and CD macrophages. The amount of C16:0 dihydroceramide (dhC16:0) is 
also shown. No significant differences were identified between HC and CD cells. Results are 
expressed as mean + SEM. (D) The amounts of sphingosine (Sph) and dihydrosphingosine 
(dhSph) in HC and CD macrophages, expressed as mean + SEM. (E) Total amounts of 
ceramide in HC and CD macrophages, expressed as mean + SEM.
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4.2.2 Sphingolipid composition of HkEc stimulated macrophages 
In the absence of an obvious difference in the sphingolipid composition of resting HC 
and CD macrophages, it was subsequently determined whether HkEc stimulated CD 
macrophages had abnormalities in sphingolipid composition. The amounts of ceramide, 
dihydroceramide and sphingoid base species in HC (n=7) and CD (n=12) macrophages 
after 4 hours stimulation with HkEc was therefore determined. 4 hours after stimulation 
was chosen as this was the point where maximal rate of secretion of TNF occured in HC 
macrophages in response to heat-killed E. coli (136), and when targeting of TNF to 
lysosomal compartments occurred in CD macrophages. 
In HC macrophages, stimulation with HkEc resulted in a significant reduction in 
C16:0 (42.3 + 29.2% decrease, p<0.05), C24:0 (18.1 + 6.3%, p<0.05) and C24:1 (24.1 + 
5.4%, p<0.01) ceramide species, and a significant increase in dihydrosphingosine (40 + 
13.5% increase, p<0.001) (Figure 4.4A, B, C, D, left panel). No other differences in 
ceramide or sphingoid base species between unstimulated and stimulated macrophages 
were statistically significant. Similarly, in CD macrophages, stimulation with HkEc 
resulted in a significant reduction in C24:0 (12 + 4.3%, p<0.05) and C24:1 (21.4 + 
3.1%, p<0.01) ceramide species, with a concomitant increase in dihydrosphingosine 
content (25.8 + 14.1%, p<0.05) (Figure 4.4A, B, C, D, right panel). Although the 
amount of C16:0 species also decreased in CD macrophages after stimulation, the 
reduction did not reach statistical significance. Comparison of mean amount (in 
pmol/mg of protein) of individual ceramide and dihydroceramide species (Figure 4.5A) 
and sphingoid bases (Figure 4.5B) did not reveal any significant differences between 
HC and CD macrophages in the HkEc stimulated state. The mean total ceramide content 
was 601.6 + 79.4 pmol/mg in HC macrophages and 565.5 + 42.1 pmol/mg in CD 
macrophages, which also did not represent a significant difference (Figure 4.5C). 
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Figure 4.4 Alterations in amounts of ceramide and sphingoid bases in HC and CD 
macrophages after HkEc stimulation. Macrophages from HC (n=7) and CD (n=8) donors 
were cultured and stimulated with HkEc for 4 hours. Ceramide and sphingoid bases were 
quantified by HPLC-MS. Alterations in the amount of (A) C16:0, (B) C24:0, (C) C24:1 
ceramides and (D) dihydrosphingosine (dhSph) are shown for HC (left panel) and CD 
(right panel) macrophages. * represents p<0.05, ** p<0.01 and *** p<0.001.
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Figure 4.5 Ceramide and sphingoid base composition of HkEc stimulated HC and CD 
macrophages. Macrophages from HC (n=7) and CD (n=12) individuals were stimulated 
with HkEc for 4 hours and ceramides and sphingoid bases quantified by high performance 
liquid chromatography tandem mass spectrometry. (A) Amounts of individual ceramide 
species (C, fatty acid carbon chain length), expressed as pmol/mg protein. Results for 
C16:0 dihydroceramide (dhC16:0) are also shown. (B) Amounts of sphingosine (Sph) and 
dihydrosphingosine (dhSph). (C) Total amount of ceramide. No significant differences 
were found between HC and CD macrophages. Results are presented as mean + SEM.
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4.2.3 Investigation of phospholipid dynamics in CD and HC macrophages 
Relative quantification of the phospholipid species PC, PI and PS in CD and HC 
macrophages was subsequently performed by ESI-MS, as a collaborative project with 
the University of Southampton. Depending on the lipid class to be detected, ESI-MS 
quantification requires use of a ‘triple quadrupole’ mass spectrometry based system and 
a variety of ‘precursor’ and ‘neutral loss’ scans. Electrospray ionisation enables 
ionisation of neutral species and transfer of ions from solution into gaseous phase. The 
ions are then subjected to an electrical field, established by an assembly of three sets of 
four parallel metal rods (‘quadrupoles’), which enables resolution of ions based on their 
mass to charge (m/z) ratio. Subsequently, the ions selected (‘precursor ions’) in the first 
quadrupole are subjected to further fragmentation in the second quadrupole, in a process 
known as ‘collision induced dissociation’. The resulting fragments (‘products’) are then 
separated again in the third quadrupole, based on m/z ratio. There are several possible 
modes of data acquisition, including a ‘precursor scan’, where a unique product ion is 
selected in the third quadrupole, and the first quadrupole scans to detect a range of 
possible precursor ions (362).  
In the case of endogenous PC, the species contain the choline headgroup of m/z 
184+. The MS is programmed to perform a “precursor analysis” to detect positively 
charged species that undergo collision induced dissociation to give rise to the 184+ 
choline fragment. A representative spectrum, resulting from all lipid components in the 
sample containing the 184+ choline species is shown (Figure 4.6A). Similarly for 
endogenous PI species, the MS is programmed, in negative ionisation mode, to perform 
a precursor scan of fragments that degenerate to produce the 241- inositol species. In the 
case of PS, a ‘neutral loss’ scan is performed, where both quadrupoles 1 and 3 scan at a 
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constant difference in m/z ratio. This is used to monitor species that undergo loss of the 
87 neutral fragment during collision induced dissociation. 
Macrophages were incubated with stable isotope labelled methyl-d9-choline, 
myo-d6-inositol and serine-d3 for 3 hours, in the presence or absence of HkEc. 3 hours 
was chosen as the appropriate time period based on the results of previous studies 
investigating phospholipid turnover in leukocytes (363) and macrophages (342). Lipids 
were subsequently extracted and the molar percentage of PC, PI and PS species 
quantified by ESI-MS. Inclusion of stable isotope labelled methyl-d9-choline, myo-d6-
inositol and serine-d3 permits distinction of ‘newly synthesised’ phospholipids from 
pre-existing or ‘endogenous’ species, thus enabling determination of metabolic flux 
rates through the phospholipid synthesis pathways (364). Demographics of individuals 
included in this study are shown (Appendix 1 Table IIB). Six patients in this study were 
receiving no treatment and eight were receiving 5-ASA. The mean body mass index 
(BMI) of the CD patients in this study was 23.3 + 3.0 kg/m
2
 (mean + standard 
deviation). One of the patients was receiving vitamin B12 replacement therapy; none of 
the other patients had any evidence of impaired nutritional status. None of the patients 
were receiving enteral nutrition. 
Endogenous and newly synthesised PC were determined in all samples, 
including unstimulated (HC n=10, CD n=13) and HkEc stimulated (HC n=7, CD n=8) 
macrophages. Endogenous and newly synthesised PS and PI were quantified in a subset 
of unstimulated (HC n=7, CD n=9) and HkEc stimulated samples (HC n=6, CD n=5). 
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4.2.4 Analysis of PC in HC and CD macrophages 
Precursor scans of m/z 184+ and m/z 193+ were used to determine endogenous and 
newly synthesised PC species respectively in CD and HC macrophages. Representative 
PC spectra from one HC individual, generated as precursor scans of m/z 184+ and 193+ 
are shown (Figure 4.6A, B). The predominant peaks at m/z 760.8 and 786.8 correspond 
to endogenous PC 16:0/18:1 and PC 18:0/18:2 species respectively (Figure 4.6A). 
Newly synthesised PC species can clearly be distinguished from endogenous PC, 
generated from the m/z 193+ precursor scan (Figure 4.6B).  The peaks at m/z 769.8 and 
m/z 795.8 correspond to newly synthesised PC 16:0/18:1 and PC 18:0/18:2 species 
respectively (9 m/z units greater than for the endogenous species). 
Relative quantification of PC species was performed from the generated spectra 
using macro software developed at the University of Southampton. Only PC species that 
made up >2 % of the total molar percentage of PC were considered detectable. In 
unstimulated HC macrophages (n=10 donors), the predominant endogenous PC species 
were PC 16:0/16:0, PC 16:0/18:1 and PC 18:0/18:2, which made up 11.7 + 0.64%, 22.0 
+ 0.73% and 13.2 + 0.66% of the total endogenous PC respectively. Similarly in 
unstimulated CD macrophages (n=13 donors), PC16:0/16:0, PC 16:0/18:1 and 
PC18:0/18:2 were the major species present, which made up 11.9 + 0.75%, 22.2 + 
0.62% and 12.3 + 0.84% of the total endogenous PC respectively. There were no 
significant differences in the molar percentage of any endogenous PC species between 
HC and CD macrophages. Stimulation with HkEc resulted in a significant reduction in 
the molar percentage of endogenous PC containing arachidonate (16:0/20:4) in both HC 
and CD macrophages. No other alterations were observed after stimulation and there 
were no significant differences between HC and CD macrophages (Figure 4.7A). 
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 Precursor of m/z 184 +
Figure 4.6 Electrospray ionisation mass spectrometric analysis of endogenous and newly 
synthesised PC. (A) Precursor scan of m/z 184+, indicating endogenous PC species. Note 
the peak at m/z 760.8, which corresponds to PC 16:0/18:1. (B) Precursor scan of m/z 193+ 
showing newly synthesised PC species 9 m/z units higher than the endogenous species, 
indicating incorporation of  the methyl-d9-choline stable isotope. The peak at m/z 769.8 
corresponds to newly synthesised PC 16:0/18:1.
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Figure 4.7 Composition of endogenous and newly synthesised PC species in HC and CD 
macrophages. Macrophages were cultured from HC individuals and CD patients, incubated 
with methyl-d9-choline for 3 hours in the presence (HC n=7, CD n=8) or absence (HC n=10, 
CD n=13) of HkEc. Lipids were extracted and PC species quantified by electrospray 
ionisation mass spectrometry. (A) Molar percentage composition of endogenous PC species, 
consisting of various carbon chain length fatty acids, in unstimulated (Uns) and HkEc 
stimulated HC and CD macrophages. (B) Molar percentage composition of newly 
synthesised (D9) PC species, in unstimulated and HkEc stimulated HC and CD 
macrophages. Results are expressed as mean + SEM. * indicates p<0.05.
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The profile of newly synthesised PC species was similar to that of the 
endogenous PC profile of HC and CD macrophages. PC 16:0/18:1 and PC16:0/18:2 
were the predominant newly synthesised species in HC and CD macrophages (Figure 
4.7B). Stimulation with HkEc increased the proportion of PC 16:0/18:1 synthesised in 
HC macrophages, and increased the fraction of synthesised PC 16:0/16:1 in CD cells. 
There were no significant differences in the molar percentage of any species between 
HC and CD macrophages, either in the unstimulated state or after stimulation with 
HkEc. 
The incorporation of methyl-d9-choline into PC was also determined over 3 
hours in HC and CD macrophages, as a measure of the global rate of synthesis of all PC 
species (Figure 4.8). The mean fractional incorporation of methyl-d9-choline into PC 
over the 3 hour period was 10.3 + 1.3% in unstimulated HC macrophages and 10.5 + 
1.5% in CD macrophages, indicating equivalent rates of PC synthesis in HC and CD 
cells. Stimulation with HkEc increased the mean fractional incorporation of methyl-d9-
choline into PC in HC macrophages (17.0 + 1.1%, p<0.01), and CD macrophages (16.9 
+ 1.1%, p<0.01) compared to unstimulated cells. Stimulation with HkEc was therefore 
associated with an increased rate of PC synthesis; however there were no significant 
differences between HC and CD macrophages. 
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Figure 4.8 Incorporation of methyl-d9-choline into HC and CD macrophage PC. 
Macrophages were cultured from HC and CD donors and incubated with methyl-d9-choline 
for 3 hours. Results are shown for unstimulated (Uns) macrophages (HC n=10, CD n=13) 
and HkEc stimulated cells (HC n=7, CD n=8). Total lipid was extracted and analysed by 
ESI-MS as  precursor scans of m/z 184+ and m/z 193+.   The fractional incorporation of 
methyl-d9-choline as a % of the total PC was determined. 
160
  
4.2.5 Analysis of PS in HC and CD macrophages 
Neutral loss scans of m/z 87 and m/z 90 were used to determine the profile of 
endogenous and newly synthesised PS species respectively in HC and CD macrophages. 
Representative PS spectra from one HC individual are shown (Figure 4.9). A 
representative neutral loss scan of m/z 87- is shown (Figure 4.9A); the peak at m/z 788.9 
corresponding to endogenous PS 18:0/18:1. A representative neutral loss scan of m/z 
90- is also shown (Figure 4.9B); peaks at m/z 763.8, 789.9, 791.9 and 813.9 correspond 
to the newly synthesised species PS 16:0/18:1, PS 18:0/18:2, PS 18:0/18:1 and PS 
18:0/20:4. Spectra were converted to centroid format and used to determine the molar 
percentage composition of endogenous and newly synthesised PS species, together with 
the overall rate of PS synthesis. 
 The predominant endogenous PS species was a monounsaturated species 
containing 18 length carbon fatty acids (PS 18:0/18:1) (Figure 4.10A). This species 
made up 44.0 + 1.9% of the endogenous PS in HC macrophages and 42.9 + 1.1% in CD 
macrophages. Nine other endogenous PS species were detectable, each of which made 
up less than 10% of the total PS. There were no significant differences in the molar 
percentage of any PS species between unstimulated HC and CD macrophages. There 
were no alterations in any endogenous PS species after stimulation with HkEc, and no 
significant differences between HC and CD macrophages in the stimulated state. 
 The predominant newly synthesised PS species over the 3 hours in unstimulated 
HC and CD macrophages contained 18 carbon length fatty acids, including PS 
16:0/18:1, PS 18:0/18:1, PS 18:0/18:2 and PS 18:0/20:4 species (Figure 4.10B). 
Although PS 18:0/18:1 made up over 40% of the endogenous PS, this species accounted 
for only 18.3 + 1.7% of the total newly synthesised PS in HC and 16.9 + 1.2% in CD 
macrophages, indicating possible differential turnover. No significant differences were  
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Figure 4.9 Electrospray ionisation mass spectrometric analysis of endogenous 
and newly synthesised PS. (A) Neutral loss scan of m/z 87 endogenous PS 
species. The peak at m/z 788.9 corresponds to PS 18:0/18:1. (B) Neutral loss scan 
of m/z 90, showing newly synthesised PS species 3 m/z units higher than the 
endogenous species, indicating incorporation of the serine-d3 stable isotope. The 
peak at m/z 791.9 corresponds to newly synthesised PS 18:0/18:1.
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Figure 4.10 Composition of endogenous and newly synthesised PS species in HC 
and CD macrophages. Macrophages were cultured from HC individuals and CD 
patients, incubated with serine-d3 for 3 hours in the presence (HC n=6, CD n=5) or 
absence (HC n=7, CD n=9) of HkEc. PS species were quantified by electrospray 
ionisation mass spectrometry. (A) Molar percentage composition of endogenous PS 
species, consisting of various carbon chain length fatty acids, in unstimulated (Uns) 
and HkEc stimulated HC and CD macrophages. (B) Molar percentage composition 
of newly synthesised (D3) PS species, in unstimulated (Uns) and HkEc stimulated 
macrophages. Results are expressed as mean + SEM. No statistically significant 
differences were identified between HC and CD.
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observed in the molar percentage composition of any PS species between unstimulated 
HC and CD macrophages. The profiles of the newly synthesised PS species were 
comparable between unstimulated and HkEc stimulated macrophages, and similarly 
there were no differences in the molar percentage of any PS species between HC and 
CD macrophages. 
 The rates of PS synthesis over 3 hours were inferred from the fractional 
incorporation of serine-d3 within the total PS (Figure 4.11). The mean fractional 
incorporation of serine-d3 into PS was 14.9 + 3.0% in unstimulated HC macrophages 
and 16.0 + 1.4% in unstimulated CD cells. This difference was not statistically 
significant, indicating equivalent rates of PS synthesis in unstimulated HC and CD 
macrophages. After stimulation with HkEc, there was no significant change in the 
fractional incorporation of serine-d3 compared with unstimulated macrophages, and the 
value for HC cells (18.1 + 4.5%) was not significantly different from CD macrophages 
(14.7 + 0.8%), indicating equivalent rates of PS synthesis after HkEc stimulation. 
4.2.6 Analysis of PI in HC and CD macrophages 
The composition of endogenous and newly synthesised PI species was determined by 
precursor scans of m/z 241- and m/z 247- respectively in HC and CD macrophages. 
Representative PI spectra from one HC individual are shown (Figure 4.12). The major 
peak at m/z 885.8 corresponds to PI 18:0/20:4 (Figure 4.12A), the predominant native 
PI species detected in HC and CD macrophages. Peaks at m/z 841.8, 865.8, 867.8 and 
891.8 correspond to the newly synthesised PI species 16:0/18:1, 18:1/18:2, 18:0/18:2 
and 18:0/20:4 (Figure 4.12B). As for PC, the spectra were used to quantify the relative 
concentrations of native and newly synthesised PI species and to estimate the rate of PI 
synthesis in HC and CD macrophages. 
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Figure 4.11 Incorporation of serine-d3 into HC and CD macrophage PS. 
Macrophages were cultured from HC and CD individuals, and incubated 
with serine-d3 for 3 hours. Results are shown for unstimulated (Uns) (HC 
n=7, CD n=9) and HkEc stimulated (HC n=6, CD n=5) macrophages. Total 
lipid was extracted and analysed by ESI-MS as neutral loss scans of m/z 87- 
and m/z 90-. The fractional incorporation of serine-d3 as a % of the total PS 
was determined.
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Figure 4.12  Electrospray ionisation mass spectrometric analysis of endogenous and 
newly synthesised PI species in macrophages. (A) Precursor scan of m/z 241-, 
indicating endogenous PI species. Note the peak at m/z 885.8, indicating endogenous 
PI 18:0/20:4. (B) Precursor scan of m/z 247-, indicating newly synthesised PI species. 
The peaks at m/z 867.8 and 891.8 correspond to newly synthesised PI 18:0/18:2 and 
18:0/20:4 respectively.
Precursor of m/z 241 -
Precursor of m/z 247 -
A
830 840 850 860 870 880 890 900 910 920 930
0
100
%
0
100
%
885.8
861.8
859.8835.7
863.7 883.7
864.8
886.9
887.8
911.8909.7 913.9
867.8
865.8
841.8
840.8 863.9
854.1
842.9
891.8
868.9
889.7
869.9
880.3
917.9
892.9
916.0901.6 919.8
B
m/z (mass/ charge ratio)
166
  
The predominant endogenous PI species detected was PI 18:0/20:4, making up 42.9 + 
2.7% and 44.0 + 1.8% of the total native PI in HC and CD macrophages respectively. 
With the exception of PI 18:0/18:2, all other species detectable contributed to less than 
10% of the total endogenous PI. The endogenous PI profiles were equivalent between 
HC and CD macrophages, and the composition was unaltered after HkEc stimulation 
(Figure 4.13A). 
The profile of newly synthesised PI species was strikingly different to that of 
endogenous PI, in both HC and CD macrophages (Figure 4.13B). In contrast to 
endogenous PI, no single species predominated; PI 18:0/20:4 accounted for only 12.3 + 
1.1% of the newly synthesised PI in HC macrophages and 12.9 + 1.8% in CD 
macrophages. PI 18:0/18:2 made up an additional 12.6 + 1.0% of the newly synthesised 
PI in HC and 13.0 + 1.3% in CD macrophages. 10 additional species accounted for the 
remaining newly synthesised PI, each contributing between 5-10% of the total in HC 
and CD cells. The difference from the endogenous PI profiles could indicate rapid 
turnover of certain PI species or a relatively stable pool of arachidonate containing-PI 
species within macrophages. The proportion of newly synthesised PI 16:0/18:1 was 
significantly reduced in CD macrophages compared to HC in the unstimulated state 
(p<0.05) (Figure 4.13B, Figure 4.14). This did not appear to be related to use of 5-ASA 
medication (Figure 4.14C). 
The fractional incorporation of myo-d6-inositol into total cellular PI was 
calculated as a measure for the global rate of PI synthesis (Figure 4.15). The mean 
fractional incorporation of myo-d6-inositol as a percentage of the total PI was 16.1 + 
2.3% in HC and 15.5 + 1.5% in CD macrophages over 3 hours, suggesting that the 
overall rate of PI synthesis is unaltered in CD macrophages. In contrast to PC, there was  
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Figure 4.13 Composition of endogenous and newly synthesised PI species in HC and CD 
macrophages. Macrophages were cultured from HC individuals and CD patients, 
incubated with myo-d6-inositol for 3 hours in the presence (HC n=6, CD n=5) or absence 
(HC n=7, CD n=9) of HkEc, and PI species quantified by electrospray ionisation mass 
spectrometry. (A) Molar percentage composition of endogenous PI species, consisting of 
various carbon chain length fatty acids, in unstimulated (Uns) and HkEc stimulated HC 
and CD macrophages. (B) Molar percentage composition of newly synthesised (D6) PI 
species, in unstimulated and HkEc stimulated HC and CD macrophages. Results are 
expressed as mean + SEM. * indicates p<0.05. 
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Figure 4.14 Alterations in the molar percentage of PI 16:0/18:1 in CD macrophages. 
(A) The molar perecentage of endogenous PI 16:0/18:1 was not significantly altered in 
CD (n=9) compared to HC (n=7). (B) The proportion of newly synthesised PI 16:0/18:1 
over 3 hours, as determined using stable isotope labelled myo-d6 inositol and ESI-MS, 
was reduced in CD macrophages compared to HC. (C) There was no difference in the 
proportion of newly synthesised PI 16:0/18:1 in patients receiving 5-ASA and those 
receiving no treatment (None). * Represents p<0.05.
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Figure 4.15 Incorporation of myo-d6-inositol into HC and CD macrophage PI. 
Macrophages were cultured from HC and CD donors and incubated with myo-d6-
inositol for 3 hours. Total lipid was extracted and analysed by ESI-MS as neutral 
loss scans of m/z 241-  and m/z 247-. Results are shown for unstimulated (Uns) 
(HC n=7, CD n=9) and and HkEc stimulated macrophages (HC n=6, CD n=5). 
No significant differences were identified.
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no alteration in the percentage incorporation after stimulation with HkEc, indicating 
comparable rates of PI synthesis in unstimulated and HkEc stimulated macrophages. 
4.2.7 Shotgun lipidomics analysis of ileal biopsies 
CD is a complex, heterogeneous condition, and may involve both a defect in 
macrophages and perturbations in the mucosal barrier (151). Therefore, in addition to 
investigations on macrophages, ‘shotgun lipidomics’ was also performed on non-
inflamed ileal biopsies from CD patients (n=5) and control individuals (n=5) to assess 
for possible defects in mucosal lipid composition. Biopsies from non-inflamed ileum 
were obtained from CD and control individuals at colonoscopy by experienced 
gastroenterologists (Dr Roser Vega, Dr Farooq Rahman). Two of the patients had 
macroscopic and microscopic evidence of active disease; the remaining patients had 
macroscopic and histologic features consistent with quiescent disease. Three patients 
were receiving no treatment, one was receiving 5-ASA and one was receiving 
methotrexate. Two patients had previous ileal resections (<20 cm); in these cases 
biopsies from the neoterminal ileum were obtained. Control individuals were 
undergoing colonoscopy for other purposes and had no evidence of inflammatory bowel 
disease. 
This work was performed as a collaborative project with Dr Xianlin Han, 
Washington University School of Medicine. Shotgun lipidomics is a 2-dimensional 
mass spectrometry based technique that permits quantitation of a vast array of lipid 
species in biological samples (276;365). Whilst the overall amounts of PC, PS, CL, PG, 
PA, sphingolipids and cholesterol in the biopsy samples did not differ between CD and 
HC (Figure 4.16A), interestingly, a significant reduction PI 16:0/18:1 (as a % of total 
PI) was observed in CD compared to HC (p<0.01) (Figure 4.16B, C). This is the same 
species that had reduced synthesis in CD macrophages compared to HC. 
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Figure 4.16 Shotgun lipidomics analysis of ileal biopsies. Ileal biopsies were obtained 
from non-inflamed ileum, and amounts of lipids were quantified by mass spectrometry. 
(A) Total phospholipid (PC, PE, CL, PG, PA, PS), sphingolipid  (sphingomyelin, SM and 
ceramide, Cer) and cholesterol (Chol) content did not differ between HC and CD patients. 
(B) Molar percentage composition of phosphatidylinositol (PI) species. (C) Reduced molar 
percentage of PI 16:0/18:1 in CD biopsies compared to HC. ** represents p<0.01.
172
  
4.3 Discussion 
In this chapter, sphingolipids and phospholipids were investigated as candidate 
molecular defects in CD macrophages. No gross abnormalities were identified in the 
ceramide, dihydroceramide or sphingoid base composition of CD macrophages, both in 
the unstimulated state and after stimulation with HkEc. In addition, the macrophage PC 
and PS composition, and rates of PC and PS synthesis, were shown to be normal in CD 
macrophages. The profile of endogenous PI species in CD macrophages also did not 
differ from HC. The newly synthesised PI species determined over a 3 hour time period 
displayed a reduced molar percentage of the monounsaturated species PI 16:0/18:1 in 
CD macrophages, although the molar percentage of other PI species, and the overall 
rates of PI synthesis were unaltered. The same species was present at reduced levels in 
ileal biopsies from CD patients. 
 Previous demonstrations of impaired pro-inflammatory cytokine release and 
apoptosis led to the hypothesis that macrophage sphingolipid or phospholipid 
composition may be an underlying abnormality in CD. Macrophages from CD patients 
release deficient levels of TNF in response to multiple stimuli, which (in the case of 
HkEc) resulted from abnormal post-translational trafficking of TNF to lysosomes (136). 
Sphingolipids and phospholipids are important components of vesicular membranes, 
and generation of PC has been shown to be critical for pro-inflammatory cytokine 
release from the Golgi apparatus in murine macrophages (197). However, given the data 
presented in this chapter, it is unlikely that gross defects in sphingolipid, PC, PI or PS 
composition underlie the impaired cytokine release observed in the majority of patients. 
Furthermore, impaired release of TNF does not appear to relate to alterations in the 
overall metabolic flux through the PC, PI or PS synthesis pathways, indicating that 
other mechanisms are likely to be responsible. 
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 There were no detectable abnormalities in the fatty acid composition of 
endogenous sphingolipids, PC, PI or PS in CD macrophages, in terms of the carbon 
chain length and degree of saturation. This could be considered surprising, given the 
results of previous studies indicating fatty acid aberrations in CD patients. In particular, 
studies have demonstrated differences in the fatty acid profiles of plasma phospholipids 
(356) and PBMCs (357) in CD patients. There are several possible explanations for this 
discrepancy. Firstly, the study by Geerling et al. (356) included patients with active 
disease in their investigation, raising the possibility the alterations observed could be 
secondary to chronic inflammation; indeed studies in quiescent patients have yielded 
conflicting results (358). Secondly the profiles of ceramides, PC, PS and PI specifically 
were determined in this study, whereas others have addressed fatty acid composition in 
terms of the total percentage of fatty acids or phospholipid species. In addition, it is well 
established that differentiation of cells is often associated with significant alterations to 
the fatty acid profile. For example, differentiation of U937 promonocytic cells with 
dimethyl sulfoxide is associated with an increase in PC species containing arachidonate 
(366). Furthermore, fatty acid synthesis and desaturation is upregulated in primary 
monocytes upon M-CSF induced differentiation, which is associated with a shift in the 
phospholipid species profile towards those containing shorter, monounsaturated fatty 
acids (342). It is therefore likely that the phospholipid profiles of CD macrophages do 
not strongly resemble those of monocytes or PBMCs, hence concurrent abnormalities 
would not necessarily be expected.  
In addition, the technique employed in this study, whilst able to distinguish 
lipids containing fatty acids of different chain lengths and degree of saturation, does not 
allow distinction between species containing omega-3 and omega-6 fatty acids with the 
same m/z ratio. Alterations in the omega-3 and omega-6 fatty acid balance have been 
described in PBMCs from CD patients (357); differences in CD macrophages could 
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therefore exist and be investigated in further studies. Techniques enabling distinction of 
individual phospholipid molecular species with the same m/z but containing different 
omega-3 or omega-6 fatty acids are currently in their infancy. However, an important 
consideration is the fact that the balance of omega-3 and omega-6 fatty acids in cultured 
cells may be largely governed by the culture medium. For example, FBS contains very 
low levels of linoleic acid, which can give rise to unphysiological cellular levels of 
omega-6 and omega-3 fatty acids, as demonstrated by studies in cystic fibrosis cell lines 
(367). A more relevant investigation may therefore be the interrogation of the omega-6 
and omega-3 fatty acid balance in mucosal biopsies or intestinal macrophages from CD 
patients. 
 CD macrophages synthesised a reduced relative percentage of PI 16:0/18:1 over 
a 3 hour time period when compared to HC, although this was not associated with a 
alteration in either the overall rates of PI synthesis or the molar percentage of 
endogenous PI 16:0/18:1. Interestingly, shotgun lipidomic analysis of ileal biopsy 
samples also revealed abnormalities in this PI species in CD. Taken together, the two 
studies suggest that the observed reduction in PI 16:0/18:1 represents a genuine 
abnormality in CD.   
Given that the overall rate of PI synthesis is normal in CD macrophages, this 
difference could relate to an alteration in the substrate preference of PI synthase in CD. 
Alternatively, abnormalities could exist in the fatty acid metabolism pathway, leading to 
altered fatty acid availability for phospholipid synthesis. The control of fatty acid 
synthesis and metabolism is a key determinant of membrane lipid composition, as 
illustrated by a recent study conducted in macrophages and dendritic cells. GM-CSF 
and IL-4 treated PBMCs were found to have reduced monounsaturated fatty acid 
species within certain phospholipid classes. This difference was attributed to decreased 
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stearoyl-CoA desaturase activity (368). Stearoyl-CoA desaturase is an enzyme involved 
in desaturation of palmitate (C16:0) and stearate (C18:0) to monounsaturated fatty 
acids. It could therefore be hypothesised that CD patients have differences in fatty acid 
synthesis and desaturation that give rise to the observed alteration in PI 16:0/18:1. 
Notably, the recent GWAS meta-analysis identified a CD-associated SNP in a region 
containing the FADS1 gene (Fatty acid desaturase 1) (115). Whilst fatty acid desaturase 
1 is distinct from stearoyl-CoA desaturase in its activity (being primarily involved in the 
conversion of essential fatty acids to highly unsaturated fatty acids), the association 
does add credence to the hypothesis that fatty acid desaturation may be relevant in the 
pathogenesis of CD.  
It is plausible that abnormalities in the mucosal PI profile could be important in 
triggering barrier dysfunction in CD patients, facilitating ingress of luminal contents 
into the bowel wall. Phospholipids are present in mucus as well as cellular components 
of the mucosa, and are understood to play a pivotal role in enhancing barrier resistance. 
Administration of PC and PI is protective in rodent acetic acid-induced colitis models 
(369), and PC is known to protect against intestinal injury induced by bile acids (370). 
Alterations in the PC composition of intestinal mucus have also been identified in 
patients with UC (371). In contrast, no striking differences were reported in ileal or 
colonic mucus from CD patients compared to controls, with the possible exception of 
sphingomyelin and PC 16:0/16:0 content, which were both moderately increased in CD. 
Other phospholipid species, including PI, were not quantified. It is therefore possible 
that the phospholipid profile of mucus from CD patients is subtly altered. Alternatively, 
the cellular components of the mucosa could have a subtly different membrane lipid 
composition. This could alter the fluidity and facilitate bacterial translocation directly, 
or enhance susceptibility to damaging agents such as emulsifiers. Whilst endogenous 
profiles of PI appeared unaltered in macrophages, it is possible that subtle alterations in 
176
  
the species of synthesised PI may have some functional effect on cytokine release, given 
the role of phosphatidylinositol phosphate derivatives in ensuring efficient secretion of 
TNF (350). Further functional studies are required to test this. 
During this study, quantitation of total macrophage cellular sphingolipid, PC, PS 
and PI species was performed. It is however recognised that there exists a significant 
‘comparmentalisation’ of lipid metabolism within cells, with particular enzymes in the 
pathway acting in specific subcellular compartments (309). The site of ‘de novo’ 
ceramide synthesis is the endoplasmic reticulum (372), whereas complex 
glycosphingolipid and sphingomyelin synthesis occurs in the Golgi apparatus. 
Breakdown of complex sphingolipids and ceramide can occur at the plasma membrane, 
or by the action of acid sphingomyelinase and acid ceramidase in the lysosomal 
compartment. Transport of sphingolipids between various compartments depends on 
vesicular transport or the action of transporter proteins such as CERT (373). 
Furthermore, analysis of subcellular membrane fractions has also revealed distinctive 
profiles of phospholipid classes and species within each fraction (364). It could be 
hypothesised that subcellular fractions of CD macrophages have abnormalities in the 
phospholipid or sphingolipid composition. However the limited yield of macrophages 
obtainable from peripheral blood samples makes such studies infeasible. 
During the course of this investigation, HkEc stimulation of macrophages was 
shown to be associated with a number of alterations in ceramides and phospholipids, 
further evidencing roles for these lipids in inflammation and the innate immune 
response to microbes. LPS, TNF and IL-1β have previously been shown to cause a rapid 
increase in the levels of ceramide in macrophage cell lines (319). Unexpectedly, in this 
study, HkEc stimulation was associated with a reduction in the C16:0, C24:0 and C24:1 
ceramides, and a concomitant increase in dihydrosphingosine content. This difference 
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could relate to differential effects of TLR and HkEc stimulation on the sphingolipid 
pathway, or alternatively the time frame investigated. Studies by MacKichan et al. 
investigated alterations in the ceramide content over a 30 minute period, whereas this 
study compared unstimulated with 4 hour HkEc stimulated macrophages. An altered 
ratio of ceramide to sphingoid bases in later stages of macrophage activation could be 
functionally important, given the diverse roles of ceramides in regulation of membrane 
structure, apoptosis and intracellular signalling, and dihydrosphingosine, which has a 
role in SNARE protein complex assembly and vesicle exocytosis (374).  
Alterations in the phospholipid profile of macrophages were also observed after 
stimulation with HkEc. These included a reduction in the amount of endogenous PC 
16:0/20:4. This is likely to relate to an increased activity of cytosolic phospholipase A2 
enzyme-α (cPLA2-α), an enzyme involved in the generation of fatty acids for prostanoid 
synthesis. cPLA2-α specifically hydrolyses arachidonate-containing phospholipids to 
release arachidonate (375), and preferentially binds PC (376). LPS stimulation is known 
to result in increased phosphorylation and activation of this enzyme (377), consistent 
with the observed reduction in PC 16:0/20:4 after stimulation. The findings are also in 
concordance with the effect of zymosan stimulation in human monocytes, which results 
in a reduction in PC species containing arachidonic acid. This has been attributed to 
increased PC hydrolysis by cPLA2-α (378). 
 In addition, an increased metabolic flux down the PC synthesis pathway was 
observed after HkEc stimulation. The rate limiting step in this pathway is catalysed by 
CCT (337), and activity is tightly regulated. Activity of CCT is dramatically increased 
on binding to membranes, which induces a conformational change in the enzyme and 
increases its affinity for CTP (379). The presence of degraded phospholipids (380) and 
membrane curvature stress (381) are known to be key modulators of enzyme activity 
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which could foreseeably increase after HkEc stimulation, thereby increasing the rate of 
metabolic flux down the PC synthesis pathway. 
In summary, in this chapter, the macrophage sphingolipid and phospholipid 
composition has been explored in CD, given the prominent roles of these molecules in 
vesicle trafficking and their relevance in cytokine secretion. Mass spectrometric 
analysis revealed no gross differences in the sphingolipid or phospholipid profiles in 
CD, although a subtle difference in the proportion of newly synthesised PI 16:0/18:1 
was identified. The same species was also present at reduced levels in ileal biopsies 
from CD patients. A number of potential mechanisms could be responsible for this 
abnormality. Given the lack of gross abnormalities in phospholipid and sphingolipid 
composition in CD macrophages, an alternative ‘hypothesis-generating’ approach was 
subsequently employed to identify molecular mechanisms of the impaired cytokine 
release. This is explored in the subsequent chapter.  
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Chapter 5: Analysis of macrophage transcriptomic abnormalities in 
Crohn’s disease 
5.1 Introduction 
CD is associated with attenuated monocyte-derived macrophage TNF release in 
response to a range of microbial agonists, as demonstrated in chapter 3. Whilst defective 
secretion is likely to relate to aberrant post-translational trafficking of pro-inflammatory 
cytokines (136), the molecular mechanisms responsible are incompletely understood. In 
chapter 3, no associations could be identified between any specific CD-susceptibility 
polymorphism and TNF release in response to HkEc and TLR2 stimulation. Whilst TNF 
release after HkEc stimulation was weakly correlated with overall genetic risk score, 
this was not the case for TNF release downstream of TLR agonists. Subsequently, a 
defective macrophage sphingolipid and phospholipid composition was postulated, given 
the roles of these lipids in vesicle trafficking and membrane structure. However, no 
profound abnormalities could be identified in the majority of the lipid species 
investigated. In this chapter, a ‘hypothesis-generating’ approach is taken to identify a 
molecular basis of impaired cytokine secretion, utilising macrophage whole genome 
expression data. Transcriptomic data were analysed using both conventional group 
comparisons and by ‘outlier’ analysis; the iterative comparison of individual patients 
with a reference group. This approach, whilst accepted in the field of oncology, has not 
previously been applied to CD and other multifactorial disorders. 
 CD is a complex and highly heterogeneous syndrome. Clinically, individual CD 
patients display variable age of onset, anatomical sites of involvement, disease course 
and response to treatment. In addition, genetic studies have revealed considerable 
genetic heterogeneity between CD patients. For example, considering the case of 
NOD2; only 8% of patients will be homozygous or compound heterozygous for disease-
associated polymorphisms, with approximately one quarter of patients heterozygous for 
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one NOD2 risk allele (255). Furthermore, the genetic risk score (GRS) in our cohort of 
patients, as calculated from a 34 SNP genotype, ranged from 0.14 to 37.2 (where 1 
represents mean population risk). Given the heterogeneity of CD, it is likely that the 
precise molecular lesions underlying impaired macrophage function and defective acute 
inflammation will be highly variable between individual patients. Furthermore, given 
the underlying ‘common disease, common variant hypothesis’ assumed by most GWAS 
(210), it is doubtful that such heterogeneous lesions would have been discovered in 
these studies. Indeed, only 23% of the total heritability of CD is thought to be explained 
by the 71 CD-associated variants identified in the recently published GWAS meta-
analysis (115). Some of the ‘missing heritability’, whilst controversial, may be 
explained by rare variants present in a subset of individuals with disease, possibly with 
large biological effects (256;257). 
Recently, studies in the field of oncology have utilised transcriptomic data to 
identify molecular abnormalities in heterogeneous tumour sets. Cancers show a 
potential parallel to multifactorial disorders such as CD, in that each individual tumour 
possesses a distinctive genetic and transcriptomic profile that results in abnormal 
protein expression and the development of a neoplastic phenotype. For this reason, 
some of the studies have focused on microarray expression profiling of individual 
tumours, as opposed to investigating tumour groups as homogeneous entities. 
Specifically, cancer outlier profile analysis (COPA) interrogates abnormally expressed 
genes in subsets of cancer samples, by identifying the probes in individual samples that 
display expression outside a set threshold percentile from the median (outliers) (382). 
Pairs of probes are identified that are most frequently detected as mutually exclusive 
outliers in the disease group, to facilitate the identification of potential chromosomal 
translocations. Application of the COPA strategy to prostate cancer led to the discovery 
of translocations between the transmembrane protease gene TMPRSS2 and the ETS 
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transcription factor genes ERG or ETV1 in subsets of samples (383). The translocations 
placed androgen-responsive promoter sequences of TMPRSS2 upstream of the 
transcription factor gene, causing over-expression of the gene family in prostate cancer. 
Hence, the chromosomal rearrangement was detected by its effects on gene expression. 
Several microarray gene expression studies have been previously performed in 
CD and UC. The majority of these focused on bowel biopsies, in which a wide spectrum 
of cells are present, although several investigated PBMCs (384;385). More recently, our 
laboratory investigated the global transcription profiles of macrophages using 
Affymetrix gene arrays. Levels of pro-inflammatory cytokine mRNA were found to be 
equivalent between HC and CD macrophages. However, 27 differentially expressed 
probe sets were identified that were common to both ileal and colonic CD, 
corresponding to nine genes which had functions in vesicle trafficking and cytoskeletal 
organisation (136). This was consistent with a failure of cytokine secretion (a vesicle-
mediated process) in CD macrophages. All of these studies used conventional group 
comparison methods for microarray data analysis. In this chapter, the results of a larger 
scale study of macrophage gene expression profiling, conducted using the Illumina 
microarray platform, are discussed. Gene expression data are interrogated in a number 
of ways, including by standard group comparisons of differential gene expression, and 
by using an ‘outlier analysis’ strategy to identify grossly under- and over-expressed 
genes in individual CD patients. The abnormal expression of one such gene is validated, 
and the functional relevance of this to the acute inflammatory deficit of CD is 
investigated. 
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5.2 Results 
5.2.1 Differentially expressed genes between CD, HC and UC macrophages 
In order to identify differences in gene expression between HC, CD and UC 
macrophages, microarray analysis of genome-wide gene expression was performed. 
Macrophages were cultured from CD patients (n=61), HC individuals (n=43) and UC 
patients (n=45). RNA was extracted from unstimulated macrophages, and macrophages 
stimulated for 4 hours with HkEc (CD n=30, HC n=14 and UC n=7). Microarray 
analysis was performed using Illumina Human-WG6 v3.0 Expression BeadChips. 
Demographics of patients included in the study are shown (Appendix 1 Table III). Eight 
CD patients in this study were receiving immunosuppressants (6-mercaptopurine, 
methotrexate or azathioprine), one patient was receiving low dose steroid therapy and 
four patients were receiving anti-TNF agents. The remainder were receiving either no 
treatment (n=16), or 5-ASA only (n=32). Four of the CD patients were related (from 
two distinct families). None of the other individuals included in the study were related.  
Expression data were log2 transformed with cubic spline normalisation between 
arrays. Data from unstimulated samples were subsequently normalised across three 
batches of experiments using an established algorithm (278). All HkEc stimulated 
samples (CD n=30, HC n=14 and UC n=7) were analysed in one single batch with 
paired unstimulated samples from all donors. Therefore, the HkEc stimulated samples 
were excluded from the batch normalisation procedure, and for comparisons of HkEc 
with unstimulated samples, non-batch normalised data were used. 
20,023 out of the total 48,802 probes (41.0%) were found to be expressed at 
detectable levels in macrophages, as determined using the detection p-values associated 
with each probe (see Materials and Methods section 2.5.3 for details). Differentially 
expressed genes were identified using the MultiExperiment viewer TM4 software suite, 
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an established software package for statistical analysis of microarray datasets (279). 
Probes were identified that were significantly different between CD and HC 
macrophages, using a threshold uncorrected p-value of p<0.01 and a minimum fold 
change of 1.2 compared to mean expression in either the HC or the UC cohort. 
 Comparing unstimulated CD with HC macrophages, 81 probes were identified 
that differed in expression at an uncorrected p-value of p<0.01 (Table 5.1). These 
probes represented 16 over-expressed genes and 55 under-expressed genes (Table 
5.1A). A number of these genes have important functions in innate immunity; notably 
NCF1, and the transcription factor STAT1, were downregulated in CD macrophages. 
Furthermore, a number of the under-expressed genes in CD macrophages are located in 
loci implicated in CD susceptibility from GWAS, including ICAM3 (115) and LST1 
(116). Comparison of CD with UC macrophages identified only 3 genes that were 
differentially expressed (Table 5.1B); CST7, RPS6KA2 and GSTM1, indicating strong 
similarity between CD and UC profiles in this analysis. In both comparisons, none of 
the genes reached statistical significance after correction for multiple testing, either 
using an adjusted Bonferroni correction or the less stringent Benjamini and Hochberg 
False Discovery rate (FDR) correction that is commonly used in microarray analysis 
(280). Therefore, the results should be interpreted with the caveat that some or all of the 
differentially expressed genes could represent false positive discoveries, and may 
indicate that the transcriptomic profile of CD macrophages is not grossly abnormal. 
 Considering HkEc stimulated macrophages, 134 probes were differentially 
expressed between HC and CD macrophages at the applied thresholds. These probes 
corresponded to 120 unique genes, 44 of which were over-expressed and 76 were under-
expressed in CD macrophages (Table 5.2, Table 5.3). Again, many of these genes have 
well-established roles in innate immune function. Consistent with the findings in  
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Over-expressed genes (p<0.01, >1.2 Fold change)
Probe ID Gene ID Fold change P-value
ILMN_1801077 ADFP* 1.42 3.40E-03
ILMN_1712475 HS3ST2 1.38 1.92E-03
ILMN_1669831 C6ORF192 1.35 5.77E-03
ILMN_2332964 LGMN* 1.35 6.39E-03
ILMN_1680738 C5ORF13 1.31 5.74E-03
ILMN_1745963 FOLR2 1.29 6.12E-03
ILMN_1784207 C1ORF128 1.25 5.33E-03
ILMN_1685625 UCP2 1.25 9.73E-03
ILMN_1787186 NOV 1.25 3.16E-03
ILMN_1704753 EPAS1 1.23 5.19E-03
ILMN_1772224 KCNJ5 1.23 4.90E-03
ILMN_1706531 ABCC5 1.22 4.86E-03
ILMN_1795342 MLPH 1.22 4.64E-03
ILMN_1709634 CMBL 1.22 5.58E-03
ILMN_1811616 EEPD1 1.22 3.62E-03
ILMN_1710124 CMTM8 1.20 5.52E-03
Under-expressed genes (p<0.01, >1.2 Fold change)
ILMN_2160476 CCL22 -1.68 2.80E-04
ILMN_1691364 STAT1* -1.64 9.14E-03
ILMN_1697309 NCF1 -1.62 8.50E-03
ILMN_1701114 GBP1 -1.48 9.62E-03
ILMN_1729801 S100A8 -1.48 3.46E-03
ILMN_1748473 GIMAP4 -1.47 1.27E-03
ILMN_1723035 OLR1 -1.44 3.54E-03
ILMN_1740418 CYP27B1 -1.44 7.10E-03
ILMN_2376108 PSMB9 -1.43 8.43E-03
ILMN_1680996 ALOX5 -1.42 2.01E-03
ILMN_1741727 QPCT -1.42 9.29E-04
ILMN_1778321 SLC2A6 -1.42 6.22E-03
ILMN_1654696 C15ORF48* -1.40 2.33E-03
ILMN_2366212 CD79B* -1.40 6.37E-03
ILMN_1803945 HCP5 -1.39 3.35E-03
ILMN_1691341 IL7R* -1.39 2.45E-03
ILMN_1751079 TAP1 -1.38 9.23E-03
ILMN_1797875 ALOX5AP -1.38 3.40E-03
ILMN_1686664 MT2A -1.37 8.35E-03
ILMN_1713751 ADAM19 -1.36 4.93E-03
ILMN_2307903 VCAM1 -1.36 4.94E-03
ILMN_1780465 CLEC5A -1.35 4.16E-03
ILMN_2404154 SERPINA1* -1.34 2.10E-03
ILMN_1774077 GBP2 -1.33 8.81E-03
ILMN_1769388 GJB2 -1.32 4.69E-03
ILMN_1779257 CD40 -1.32 7.15E-03
ILMN_1691071 FCRLA -1.32 6.50E-03
ILMN_1655549 SIGLEC10 -1.31 5.05E-04
ILMN_1687538 ETS1 -1.31 6.84E-03
ILMN_1769383 GIMAP5 -1.31 8.70E-03
ILMN_2376204 LTB* -1.30 7.18E-03
ILMN_2239754 IFIT3 -1.30 5.81E-03
ILMN_2329429 GIMAP6 -1.29 3.64E-03
ILMN_1747305 GIMAP8 -1.29 4.60E-03
ILMN_2325506 BCAS4 -1.28 8.89E-03
ILMN_1723412 ASCL2 -1.28 9.28E-03
ILMN_1663390 CDC20 -1.27 6.16E-03
ILMN_1674063 OAS2 -1.27 9.62E-03
ILMN_2212763 ICAM3 -1.26 6.12E-04
ILMN_1671054 HLA-A -1.26 5.48E-04
ILMN_1714433 MARCKSL1 -1.25 9.14E-04
ILMN_1786065 UHRF1 -1.25 3.40E-03
ILMN_1758418 TNFSF13B -1.24 6.33E-03
ILMN_1718936 LST1 -1.24 3.80E-03
ILMN_1663195 MCM7 -1.23 4.81E-03
ILMN_2049766 NFE2L3 -1.23 3.60E-03
ILMN_1725170 LOC650557 -1.23 5.98E-03
ILMN_1682799 STAMBPL1 -1.22 5.01E-03
ILMN_2176063 FCGR1A -1.22 8.23E-03
ILMN_2391051 FCGR1B -1.22 5.00E-03
ILMN_2373062 RHBDF2* -1.22 4.64E-03
ILMN_2109708 ECGF1 -1.21 8.33E-03
ILMN_2337928 CXCR5 -1.21 2.69E-03
ILMN_2042771 PTTG1 -1.21 6.11E-03
ILMN_1769911 SLC38A1 -1.20 8.62E-03
Table 5.1 Differentially expressed genes in unstimulated CD macrophages. Whole genome
microarray analysis of gene expression was performed using Illumina Human-WG v3.0
expression arrays. Differentially expressed genes were identified using a minimum fold
change of 1.2 and p<0.01 (uncorrected for multiple testing). (A) Differentially expressed
genes between CD and HC macrophage groups. (B) Differentially expressed genes between
CD and UC macrophage groups. Mean fold changes in CD compared to the comparator
group are shown. * indicates genes where multiple probes were identified as differentially
expressed, the most significant of which are shown. None of the genes remained statistically
significant after correction for multiple testing.
Probe ID Gene ID Fold change P-value
ILMN_1679826 CST7 1.21 6.28E-03
ILMN_1716218 RPS6KA2 1.23 2.97E-03
ILMN_1762255 GSTM1 1.28 8.02E-03
A
B
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Over-expressed genes (p<0.01, >1.2 Fold change)
Probe ID Gene ID Fold change P-value
ILMN_1713638 ICHTHYIN 1.81 3.03E-03
ILMN_1776967 LRRC50 1.66 4.16E-03
ILMN_1784863 CD36 1.59 5.48E-03
ILMN_1705570 H2AFY2 1.53 7.97E-03
ILMN_1671478 CKB 1.52 9.25E-03
ILMN_1689088 COLEC12 1.50 6.91E-03
ILMN_1680110 C10ORF116 1.48 2.59E-03
ILMN_2370091 NGFRAP1* 1.47 2.74E-03
ILMN_1687751 BAALC* 1.42 1.91E-03
ILMN_1725311 GCGR 1.40 3.96E-03
ILMN_1793615 ME3 1.40 7.88E-03
ILMN_1753370 ABTB2 1.39 5.14E-03
ILMN_1669831 C6ORF192 1.38 7.75E-03
ILMN_1789361 PKD2L1 1.37 2.81E-03
ILMN_1797293 SIGLEC15 1.30 5.93E-03
ILMN_1704753 EPAS1 1.28 9.55E-03
ILMN_2386008 MPZL1* 1.28 6.73E-05
ILMN_1815023 PIM1 1.28 6.07E-03
ILMN_2336130 SULT1A4 1.28 6.56E-03
ILMN_1815283 SULT1A3 1.27 2.77E-03
ILMN_2374036 CTSL1* 1.26 6.02E-03
ILMN_1781536 FAH 1.26 2.16E-03
ILMN_1703946 ADORA2B 1.26 7.34E-03
ILMN_2393149 ALOX15B 1.25 8.17E-03
ILMN_1872457 HS.547277 1.25 4.50E-03
ILMN_1718607 TSPAN4 1.25 2.09E-03
ILMN_1695962 SLC12A9 1.24 4.14E-03
ILMN_1677305 PVR 1.24 5.81E-03
ILMN_1791569 PLXNA1 1.24 1.86E-03
ILMN_1772224 KCNJ5 1.24 6.27E-03
ILMN_1751898 C12ORF4 1.23 3.22E-05
ILMN_1658333 ECM1 1.22 9.05E-03
ILMN_2282641 TBXAS1 1.22 1.81E-03
ILMN_1656521 CGI-96 1.22 9.92E-03
ILMN_1795839 SCCPDH 1.22 4.94E-04
ILMN_1812062 SGPP2 1.22 8.25E-03
ILMN_1652549 DTNA* 1.21 7.27E-04
ILMN_1695763 PDIA5 1.21 8.03E-04
ILMN_1745116 ABHD12 1.21 3.00E-03
ILMN_1651296 LOC143666 1.21 7.20E-03
ILMN_1706598 ACPL2* 1.21 1.62E-03
ILMN_1672605 C7ORF41 1.21 7.00E-03
ILMN_2285817 FAM89A 1.20 7.54E-03
ILMN_2355462 CYFIP1 1.20 3.72E-03
Table 5.2 Over-expressed genes in HkEc stimulated CD macrophages in
comparison to HC. Whole genome microarray analysis of gene expression was
performed using Illumina Human-WG6 v3.0 arrays, and differentially expressed
genes were identified using a threshold fold change of 1.2 and p<0.01
(uncorrected for multiple testing). Mean fold changes in CD compared to HC
macrophage groups are shown. * indicates genes where multiple probes were
identified as differentially expressed, the most significant of which are shown.
None of the genes remained statistically significant after correction for multiple
testing.
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Under-expressed genes (p<0.01, 1.2 Fold change)
Probe ID Gene ID Fold change P-value
ILMN_1697309 NCF1 -1.85 6.23E-03
ILMN_1693009 FGL2 -1.77 5.44E-03
ILMN_1782704 CD19 -1.59 4.20E-03
ILMN_2109416 NAPSB -1.56 7.65E-03
ILMN_1741727 QPCT -1.54 3.04E-03
ILMN_1729801 S100A8 -1.53 3.97E-03
ILMN_1677441 C20ORF123 -1.51 3.81E-03
ILMN_1667081 CCND2* -1.50 1.60E-03
ILMN_1661646 BANK1 -1.47 5.65E-03
ILMN_1810214 JUND -1.47 4.49E-03
ILMN_1670134 FADS1 -1.46 4.77E-03
ILMN_1790689 CRISPLD2 -1.42 3.73E-03
ILMN_1738675 PTPN6 -1.42 9.68E-03
ILMN_1680996 ALOX5 -1.41 7.12E-03
ILMN_2325506 BCAS4 -1.41 8.22E-03
ILMN_1661109 ATF3 -1.41 2.92E-03
ILMN_1677038 FLJ21986 -1.40 1.30E-03
ILMN_2338452 SERPINA1 -1.40 3.78E-03
ILMN_1655549 SIGLEC10 -1.40 2.94E-03
ILMN_1710962 TMEM97 -1.37 3.14E-03
ILMN_1727098 PPP1R16B -1.37 6.94E-03
ILMN_1740875 FPR2 -1.37 3.98E-03
ILMN_1699669 BLR1 -1.35 8.93E-04
ILMN_1800540 CD55 -1.34 1.83E-03
ILMN_1723035 OLR1 -1.34 1.21E-03
ILMN_1671054 HLA-A -1.34 5.24E-03
ILMN_1756501 ST6GAL1 -1.34 8.26E-04
ILMN_1691930 CBX6 -1.34 1.52E-03
ILMN_1685580 CBLB -1.33 1.94E-03
ILMN_2217935 RFC1 -1.32 6.21E-03
ILMN_1682312 CYBB -1.32 6.34E-03
ILMN_1663390 CDC20 -1.31 6.13E-03
ILMN_1683450 CDCA5 -1.31 2.08E-03
ILMN_2345353 LST1* -1.31 1.06E-03
ILMN_1657395 HMGCR -1.30 2.67E-03
ILMN_1786065 UHRF1 -1.30 3.75E-03
ILMN_1756928 RTN1 -1.30 5.33E-04
ILMN_2144088 FDFT1 -1.30 1.68E-03
ILMN_1677607 SC5DL -1.30 5.38E-03
ILMN_2319952 VDR -1.29 2.95E-03
ILMN_1738058 CPNE6 -1.28 5.97E-03
ILMN_1718766 MT1F -1.28 1.62E-03
ILMN_2224143 MCM3 -1.27 3.55E-03
ILMN_2078697 ALPK1 -1.27 4.26E-03
ILMN_1686097 TOP2A -1.27 6.04E-03
ILMN_2072296 CKS2 -1.27 3.69E-03
ILMN_2073604 EBP -1.26 5.52E-03
ILMN_1809590 GINS2 -1.26 5.44E-03
ILMN_1712452 KIF20B -1.26 4.27E-04
ILMN_2336595 ACSS2 -1.26 9.38E-03
ILMN_1737205 MCM4 -1.25 1.56E-04
ILMN_1732516 KNTC1 -1.25 1.66E-04
ILMN_2075334 HIST1H4C -1.25 1.38E-03
ILMN_1793859 ALDH2 -1.24 9.59E-03
ILMN_1773125 ENTPD1 -1.24 7.00E-03
ILMN_1714730 UBE2C -1.24 5.21E-03
ILMN_2370365 RFC4 -1.24 8.03E-04
ILMN_1722811 CDKN1B -1.24 8.49E-03
ILMN_1732296 ID3 -1.23 1.62E-03
ILMN_1798654 MCM6 -1.23 6.34E-03
ILMN_1751143 C7ORF23 -1.23 7.04E-03
ILMN_1671554 LPIN1 -1.22 6.14E-03
ILMN_1781942 HMMR -1.21 5.54E-03
ILMN_1775708 SLC2A3 -1.21 8.87E-03
ILMN_1663068 MGC33556 -1.21 2.99E-03
ILMN_2216582 LYL1 -1.21 2.65E-03
ILMN_1767470 SCPEP1 -1.21 9.82E-03
ILMN_1716895 RPA3 -1.21 1.74E-04
ILMN_1814985 PDLIM7 -1.21 8.77E-03
ILMN_1755974 ALDOC -1.21 5.31E-03
ILMN_1802160 XIRP1 -1.21 8.30E-03
ILMN_2118472 C10ORF58* -1.21 6.97E-03
ILMN_1771593 RRM1 -1.20 4.06E-03
ILMN_2366703 SGK3 -1.20 1.13E-03
ILMN_2216918 SHPK -1.20 8.09E-03
ILMN_1668865 SLC2A14 -1.20 6.86E-03
Table 5.3 Under-expressed genes in CD macrophages after HkEc stimulation.
Differentially expressed genes were identified compared to HC using a threshold fold
change of 1.2 and p<0.01 (uncorrected for multiple testing). Mean fold changes in CD
compared to HC macrophage groups are shown. * indicates genes where multiple
probes were identified as differentially expressed, the most significant of which is
shown. None of these genes remained statistically significant after correction for
multiple testing.
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unstimulated macrophages, NCF1 was found to be under-expressed in CD macrophages 
after HkEc stimulation. Furthermore, CYBB, a gene encoding the cytochrome b-245 β  
chain of NADPH oxidase (386) was also downregulated in CD macrophages compared 
to HC. A number of the differentially expressed genes may also function in cytoskeletal 
control and vesicle trafficking. For example, LRRC50, a gene implicated in dynein arm 
assembly and regulation of actin-based brush border microvilli (387), was over-
expressed in CD macrophages. In concordance with previous findings using the 
Affymetrix platform, no difference in the expression of pro-inflammatory cytokines 
such as TNF, IL-6, IFN-γ could be observed. However, there was surprisingly little 
overlap between the genes identified as differentially expressed in the previous 
Affymetrix dataset. None of the 18 differentially regulated genes identified as common 
between ileal and colonic CD (136) were significantly altered in this study. As for 
unstimulated macrophages, none of the genes reached statistical significance after 
correction for multiple testing. Comparison of CD with UC macrophages after HkEc 
stimulation revealed four over-expressed and three under-expressed genes (Table 5.4), 
suggesting minimal differences in expression between these two groups. 
 The lack of significance after correction for multiple testing may partly reflect 
the presumed heterogeneity of genetic and environmental factors contributing to CD. 
Therefore, the grouped microarray expression data were analysed for common Gene 
Ontology (GO) processes (388), and for the most significant pathway networks using 
GeneGo software, because these approaches were considered more likely to detect the 
effects of many heterogeneous risk factors on a small number of processes and 
pathways. 
 MetaCore pathway analysis software was used to determine the GO and GeneGo 
pathway networks significantly enriched within the datasets (taking an uncorrected p- 
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Table 5.4 Differentially expressed genes in CD compared to UC macrophage
groups after HkEc stimulation. A threshold fold change of 1.2 and p<0.01
(uncorrected for multiple testing) was used to determine genes that were
differentially expressed. Fold change in the CD group compared to UC is
shown. * Represents genes where more than one probe was identified as
significantly different. None of the genes were significant after multiple
testing correction was performed.
Over-expressed genes
Probe ID Gene ID Fold change P-value
ILMN_1790692 GNLY* 2.34 1.76E-03
ILMN_1682993 NKG7 1.63 5.76E-03
ILMN_1805449 TAPBPL 1.28 6.15E-03
ILMN_1737818 C12ORF43 1.26 7.86E-03
Under-expressed genes
Probe ID Gene ID Fold change P-value
ILMN_1797594 NFAT5 -1.23 9.72E-03
ILMN_1801616 EMP1 -1.24 6.53E-03
ILMN_2218935 GPR37 -1.30 6.53E-03
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value p<0.01 and 1.2 fold change as the threshold). Within the unstimulated 
differentially expressed gene list (comparing CD with HC), the most significantly 
enriched GO terms within the biological processes category included immune system 
processes, response to interferon-γ and defence response (Table 5.5A). In comparison, 
within the HkEc stimulated differential gene list, the most significantly enriched GO 
processes included small molecule metabolic processes, DNA strand elongation, 
immune effector processes and processes related to adenylate cyclase G protein 
signalling pathways (Table 5.5B). Amongst the unstimulated differential gene list, 
significantly enriched pathway networks included ‘antiviral actions of interferons’, and 
various pathways relating to immune response, cell cycle and apoptosis (Table 5.5C). In 
contrast, differentially expressed genes between HkEc stimulated HC and CD 
macrophages showed enrichment for the ‘AP-1 in regulation of cellular metabolism’ 
pathway, and various signalling pathways involved in the immune response and 
development (Table 5.5D). Furthermore, cytoskeletal remodelling pathways were 
significantly enriched amongst this dataset, consistent with the hypothesis that the 
cytoskeleton could play a role in the dysfunctional macrophage response to HkEc in 
CD. 
5.2.2 Principal component analysis of CD, HC and UC macrophage gene expression 
Principal component analysis (PCA) was also conducted to determine whether global 
macrophage gene expression profiles could be separated on the basis of disease or batch 
of microarray analysis. PCA is a mathematical algorithm for reducing the 
dimensionality of datasets, by finding the principal components (directions) along 
which the variation is maximal. PCA plots of samples, where each data point represents 
expression values of all the expressed probes in the array, can be used to visually assess 
similarities and differences between samples and whether they can be grouped (389). 
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GO processes: HkEc stimulated CD versus HC P-value Dataset
genes
Total
genes
small molecule metabolic process 4.67E-11 47 2570
DNA strand elongation involved in DNA replication 2.94E-09 7 35
DNA strand elongation 4.47E-09 7 37
regulation of immune effector process 6.76E-09 14 282
DNA-dependent DNA replication 8.34E-09 9 89
alcohol metabolic process 2.51E-08 19 608
second-messenger-mediated signaling 2.64E-08 16 424
activation of adenylate cyclase activity by G-protein signaling pathway 3.78E-08 8 75
positive regulation of adenylate cyclase activity by G-protein signaling pathway 3.78E-08 8 75
regulation of adenylate cyclase activity involved in G-protein signaling pathway 3.78E-08 8 75
GO processes: Unstimulated CD versus HC P-value Dataset
genes
Total
genes
immune system process 1.06E-18 40 1729
response to interferon-gamma 6.70E-17 15 136
interferon-gamma-mediated signaling pathway 1.78E-16 13 88
response to cytokine stimulus 5.03E-16 23 548
defense response 1.26E-15 31 1197
immune response 1.45E-15 29 1028
cytokine-mediated signaling pathway 5.03E-15 18 313
cellular response to interferon-gamma 5.87E-15 13 114
cellular response to cytokine stimulus 1.42E-13 18 380
response to stress 4.94E-13 45 3204
A
B
GeneGO Pathway Networks: Unstimulated CD versus HC P-value Dataset
genes
Total
genes
Immune response_Antiviral actions of Interferons 6.95E-07 5 52
Immune response_MIF-mediated glucocorticoid regulation 2.43E-03 2 22
Development_Thrombopoetin signaling via JAK-STAT pathway 2.43E-03 2 22
Immune response_Antigen presentation by MHC class I 3.92E-03 2 28
Cell cycle_Role of APC in cell cycle regulation 5.10E-03 2 32
Cell cycle_Spindle assembly and chromosome separation 5.42E-03 2 33
Immune response_Role of integrins in NK cells cytotoxicity 7.14E-03 2 38
Immune response_Th1 and Th2 cell differentiation 7.89E-03 2 40
Apoptosis and survival_Anti-apoptotic TNFs/NF-kB/Bcl-2 pathway 8.28E-03 2 41
Apoptosis and survival_Lymphotoxin-beta receptor signaling 8.68E-03 2 42
C
D GeneGO Pathway Networks: HkEc stimulated CD versus HC P-value Datasetgenes Totalgenes
Transcription_Role of AP-1 in regulation of cellular metabolism 1.43E-07 13 38
Cell cycle_ESR1 regulation of G1/S transition 2.01E-07 12 33
Immune response_Human NKG2D signaling 1.16E-06 12 38
Development_Thrombopoietin-regulated cell processes 1.31E-06 13 45
Development_HGF signaling pathway 2.25E-06 13 47
Immune response_IL-2 activation and signaling pathway 3.77E-06 13 49
Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling 7.42E-06 20 111
Cytoskeleton remodeling_Cytoskeleton remodeling 7.59E-06 19 102
Development_HGF-dependent inhibition of TGF-beta-induced EMT 1.03E-05 10 32
Table 5.5 Functional annotation of differentially expressed genes between CD and HC
macrophage groups. Analysis was conducted using MetaCore Pathway analysis
software. The most significantly enriched Gene Ontology (GO) processes amongst
(A) unstimulated and (B) HkEc stimulated differential gene lists are shown. The most
highly significantly enriched GeneGo pathway networks in the (C) unstimulated and
(D) HkEc stimulated differential gene lists are also shown. The enrichment p-values
and number of genes in the dataset (dataset genes) in comparison to the total GO
database genes (total genes) are displayed in all tables.
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Considering the unstimulated macrophage dataset, principal components 1 and 2 
accounted for 25.8% and 10.2% of the data variability respectively. A further 5.7% of 
the variance was explained by principal component 3. Unstimulated samples from 
batches 1, 2 and 3 could not be separated by PCA (Figure 5.1A), suggesting that after 
the normalisation procedure, gross batch effects were not present. Unstimulated 
macrophage gene expression profiles from CD and UC patients and HC individuals 
could not be distinguished by disease group using PCA analysis (Figure 5.1B).  
Similar results were obtained for HkEc stimulated samples. As expected, PCA 
was able to separate unstimulated samples from HkEc stimulated samples from all 
donors (Figure 5.2A), consistent with clear transcriptomic differences that occur on 
macrophage activation. However, PCA analysis of HkEc stimulated samples was not 
able to separate samples on the basis of disease grouping (Figure 5.2B). Therefore CD 
macrophages do not appear to have a distinct global expression signature or gross 
transcriptomic abnormality, when compared to either HC individuals or to patients with 
UC. 
5.2.3 Identification of outlier probes in CD, HC and UC subjects and their biological 
function 
Given the heterogeneity of CD, and the lack of striking differentially expressed genes 
between the HC, CD and UC groups, a customised outlier analysis was subsequently 
used to detect gross abnormalities in gene expression (outliers) in individual subjects, in 
comparison to the HC cohort. Probes were identified that were significantly over- or 
under- expressed in unstimulated macrophages from individual CD and UC patients 
compared to the HC cohort (see Materials and Methods section 2.5.3 for full details). 
Probes that reached a threshold p-value of p<0.005 (calculated using Z-scores, a Z score 
of ~2.5 corresponding to a p<0.005) and a minimum fold change of 1.5 compared to  
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Figure 5.1 Principal component analysis of unstimulated macrophage gene
expression profiles from CD, UC and HC patients. Array expression data were log2
transformed and PCA analysis was performed using MultiExperiment viewer TM4
Microarray software suite. Scatterplots for principal components (PC) 1 and 2 are
shown, with the microarray results for each sample represented as a single point.
(A) Array samples colour coded by batch. (B) Samples colour coded by disease
grouping.
Batch 1 (n=54)
Batch 2 (n=60)
Batch 3 (n=35)
A
B
HC (n=43)
CD (n=61)
UC (n=45)
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Figure 5.2 Principal component analysis of unstimulated and HkEc stimulated
macrophages. Microarray expression data were log2 transformed and PCA analysis
performed using MultiExperiment viewer TM4 software suite. Scatterplots for
principal components (PC) 1 and 2 are shown, with the microarray results for each
sample represented as a single point. (A) Principal component analysis of paired
unstimulated and HkEc stimulated samples from CD and UC and HC macrophages,
showing separation into HkEc (red) and unstimulated (black) groups. (B) Principal
component analysis of HkEc stimulated macrophages from CD, HC and UC donors,
colour coded by disease grouping.
HkEc (n=51)
Uns (n=51)
A
B
PC1
PC2
PC1
PC2
HC (n=14)
CD (n=30)
UC (n=7)
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mean expression in the HC cohort were considered to be significant outliers in an 
individual subject. Nineteen probes with expression that was significantly different 
between male and female individuals at FDR-corrected p<0.001 were excluded from the 
outlier analysis (Table 5.6). 
Customised software for outlier analysis was developed in collaboration with Daniel 
Roden and Anna Lobley, Department of Computer Sciences, UCL. This software 
permitted identification of outlier probes in individual patients and their visualisation by 
volcano plots (Figure 5.3A). The software also generated tables detailing the outlying 
probes in each individual patient (Figure 5.3B), and in the overall cohort. Outlier probes 
in HC subjects were also determined, by comparing expression of all probes in each 
individual subject with the remainder of the HC population. 
 The median number of outlier probes per individual was 27 (interquartile range 
16-45) in the CD group, compared to 22 (interquartile range 10-76) and 25 (interquartile 
range 13-38) per individual in the HC and UC cohorts respectively (Figure 5.4A). None 
of these differences were statistically significant. Of the total 1,858 outlier probes 
identified in the CD cohort, 712 were under-expressed and 1,146 were over-expressed 
in one or more individual CD patients compared to mean HC expression. 20.7% of the 
under-expressed and 41.5% of the over-expressed outlier probes identified in the CD 
population were also abnormally expressed in one or more HC individuals. A further 
18.0% of the under-expressed and 32.1% of the over-expressed outliers in the CD 
cohort were also identified as abnormal in one or more UC patients, leaving 478 over-
expressed and 585 under-expressed outlier probes that were unique to the CD cohort 
(Figure 5.4B, C).  
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Table 5.6 Differentially expressed probes between male and female individuals.
Probes that were differentially expressed between male and female individuals (FDR
p<0.001) were excluded from subsequent outlier analysis. Illumina probe identities
(ID), corresponding gene identities, raw fold change (in male group compared to
female group), log2 transformed fold change and uncorrected p-values are shown. All
probes were significant after FDR correction at p<0.001
Probe ID Gene ID Chromosome Raw foldchange
Log2 Fold
change
Uncorrected
P-value
ILMN_1783142 RPS4Y1 Yp11.3 15.45 3.9499 9.59E-71
ILMN_1670821 CYORF15A Yq11.2 3.30 1.7224 2.14E-68
ILMN_1755537 EIF1AY Yq11.2 7.89 2.9804 4.83E-67
ILMN_1685690 JARID1D Yq11.2 2.92 1.5461 2.17E-63
ILMN_2228976 EIF1AY Yq11.2 2.15 1.1055 1.26E-56
ILMN_2090059 ZFY Yp11.3 1.49 0.5705 6.01E-42
ILMN_1764573 XIST Xq13.2 -1.56 -0.6446 1.10E-34
ILMN_1710136 HDHD1A Xp22.3 -1.33 -0.413 8.06E-34
ILMN_1776195 TMSB4Y Yq11.2 1.34 0.4245 1.37E-33
ILMN_1810577 RPS4X Xq13.1 -1.46 -0.5505 5.77E-31
ILMN_2166831 RPS4X Xq13.1 -1.47 -0.5522 2.45E-28
ILMN_1687484 ZFX Xp22.1 -1.21 -0.2799 9.72E-24
ILMN_1654488 UTX Xp11.3 -1.29 -0.3689 1.05E-23
ILMN_1756506 CYORF15B Yq11.2 1.19 0.2481 6.34E-19
ILMN_1873540 HS.412918 Yq11.2 1.19 0.2469 1.34E-18
ILMN_1786834 PRKX Xp22.3 -1.33 -0.412 3.25E-16
ILMN_1794392 DDX3X Xp11.4 -1.21 -0.2705 5.66E-15
ILMN_2205050 PRKX Xp22.3 -1.31 -0.3889 1.18E-14
ILMN_1684873 ARSD Xp22.3 -1.62 -0.6935 2.83E-10
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Figure 5.3 Macrophage gene expression outliers in a representative CD patient (CD1).
Gene expression outliers in unstimulated macrophages were identified by calculation of
Z-scores and associated p-values for all expressed probes in each individual CD patient
(n=63), relative to mean expression in the HC cohort (n=43). Probes that reached a
minimum threshold of p<0.005 and 1.5 fold change were considered as outliers.
(A) Volcano plot showing fold change of all expressed probes (on a log2 scale) in one CD
patient (CD1) compared to mean HC expression, and corresponding p-values (on a –log10
scale). Under-expressed probes identified as outliers are shown in green and over-
expressed probes in red. Probes with expression that was significantly different between
male and female individuals were excluded from the analysis (blue). (B) Identities (ID) of
outlier probes and corresponding genes in this individual, showing raw and log
transformed fold changes and p-values, compared to expression in the HC cohort.
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B Over-expressed probes
Probe ID Gene ID Raw foldchange
Log2 Fold
change P-value -Log10 p-value
Volcano plot
identity
ILMN_2137625 LOC150763 1.67 0.74 2.34E-04 3.63 a
ILMN_2169801 TPSAB1 42.22 5.4 2.75E-04 3.56 b
ILMN_1660599 LOC653186 1.67 0.74 3.80E-04 3.42 c
ILMN_1676256 TPSAB1 33.82 5.08 4.37E-04 3.36 d
ILMN_1668134 GSTM1 3.39 1.76 6.31E-04 3.2 e
ILMN_1761312 CRHBP 2.3 1.2 7.08E-04 3.15 f
ILMN_1756469 GAMT 1.72 0.78 1.07E-03 2.97 g
ILMN_1762255 GSTM1 3.94 1.98 1.74E-03 2.76 h
ILMN_2346997 RAB23 1.89 0.92 2.69E-03 2.57 i
ILMN_2150851 SERPINB2 1.57 0.65 2.75E-03 2.56 j
ILMN_1668039 GYPC 1.93 0.95 4.17E-03 2.38 k
ILMN_1764754 RAMP1 2.35 1.23 4.90E-03 2.31 l
Under-expressed probes
Probe ID Gene ID Fold change Log2 Foldchange P-value -Log10 p-value
Volcano plot
identity
ILMN_1761450 DHRS4L2 -3.41 -1.77 1.23E-05 4.91 m
ILMN_1762666 DHRS4 -2.57 -1.36 1.58E-04 3.8 n
ILMN_2381899 OPTN -2.46 -1.3 3.02E-04 3.52 p
ILMN_1660923 HCG4 -3.46 -1.79 8.32E-04 3.08 q
ILMN_1717477 PSD3 -1.93 -0.95 1.38E-03 2.86 r
ILMN_2262288 EEF1G -2.27 -1.18 3.63E-03 2.44 s
ILMN_1676014 LOC728635 -2.03 -1.02 3.89E-03 2.41 t
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Number of outlier 
probes per individual 
(median)
Interquartile range
CD (n=61) 27 16-45
UC (n=45) 25 13-38
HC (n=43) 22 10-76
A
B C
Figure 5.4 Numbers of outlier probes in unstimulated macrophages from CD, UC and 
HC individuals. (A) Median number of outlier probes per individual in CD, UC and HC 
patient macrophages with interquartile range. (B) Venn diagram showing the total 
number of under-expressed outlier probes in the CD, UC and HC cohorts, and number 
of overlapping outliers between the groups. (C) Corresponding results showing total 
number of over-expressed outliers detected in the CD, UC and HC cohorts.
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MetaCore pathway analysis software was used to determine GO processes that were 
enriched within the total CD, UC and HC outlier probe list. The most highly 
significantly enriched GO processes within the CD outlier probes included cellular and 
metabolic processes, response to stress, response to wounding, immune system 
processes, cell death and establishment of localisation (Table 5.7A). The GO processes 
significantly enriched in the HC outlier probes were similar to CD (Table 5.7B), 
suggesting that overall, outliers in HC and CD macrophages have similar functional 
ontologies. Notably establishment of localisation and transport were amongst the top 20 
most significant GO processes in the CD outliers but not in the HC group. 
5.2.4 Overlap between macrophage gene expression outliers and GWAS susceptibility 
loci 
To date, GWAS have identified 71 genetic polymorphisms associated with CD 
(115;116). In many cases the identified polymorphism may not represent the true 
pathogenic variant, and is likely to exist in linkage disequilibrium with other SNPs, 
giving rise to a ‘susceptibility locus’ containing several candidate genes. The 
unstimulated outlier gene list obtained in this study was screened to identify individual 
CD and UC patients with abnormal expression of genes linked to IBD by GWAS 
(115;116;390). Using the gene expression outlier analysis strategy, ten genes located in 
susceptibility loci were found to be abnormally expressed in our CD cohort, of which 
urotensin 2 (UTS2), caspase recruitment domain family, member 9 (CARD9) and 
chemokine (C-C motif) ligand 7 (CCL7) were identified as outliers in macrophages 
from two or more CD patients (Figure 5.5A, B). These may represent important targets 
for future investigation, and in particular, sequencing of the relevant genomic interval in 
these individuals could be conducted to search for rare variants or novel mutations. 
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GO processes: CD outliers P-value
Dataset
genes
Total
genes
Cellular process 2.03E-26 1280 14811
Metabolic process 2.20E-23 931 10001
Cellular metabolic process 3.45E-22 805 8403
Small molecule metabolic process 1.58E-21 317 2570
Response to stress 2.57E-21 374 3204
Primary metabolic process 4.56E-20 797 8428
Response to wounding 2.95E-16 173 1251
Positive regulation of molecular function 6.80E-16 178 1312
Positive regulation of catalytic activity 1.43E-15 158 1123
Regulation of catalytic activity 2.90E-15 238 1959
Cell death 2.91E-15 158 1132
Positive regulation of biological process 4.52E-15 384 3611
Death 5.02E-15 158 1139
Regulation of molecular function 5.03E-15 271 2328
Immune system process 7.19E-15 215 1729
Negative regulation of biological process 7.22E-15 344 3158
Transport 2.86E-14 379 3596
Establishment of localization 4.16E-14 383 3652
Negative regulation of cellular process 4.98E-14 317 2891
Regulation of biological quality 5.49E-14 319 2916
GO processes: HC outliers P-value
Dataset
genes
Total
genes
Response to stress 8.59E-40 576 3204
Immune system process 9.66E-39 365 1729
Positive regulation of biological process 6.58E-31 599 3611
Regulation of programmed cell death 1.28E-29 296 1430
Regulation of apoptosis 6.35E-29 292 1416
Regulation of cell death 1.01E-28 299 1467
Response to wounding 1.76E-28 266 1251
Response to organic substance 1.36E-27 398 2187
Immune response 1.88E-27 229 1028
Regulation of immune system process 3.34E-27 229 1032
Positive regulation of cellular process 5.23E-27 539 3261
Response to stimulus 1.92E-26 1130 8211
Cellular process 3.63E-26 1828 14811
Defense response 6.15E-26 251 1197
Multi-organism process 6.96E-24 274 1392
Small molecule metabolic process 1.01E-23 436 2570
Negative regulation of biological process 1.51E-23 512 3158
Metabolic process 2.23E-23 1313 10001
Cellular response to chemical stimulus 3.41E-22 288 1526
Negative regulation of cellular process 3.47E-22 472 2891
Table 5.7 Functional analysis of CD and HC gene expression outliers by
gene ontology (GO) annotation. Analysis of functional ontology of all
outlier probes detected in unstimulated CD and HC macrophages was
performed using MetaCore Pathway analysis software. The 20 most
significantly enriched GO processes within (A) the CD outlier dataset and
(B) the HC outlier datasets are shown, with associated p-values. The
number of genes in each GO process present in the dataset (dataset genes)
in comparison to the total GO database (total genes) are shown.
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dbSNP ID Chromosome
Number of outlier individuals (p<0.005)
CD (61) UC (45) HC (43)
Genes of Interest Down Up Down Up Down Up
rs35675666 1p36
TNFRSF9, ERFFI1,
UTS2 5 2 2
rs4077515 9q34 CARD9 2 2
rs3091315 17q12 CCL2, CCL7 2
rs1456896 7p12 IKZF1 1 1 2
rs102275 11q12 FADS1 1
rs694739 11q13 PRDX5, ESRRA 1 1
rs11742570 5p13 PTGER4 1
rs740495 19p13 GPX4, SBNO2 1
rs3180018 1q22 SCAMP3, MUC1 1 1
rs4656940 1q23 ITLN1 1 1
A
B C
Figure 5.5 Abnormal macrophage expression of genes located in CD GWAS
susceptibility loci in CD, UC and HC individuals. (A) SNPs associated with CD by
GWAS, with their associated chromosomal location and genes located in the region of
interest. The number of outlier individuals identified in the CD, UC and HC cohorts are
shown. Genes that were identified as outliers are highlighted in bold. (B) Dot plot
showing under-expression of CARD9 in two patients with CD and two patients with UC
(shaded area). (C) Dot plot showing over-expression of UTS2 in five CD patients, two
UC patients and two HC individuals (shaded area). Two additional patients with
apparent over-expression marginally fall outside the significance threshold. Dot plots
are shown on a logarithmic (to base 2) scale. All data shown are for unstimulated
macrophages.
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5.2.5 Outlier probes common between CD patients 
The majority of abnormally expressed probes were specific to individual CD patients, 
with only 19.8% of under- and 25.5% of over-expressed probes detected as outliers in 
two or more subjects.  The most frequent under-expressed outlier was present in seven 
CD patients, and the most frequently detected over-expressed outlier probe was found in 
11 individuals (Figure 5.6A). Probes that were identified as abnormal in five or more 
CD patients are shown with the corresponding frequency with the HC and UC cohorts 
(Figure 5.6B). All of these outlier probes were detected as outliers in two or fewer HC 
individuals; the frequency was more variable in the UC cohort. A number of probes 
were not identified as outliers in any of the UC patients tested, such as ILMN_2103107 
and ILMN_2105441, which correspond to ADAM-like, decysin 1 (ADAMDEC1) and 
immunoglobulin J polypeptide (IGJ) respectively, whereas others (such as 
ILMN_1664641, mediator subunit complex 4, MED4) were abnormally expressed in 
over 10% of UC patients. Interestingly, several of the frequently identified gene 
expression outliers have functional roles in apoptosis, which is impaired in CD 
macrophages in response to phorbol ester stimulation (205).   
The most commonly under-expressed outlier probe in the CD cohort was 
ILMN_2381899, corresponding to the optineurin (OPTN) gene. Optineurin was under-
expressed in seven CD patients (11.5% of the CD cohort investigated) and one 
individual with UC (2.2% of UC patients) (Figures 5.6B and Figure 5.7). No HC 
individuals were identified with deficient expression in this study. The optineurin 
predicted protein consists of 577 amino acids and has some predicted structural 
homology to NF-κB essential modulator (NEMO), a regulator of NF-κB activation 
(391). Recent functional studies have identified roles for optineurin in vesicle 
trafficking and maintenance of the Golgi apparatus (392), as well as in autophagy and  
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Figure 5.6 Outlier probes common between CD patients. (A) Percentage of outlier probes
detected in 1, 2 or more individuals, for the CD and UC cohorts. The majority of outlier
probes were private to one individual only. (B) Under- and over-expressed outlier probes
detected in 5 or more CD patients, showing corresponding number of CD, UC and HC
patients detected as outliers, and functional role of the identified genes.
A
B
Under-expressed outlier probes (p<0.005, -1.5 fold change)
Probe ID Gene ID
Number of Individuals
Role/Function Illustrative referenceCD (61) UC (45) HC (43)
ILMN_2381899 OPTN 7 1 0 Vesicle trafficking,autophagy
Wild P et al. 2011; Science
333(6039):228-33
ILMN_1772459 RPS23 7 4 1 Protein synthesis Vladimirov SN et al. 1996; Eur JBiochem.239(1):144-9
ILMN_2103107 ADAMDEC1 6 0 1 Disintegrin andmetalloproteinase
Bates EE et al. 2002;
Immunogenetics 54(2):96-105.
Over-expressed outlier probes (p<0.005, 1.5 fold change)
Probe ID Gene ID
Number of Individuals
Role/Function Illustrative referenceCD (61) UC (45) HC (43)
ILMN_2409384 SIGLEC7 11 1 1 Inhibitor of cell signaling Avril T et al. 2004; J Immunol173(11):6841-9.
ILMN_1710124 CMTM8 6 1 0 Apoptosis, EGFR signaling Li D et al. 2007. Int J Biochem CellBiol 39(11):2107-19.
ILMN_1875123 HS.572219 6 2 1 Unknown
ILMN_1905324 HS.145134 6 4 2 Unknown
ILMN_1662038 LARGE 5 3 0 Glycosyltransferase Peyrard M et al. 1999.; PNAS96(2):598-603
ILMN_1664641 MED4 5 5 1 Gene transcription
ILMN_1671818 UTS2 5 2 2 Vasoconstriction,apoptosis
Ames R et al. 1999; Nature
401(6750):282-6.
ILMN_1732198 UTS2 5 3 2 Vasoconstriction,apoptosis
Ames R et al. 1999; Nature
401(6750):282-6.
ILMN_1691860 SPRY1 5 2 0 MAP kinase activator,Intracellular signaling
Lee JS et al. 2009; J Immunol
183(11):7178-86.
ILMN_1695290 FERMT2 5 2 0 Integrin signaling andActivation
Lai-Cheong JE et al. 2010; Int J
Biochem Cell Biol. ;42(5):595-603.
ILMN_1707717 BAALC 5 3 0 Unknown .
ILMN_1808566 TMEM180 5 0 0 Unknown
ILMN_1760412 SHISA2 5 4 2 Development, cellsignaling
Nagano T et al. 2006. Development.
133(23):4643-54.
ILMN_2105441 IGJ 5 0 0 Immunoglobulin linkermolecule
Koshland ME. et al 1985; Annu Rev
Immunol 3:425-53
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Figure 5.7 Abnormal optineurin (ILMN_2381899) expression in unstimulated
CD macrophages. Microarray expression data were interrogated to identify gene
expression abnormalities in individual CD and UC patients, using a threshold p-
value of p<0.005 and a minimum fold change of 1.5 compared to HC. (A) log2-
transformed expression data for optineurin, the most commonly underexpressed
gene identified in the outlier analysis. Seven CD patients and one UC patient
were identified with deficient optineurin expression (shaded area). Numbers in
each group are shown in italics. (B) Differentially expressed probes between CD
optineurin outlier patients (n=7) and HC (n=43), using classical group
comparison of differential gene expression (uncorrected for multiple testing). No
probes were significant after correction for multiple testing, with the exception of
ILMN_2381899, OPTN (*).
Probe ID Gene ID Chromosome Fold change P-value
ILMN_2381899* OPTN 10p13 -2.42 1.69E-12*
ILMN_1781656 SCGB1D1 11q12 1.16 6.46E-05
ILMN_1731134 LOC730686 2q34 1.10 1.19E-04
ILMN_1773427 KANK1 9p24 1.53 1.37E-04
ILMN_1716869 GPM6A 4q34 1.10 1.72E-04
ILMN_1682399 CLOCK 4q12 1.25 2.00E-04
ILMN_1829389 HS.540247 15q22 1.09 2.01E-04
ILMN_1706511 TEF 22q13 1.13 2.13E-04
ILMN_1757370 SMPD1 11p15 1.20 2.19E-04
ILMN_2364357 RPS6KB2 11q13 1.21 2.35E-04
A
B
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clearance of intracellular bacteria (393). Abnormal optineurin expression is therefore a 
strong candidate molecular defect in a subset of CD macrophages, which could 
influence pro-inflammatory cytokine release via effects on vesicle trafficking. Genetic 
variation and mutations in the OPTN gene have previously been associated with 
primary open angle glaucoma (394), amyotrophic lateral sclerosis (ALS) (395) and 
Paget’s disease of bone (396), however no studies have linked abnormalities in the 
OPTN gene to CD. 
It is recognised that the presence of different SNPs between Illumina array 
probes and target transcripts can lead to mismatching and defective hybridisation, 
giving rise to ‘artifactual’ differences in gene expression (397). Therefore, before 
selecting candidates for further validation and functional study, a publically accessible 
database (397) of Illumina probe annotations was searched to determine whether any of 
the down- or up-regulated outlier probes common to five or more patients contained 
recognised variants. Only ILMN_1772459 (corresponding to RPS23) and 
ILMN_2409384 (corresponding to SIGLEC7) contained recognised SNPs within the 
probe sequence (rs3738 and rs273662 respectively). None of the other outlier probes 
common to five or more patients contained recognised SNPs, including 
ILMN_2381899, corresponding to optineurin. Sequencing of the OPTN probe region 
(50 nucleotides) in the seven CD outlier patients furthermore revealed perfect alignment 
with ILMN_2381899, indicating that the abnormal expression of optineurin is not due 
to defective probe hybridisation. 
Transcriptomic abnormalities that occur concurrently with optineurin deficiency 
could be important mechanistically, for example by indicating contiguous gene 
deletions or duplications, defects in a common transcription factor, or secondary effects. 
Therefore, gene lists generated by the customised software were searched for the 
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presence of common outliers between individuals, and classical comparison of group 
differential gene expression was performed between the optineurin outlier CD patients 
(n=7) and HC individuals (n=43). No other outlier probes were common to three or 
more optineurin outlier individuals.  Furthermore, classical group comparison of 
optineurin outlier patients with HC revealed no differentially expressed probes between 
the two groups after FDR correction (with the exception of ILMN_2381899, OPTN, as 
expected), suggesting the absence of other common gross transcriptomic abnormalities 
in these patients. The ten most significantly different probes (before multiple testing 
correction) are shown (Figure 5.7B). 
5.2.6 Identification of optineurin gene expression outlier patients in other array 
datasets 
The HkEc stimulated macrophage gene expression dataset obtained using the Illumina 
BeadChip array was subsequently interrogated for the presence of optineurin outlier 
patients. Using the same thresholds as previously, one CD patient was discovered to be 
a gene expression outlier for optineurin (Figure 5.8A). This patient was previously 
identified as having abnormal expression of optineurin in unstimulated macrophages. 
Furthermore, the previously published Affymetrix gene expression dataset (136) 
was also investigated to identify additional CD patients with abnormal optineurin 
expression. UC patients were not included in this analysis due to batch differences in 
the level of expression between datasets that could not be resolved using conventional 
normalisation methods. One patient was identified with reduced expression of 
optineurin in unstimulated macrophages compared to HC (fold change compared to HC 
-3.24, p=0.009) (Figure 5.8B). This patient was not included in the Illumina study 
cohort. No outliers were identified in the HkEc stimulated dataset using the Affymetrix 
platform, although data were not available from the patient with abnormal expression  
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Figure 5.8 Abnormal optineurin expression in individual CD patients in two 
distinct array datasets. Patients were identified that were outliers for macrophage 
optineurin expression, using a threshold p-value of p<0.005 and a minimum fold 
change of 1.5 compared to mean HC expression. (A) Illumina microarray 
expression data of optineurin in cultured macrophages after stimulation for 4 hours 
with HkEc, showing one outlier CD patient (shaded area). (B) Affymetrix 
expression data of optineurin in unstimulated macrophages, showing one outlier 
individual (shaded area). Expression data are presented on a log2 scale. Numbers in 
each group are shown in italics.
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identified in the unstimulated dataset. Overall, the results support the concept that a 
subgroup of CD patients have abnormal macrophage expression of optineurin, which 
can be detected under multiple conditions and across different microarray platforms. 
5.2.7 Validation of abnormal optineurin expression in a subset of CD patients 
In order to validate the abnormal expression of optineurin in the subset of patients 
identified in the microarray outlier analysis, TaqMan® real time quantitative PCR was 
performed. The relative expression of optineurin in the six of the outlier individuals was 
quantified in comparison to six HC individuals selected at random from the microarray 
study cohort. Results were normalised to expression levels of the housekeeper gene 
GAPDH. The outlier patients investigated had decreased optineurin expression 
compared to the HC individuals tested (mean reduction ~2.7 fold). This reduction was 
highly statistically significant (p<0.001) (Figure 5.9A), confirming the abnormality in 
macrophage optineurin expression in these CD patients at the mRNA level. 
 Western blotting was also performed in preliminary studies to investigate 
whether macrophage optineurin expression was reduced at the protein level. Samples 
from the one available outlier patient were compared with one HC lysate, in the 
unstimulated state, and after 4 and 24 hours stimulation with HkEc. A band was 
detectable at ~74kDa corresponding to the optineurin protein, in concordance with 
previously published studies (398). Macrophage expression of optineurin was reduced 
in all conditions compared to the controls tested (Figure 5.9B). Unfortunately cell 
lysates were not obtained from the majority of optineurin outlier individuals, preventing 
a more extensive assessment of optineurin protein expression. 
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Figure 5.9 Validation of abnormal optineurin (OPTN) expression in a subset of 
CD patients, identified as gene expression outliers from the microarray study.
 (A) TaqMan quantitative PCR of OPTN expression in unstimulated macrophages 
from the patients identified as outliers, relative to randomly selected HC 
individuals. Numbers in each group are shown in italics. Data are presented as 
mean + SEM. *** represents p<0.001. (B) Western blot of macrophage OPTN 
expression in an outlier patient compared to a control individual. Results are 
shown for unstimulated samples (Uns), and 4 and 24 hours after HkEc stimulation. 
Position of molecular weight markers are shown.
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5.2.8 Phenotype and genotypes of optineurin outlier patients 
The clinical phenotypes of the CD patients with abnormal optineurin expression were 
surprisingly diverse (Figure 5.10A). Of the seven patients from the Illumina study, two 
individuals were related (individuals 1 and 6). The majority of the patients were male, 
although one patient with low optineurin expression was female. The average age of the 
seven patients was 48.3 + 16.8 (mean + standard deviation). All of the patients were 
Caucasian. Most had either ileal or ileocolonic involvement, but a wide range in age of 
diagnosis. Four of the patients had inflammatory disease, one had stricturing and two 
had fistulating disease. The seven patients were receiving a variety of medical regimens 
at the time of venesection, although notably, one patient was receiving no treatment and 
three were taking 5-ASA compounds only. The phenotypes of the UC patient, and one 
individual identified in the Affymetrix array cohort are also presented. 
 Considering the genotypes of the optineurin outlier individuals, one patient was 
homozygous for the G908R NOD2 polymorphism, and the related individual was 
heterozygous for this variant. However, none of the other individuals in the Illumina 
study had any of the three CD-associated polymorphisms in NOD2. Interestingly, five 
of the individuals had an overall CD GRS (calculated from a 34-SNP genotype) that 
was below average for the healthy population, suggesting that the 34 polymorphisms 
genotyped do not play a major role in the development of CD in these patients. The two 
related individuals both had a GRS of 1.65 or above. The outlier patient identified in the 
Affymetrix study was compound heterozygous for CD-associated variants in NOD2 and 
had a GRS of 9.03. 
Macrophage TNF secretion after bacterial stimulation was also determined from 
four of the optineurin outlier patients and compared to the HC response. Median 
macrophage TNF release from the optineurin outlier patients after HkEc stimulation  
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Cohort
Diagnosis Gender Age Current 
smoking
Treatment
Montreal 
classification
NOD2 
genotype
GRS
1# Illumina CD M 23 No MTX A1L1+4B3p mt/wt 1.65
2 Illumina CD M 60 No Steroid A2L1B3 wt/wt 0.62
3 Illumina CD M 36 No None A2L3B2 wt/wt 0.45
4 Illumina CD M 34 No 5-ASA A2L3B1 wt/wt 0.34
5 Illumina CD F 62 No 5-ASA A3L2B1 wt/wt 0.7
6# Illumina CD M 58 No MTX A2L3B1 mt/mt 2.03
7 Illumina CD M 65 Yes 5-ASA A3L1B1 wt/wt 0.44
8 Illumina UC M 48 No 5-ASA 
9 Affymetrix CD M 75 No 5-ASA A2L2B3 mt/mt 9.03
A
B C
Figure 5.10 Phenotypes of optineurin outlier patients. (A) Details of patients identified as 
abnormal for optineurin (OPTN) expression by microarray gene expression outlier analysis. 
The microarray study in which the patients were identified is shown with demographics. 
Treatment regimes at the time of venesection are detailed for each patient (5-ASA = 5-
aminosalicylates, MTX = methotrexate). The NOD2 genotypes (where wt represents wild 
type allele, mt represents CD-associated variant allele) and calculated genetic risk score 
(GRS) based on a 34 SNP genotype are also shown. # indicates related individuals. 
(B) TNF release from optineurin outlier patient macrophages in response to HkEc 
stimulation, compared to HC and CD patients. Data are presented on a logarithmic scale
 (C) Deficient TNF release from optineurin outlier patient macrophages in response to 
stimulation with Pam3CSK4 (PAM3). Data are represented on a logarithmic scale. 
* represents p<0.05.
Microarray
HkEc PAM3
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was 11,762 pg/ml (interquartile range 10,897-13,232 pg/ml), compared to 21,991 pg/ml 
(interquartile range 11,080-35,059 pg/ml) from HC individuals, however this reduction 
did not reach statistical significance (Figure 5.10B). In response to TLR2 stimulation, 
macrophage TNF release was significantly (p<0.05) attenuated from the optineurin 
outlier patients compared to HC individuals (Figure 5.10C). Therefore, the macrophage 
abnormality of TNF secretion in these patients is consistent with that identified in the 
overall CD cohort, but more striking after TLR2 than HkEc stimulation. 
5.2.9 Functional relevance of abnormal optineurin expression in TNF release 
 In order to test whether low expression of optineurin had any functional 
relevance to TNF secretion after bacterial stimulation, optineurin expression was 
depleted in THP-1 cells using siRNA. 24 hours after transfection with specific a siRNA 
targeted against optineurin, cells were stimulated with HkEc  and Pam3CSK4, and TNF 
release determined after 6 hours. Results were compared to mock transfected cells 
(without siRNA) and cells transfected with a non-targeting siRNA to control for 
potential off-target effects. Western blotting revealed a reduction in optineurin 
expression of ~60% in cells transfected with the OPTN siRNA compared to mock 
transfected cells. No significant difference in optineurin expression was observed in 
cells transfected with the negative control siRNA (Figure 5.11A, B). The proportion of 
viable cells after siRNA transfection was equivalent between mock, negative control 
and optineurin knockdown cells, as determined by propidium iodide staining and flow 
cytometry (Figure 5.18C). 
 After TLR2 stimulation with Pam3CSK4, TNF release was significantly 
attenuated from cells transfected with siRNA directed against optineurin (p<0.01) in 
comparison to mock transfected cells (Figure 5.12A). There was no significant 
difference between TNF release after TLR2 stimulation from mock transfected cells and  
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Figure 5.11 Knockdown of optineurin in THP-1 cells using siRNA. (A) Western blot showing 
depletion of optineurin (OPTN) in siRNA transfected cells in comparison to mock and  control 
siRNA tranfected cells. OPTN is detected as a 74 kDa band. Actin loading controls are also 
shown. (B) Quantification of OPTN depletion in knockdown cells by densitometry. Results are 
expressed as % of mock transfected cells. Data are mean of 6 experiments with SEM. ** 
represents p<0.01. (C) Viability (as a % of total cell population) 24 hours after transfection was 
determined by propidium ioidide staining and flow cytometry. There were no significant 
differences in viability between mock, negative control and OPTN siRNA transfected cells.
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Figure 5.12 Impaired TNF release from optineurin depleted THP-1 cells after 
TLR2, but not HkEc stimulation. THP-1 cells were transfected with siRNA 
directed against optineurin (OPTN), non targeting siRNA (negative control) or 
mock transfected (without siRNA). After 24 hours, cells were stimulated with 
(A) Pam3CSK4 or (B) HkEc for 6 hours and amount of TNF released determined 
by bioassay. Results are mean + SEM of 6 experiments, presented as % of mock 
transfected cells. ** represents p<0.01 compared to mock transfected cells.
A
B
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cells transfected with the control siRNA. After HkEc stimulation, no significant 
differences in TNF release were observed between mock, negative control and 
optineurin siRNA transfected cells (Figure 5.12B). 
5.2.10 DNA sequence variants associated with abnormal optineurin expression 
Given the deficient expression of optineurin observed in the subset of outlier patients, 
the OPTN gene was sequenced in seven of these individuals to test for the presence of 
mutations and polymorphisms. The OPTN gene is located on chromosome 10 and 
consists of 16 exons, 13 of which code for the optineurin protein (394). All exons and 
exon-flanking sequences were sequenced from the genomic DNA of optineurin outlier 
individuals. In addition, sequencing was conducted of ~2 kilobase (kb) regions up- and 
downstream of the OPTN gene. No novel mutations were detected in these regions in 
any of the patients tested; all sequence variants identified had been previously 
documented in dbSNP and/or the 1000 Genomes Project. 
Heterozygous missense mutations in OPTN have been previously linked to 
primary open angle glaucoma, including the E50K, M98K and R545Q mutations (394). 
More recently, a homozygous deletion of exon 5, a nonsense mutation (Q298X) and a 
missense mutation (E478G) have been identified in patients with amyotrophic lateral 
sclerosis (ALS) (395). None of these mutations could be identified in any of the patients 
with abnormal optineurin expression. 
Although no novel mutations were found, a number of recognised SNPs were 
identified in the outlier patients (Figure 5.13A, B). Notably, five patients were 
homozygous for the rs765884, rs12415716 and rs7098640 minor alleles, and the 
remaining two individuals were heterozygous for the variant SNPs. Rs765884 is located 
in an intronic region upstream of exon 9, whereas rs12415716 and rs7098640 are 
located downstream of the last exon (Figure 5.13C). Six of the seven patients also had  
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rs 12415716
Patient
Control
SNP Wild typeallele
Minor
allele
Minor allele
Frequency
OPTN outlier patient
1 2 3 4 5 6 7
rs3829924 G A 0.038 G/G G/G A/G G/G G/G G/G G/G
rs11548142 G A 0.2 G/G G/G A/A G/G A/A G/G A/A
rs10906303 A G 0.18 G/G G/G A/A G/G G/G A/A
rs2234968 G A 0.17 G/G G/G A/A G/G G/G A/A
rs4748020 G C 0.22 C/C G/G G/G C/C G/G C/C G/G
rs765884 T C 0.202 C/C C/T C/C C/C C/C C/T C/C
rs12415716 T G 0.196 G/G G/T G/G G/G G/G G/T G/G
rs7098640 T C 0.195 C/C C/T C/C C/C C/C C/T C/C
A
B
C
Figure 5.13 Single nucleotide polymorphisms (SNPs) identified in the OPTN region
in outlier patients. (A) Recognised SNPs detected in outlier individuals . The minor
allele frequency shown is derived from HapMap and/or the 1000 Genome project.
Patients carrying a minor allelic variant are highlighted in red for each SNP.
(B) Representative DNA sequence chromatogram from an outlier patient and control
individual. The outlier patient is homozygous for the minor allele (G) of rs12415716;
the control patient is homozygous wild type (T). (C) Schematic diagram of the OPTN
gene, showing the position of the identified SNPs. Exons (grey boxes) are numbered.
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sequence variants in exon 1. These included three individuals who were homozygous 
for the rs11548142 minor allele, and three other patients who were homozygous for a 
distinct polymorphism (rs4748020). One individual was heterozygous for an uncommon 
sequence variant in the promoter region of OPTN (rs3829924). 
SNP annotation and proxy search (SNAP) was subsequently used to determine 
whether any of the identified SNPs were in linkage disequilibrium. This software 
package utilises genotype data from the HapMap and 1000 genome projects to calculate 
linkage disequilibrium data between polymorphisms, and identify proxy SNPs (271). 
The rs765884, rs12415716 and rs4748020 SNPs are in strong disequilibrium, indicated 
by the linkage disequilibrium D
’
 values of 1, and r
2
 correlation co-efficient values of 
greater than 0.8. In addition, a number of other SNPs are in linkage disequilibrium with 
the SNPs identified in the outlier patients. Results for rs12415716 are presented (Figure 
5.14A, B). This observation suggests that the optineurin outlier patients may have a 
common haplotype (a combination of alleles at adjacent loci that are inherited together). 
Of the other SNPs identified, two were in linkage disequilibrium (rs10906303 and 
rs2234968, r
2
=0.98). Linkage disequilibrium data were not available for rs4748020. 
In order to assess whether the common haplotype identified in the optineurin 
outlier patients was associated with reduced optineurin expression, data from expression 
quantitative trait loci (eQTL) studies were interrogated using Genevar (GENe 
Expression VARiation) software (272). eQTL studies investigate associations between 
thousands of genotyped SNPs and transcriptomic data in particular cell or tissue types, 
derived from microarray analysis. No eQTL data were available for the SNPs directly 
identified in the outlier patients. However, rs17512962, a proxy SNP identified to be in 
linkage disequilibrium with rs12415716, was significantly associated with expression in 
fibroblasts (Figure 5.15A) (399). 
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SNP Genomic position D' r2
rs67121368 13214765 1 1
rs12415683 13212878 1 1
rs17512962 13209072 1 1
rs67978856 13202389 1 1
rs57199113 13200218 1 0.917
rs57057378 13200041 1 0.917
rs765884 13204338 1 0.913
rs7098640 13222655 1 0.879
Figure 5.14 Linkage disequilibrium between single nucleotide
polymorphisms identified in optineurin outlier patients. SNP annotation and
proxy search software was used to determine whether SNPs detected were
in linkage disequilibrium. (A) Polymorphisms in linkage disequilibrium
with rs12415716 using a threshold r2 of 0.8. Polymorphisms identified in the
outlier individuals are highlighted in red. (B) Diagram of linkage
disequilibrium between rs12415716 and other SNPs (highlighted in orange).
The double-headed arrow shows the region where r2 >0.8 between
rs12415716 and the other SNPs. The positions of SNPs and the OPTN gene
(green) on chromosome 10 are shown. Data are shown are according to
human genome reference assembly GRCh37.
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Figure 5.15 Association of single nucleotide polymorphisms in the OPTN region with 
optineurin (OPTN) expression. (A) Rs17512962, which is in linkage disequilibrium with 
rs12415716 (r2=1), is associated with OPTN expression in fibroblasts. Data are derived 
from an expression quantitative trait locus study (399). (B) Association of rs12415716 
genotype with optineurin expression (from microarray data) in the CD cohort. (C) 
Corresponding results for the HC cohort. *** represents p<0.001. Data are presented on a 
logarithmic (to base 2) scale.
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To determine whether the haplotype was likewise associated with macrophage 
optineurin expression in the microarray study cohorts, CD patients (n=43) and HC 
individuals (n=38) were genotyped for rs12415716. In the CD cohort, 26 individuals 
were homozygous for the wild type allele (T), 15 individuals were heterozygous and 5 
individuals were homozygous for the minor allele (G), giving an overall minor allele 
frequency of 0.27. The allele frequencies were similar in HC; the minor allele occurring 
at an overall frequency of 0.29. As expected from the eQTL studies, there was a 
significant difference in optineurin expression between wild type individuals, 
individuals heterozygous for the minor allele and individuals homozygous for the minor 
allele (all p<0.001) (Figure 5.15B). 
HC individuals homozygous for the wild type allele had significantly greater 
expression of optineurin than individuals heterozygous for the wild type allele. Two HC 
individuals in the study were homozygous for the minor allele. These individuals did 
not display the gross abnormalities in expression observed in CD outliers, suggesting 
that the presence of the haplotype may be necessary but not sufficient to cause abnormal 
optineurin expression (Figure 5.15C). 
5.3 Discussion 
In this chapter, the global transcription profiles of HC, CD and UC macrophages are 
interrogated in an attempt to identify molecular lesions responsible for attenuated pro-
inflammatory cytokine release observed in CD. Although a number of differentially 
expressed genes were identified between HC and CD groups which could be of 
functional relevance, none of these remained significant after correction for multiple 
testing. Furthermore, PCA analysis was unable to separate samples on the basis of 
disease grouping. Therefore, whilst subtle differences may exist between HC and CD, 
the transcription profiles of CD macrophages do not display gross abnormalities or a 
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unique overall expression signature. Furthermore, very few differentially expressed 
genes could be identified when comparing CD with UC, suggesting similarity between 
these two groups. 
The absence of striking differences in global gene expression was surprising, 
given the previous reports of differentially expressed genes in PBMCs from CD patients 
(385), and furthermore in HkEc stimulated macrophages in a previous study conducted 
by our laboratory (136). In their study, Burczynski et al. investigated PBMC expression 
profiles from patients with a Crohn’s Disease Activity Index (CDAI) score of 220-400; 
it is therefore possible that disease activity could have been a confounding factor. This 
is however unlikely to explain the difference between the study previously published by 
our laboratory and the present findings, given that both investigations excluded patients 
with active disease. Whilst discrepancies in gene expression can also arise from 
differences in sample processing (400) and cell culture conditions, in both cases 
macrophages were cultured in the same manner from PBMCs. 
 An important difference between the two studies conducted was the microarray 
platform utilised for expression analysis. The previous investigation interrogated 
genome-wide expression using Affymetrix GeneChip arrays, whereas the current study 
utilised Illumina bead-based arrays. There are several notable differences between the 
two array platforms, including the nature of the probes used to detect and quantify 
transcripts. Affymetrix GeneChip array probes are oligonucleotides typically 25 
nucleotides in length, synthesised at predefined locations on the array (401;402). In 
contrast, Illumina arrays utilise long oligonucleotide probes, which are attached to 
microbeads and assembled randomly onto the array. Decoding algorithms are 
subsequently required to determine the location of each probe (402;403). Whilst studies 
such as the MicroArray Quality Control project have demonstrated concordance 
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between the results of Affymetrix and Illumina arrays (404), others have indicated 
subtle differences. For example, expression levels for low expressed transcripts appear 
to be less reproducible across platforms than abundant transcripts (402). Different 
methods of data processing between array platforms, such as normalisation, background 
subtraction and statistical thresholds employed, may also affect the observed 
concordance (405). It is therefore possible that the different array platforms used could 
contribute to the lack of concordance in the differentially expressed genes identified in 
the two experiments. 
 Patient heterogeneity is another likely reason for the different results obtained 
between the Affymetrix and the Illumina analysis, and may also explain the lack of 
differentially regulated genes observed in the present study after correction for multiple 
testing. CD is a complex and heterogeneous syndrome, demonstrated by the diversity in 
clinical phenotypes and genetic architecture between patients. It is therefore likely that 
molecular mechanisms giving rise to functional abnormalities in CD will be highly 
diverse. Analysis of the Affymetrix dataset identified 18 differentially regulated genes 
of known function in HkEc stimulated macrophages, nine of which participate in vesicle 
trafficking and cytoskeletal re-organisation (136). Interestingly, some of the genes 
identified as potentially abnormal in this study (without FDR correction) related to 
cytoskeletal control, such as LRRC50, and pathway analysis software also identified 
‘cytoskeletal remodelling’ as an enriched process within this differential gene list. It is 
therefore plausible that whilst the identities of differentially expressed genes differ 
between patient cohorts, some have overlapping biological functions. 
In view of the heterogeneity of CD, an ‘outlier analysis’ strategy was employed 
to identify abnormally expressed genes in individual CD patients. Using this analysis, a 
subset of patients was identified with abnormal expression of optineurin. The previously 
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described functional roles of optineurin in vesicle trafficking and protein secretion (392) 
implicated it as a likely candidate to influence pro-inflammatory cytokine secretion, and 
indeed depletion of optineurin expression in a monocytic cell line caused reduced TNF 
release in response to TLR2 stimulation. Together, these findings demonstrate how a 
‘individualised approach’ to analysis of microarray data, using strategies such as the 
customised outlier analysis, has the potential to be highly informative in identifying rare 
or uncommon defects in gene expression in individual CD patients, which have pivotal 
functional consequences. 
Optineurin is a ubiquitously expressed protein that localises to the perinuclear 
region and intracellular vesicles, especially those in close proximity to the plasma 
membrane (392). It interacts with a number of other proteins critical in intracellular 
trafficking and cytoskeletal control, including myosin VI, Rab8 and huntingtin (406). 
Given the observation of impaired post-translational handling of pro-inflammatory 
cytokines in CD macrophages, it is very plausible that a reduction in optineurin 
expression attenuates TNF release by impeding efficient intracellular trafficking 
processes. In further support of this, recent work has implicated key roles for optineurin 
in both the maintenance of Golgi structure (392) and in secretory vesicle fusion (407). 
Depletion of optineurin expression in cell lines attenuates secretion of proteins such as 
vesicular stomatitis virus glycoprotein (392), reduces the number of vesicle fusion 
events at the plasma membrane (407) and inhibits directed migration towards growth 
factors (398). Furthermore, optineurin is localised to recycling endosomes. In these 
vesicles, optineurin has been shown to interact with the transferrin receptor and regulate 
its trafficking to the juxtanuclear region (408). Interestingly, TNF and IL-6 secretion 
occurs via recycling endosomal compartments in cell lines (198). It is tempting to 
speculate that abnormal optineurin expression precipitates a dysregulation of recycling-
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endosome dependent trafficking in CD macrophages, which impairs efficient TNF 
release on encountering bacterial stimuli.  
Surprisingly, depletion of optineurin in the cell line did not strongly affect TNF 
secretion after HkEc stimulation. This is mirrored in cultured primary macrophages 
from the outlier patients. Pam3CSK4 is a synthetic ligand that binds TLR1/2 
specifically, whereas HkEc contains ligands such as LPS capable of TLR4 activation. It 
is likely that the factors governing pro-inflammatory cytokine release, including the 
post-translational trafficking machinery, are likely to be subtly distinct between 
microbial stimuli. Indeed, investigations described in chapter 3 support this argument, 
as a relationship was detected between the GRS (calculated from a 34 SNP genotype of 
GWAS susceptibility loci) and macrophage TNF release in response to HkEc, but not 
TLR2. 
As optineurin is a multifunctional protein that is also known to influence NF-κB 
activation by antagonising the effects of NEMO (409), further work is also required to 
determine the precise mechanism by which deficient optineurin expression impairs TNF 
release in response to TLR2. Such investigations could include incubation of control 
and optineurin depleted cells with inhibitors of protein trafficking and lysosomal 
function, and determining the effect on intracellular levels of TNF, as conducted 
previously in primary macrophages from CD patients. Microscopy studies of control, 
knockdown and primary patient macrophages could also prove extremely valuable in 
delineating potential mechanisms. In particular, immunocytochemistry and confocal 
microscopy should be performed to determine whether optineurin colocalises with TNF 
in vesicular compartments such as recycling endosomes. In addition, total internal 
reflection fluorescence microscopy (TIRF) could be employed to track vesicular 
transport, to determine whether abnormalities identified in optineurin deficient cell lines 
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are mirrored in cultured primary macrophages from the optineurin outlier patients. 
Furthermore, it would be interesting to investigate whether macrophages from this 
subset of patients have any defects in directed migration or lamellipodia formation 
(membrane projections that form at the leading edge of motile cells), given that in vitro 
depletion of optineurin is associated with abnormalities in these processes (398). 
Recently, a key role for optineurin in autophagy of intracellular bacteria was 
identified (393), representing a major advance in current understanding of optineurin 
and its functions in innate immunity. Optineurin was shown to act as an autophagy 
receptor. At a molecular level, optineurin was shown to be recruited to ubiquitinated 
forms of Salmonella within the cell cytosol, where it interacts with TANK-binding 
kinase (TBK1). TBK1 phosphorylates optineurin, which enhances its affinity for LC3. 
Consequentially, clearance of intracellular Salmonella is promoted. Thus, cells deficient 
in optineurin have impaired autophagy against Salmonella increased intracellular 
bacterial proliferation (393). The autophagic handling of intracellular bacteria in the 
optineurin outlier patients should be further explored, in comparison to both control 
individuals and other CD patients. UC patients, including the one optineurin outlier 
patient identified in this study, should also be investigated. It is possible that the 
impaired release of TNF observed downstream of TLR2 stimulation mechanistically 
relates to impaired induction of autophagy, given that this process may have a role in 
TNF release downstream of TLR stimulation (237). 
Heterogeneity between individual CD patients and control individuals, the 
potential for confounding factors, and constraints on in vivo testing in human subjects 
all present problems when attempting to prove the contribution of a specific molecule to 
the development of disease. Studies using knockout mice, in which the environment and 
mouse genetic background can be readily controlled, may be highly informative in 
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validating the in vivo significance of candidate molecules such as optineurin to disease 
pathogenesis. Recently, our laboratory has obtained mice with a targeted insertion in the 
OPTN gene that disrupts expression. Interestingly, these mice are viable and do not 
display gross ocular or neurological phenotypes. Macrophages from these mice should 
be cultured to validate the attenuated pro-inflammatory cytokine release observed in 
patient and siRNA-knockdown cells, and any other abnormalities identified in future 
work. Furthermore, the in vivo significance of optineurin deficiency in the development 
of bowel inflammation could be tested using classical inducers of colitis in rodents, 
such as DSS (410) and haptens such as trinitrobenzene sulfonic acid (411). In addition 
to comparing changes in weight, bleeding and histological scores in the knockout mice 
with littermate controls, infiltration of acute inflammatory cells such as neutrophils to 
the lamina propria and submucosa could be determined during the acute phase of colitis 
induction. This has previously been performed in studies of TLR4 knockout mice, 
which demonstrated more pronounced bleeding and impaired recruitment of neutrophils 
(148). 
Optineurin has previously been linked to diverse diseases, including glaucoma 
(394), ALS (395) and Paget’s disease (396), which may be a testament to its 
multiplicity of functions in a variety of different cell types. In this study, no mutations 
previously associated with human disease were identified, although a distinct haplotype 
was present in all optineurin outlier patients. The previous association of optineurin 
with neurological and ocular disorders does not preclude its potential relevance to other 
diseases such as CD. Indeed, sequencing of the NOD2 gene has demonstrated how 
heterogeneous lesions affecting the same molecule can give rise to distinct syndromes. 
Sequence variants in the leucine-rich repeat domain of NOD2 are associated with CD 
(211), whereas mutations in the nucleotide binding domain of NOD2 cause Blau 
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syndrome (412). Whilst CD and Blau syndrome share some phenotypic overlap, the 
latter is not associated with bowel inflammation (413).  
The optineurin outlier patients identified were homozygous or heterozygous for 
the minor allele of various SNPs in the optineurin gene region. As these SNPs are in 
strong linkage disequilibrium, the presence of a common haplotype is suggested. 
Furthermore, the results indicate that the abnormal optineurin expression is at least 
partially genetically determined. As multiple variants in linkage disequilibrium are 
present in the genomic region, it is difficult to pinpoint which of these, if any, are 
crucial in determining optineurin expression. It is also possible that all are in linkage 
disequilibrium with another variant or mutation that is as yet unidentified. Further 
sequencing of the OPTN region, including intronic sequences, together with functional 
data, may help clarify this issue. 
If a reduction in optineurin expression gives rise to a macrophage defect of 
relevance to CD, and certain SNPs are associated with optineurin expression, it is 
surprising that polymorphisms in the OPTN gene have not to date been linked to CD by 
GWAS. Such studies compare allele frequency of polymorphisms between thousands of 
disease cases and controls to identify significant associations (115;116), and notably 
rs17512962 has been included in some of these analyses. However, although the 
optineurin outlier patients were either homozygous or heterozygous for several minor 
allelic variants, these polymorphisms were also detected in other CD patients and HC 
individuals within the cohort. In these individuals, macrophage optineurin expression 
was within normal limits. Therefore, the presence of a specific haplotype may be 
necessary, but not in itself sufficient, to cause deficient levels of optineurin expression. 
In this case, additional defects in the transcriptional regulation of the OPTN gene could 
act to compound the effect of the haplotype on optineurin expression. It is possible that 
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in a subset of individuals, the presence of an additional rare mutation gives rise to a 
profound defect in optineurin expression. Although no novel mutations could be 
detected in the OPTN exonic region, intronic genetic variation is well established to 
influence gene expression (414;415). Furthermore, rare alterations in trans-acting 
elements such as transcription factors could act in concert with a variant or mutation in 
cis to give rise to grossly deficient expression. Given the potentially limited power of 
current GWAS to identify rare abnormalities (256-258), in these scenarios it is plausible 
that an association with OPTN and CD would not be identified.  
Combinations of relatively uncommon SNPs could also be the critical 
determinant of abnormal optineurin expression. In addition to the haplotype, SNPs were 
also identified in exon 1 in six of the patients; these could also exert effects on 
optineurin expression. One of these, rs4748020, has not been studied in GWAS and no 
proxy markers of this SNP exist. A combination of minor alleles (that are not usually in 
linkage disequilibrium) may be critical in determining abnormal optineurin expression 
and CD susceptibility; if the co-inheritance of these is an uncommon event, GWAS may 
be unable to identify the association.  
In addition to optineurin, a host of other gene expression outliers in CD were 
identified in this study, some of which could represent important targets for future 
investigation. The majority of gene expression outliers were private to individual 
patients, which may be in keeping with the recent prediction that each person possesses 
on average at least 60 new mutations in their genome (416). Ten outlier genes mapped 
to regions of CD association by GWAS. These included UTS2, encoding a potent 
vasoconstrictor (417), and CARD9, encoding a caspase recruitment domain-containing 
protein that may have a role in NF-κB activation and apoptosis (418), and in the innate 
immune response to fungal stimuli (419). Given that CD is associated with diminished 
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blood flow at sites of subcutaneous bacterial injection, and impaired macrophage pro-
inflammatory cytokine in response to various microbial stimuli (including C. albicans, 
as demonstrated in chapter 3), UTS2 and CARD9 could be relevant candidates for 
future study. It would be interesting to conduct sequencing of the relevant genomic 
locus in these individuals, to genotype for the relevant susceptibility polymorphism and 
identify any concurrent mutations or structural abnormalities. Preliminary studies 
conducted by our laboratory have validated the gross overexpression of urotensin 2 in a 
subset of individuals, and revealed that all urotensin 2 outlier individuals are 
homozygous for the risk-associated allele in this region. Further sequencing of the UTS2 
genomic locus in these patients is therefore now a priority, using techniques such as 
next generation sequencing. 
In a wider context, a personalised approach to understanding transcriptomic 
abnormalities in individual patients could be a powerful means of investigating 
heterogeneous disorders, especially when integrated with other techniques such as DNA 
sequencing and functional assays. Previously, analogous strategies have been attempted 
in oncology (383) and psychiatric research (420). Whilst the basic premise was the 
same, each of the studies employed distinct methods for detecting gene expression 
outliers in individuals or subsets of patients. One utilised an ‘extreme values’ analysis 
based on fold change from mean expression in a control cohort, using data from 
multiple cortical regions of the brain as an internal validation to identify relevant gene 
expression outliers (420). In oncology, the COPA algorithm has been employed with 
considerable success. This identified a subset of prostate cancer samples that displayed 
overexpression of the ETS transcription factor genes ERG and ETV1, leading to the 
important discovery of TMPRSS2-ETS chromosomal translocations in a subset of the 
samples (383). COPA identifies pairs of genes that have the largest number of mutually 
exclusive outliers in the disease group (ie samples that are outliers for gene X and 
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samples that are outliers for gene Y, but never both). The threshold set for outlier 
detection is based upon median absolute deviation of expression within the disease 
grouping (382). Whilst this is a powerful tool for detecting chromosomal translocations, 
the strategy may be less applicable to complex disorders. The ‘outlier analysis’ 
technique developed here compares the transcriptomic profile of an individual patient 
with a panel of control individuals independently of other samples in the disease 
grouping, facilitating the identification of rare defects in expression in individual 
patients. 
Whilst providing interesting results, the microarray outlier analysis should be 
regarded primarily as a ‘hypothesis-generating’ tool, whereby abnormal gene expression 
in individual patients is interrogated to identify candidates for future functional 
investigations, as demonstrated for optineurin. The strategy may well be applicable to 
other heterogeneous disorders. Important prerequisites for such studies include 
availability of mRNA for quantitative PCR analysis, to validate that the observed 
changes in gene expression are genuine and not artefacts of analysis or poor probe 
hybridisation. Furthermore, knowledge of functional abnormalities in the cell or tissue 
in question is crucial, to enable prioritisation of candidates and testing of their 
functional relevance. Nevertheless, when combined with other strategies, the outlier 
analysis strategy could be of considerable use in identifying rare defects of biological 
significance in individual patients, and potentially understanding the nature of some of 
the ‘missing heritability’ of complex disorders.  
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Chapter 6: General Discussion 
6.1 Summary of investigations conducted and novel findings 
CD is a complex, heterogeneous condition predominately affecting the gastrointestinal 
tract. The CD phenotype is characterised by a systemic defect in neutrophil recruitment 
to acute inflammatory sites, and delayed bacterial clearance. Macrophages from CD 
patients were previously found to release attenuated levels of certain pro-inflammatory 
cytokines in response to HkEc. Sub-optimal release of these critical inflammatory 
factors was related to their abnormal post-translational trafficking and degradation in 
lysosomal compartments (136). 
In chapter 3, the selective impairment in macrophage pro-inflammatory cytokine 
release in response to HkEc was validated in a new cohort of CD patients. TNF and 
IFN-γ release were attenuated, whilst secretion of other pro-inflammatory cytokines 
such as IL-2 and IL-1β, the chemokine IL-8, and anti-inflammatory cytokine IL-10 
were normal, in concordance with previous findings. TNF release was depressed in 
response to multiple microbial stimuli, including TLR2 and TLR4 ligands and the yeast 
C. albicans, demonstrating that the phenomenon is not restricted to the response to 
HkEc. Defective TNF release was unrelated to the age of patient, gender, smoking 
status and use of 5-ASA or immunosuppressant medication. The impairment in TNF 
release downstream of TLR2 was more severe in patients with stricturing disease than 
those with inflammatory disease, whereas for TLR4, the defect was more pronounced in 
patients with colonic disease. 
 Genetic studies such as GWAS have identified SNPs that are associated with 
CD. No significant associations could be identified between the genotype for any 
individual polymorphism and the secreted levels of TNF in response to TLR2 or HkEc 
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stimulation. Calculation of an overall GRS, based on the genotypes of the 34 SNPs, 
revealed several differences between patients and HC individuals with a greater overall 
burden of GWAS risk alleles compared to those with a lower burden. Macrophages 
from patients with a GRS of greater than 1 released significantly less TNF in response 
to HkEc than those with a GRS of less than 1; furthermore, a weak negative correlation 
was observed between TNF release and GRS. Surprisingly, this relationship was not 
evident for TLR2 stimulation and somewhat paradoxically, macrophages from HC 
individuals with a GRS above 1 released greater amounts of TNF downstream of TLR2 
than those with a GRS less than 1. 
 In chapter 4, it was hypothesised that abnormalities in the cellular sphingolipid 
and phospholipid composition could account for the defective macrophage function 
observed in CD. However, no differences in endogenous ceramide, dihydroceramide, 
sphingomyelin, PC, PS and PI species were detected in CD macrophages. Furthermore, 
studies using deuterated choline, serine and inositol revealed equivalent rates of overall 
metabolic flux through the PC, PS and PI synthesis pathways between HC and CD cells, 
therefore excluding gross defects in the global rates of synthesis of these lipids as the 
underlying mechanism of impaired cytokine secretion from CD macrophages. However, 
a reduced molar percentage of one specific PI species (PI 16:0/18:1) was synthesised 
over a defined time period in CD macrophages; reduced levels of this same species were 
detected in ileal biopsies from CD patients. 
 A ‘hypothesis-generating’ approach was subsequently employed to identify 
candidate molecular lesions in CD macrophages, by analysis of transcriptomic data 
from microarray experiments. Although no striking differences were apparent in the 
expression profiles of CD macrophages using classical group comparisons of gene 
expression, a customised outlier analysis strategy identified distinct abnormalities in 
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individual CD patients. Several interesting outliers were identified in different patients. 
The most commonly under-expressed outlier gene in the CD cohort was optineurin, a 
molecule implicated in vesicle trafficking, autophagy and intracellular bacterial 
clearance. The reduction in optineurin expression was validated in this subset of 
patients, and was associated with the presence of a specific haplotype in the optineurin 
genomic region. Depletion of optineurin in THP-1 cells resulted in reduced secretion of 
TNF in response to Pam3CSK4. This investigation therefore identified a subgroup of CD 
individuals with defective macrophage optineurin expression, of relevance to the 
impaired pro-inflammatory cytokine release observed after TLR stimulation. This 
‘individualised approach’ to analysis of transcriptomic data may represent a powerful 
strategy to identifying molecular lesions of functional significance in other 
heterogeneous disorders. 
6.2 Discussion of novel findings, implications and study limitations 
6.2.1 Impaired macrophage function in Crohn’s disease 
Numerous theories have been proposed as to the underlying cause of CD, including 
abnormal mucosal barrier function, infection with microbial agents such as MAP and 
adherent, invasive E. coli, autoimmunity and immunodeficiency (421). This study 
provides further evidence for disordered innate immune function in CD in response to 
multiple microbial stimuli, and indicates the likely complexity and heterogeneity of 
molecular lesions underlying this abnormality. 
 In vivo studies have demonstrated a depressed acute inflammatory response to 
bacterial stimuli in CD. Whilst neutrophil accumulation to sites of acute inflammation is 
impaired (134-136), the function of these cells for the most part appears normal (179) 
(with the exception of respiratory burst activity, which is marginally reduced after 
stimulation with PMA (185)). Macrophages are phagocytic cells that are also pivotal in 
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acute inflammation, secreting cytokines and chemokines that enable recruitment of 
leukocytes from the bloodstream to acute inflammatory sites. A critical function of TNF 
is upregulation of adhesion molecules on endothelial cells, facilitating interaction with 
leukocytes and their extravastation through the capillary wall (285). Defective release of 
pro-inflammatory cytokines such as TNF by macrophages in response to a range of 
microbial stimuli therefore provides an attractive explanation for the sub-optimal 
recruitment of neutrophils observed in CD. Consequentially, delayed neutrophil 
recruitment would result in impaired clearance of material at sites of ingress of the 
bowel wall. The persistence of this material would act as a trigger for adaptive 
immunological responses, which develop to compensate for the initial failure of 
microbial clearance. This model is consistent with a number of animal studies, where 
absence of TNF or innate immune receptors such as TLR4 is detrimental in the early 
phases of DSS-induced colitis (148;286).  
It should also be noted that defective release of pro-inflammatory cytokines by 
macrophages could have pleiotropic consequences beyond impaired neutrophil 
recruitment, potentially contributing to CD pathogenesis. In particular, recognition of 
bacterial components via TLRs may have an important role in the maintenance of 
intestinal barrier homeostasis, as demonstrated by animal studies (422). The severe 
intestinal injury observed in MyD88 knockout mice after DSS administration (422) was 
proposed to relate to defective induction of pro-inflammatory cytokines such as IL-6, 
which may have a role in protection of the epithelium by regulation of trefoil factors 
(423). Furthermore, in the present study, patients with stricturing forms of CD had a 
more pronounced abnormality in TNF secretion in response to TLR2 stimulation. It is 
therefore possible that an impaired macrophage response downstream of TLR2 could be 
a contributing factor in stricture pathogenesis. This could be an indirect association, for 
example by predisposing to a more severe disease course, or alternatively, the 
234
  
macrophage response to TLR2 could influence the process of stricture formation 
directly. The pathogenesis of stricture formation is incompletely understood, but could 
relate to an increased proliferation and/or reduced migratory potential of intestinal 
myofibroblasts (293). TNF has been shown to influence migration of fibroblasts 
(424;425), although the effects are complex and dependent on the tissue, stimulus dose 
and timing. Polymorphisms in the PRR NOD2 have been associated with a stricturing 
disease course (294), suggesting that an innate immune response to microbes could be 
important in the development of strictures, although further studies are required to fully 
establish the link. 
 An inherent failure of macrophage TNF secretion in response to bacterial stimuli 
would initially seem inconsistent with the current management of CD, given the 
efficacy of immunosuppressants and TNF antagonists such as infliximab. There are 
several important points when considering this apparent paradox. Firstly, CD is 
proposed to arise from an initial failure of neutrophil recruitment and bacterial clearance 
(136). Pathological lesions are hypothesised to develop in a subsequent, temporally 
distinct phase, characterised by chronic inflammation, giving rise to the symptoms 
experienced by the patient (151). Given the leukocytic infiltration and dramatic 
elevation in pro-inflammatory cytokine levels observed in the bowel wall at this later 
stage, it is unsurprising that immunosuppressive therapies, which suppress NF-κB 
activation and inhibit lymphocyte proliferation are beneficial, whilst unlikely to be 
influencing the putative upstream defect. Furthermore, certain immunosuppressants 
such as steroids, whilst efficacious for induction of remission, are less effective for 
prevention of recurrence (11). 
 In addition, the mechanism by which TNF antagonists exert benefit in CD may 
be more complex than originally thought (80). Infliximab and adalimumab are 
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humanised monoclonal antibodies directed against TNF. However, these therapies are 
also known to stimulate apoptosis of lamina propria T lymphocytes (possibly by 
binding to transmembrane forms of TNF) (208), a process that may also be defective in 
CD (205;207). Interestingly, etanercept, a recombinant fusion protein directed against 
TNF, does not show the same capacity to induce apoptosis (426), and failed to 
demonstrate significant clinical benefit in CD in a randomised controlled trial (427). 
Furthermore, the onset of CD has been documented in patients with rheumatological 
conditions following etanercept administration (428). Registry data collated over a 10 
year period suggests an increased incidence of IBD in juvenile idiopathic arthritis 
patients treated with etanercept compared to the general paediatric population; the 
majority of these patients had histopathological features consistent with CD (429). 
 A significant difficulty in the investigation of complex syndromes such as CD is 
the discrimination of primary or initiating factors from those that are related to the 
disease process itself, or secondary to factors such as treatment regimens. In this study, 
defective macrophage cytokine secretion was observed in patients with quiescent 
disease and was unrelated to use of medication at the time of sample collection, arguing 
in favour of a primary abnormality. Furthermore, macrophages cultured from patients 
with UC do not display the same abnormalities in cytokine secretion, as shown in 
chapter 3 and elsewhere (163), indicating that the defect is not simply consequential to a 
chronic inflammatory condition. The relationship between an increased burden of 
GWAS risk alleles and diminished cytokine release in response to HkEc indicates that 
this response is at least partially genetically determined, again consistent with a primary 
functional abnormality in CD. Further work to clarify whether cytokine secretion 
represents a primary defect could include investigation of macrophage cytokine release 
from healthy relatives of affected patients with CD, in a similar manner to studies of 
intestinal permeability (44) and ASCA (96). Large scale population studies 
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investigating macrophage cytokine release with the development of CD would be 
valuable, but are likely to be infeasible without considerable adaptations to the current 
methodology. Examination of concordance of macrophage cytokine release between 
monozygotic and dizygotic twins would help delineate the contribution of genetic and 
environmental factors to this process. 
  Macrophages display plasticity and functional heterogeneity, which is partly 
dependent on their surrounding environment. The present study investigated pro-
inflammatory cytokine release from peripheral blood monocyte-derived macrophages in 
response to microbial stimuli, and candidate molecular lesions responsible for the 
observed abnormalities. In support of investigating this cell type, the impaired acute 
inflammatory response observed in CD is a systemic abnormality, as demonstrated by 
various in vivo studies, including skin windows (134), epithelial trauma models in the 
bowel (135), and subcutaneous injection of killed E. coli (135;136). Furthermore, 
resident intestinal macrophages in the bowel are derived and continually replenished 
from peripheral blood derived monocytes (430).  
In spite of this, intestinal macrophages within the mucosa may have a distinctive 
phenotype from that of peripheral blood mononuclear cells under normal physiological 
conditions. Intestinal macrophages isolated from intestinal tissue sections have been 
reported to express low levels of CD14 and other innate immune receptors. Cultures of 
these cells secrete reduced levels of pro-inflammatory cytokines in comparison to blood 
monocytes upon LPS stimulation, whilst retaining phagocytic capacity (431). Other 
studies have indicated that the mucosal situation may in fact be more complex than this. 
Recently, a subset of pro-inflammatory, CD14 positive macrophages was identified in 
healthy intestinal mucosal tissue of control individuals and patients with IBD. These 
cells secrete higher levels of pro-inflammatory cytokines such as TNF, IL-23 and IL-6 
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after bacterial stimulation than the low CD14 expressing macrophages previously 
described (432). Further work to clarify the extent to which intestinal macrophage 
subsets recapitulate the abnormalities identified in peripheral blood monocyte-derived 
macrophages would be helpful in validating the relevance for CD pathogenesis. 
Availability of tissue samples from patients with quiescent disease, and the number of 
cells that can be obtained, are however significant limiting factors in such studies. 
 Finally, it should be remembered that whilst the defect in cytokine release in 
cultured CD macrophages ex vivo was unrelated to certain environmental factors such as 
age of patient and smoking, the in vivo relevance of such factors cannot be disregarded. 
Smoking is associated with increased risk of CD (2), and it is possible that cigarette 
components could worsen an underlying abnormality in macrophage function in vivo. 
Nicotine, a constituent of cigarette smoke, has been reported to suppress macrophage 
pro-inflammatory cytokine production via nicotinic acetylcholine receptors (433;434). 
Emerging evidence also suggests intestinal bacterial components may themselves 
modulate macrophage function. Bifidobacteria, which are reduced in CD (118), are 
understood to enhance innate immune cell function, including pro-inflammatory 
cytokine release (119). In contrast, other microbial species could exert detrimental 
effects. For example, microbial mannans (present in yeast and certain mycobacteria) 
may  have a suppressive effect on the ability of macrophages to kill mucosal strains of 
E. coli (98). The contribution of such factors to the impairment in cytokine release 
observed in cultured macrophages has not been directly addressed in this study. Whilst 
macrophages in this study were cultured ex vivo from peripheral blood monocytes for 5 
days, making a strong influence of bacterial components and serological factors seem 
unlikely, potential effects cannot be ruled out. 
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6.2.2 Molecular mechanisms underlying impaired cytokine release and macrophage 
function 
 Identification of the molecular defects responsible for impaired cytokine release 
in CD macrophages is a considerable challenge, for several reasons. Firstly, CD is a 
complex and heterogeneous syndrome. A number of findings presented in this thesis 
illustrate this heterogeneity, including the wide variation in macrophage TNF release 
and GRS between patients, the stimulus specific differences in TNF release between 
phenotypes, and the lack of unifying transcriptomic abnormalities in the CD group. It is 
therefore likely that the underlying molecular lesions will be highly variable between 
patients. 
Secondly, given that no abnormality has been observed in the control of 
cytokine gene transcription in CD macrophages, the proposed defect relates to 
perturbations in post-translational trafficking and mistargeting of cytokines to lysosomal 
compartments (136). The pathways of cytokine secretion remain relatively undefined, in 
stark contrast to intracellular signalling pathways. Whilst work in cell lines and murine 
macrophages have elucidated a number of molecules and vesicle subsets involved (189), 
the direct applicability to primary human macrophages has not yet been confirmed. In 
this study, a correlation was observed between release of TNF and IL-6 and IFN-γ 
indicating that the attenuated secretion is related. Interestingly, TNF and IL-6 release 
from cell lines is understood to involve recycling endosomes (198), suggesting this 
vesicle could be abnormal in CD macrophages.  
A correlation was also observed between defective release of TNF downstream 
of TLR2, TLR4 and HkEc stimulation, indicating some likely degree of overlap in the 
mechanisms of impaired cytokine release between these stimuli. However, despite this 
potential overlap, other evidence presented in this thesis in fact suggests subtly distinct 
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molecular defects may be important in individual patients downstream of each 
microbial stimulus. Firstly, there are a number of stimulus-specific differences in 
macrophage TNF release between patient phenotypes. Secondly, a relationship between 
overall GRS and TNF release downstream of HkEc, but not TLR2 stimulation, is 
observed. Finally, abnormal optineurin expression in a subset of patients appears to be 
more strongly associated with abnormal release of TNF downstream of TLR2 rather 
than HkEc stimulation, a pattern that is mirrored in cell lines depleted of optineurin 
expression.  
In spite of various strands of evidence suggesting lipid abnormalities in CD, and 
the established roles of sphingolipids and phospholipids in membrane structure, 
cytokine secretion and autophagy (197;317), no gross defects in the macrophage lipid 
composition could be identified in this study. Furthermore, the overall rate of metabolic 
flux through the PC, PS and PI synthesis pathway was normal in CD macrophages. This 
indicates that a gross abnormality in these lipid species is not likely to be the underlying 
mechanism of impaired cytokine release, although the possibility of more subtle defects 
(such as in particular subcellular macrophage compartments) and/or defects in 
individual patients cannot be excluded. Although no differences in endogenous 
composition of PI were observed in CD macrophages, unstimulated CD macrophages 
synthesised a reduced relative percentage of PI 16:0/18:1 over a 3 hour period. 
Interestingly, this species was also reduced in ileal biopsies from CD patients. The 
differences may indicate abnormal turnover of this PI species in CD, due to an 
abnormality in fatty acid synthesis or desaturation. Further work is required to clarify 
the mechanism and relevance for macrophage or intestinal barrier function. 
Classical group comparisons of differential gene expression between CD 
macrophages and HC and UC patients did not identify striking abnormalities. This is 
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not entirely surprising, given the heterogeneity in clinical presentation, genetic 
architecture and functional defects observed in CD. In view of this heterogeneity, an 
outlier analysis of transcriptomic data was subsequently undertaken to identify 
abnormalities in gene expression in individual patients. This identified a subset of 
patients with significantly reduced expression of optineurin, which may account for the 
attenuated TLR2 response observed in macrophages from these patients. Given the 
previously described roles of optineurin in trafficking of vesicles such as recycling  
endosomes (407;408), it is very plausible that optineurin has a role in post-translational 
trafficking of cytokines from the Golgi apparatus to plasma membrane; when optineurin 
expression is reduced, delivery of these molecules to the plasma membrane is impaired. 
Further studies are needed to test this hypothesis, using inhibitors of protein trafficking 
and macrophages isolated from optineurin knockout mice. In addition to optineurin, 
various other genes were identified as common outliers between patients, including 
ADAMDEC1, a disintegrin and metalloprotease. Both optineurin and ADAMDEC1 are 
currently being investigated as potential candidates using knockout mice, in two 
ongoing clinical fellowships in this laboratory. 
 CD is a multifactorial condition, which may involve both temporally distinct 
stages and dysregulation of a variety of cells and tissues (151). The molecular 
mechanisms underlying the functional abnormalities that characterise CD are likely to 
overlap. This study has not directly addressed whether the identified defects represent 
‘macrophage specific’ phenomena, or more generalised abnormalities in multiple cell 
types (which could also be important in the disease pathogenesis). An interesting 
avenue of investigation would be determination of whether monocytic cells display 
some of the functional and molecular abnormalities identified in cultured macrophages. 
Identification of defects common to both monocytes and macrophages would facilitate 
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larger scale screening projects of CD patient cohorts, eliminating the requirement for 
tissue culture in such studies.  
In addition, gastrointestinal epithelial cells also have a role in the host response 
to microbial components (435). They express TLRs and NLRs such as NOD2 (436), 
enabling induction of protective responses such as autophagy (241) and defensin 
secretion (436) on encountering microbes. Epithelial cells also secrete low levels of 
certain cytokines and chemokines in response to bacterial stimuli (437;438), and indeed 
stimulation of epithelial TNF release has been proposed to account for the protective 
effects of probiotic administration in the SAMP mouse model of ileitis (121). 
Furthermore, epithelial cells, and especially specialised M cells, are important in 
controlling the ingress of luminal contents to the underlying tissues (51). Interestingly, 
optineurin and its binding partner myosin VI are expressed in polarised epithelial cell 
lines, where they play a role in sorting of basolateral membrane proteins (439). Future 
studies could address whether the optineurin outlier patients have similarly reduced 
expression of this molecule in the epithelium, and any functional consequences of this. 
Determination of intestinal barrier function and permeability in the optineurin knockout 
mice would also be helpful in answering this question. 
Over 70 distinct genetic loci have been associated with CD by GWAS 
(115;116). The precise mechanisms by which the associated variants influence disease 
pathogenesis remain incompletely understood, although many of the genes located in 
the susceptibility loci are known or suspected to have critical roles in innate immunity. 
Whilst no single variant was significantly associated with macrophage TNF release in 
this study, patients with a greater burden of GWAS risk alleles released reduced TNF in 
response to HkEc than those with a lower overall burden. This suggests that CD-
associated risk variants could have a collective effect to impair TNF release in response 
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to HkEc. Furthermore, the results of GWAS studies appear to be consistent with 
functional demonstrations of defective innate immunity in CD, and specifically 
macrophage pro-inflammatory cytokine release in response to HkEc. Future studies 
should clarify which of the variants are responsible for the relationship, whether the 
association is direct or indirect, whether they act together in pathways, and functional 
mechanisms.  
In contrast, this relationship was not observed for TLR2 stimulation, suggesting 
that the identified susceptibility loci do not play a significant role in the attenuated TNF 
release in response to TLR2. Other molecular abnormalities, including deficient 
optineurin expression, are likely to play a role in this defective response in individual 
patients. On one hand, attenuated TNF release downstream of TLR2 could in itself be 
critical in the development of CD, particularly if stimuli that are primarily detected by 
this receptor were to penetrate into the bowel wall. At the other end of the spectrum, a 
strong TLR2 response may act to compensate for other abnormalities, such as an 
increased burden of GWAS risk alleles, enabling a greater amount of TNF to be 
released and thus facilitating adequate neutrophil recruitment and clearance of microbial 
material. This could be important if a high load of bacteria such as E. coli were to reach 
the underlying tissues. Whilst deficient optineurin expression may act to impair TNF 
release downstream of TLR2 activation in a subset of patients, the molecular 
mechanisms underlying a vigorous, compensatory response in a subset of HC 
individuals, and the attenuated TNF release observed in other CD patients with normal 
optineurin expression, are not yet clear. 
 Taken together, the 71 GWAS variants identified to date are estimated to 
account for approximately 20% of the heritability of the disease (115). The nature and 
strategies for discovering the genetic variation that makes up the ‘missing heritability’ 
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remain hotly debated (256;257). It is evident that simply conducting larger scale GWAS 
in their current form is unlikely to solve the problem. It is likely that much of the 
undiscovered genetic variation could exert powerful biological effects, including on 
macrophage function and bacterial clearance. Large scale sequencing projects are 
already under way in CD; the interpretation of these are helped by the 1000 Genomes 
project (440). It is likely that such projects will identify mutations and rare variants in 
CD patients; it will be important to test the functional effects of these on macrophage 
pro-inflammatory cytokine release downstream of different stimuli. 
However, the relatively large number of private mutations in each individual 
(416), the capacity of multiple variants to exist in linkage disequilibrium, and the fact 
that large scale sequencing can generate false positive results due to sequencing errors 
(441), all make identification of the true causal mutations difficult. It is likely that 
integrated approaches, utilising both data from GWAS studies, whole genome 
sequencing projects and transcriptomic information could facilitate the determination of 
which variants are likely to be biologically relevant. Furthermore, in an era of 
‘personalised medicine’, integrating genomic sequence information with knowledge of 
the abnormally expressed genes in an individual patient, and understanding their 
functional consequences, could be a worthwhile approach to deciphering the molecular 
pathogenesis of heterogeneous disorders and identifying relevant biomarkers in 
individual patients.  
6.2.3 Implications for CD pathogenesis and therapeutic strategies 
The findings presented in this thesis have a number of implications for the pathogenesis 
of CD and future therapeutic directions. Whilst the development of CD is likely to occur 
in temporally distinct phases in conjunction with abnormalities in a multiplicity of 
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cellular components, this study further establishes the concept that sub-optimal innate 
immune interactions with microbial stimuli may be central to the disease pathogenesis.  
Penetration of luminal contents into the bowel wall is likely to be the initial 
triggering event in CD, which could be due to abnormal transcellular and paracellular 
permeability and/or interactions of the intestinal microflora with the mucosa. 
Permeability is likely to be influenced by exogenous factors, including emulsifying 
agents. Furthermore, the balance of mucosal lipid composition may also play a role in 
this process, although further work is required to establish this.  
Subsequently, in healthy individuals, strong macrophage pro-inflammatory 
cytokine secretion ensures adequate neutrophil recruitment to sites of bacterial ingress 
in the bowel, enabling clearance of microbial material in a timely fashion. In patients 
with CD, pro-inflammatory cytokine secretion from macrophages is impaired in 
response to this material. This at least in partly due to mistargeting of pro-inflammatory 
cytokines to lysosomal compartments. 
Heterogeneous molecular lesions underlie the impaired pro-inflammatory 
cytokine release. These may influence bacterial recognition (such as NOD2 variation), 
cytokine induction and secretion (products of GWAS loci, defective optineurin 
expression), and autophagy. These abnormalities are highly variable between patients. 
Furthermore, the most pertinent defects are likely to be different depending on the load 
and nature of the penetrating stimulus. Additional mechanisms (including a strong 
TLR2 response and the IL-23 axis), with modifying influences from environmental 
factors and microbial stimuli, may also be vital in compensating or compounding the 
defect in macrophage function in vivo. The attenuated macrophage pro-inflammatory 
cytokine release in CD results in delayed neutrophil recruitment and bacterial clearance 
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at sites of ingress. The persistence of this material would provoke a chronic 
inflammatory response (Figure 6.1). 
If CD arises from impaired phagocyte function, therapies directed at stimulating 
innate immune function may be useful in CD. A randomised, placebo controlled trial of 
sargramostim (GM-CSF) published in 2005 indicated some potential benefit in active 
CD. Whilst the primary endpoint (decrease in CDAI score of at least 70 points at the 
end of treatment) was not significantly different between the sargramostim and placebo 
arms, significant improvement was observed as defined by secondary endpoints, 
including remission rate and fall in CDAI score by 100 points (18). Other 
immunostimulatory cytokines, such as IFN-γ, could also be useful but have yet to be 
fully evaluated. Such studies should take into account the clinical, genetic and 
functional heterogeneity between individual patients. Interestingly, the results of a 
phase 1 trial of sargramostim in paediatric CD were encouraging (17), but larger scale 
studies are required before translation into routine clinical practice. In the longer term, 
further study and characterisation of the gene expression outliers identified in this study 
could lead to novel therapeutic targets in subsets of patients, and new biomarkers for the 
diagnosis of CD and response to treatment. 
6.3 Future directions 
The studies conducted in this thesis have identified a number of interesting areas for 
future investigation, including: 
6.3.1 Macrophage cytokine secretion and genotype correlations 
 Correlation of defective TNF release in response to HkCa with the presence and 
titre of ASCA in patients with CD and their healthy relatives. A dysregulated 
innate immune response to C. albicans could provide a potential mechanistic  
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Figure 6.1 Defective macrophage function in Crohn's disease: a proposed pathogenic 
schema. Attenuated macrophage release of TNF οccurs downstream of microbial stimuli in 
CD, including E. coli, TLR2 and TLR4 ligands and C. albicans, resulting in impaired 
neutrophil recruitment and delayed bacterial clearance when these microbial ligands 
penetrate into the bowel wall. The impaired pro-inflammatory cytokine release largely 
relates to aberrent post-translational trafficking of these molecules in CD macrophages, 
possibly involving recycling endosomes. Heterogeneous and complex molecular defects are 
likely to underly the defective cytokine release. In a subset of patients, reduced optineurin 
(OPTN) expression results in attenuated TNF release downstream of TLR2 activation. 
Deficient optineurin expression may also impair autophagy and intracellular bacterial 
clearance. Genetic factors linked to CD by GWAS also influence the macrophage response, 
including NOD2 variation in the case of MDP stimulation. Furthermore, an increased burden 
of GWAS risk alleles has a cumulative effect to depress TNF release in response to E. coli. In 
HC individuals, a strong TLR2 response may be able to compensate for a high load of 
GWAS risk alleles. Environmental factors such as smoking and microbial components are 
also likely to influence the macrophage response in vivo.
Microbial protective factors
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connection between the colonisation of C. albicans and ASCA in CD patients 
and their healthy relatives, which warrants further study. Subject to ethical 
permission, the response to subcutaneous injection of HkCa could also be 
examined in CD patients. Recently, polymorphisms in the CARD9 locus have 
been associated with CD (115), and several patients were identified as gene 
expression outliers for CARD9 in the transcriptomic study. As CARD9 may be 
involved in the innate immune response to fungi (419), future work could 
interrogate a possible relationship between the polymorphism, defective 
expression in the outlier patients and abnormal pro-inflammatory cytokine 
release to C. albicans. 
Given that the mannan epitope for ASCA is also present in 
mycobacterial species such as MAP (98), and defective macrophage TNF 
release may also occur in response to these species (187), it would be interesting 
to perform parallel comparison studies of the response to these two organisms.  
 Determination of intestinal macrophage cytokine secretion in response to 
microbial stimulation. Whilst a well designed experiment should ideally include 
investigation of intestinal macrophages isolated from patients with quiescent CD 
on minimal treatment, such studies are unlikely to be feasible. The serial biopsy 
technique utilised previously (135) could be adapted specifically to investigate 
TNF production at sites of repeated trauma in the bowel. 
 Further investigation of the role of CD-susceptibility variants in macrophage 
pro-inflammatory cytokine secretion after bacterial stimulation. The present 
study indicated a relationship between attenuated TNF release after HkEc 
stimulation and overall GRS. Larger scale studies may be required to identify 
specific variants responsible for this association; which should be interpreted in 
the light of functional investigations in primary macrophages and macrophage 
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cell lines. A trend towards reduced TNF release after HkEc stimulation was 
observed in CD and HC individuals homozygous for CD-associated variants in 
NOD2; extension of the study to test larger numbers of individuals with these 
variants would increase the power to detect a small difference. Furthermore, 39 
new susceptibility loci were identified in a more recent GWAS meta-analysis of 
CD. Several of these contain genes with putative roles in vesicle trafficking, 
including VAMP3 and SCAMP3 (115). It would be interesting to genotype 
patients and controls for these additional variants and investigate associations 
with macrophage TNF release. However, given the prevalence of these alleles in 
the HC population and their small contribution to the overall heritability of CD, 
it is likely that any effect will be subtle. 
 Investigation of macrophage cytokine secretion in unaffected relatives of CD 
patients, and mono- and dizygotic twins. This would help prove whether 
diminished macrophage cytokine secretion is a primary abnormality, and the 
relative contribution of genetic and environmental factors to the phenomenon. 
Genotyping and calculation of the genetic risk score should be performed in 
these individuals, and any correlation with macrophage cytokine release, and 
other parameters such as intestinal permeability determined. 
 Parallel investigation of vesicle trafficking in CD macrophages. Such studies are 
currently in progress in our laboratory. Findings presented here, coupled with 
recent work in macrophage cell lines point to the recycling endosomal 
compartment as potentially defective in these cells. This could be further 
investigated, for example, by tracking transferrin receptor recycling. 
Furthermore, the observation of abnormal optineurin expression in a subset of 
patients could be indicative of defects in vesicle subsets (discussed in 6.3.3) 
which warrant further investigation.  
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6.3.2 Lipid investigations in CD 
 Determination of fatty acid synthesis and metabolism in cultured macrophages 
from CD patients. A reduced molar percentage of PI 16:0/18:1 was synthesised 
in CD macrophages, which may relate to an underlying defect in fatty acid 
synthesis, desaturation or metabolism. Such studies could employ stable isotope 
labelled acetate to determine synthesis over defined time points. Patients could 
also be genotyped for CD-associated variants in FADS1, SPTLC2 and ACSL6, 
and relationships between the genotype and fatty acid synthesis could be 
determined. 
 Further investigation of the PI changes apparent in the intestinal mucosa in CD. 
This could include characterisation of PI species present within colonic and ileal 
mucus, and investigation of PI composition and synthesis in cellular components 
isolated from mucosa, such as intestinal macrophages. 
6.3.3 Macrophage transcriptomic abnormalities in CD 
 Further study of the role of optineurin in macrophage TNF release, and the 
functional consequences of abnormal expression in CD. To clarify the 
mechanism by which optineurin influences TNF release, optineurin depleted 
cells could be incubated with inhibitors of intracellular trafficking such as 
brefeldin-A, monensin, ammonium chloride and chloroquine (as previously 
performed in primary CD macrophages (136)) and intracellular levels of pro-
inflammatory cytokines quantified by western blotting. The possibility of 
colocalisation of TNF with optineurin in vesicles could be examined by confocal 
microscopy. In primary macrophage cultures from the outlier patients, TIRF 
could be used to follow vesicle transport and quantify fusion events at the 
plasma membrane. Furthermore, investigation of autophagy, directed migration 
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and lamellipodia projection is warranted, given the ascribed roles of optineurin 
in these processes. 
 Investigation of optineurin expression in other cell types from the outlier 
patients, such as monocytes, to clarify whether the abnormality is macrophage 
specific or global. More generally, optineurin expression could also be 
determined in other cellular and tissue samples from CD patients, such as 
intestinal biopsy samples. The functional consequences of abnormal optineurin 
expression on handling of Gram positive and Gram negative bacteria could be 
determined in a variety of cell types. 
 Investigation of the in vivo functional significance of abnormal optineurin 
expression. Our laboratory has obtained mice with a targeted insertion within the 
OPTN locus, that acts to disrupt expression of this gene. These mice are viable, 
and interestingly do not appear to develop spontaneous neurological, ocular or 
gastrointestinal phenotypes (unpublished finding). In order to determine whether 
optineurin deficiency impacts on the development and course of intestinal 
inflammation, these mice could be treated with DSS and TNBS, both of which 
are classical inducers of colitis. Given that CD involves an abnormal immune 
response to luminal microbes, investigation of infection-induced colitis models, 
such as Citrobacter rodentium may also be relevant. Finally, macrophages from 
these mice should be cultured and pro-inflammatory cytokine release examined 
in response to TLR stimulation, to validate findings in THP-1 cells. Similar 
studies are also in progress for ADAMDEC1, which was under-expressed in six 
patients with CD. 
 Further sequencing of the OPTN genomic region in the optineurin outlier 
patients, including intronic regions to identify possible mutations in linkage 
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disequilibrium with the variants identified in this study, and their assessment as 
potential candidates.  
 Sequencing of UTS2, CARD9 and other outlier genes located in regions of CD 
susceptibility. A number of individuals were identified as gene expression 
outliers for genes located in CD susceptibility loci. Given the limited capacity of 
GWAS to identify rare variants, it is possible that these patients have a rarer 
variant or structural abnormality in this region in linkage disequilibrium with a 
common variant that leads to a gross abnormality in expression. 
 Extension of the gene expression outlier strategy to identify abnormally 
expressed genes in individuals with other heterogeneous disorders, and 
validation of their functional relevance. Specifically, transcriptomic data has 
already been obtained from 45 individuals with UC. Macrophages from UC 
patients release abnormal levels of CXCL10 on LPS stimulation (163); this 
dataset should be fully interrogated for abnormalities in gene expression that 
could provide a molecular basis for this exaggerated immune response. 
 Correlation of abnormally expressed genes in CD macrophages with GWAS 
susceptibility polymorphisms. A number of differentially expressed genes 
(before correction for multiple testing) identified in CD macrophages have been 
previously associated with GWAS susceptibility. Correlation of this abnormal 
expression with genotype information from these patients may shed light on the 
mechanisms by which these variants influence CD pathogenesis. 
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6.4 Conclusion 
CD is a heterogeneous, multifactorial syndrome that is associated with considerable 
lifelong morbidity. Whilst its cause remains controversial, a considerable body of 
evidence now suggests that impaired acute inflammation and defective bacterial 
clearance may be critical factors. This thesis has provided a number of novel insights 
into the molecular pathogenesis of this chronic condition. Macrophages from CD 
patients release deficient levels of TNF in response to a range of microbial stimuli, 
including HkEc, TLR agonists and HkCa. The macrophage defect does not result from 
gross abnormalities in macrophage sphingolipid or phospholipid composition. In the 
case of HkEc, this attenuation of TNF release is partially related to an increased burden 
of GWAS risk alleles. A subset of CD patients also display abnormal macrophage 
expression of optineurin, which results in defective TNF release downstream of TLR2 
stimulation. These findings increase our understanding of CD as a condition 
characterised by sub-optimal macrophage function, and indicate some of the likely 
molecular defects responsible in individual patients. In the future, this may facilitate the 
development of novel therapeutic strategies for CD.  
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Demographics of patients and volunteers 
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HC CD
Number 41 101
Gender (M:F) 21:20 37:64
Mean age 32.8 41.6
Age standard deviation 9.93 15.3
Age range 20-59 18-75
Smokers 5 20
Treatment
No medication 25
5-ASA only 76
Immunosuppressants 0
Disease location
L1 32
L2 44
L3 24
L4 1
Age of onset
A1 15
A2 65
A3 21
Disease behaviour
B1 63
B2 23
B3 15
Perianal involvement 9
Genotype information 36 97
HC CD UC
Number 39 43 25
Gender (M:F) 23:16 20:23 13:12
Mean age 36.7 38.3 41.5
Age standard deviation 11.3 13.6 15.8
Age range 21-63 20-65 22-74
Smokers 3 4 3
Treatment
No medication 14 12
5-ASA only 21 11
Immunosuppressants 8 2
Disease location
L1 13*
L2 16
L3 12*
L4 2
Age of onset
A1 11
A2 27
A3 4
Unknown 1
Disease behaviour
B1 22
B2 12
B3 9
Perianal involvement 2
Genotype information 37 41
Appendix Table I. Demographics and Montreal classification of patients included in
macrophage cytokine secretion assay studies (chapter 3). (A) Study investigating response to
HkEc. (B) Study investigating macrophage response to TLR agonists. * One patient had ileal
(L1) disease with upper GI (L4) involvement, another patient had ileocolonic (L3) disease
with upper GI (L4) involvement. (C) Study investigating macrophage response to HkCa..
Immunosuppressants include methotrexate, azathioprine or 6-mercaptopurine.
A B
HC CD
Number 16 18
Gender (M:F) 6:10 7:11
Mean age 38.4 39.4
Age standard deviation 11.3 14.5
Age range 23-57 20-65
Smokers 1 2
Treatment
No medication 6
5-ASA only 10
Immunosuppressants 2
C
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Unstimulated HkEc stimulated
HC CD HC CD
Number 10 13 7 8
M:F 5:5 6:7 5:2 4:4
Mean age 33.5 36.5 34.8 35.1
Age standard deviation 9.2 13.7 10.4 11.6
Age range 22-55 23-70 22-55 23-61
Smokers 1 1 0 1
Treatment
No medication 6 3
5-ASA 7 5
Mean BMI 23.7 23.3 23.3 23.3
BMI standard deviation 3.5 3.0 3.8 3.7
BMI range 17.8-30.5 19.4-29.4 17.8-30.5 19.4-29.4
Unstimulated HkEc stimulated
HC CD HC CD
Number 7 8 7 12
M:F 5:2 4:4 5:2 6:6
Mean age 44.1 36.2 44.1 39.7
Age standard deviation 15.6 12.9 15.6 14.8
Age range 23-63 19-63 23-63 19-65
Smokers 0 0 0 1
Treatment
No medication 2 4
5-ASA 6 8
Appendix Table II Demographics of patients included in lipid studies (chapter
4). (A) Demographics of patients included in sphingolipid study.
(B) Demographics of patients included in phospholipid study with body mass
index (BMI). (C) Demographics of patients included in shotgun lipidomics study.
HC CD
Number 5 5
M:F 1:4 3:2
Mean age 40.0 33.1
Age standard deviation 17.8 10.1
Age range 21-54 20-46
Smokers 0 0
Treatment
No medication 3
5-ASA 1
Methotrexate 1
Previous resection 2
Active disease 2
A
B
C
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HC CD UC
Number 43 61 45
Gender (M:F) 24:19 31:30 20:25
Mean age 36.8 39.0 40.4
Age standard deviation 10.9 14.2 13.2
Age range 21-61 18-69 21-74
Current smokers 4 7 4
Treatment
No medication 16 31
5-Aminosalicylates 32 13
Immunosuppressants 8 1
Steroid 1 0
Biologic 4 0
Site of disease
L1 19*
L2 15
L3 25*
L4 2
Age of onset
A1 14
A2 39
A3 8
Disease behaviour
B1 32
B2 12
B3 17
Perianal involvement 9
Appendix Table III. Demographics and Montreal classification of patients
included in microarray studies. * 1 patient with ileal disease had upper GI
(L4) involvement, and 2 patients with ileocolonic disease had upper GI
involvement. Immunosuppressants include azathioprine, 6 mercaptopurine or
methotrexate. Biologic therapies include infliximab and adalimumab.
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Crohn’s disease (CD) is a chronic inflamma­
tory disorder, primarily affecting the gastro­
intestinal tract. It arises through an aberrant 
interaction between the bowel contents and 
the immune system, although the mechanistic 
basis of disease pathogenesis remains poorly 
understood. To date, numerous hypotheses 
have been proposed including atypical infec­
tion, the presence of abnormal particulate ma­
terial within the bowel, and autoimmunity 
(Marks and Segal, 2008). Most current theories 
center on disordered T lymphocyte activation 
(Xavier and Podolsky, 2007). Although T lym­
phocytes are important in the induction and 
maintenance of the chronic inflammatory phase, 
their involvement in the induction of CD le­
sions remains unproven.
Recent genome­wide association studies 
(GWAS) have generated considerable inter­
est after the identification of >30 polymor­
phisms that increase susceptibility to CD 
(Wellcome Trust Case Control Consortium, 
2007; Barrett et al., 2008). Several of these 
refocus attention on the innate immune system. 
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Disordered macrophage cytokine secretion 
underlies impaired acute inflammation  
and bacterial clearance in Crohn’s disease
Andrew M. Smith,1 Farooq Z. Rahman,1 Bu’Hussain Hayee,1  
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The cause of Crohn’s disease (CD) remains poorly understood. Counterintuitively, these 
patients possess an impaired acute inflammatory response, which could result in delayed 
clearance of bacteria penetrating the lining of the bowel and predispose to granuloma 
formation and chronicity. We tested this hypothesis in human subjects by monitoring 
responses to killed Escherichia coli injected subcutaneously into the forearm. Accumulation 
of 111In-labeled neutrophils at these sites and clearance of 32P-labeled bacteria from them 
were markedly impaired in CD. Locally increased blood flow and bacterial clearance were 
dependent on the numbers of bacteria injected. Secretion of proinflammatory cytokines by 
CD macrophages was grossly impaired in response to E. coli or specific Toll-like receptor 
agonists. Despite normal levels and stability of cytokine messenger RNA, intracellular levels 
of tumor necrosis factor (TNF) were abnormally low in CD macrophages. Coupled with 
reduced secretion, these findings indicate accelerated intracellular breakdown. Differential 
transcription profiles identified disease-specific genes, notably including those encoding 
proteins involved in vesicle trafficking. Intracellular destruction of TNF was decreased by 
inhibitors of lysosomal function. Together, our findings suggest that in CD macrophages, an 
abnormal proportion of cytokines are routed to lysosomes and degraded rather than being 
released through the normal secretory pathway.
© 2009 Smith et al. This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
T
h
e 
Jo
u
rn
al
 o
f 
E
xp
er
im
en
ta
l 
M
ed
ic
in
e
 o
n
 D
ecem
ber 13, 2011
jem.rupress.org
D
ow
nloaded from
 
Published August 3, 2009
http://jem.rupress.org/content/suppl/2009/08/02/jem.20091233.DC1.html 
Supplemental Material can be found at:
1884 INFLAMMATION AND MACROPHAGES IN CROHN’S | Smith et al.
Figure 1. Neutrophil accumulation and subsequent clearance of E. coli from the tissues is markedly delayed in a dose-dependent manner in CD. 
111Indium-labeled autologous neutrophils were injected intravenously at the same time as killed E. coli were injected subcutaneously into each forearm.  
(a) Radioactivity measured over the injection sites showed a much smaller proportion of labeled cells accumulating in CD subjects. (b) -Camera image of 
a CD patient at 24 h after injection, demonstrating focal accumulations of radioactivity at bacterial injection sites (arrows) and confirming lack of bowel 
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inflammation. (c) 32P-labeled killed E. coli were injected into the subcutaneous tissues of the forearm and radioactivity was measured at the skin surface. 
Clearance of radioactivity was much slower in CD than in HC or UC. Extrapolating these curves indicated that almost complete removal (99%) would take 
10.2 and 7.1 d in HC and UC subjects, respectively, compared with 44.3 d in CD. (d and e) Effect of increasing bacterial dose from 105 to 108 on blood flow 
at injection site (d) and bacterial clearance (e). The numbers of subjects studied in the dose response experiment are depicted in e. All results are expressed 
as mean ± SEM (**, P < 0.01; ***, P < 0.001).
 
The CARD15 (caspase-recruitment domain 15) gene remains 
the best studied and encodes a pathogen­recognition pro­
tein primarily expressed within phagocytes (Hugot et al., 
2001; Ogura et al., 2001). Its product, NOD2, responds to 
bacteria­derived peptidoglycan by stimulating proinflam­
matory cytokine release, a function attenuated by the de­
scribed polymorphisms. Other significantly replicated 
associations include the ATG16L1 and IRGM genes cod­
ing for proteins involved in autophagy.
Although these associations are highly significant when 
comparing very large population groups and are valuable in 
providing an indication of cellular processes and pathways 
involved in CD pathogenesis, the effect sizes at any individ­
ual locus are weak (the majority incurring odds ratios <1.6), 
and polymorphisms are common in healthy control (HC) 
subjects. For example, the incidence of one or two CD­ 
related mutations in the gene for NOD2 in the general popu­
lation is 15 and 0.5%, respectively, whereas in CD the figures 
are 28 and 8% (Cuthbert et al., 2002; Hugot et al., 2007). 
However, only 1 in 1,000 of the population develop CD, 
which means that in a general population of 100,000 individ­
uals, roughly 15,000 will have one relevant mutation and 500 
will have two such mutations. This population will have 
100 cases of CD, in whom there will only be 28 single and 
8 double mutations on the NOD2 gene. The numbers are 
even more dramatic when examining mutations at the 
ATG16L1 (autophagy) locus with 27,000 of the general pop­
ulation having the GG CD­related genotype as compared 
with 37 patients (Hampe et al., 2007). GWASs have been in­
formative but have failed to explain the cause of the diseases 
under investigation (Donnelly, 2008). All 32 CD­associated 
genes combined have been calculated to contribute <20% of 
the heritable risk (Barrett et al., 2008), leading to the concept 
of the “missing heritability” (Maher, 2008).
It was realized >30 yr ago that the acute inflammatory re­
sponse in respect to neutrophil recruitment was defective in 
CD (Segal and Loewi, 1976). More recently, we have docu­
mented defective neutrophil accumulation and cytokine lev­
els at sites of intestinal and skin trauma (Marks et al., 2006). 
These defects in acute inflammation were independent of the 
CARD15 genotype. Further investigation demonstrated re­
duced blood flow in the skin upon bacterial challenge that 
could be partially corrected by the administration of sildena­
fil. We concluded that a general phenotypic abnormality can 
be revealed in CD when the innate immune system is stressed 
in vivo, namely that acute inflammation is generally and se­
verely impaired. We propose that the consequence of a weak 
initial reaction to the ingress of gut bacteria into the tissues 
would be their defective removal and that this persistence 
could drive secondary chronic inflammation. A unique set of 
experiments were performed to test this hypothesis directly 
by measuring the accumulation of neutrophils and clearance 
of bacteria from the tissues of CD patients. In addition, in vitro 
studies were performed using monocyte­derived macro­
phages to identify a defective mechanism, which could ex­
plain the diminished acute inflammatory response in CD 
patients. In the absence of a single causative gene and, hence, 
an accurate animal model of CD, these experiments had to be 
conducted on human subjects.
RESULTS
Neutrophil recruitment to sites of bacterial injection
We first determined whether the previously observed im­
paired recruitment of neutrophils to sites of local trauma in 
CD extended to the inflammation induced by bacteria in the 
tissues (Segal and Loewi, 1976; Marks et al., 2006). Autologous 
neutrophils were labeled with 111indium (Segal et al., 1981) 
and injected intravenously at the same time as Escherichia coli 
were inoculated into the volar aspect of each forearm in HC 
(n = 6) and CD (n = 5) subjects. The labeled neutrophils ac­
cumulated at the sites of bacterial injection (Fig. 1 a) in addi­
tion to the previously described distribution to the spleen, 
liver, and bone marrow (Fig. 1 b).
In HC subjects, significant cellular recruitment could be 
measured at 4 h (889 ± 53 cpm; n = 6), and this increased 
over a 24­h period (1,738 ± 98 cpm; n = 6), at which time 
0.17 ± 0.014% of the injected dose of radioactivity was 
present at each injection site (Fig. 1 a). Assuming a whole 
body pool of roughly 1011 neutrophils (Cartwright et al., 
1964), this represents 108 cells to deal with the 3 × 107 bac­
teria injected. The results were very different in CD subjects 
(P < 0.0001; Fig. 1 a), with less than one­third of the normal 
numbers of neutrophils accumulating at 4 h (290 ± 52 cpm; 
n = 5) and 24 h (555 ± 78 cpm; n = 5).
Clearance of 32P-labeled E. coli
A functional consequence of reduced neutrophil influx was 
assessed by measuring the clearance of 32P­labeled E. coli from 
the forearm in HC (n = 16), CD (n = 14), and ulcerative coli­
tis (UC; n = 3) subjects. Immediately after inoculation, surface 
counts at each injection site were 2,688 ± 160 cpm (mean ± 
SEM). In all groups, clearance followed biphasic nonexpo­
nential kinetics, with a rapid initial phase followed by a slower 
secondary phase (Fig. 1 c). An overall test for equality demon­
strated that clearance curves for HC and CD subjects were 
significantly different (P = 9 × 106), with a marked delay in 
CD compared with HC. UC subjects demonstrated clearance 
profiles similar to those of HC. Extrapolating clearance curves 
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amined the influence of NOD2 status on TNF secretion by 
macrophages in response to TLR2 or TLR4 agonists. The pres­
ence of one or two CD­associated mutations in the NOD2 
gene had no effect on TNF secretion (Fig. S2 b).
Differences in monocyte/macrophage populations and 
maturation were investigated in the three groups (Fig. S3). 
The initial M1 (CD14+/CD16) and M2 (CD14+/CD16+) 
monocyte population were similar in the all three groups, as 
were messenger RNA (mRNA) levels of the macrophage 
maturation markers F4/80, L­selectin, and ICAM­1 after in 
vitro differentiation.
Macrophage mRNA transcription profiles
To account for impaired cytokine secretion, we examined 
global transcription profiles of macrophages. RNA was exam­
ined from macrophages from HC (n = 26), ileal (n = 10), co­
lonic CD (n = 16), and UC (n = 20) subjects, before and after 
exposure to HkEc. The proinflammatory cytokines GM­CSF, 
IL­6, IFN­, and TNF, which had demonstrated diminished 
secretion, were tested by quantitative PCR and found to have 
mRNA levels equivalent to those of HC after HkEc stimula­
tion (Table S1). However, disease­specific changes were ob­
served and are presented in Fig. 3. A four­way Venn diagram 
shows the numbers of probe sets differing in expression level 
(P < 0.01 and fold change >1.2) before and after stimulation 
between either group of CD patients and HC subjects (Fig. 3 a). 
Significant changes from HC levels were observed in the ex­
pression of hundreds of genes in the different groups, which 
were internally consistent. Surprisingly little overlap was ob­
served between profiles of HkEc­stimulated macrophages in 
ileal and colonic CD.
The identities of the differentially regulated genes com­
mon to ileal and colonic CD, and the cellular processes in 
which they are involved, are shown in Fig. 3 (d and i). The 
27 probe sets represent 18 genes of known function. Of these, 
nine have previously been reported as participating in vesicle 
trafficking and cytoskeletal organization, suggesting that the 
problem may lie in the posttranscriptional processing, stor­
age, or secretion of cytokines. The data were also analyzed by 
determining the most significantly induced or repressed genes 
in individual groups, with false discovery rate (FDR) correc­
tion applied. These gave similar results to those shown in Fig. 3 
(Fig. S4; Tables S2 and S3), demonstrating an overrepresen­
tation of genes involved in vesicle trafficking and cytoskel­
etal organization.
To control for nonspecific effects resulting from chronic 
bowel inflammation, we conducted similar analyses on 
macrophages from UC patients. In UC, a total of 354 and 
554 probe sets differed from HC, before and after HkEc 
stimulation, respectively. There was very little overlap be­
tween differentially expressed genes in CD and UC (Fig. 3, 
b and c). Of those genes common to both, a relatively large 
proportion was also involved in vesicle trafficking and cy­
toskeletal organization, as well as RNA metabolism and 
cellular signaling (Fig. 3 d, ii­iv). However, although most 
of the differentially expressed genes common to both CD 
to a point where 99% of inoculated material would have been 
cleared gave total clearance times of 10.2 d (95% confidence 
interval: 8.3–13 d) in HC, 7.1 d (5.4–10.4 d) in UC, and 44.3 d 
(21.8– d) in CD. Patients were subdivided into those with 
ileal or colonic involvement, as CD is a syndrome with both 
clinical and genetic evidence to suggest that precise patho­
genic mechanisms operating in each region of the bowel may 
differ. Clearance appeared to be faster in the ileal (n = 5) than 
in the colonic (n = 9) CD subjects, but the differences were 
not statistically significant (Fig. S1 a). In addition, the presence 
of CD­associated mutations in CARD15 had no effect on 
bacterial clearance (Fig. S1 b).
The numbers of bacteria injected had an important effect 
on local blood flow and bacterial clearance. In HC subjects, 
blood flow increased about sevenfold between doses of 105 
and 108 organisms (Fig. 1 d). Blood flow levels in CD patients 
were similar to those in HC between dosages of 105 and 107 
bacteria. Doses >3 × 107 resulted in significantly reduced 
blood flow in CD subjects, with levels approximately half 
those recorded for HC. Bacterial clearance was dramatically 
different between the two groups (Fig. 1 e). In HC subjects, 
clearance rates were relatively stable between 105 and 3 × 107 
organisms and actually increased at the highest dose, whereas 
in CD, although it was normal at 105 and 106, there was a 
dramatic and highly significant (P < 0.0001) drop in clearance 
at and above 107 bacteria.
Macrophage cytokine secretion
Dramatic differences were observed in the secretion of a panel 
of inflammation­related cytokines and chemokines by periph­
eral blood monocyte­derived macrophages after 24 h of stim­
ulation with heat­killed E. coli (HkEc; Fig. 2). We observed 
distinct profiles in patients with ileal and colonic CD. The 
proinflammatory cytokines TNF, IL­4, IL­5, IL­13, IL­15, 
and IFN­ were reduced in all CD patients, whereas IL­6, 
IL­12(p70), G­CSF, and GM­CSF were only low in colonic 
CD and IL­17 was only low in ileal CD. Direct comparisons 
between macrophages from ileal and colonic CD subjects 
identified IL­6, IFN­, and G­CSF as significantly different 
between the two phenotypes. All three were released at lower 
levels by colonic compared with ileal CD macrophages. In 
contrast, macrophages from patients with UC secreted proin­
flammatory cytokines at levels similar to, or greater than, HC 
subjects. All patients released normal levels of the antiinflam­
matory cytokines IL­1Ra and IL­10 and the chemokines 
RANTES, IP­10, MCP­1, and IL­8.
In addition, we examined the secretion of IL­5, IL­6, IL­10, 
IL­17, GM­CSF, MCP­1, and IP­10 at 24 h by macro­
phages after stimulation with the TLR2 ligand Pam3CSK4. 
Secretion of IL­5 and GM­CSF were both reduced irrespec­
tive of CD phenotype, whereas secretion of IL­6 and IL­17 
were low from patient macrophages with colonic or ileal 
CD, respectively (Fig. S2 a). Previously, we have extensively 
studied CD patients with NOD2 mutations using muramyl 
dipeptide and reported transcription profile and cytokine se­
cretion abnormalities (Marks et al., 2006). We have now ex­
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lighting the fact that UC and CD are distinct diseases, pos­
sibly at opposite ends of the inflammatory response (Marks 
and Segal, 2008).
groups were similarly up­ or down­regulated in compari­
son with HC (Fig. 3 d, i), the majority of those common to 
UC and CD changed reciprocally (Fig. 3 d, ii­iv), high­
Figure 2. Proinflammatory cytokine secretion by macrophages from CD patients is deficient in response to E. coli. Supernatants from macro-
phages stimulated for 24 h with HkEc were tested for the levels of cytokines and chemokines. (a) Macrophages from HC subjects released varying 
amounts of cytokines and chemokines after HkEc stimulation. (b) Cytokine and chemokine release expressed as a percentage of that secreted by HC cells 
(blue bar) from ileal and colonic CD patients. The numbers of subjects in each group are shown on left; each patient was used once. All results are ex-
pressed as mean ± SEM (*, P < 0.05; **, P < 0.01; ***, P < 0.001).
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scription occurred in CD (n = 7) and HC (n = 8) macro­
phages after HkEc stimulation at equivalent levels (Fig. 4 a). 
TNF mRNA stability was determined using actinomycin­d 
(an inhibitor of RNA polymerase) and was identical between 
HC and CD macrophages after HkEc stimulation (Fig. 4 b).
Cell lysates were prepared from macrophages from HC 
(n = 6) and colonic CD (n = 6) subjects, and intracellular TNF 
was quantitated by Western blotting (Fig. 4, c and d). The 
level of intracellular TNF in HkEc­stimulated macrophages 
was lower in CD (P < 0.05) than HC (Fig. 4, c and d). The 
Transcription, translation, and secretion of cytokines  
by macrophages
Our observations of diminished proinflammatory cytokine 
secretion, equivalent cytokine steady­state mRNA levels, 
and a high proportion of abnormally expressed genes associ­
ated with vesicle trafficking and cytoskeletal organization in 
CD led us to investigate further aspects of RNA metabolism 
and intracellular protein handling. Cytokine transcriptional 
activation was investigated using macrophages transfected 
with a TNF promoter–luciferase reporter. TNF gene tran­
Figure 3. Abnormal transcriptional profiles of CD macrophages on Affymetrix gene arrays. (a) Venn diagram shows the number of probe sets dif-
fering in expression (P < 0.01) between ileal and colonic CD versus HC macrophages in the unstimulated state and after exposure to HkEc. (b and c) As in a, 
but comparing differentially expressed probe sets between ileal and colonic CD and UC versus HC in unstimulated (b) and HkEc-stimulated (c) cells. (d) i-iv 
designate overlaps of differentially expressed genes of known function after HkEc stimulation between disease groups, as labeled in Venn diagrams.
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Figure 4. Intracellular levels of TNF are lower in CD, despite normal transcription and mRNA stability, but restored to normal in the pres-
ence of Bref-A and lysosome inhibitors. (a) Macrophages transfected with an adenoviral vector containing a TNF promoter and luciferase reporter 
demonstrated equivalent TNF transcription levels in HC (n = 8) and CD (n = 7) subjects. (b) TNF mRNA stability is comparable in HC and CD macrophages 
after stimulation with HkEc. (c) Intracellular levels of TNF after HkEc stimulation with or without Bref-A were determined by Western blotting. (d) CD con-
tained significantly lower levels of intracellular TNF than HC macrophages after HkEc stimulation but returned to normal levels with the inclusion of Bref-
A (n = 6 in all groups). (e) Intracellular levels of TNF after HkEc stimulation with or without lysosomal inhibitors were determined by Western blotting.  
(f) Inhibitors of lysosomal proteolysis increase intracellular TNF levels in HC and CD macrophages (n = 4 in all groups; gray line denotes level of HkEc 
alone). Significance levels are compared with HkEc alone. All patients in these studies had colonic CD and subjects were used once per assay. Results are 
shown as mean ± SEM (*, P < 0.05).
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Figure 5. Intracellular levels of chemokines and cytokines after HkEc stimulation in the presence of vesicle trafficking and lysosomal inhibi-
tors. (a) Intracellular cytokine array profiles obtained from macrophages stimulated with HkEc in the presence of absence of either Bref-A or monensin.  
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(b) Cytokine array map. (c) Various chemokines and cytokines demonstrate reduced intracellular levels in CD macrophages after HkEc stimulation and are 
either normalized or elevated after Bref-A or monensin treatment (n = 4 in all groups). All patients studied had colonic CD and subjects were used once 
per assay. Results shown are mean ± SEM (*, P < 0.05; ***, P < 0.001).
 
inclusion of brefeldin A (Bref­A), a potent inhibitor of ER­to­
Golgi protein transport during macrophage HkEc stimula­
tion resulted in approximately equivalent levels of intracellular 
TNF in both CD and HC (Fig. 4, c and d). The results ob­
tained with Bref­A demonstrated that TNF translation occurs 
normally in CD macrophages.
We investigated the role of the lysosome in intracellular 
cytokine trafficking with the inclusion of monensin, NH4Cl, 
or chloroquine during macrophage HkEc stimulation. NH4Cl 
and chloroquine partition into acidic compartments and ele­
vate the pH, whereas monensin is a proton ionophore with 
similar but more potent effects. In HkEc­stimulated macro­
phages from colonic CD patients (n = 4), all three inhibitors 
of lysosomal function increased intracellular levels of TNF by 
between twofold and sevenfold (Fig. 4, e and f). Incubating 
macrophages with the proteosome inhibitor MG132 was 
without effect (unpublished data).
In addition to TNF, the intracellular levels of GRO­, 
IL­1­, IL­6, MIP­1, and MIP­1 were also depressed in 
CD macrophages after HkEc stimulation (Fig. 5). The inclu­
sion of Bref­A resulted in the normalization of intracellular 
levels of all the cytokines and chemokines tested (Fig. 5, 
a and c). In comparison, monensin either normalized the in­
tracellular levels (IL­1, IL­6, and MIP­1) or resulted in a 
significant elevation compared with HC (n = 4; GRO­ and 
MIP­1; Fig. 5, a and c).
DISCUSSION
In contrast to the relatively weak genetic effects identified in 
the GWAS (Wellcome Trust Case Control Consortium, 2007), 
a common major phenotypic abnormality becomes apparent 
in CD when the innate immune system is stressed in vivo. 
This is the result of a severely impaired acute inflammatory 
response in these individuals (Marks et al., 2006). We have 
suggested that the intensity of the inflammatory response in 
the whole population follows a normal Gaussian distribution. 
Individuals at the extreme lower tail of this spectrum, as a 
consequence of the additive effect of many gene variants, are 
at risk of CD. NOD2, and potentially other systems, provide 
a compensatory boost to acute inflammation, which is pro­
tective in this setting (Marks and Segal, 2008).
These studies provide the first demonstration in CD that 
there is a profound defect in the recruitment of neutrophils 
after the introduction of E. coli into the tissues and that the 
subsequent clearance of these organisms is grossly delayed in 
this condition. This bacterium was used in these studies be­
cause it is the major aerobic component of the bowel flora 
and present in those regions of the gut affected by CD (Fine­
gold, 1969). E. coli have been implicated in the pathogenesis 
of CD (Rhodes, 2007), have been found within macrophages 
in Crohn’s tissue (Liu et al., 1995), and have also been cul­
tured from draining mesenteric lymph nodes (Ambrose et al., 
1984b). Granulomas removed from CD tissue have been 
shown by PCR to contain E. coli DNA (Ryan et al., 2004), 
and an ileal CD E. coli isolate (LF82) was capable of inducing 
granuloma formation in vitro (Meconi et al., 2007). In addi­
tion, we had previously shown that there was an important 
abnormality of acute inflammation in response to E. coli in 
CD (Marks et al., 2006).
The observed abnormalities in CD did not occur as a 
consequence of the inflammatory process, drug therapy, or 
bowel ulceration. All the patients were in remission and most 
were not on therapy, with a minority receiving 5­aminosali­
cylic acid–containing drugs. Bacterial clearance was normal 
in the control group of subjects with UC, who were also in 
remission and on 5­aminosalicylic acid or no treatment.
The rate at which neutrophils accumulate at sites of bacte­
rial ingress into the tissues is crucial to the final outcome. It has 
previously been demonstrated that in a three­dimensional tis­
sue matrix, bacterial phagocytosis is directly related to neutro­
phil numbers (Li et al., 2004). In the absence of adequate 
neutrophil recruitment, monocytes and macrophages might 
function in a containing role, such that material remaining after 
inoculation is surrounded and only slowly degraded (Issekutz 
et al., 1981). This is supported by the recovery of bacterial 
products from Crohn’s granulomata (Ryan et al., 2004).
The consequence of the delayed neutrophil accumulation 
is that foreign fecal material is not cleared adequately from 
the tissues, leading to granulomatous inflammation. Congen­
ital monogenic innate immunodeficiencies, in which neutro­
phil dysfunction predominates, frequently manifest bowel 
inflammation that is indistinguishable from CD (Rahman 
et al., 2008). These disorders are also associated with major 
defects in the clearance of foreign material caused by failure 
of neutrophils to accumulate in sufficient numbers (congeni­
tal neutropenias and leukocyte adhesion deficiency), poor di­
gestion within excessively acidic phagolysosomes (chronic 
granulomatous disease and glycogen storage disease­1b), and 
impaired vesicle trafficking and fusion of the granules and 
phagosomes (Chediak­Higashi and Hermansky­Pudlak syn­
dromes). The genes underlying these disorders have not been 
detected by GWAS of CD because of their extreme rarity.
In the absence of a monogenic lesion in the immune sys­
tem, CD patients might also be unduly susceptible to bacterial 
infection, although the necessary large­scale studies have not 
been performed (Kyle, 1980; Ambrose et al., 1984a; Kaplan 
et al., 2007). It becomes more difficult to assess the incidence 
of disease­specific infection once a diagnosis of CD has been 
made because of confounding factors including surgery, mal­
nutrition, immunosuppressant therapy, and bowel­related 
complications such as abscesses and fistulae. Another consid­
eration is bacterial load. Most acute infections originate from 
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cretion of a panel of inflammatory cytokines and chemokines 
by macrophages in response to stimulation with E. coli or 
TLR ligands and observed the production of dramatically 
low levels of proinflammatory cytokines in cells from CD 
patients. In our previous study, we found local levels of IL­8 
and IL­1 to be low after trauma to the skin and bowel 
(Marks et al., 2006). In the current study, we have found that 
macrophages secrete normal amounts of IL­8 after stimula­
tion with bacteria. This discrepancy between tissue levels and 
isolated macrophages in response to E. coli could lie in the 
type of cells producing IL­8 in skin windows and bowel bi­
opsies, and/or in a different agonist. Neutrophils themselves 
produce copious amounts of IL­8 and IL­1, so the lower 
levels in skin windows and bowel biopsies in CD are consis­
tent with the reduced recruitment at these sites (Fujishima 
et al., 1993; Greten et al., 2007). In the study by Marks et al. 
(2006), the release of IL­8 by macrophages from CD patients 
was diminished after stimulation with wound fluid, TNF, and 
C5a but unaltered after stimulation with the TLR4 ligand li­
popolysaccaride. IL­8 release is normal after bacterial stimula­
tion (whole E. coli as well as TLR2 stimulation), so the lower 
levels in the in vivo study could be the result of activation of 
macrophages by nonmicrobial agonists.
To explain the cause of impaired cytokine secretion by 
macrophages from CD patients, we examined the profiles of 
RNA expression against a chip containing fragments of genes 
representing the whole human transcriptome. The first im­
portant observation was that macrophages from patients with 
colonic or ileal CD and UC exhibited distinct expression 
profiles when compared with HC, identifying these as three 
separate disease clusters. Second, levels of mRNA encoding 
proinflammatory cytokines were normal in unstimulated and 
HkEc stimulated macrophages, providing evidence that the 
defective secretion was not at the level of gene transcription.
A possible mechanism responsible for diminished proin­
flammatory cytokine release was provided by examining the 
abnormally expressed genes common to both types of CD 
after HkEc stimulation. Approximately half of the genes had 
some association with cellular secretory systems, suggesting 
that impaired macrophage secretion is responsible for the di­
minished proinflammatory cytokine release. The failure of a 
secretory system would provide a generic mechanism for the 
impaired release of several functionally related cytokines. 
Hermansky­Pudlak syndrome and Chediak­Higashi disease, 
both of which are associated with noninfectious granuloma­
tous enterocolitis, are the result of primary abnormalities in 
the cytoskeletal transport of vesicles (Rahman et al., 2008). 
These findings are particularly compelling given the recent 
descriptions of variants in autophagy genes which are associ­
ated with CD susceptibility (Hampe et al., 2007; Parkes et al., 
2007; Rioux et al., 2007). Autophagy involves vesicle traf­
ficking in the formation of double­membrane vesicles that 
deliver cytoplasmic material to the lysosomes (Levine and 
Deretic, 2007). Additionally, autophagy is required to kill 
and remove intracellular organisms in macrophages, so its 
dysfunction is consistent with the theme we have developed: 
a small number of inoculating organisms, which even the 
dampened immunity in CD appears to be able to control. Our 
findings of the relationship between bacterial dose and clear­
ance are important in this respect because they demonstrate 
that CD patients can deal efficiently with small numbers of or­
ganisms in the tissues but that the clearance mechanisms are 
overwhelmed by a large bolus of bacteria. CD occurs almost 
exclusively in the terminal ileum and colon, which respec­
tively contain 108 and 1011 bacteria/ml, higher than the 
105 bacteria/ml or less in other regions of the small bowel 
(Farthing, 2004). Reflux through the ileocaecal valve carries 
caecal contents into the terminal ileum, elevating the micro­
bial levels in this region (Malbert, 2005). After surgery, recur­
rence is seen in 80% of cases, and where small bowel has 
been resected, recurrence generally occurs in the small bowel 
just proximal to the anastomosis. This indicates that recurrence 
is highly dependent on the proximity to the large bowel con­
tents rather than a specific abnormality associated with the 
terminal ileum (Cameron et al., 1992). Therefore, the large 
bowel and adjacent ileum provide a unique environment in 
the body that contains a massive bacterial load, which can gain 
instant access to the tissues if the mucosal barrier is breeched.
The detrimental effect of fecal content in the tissue might 
not primarily result from the infectious nature of the organ­
isms, as many are not particularly virulent, but by the quan­
tity of organic material that must be removed before resolution 
can occur. Difficulty in clearing exogenous organic material 
could also account for the false­positive results in CD to Kveim 
tests, which were conducted to diagnose sarcoidosis by in­
jecting a preparation of the spleen of a patient into the skin, 
which was subsequently examined for a granulomatous re­
sponse (Mitchell, 1971).
Clearly, the retention of fecal material in the tissues of the 
wall of the bowel will have major local and systemic inflamma­
tory, immunological, and constitutional consequences. Many 
of the immunological studies conducted on Crohn’s patients, 
such as those implicating adaptive immunity in local tissue 
damage (Xavier and Podolsky, 2007), might be measuring sec­
ondary immunological responses to this foreign material.
We then turned our attention to identifying the mecha­
nism underlying impaired neutrophil accumulation. CD is 
caused by the complex interplay of many genes coupled with 
bacterial exposure, which makes it difficult, if not impossible, 
to identify specific molecular lesions common to these pa­
tients, and GWASs clearly indicate that there are no domi­
nant causative genes. However, the characteristic pathological 
features of the condition are suggestive of a common cellular 
pathology produced by the various additive molecular aetiol­
ogies. The neutrophils themselves appear functionally normal 
(Moráin et al., 1981), and their diminished migration to acute 
inflammatory sites in the skin or bowel has been attributed to 
defective local cytokine production (Marks et al., 2006). These 
mediators are primarily secreted by resident tissue macro­
phages (Medzhitov, 2008), which, in the bowel, are derived 
and continually replenished from peripheral blood mono­
cytes (Smythies et al., 2006). We therefore measured the se­
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Failure to clear foreign material from the tissues induces a 
chronic granulomatous reaction around the retained organic 
material over a much longer time frame. The accumulation of 
macrophages and T lymphocytes in these granulomata leads to 
local tissue damage and constitutional symptoms through the 
sustained secretion of cytokines (Bazzoni and Beutler, 1996). 
Even if the net production of cytokines by each cell were 
lower than normal, the overall number of cells is so great that 
damaging concentrations are produced. In this setting, drugs 
directed against TNF can prove beneficial by direct cytokine 
blockade, by inducing leukocyte apoptosis, and by stimulating 
the effect of Treg cells, which suppress inflammation (Wong 
et al., 2008). A clear example of the dichotomous effect of TNF 
is provided by the dextran sodium sulfate (DSS) bowel inflam­
mation model in TNF knock­out mice. Contrary to initial 
expectations, mice deficient in this cytokine are more suscep­
tible to the induction of bowel inflammation by DSS, whereas 
TNF inhibition is effective in ameliorating established DSS 
colitis in wild­type animals (Naito et al., 2003).
The relationship of impaired cytokine secretion to disor­
dered packaging and vesicle transport, rather than defects in 
their production or stability, provides a novel insight into the 
mechanisms underlying the pathogenesis of CD. Similar 
mechanisms could lead to abnormalities in other relevant cell 
types, such as the Paneth cell (Cadwell et al., 2008). A basic 
abnormality in macrophage biology could also explain ex­
traintestinal manifestations of CD, such as arthritis, and le­
sions in the eyes, skin, lungs, and other tissues (Ephgrave, 2007). 
There may be many other diseases that present with exuber­
ant granulomatous inflammation as a result of an underlying 
failure of acute inflammation and innate immunity, leading 
to defective clearance of the initiating agent.
MATERIALS AND METHODS
Patients. These studies were approved by the Joint University College Lon­
don (UCL)/UCL Hospitals (UCLH) Committee for the Ethics of Human 
Research (project numbers 02/0324 and 04/Q0502/29) and the Administra­
tion of Radioactive Substances Advisory Committee (RPC597­790). Patients 
from the Gastroenterology outpatient clinic at UCLH who met inclusion cri­
teria were recruited to participate in the study. All patients had definitive diag­
noses of CD or UC, which were confirmed using standard diagnostic criteria, 
with quiescent disease (Harvey­Bradshaw or Mayo score <3; Harvey and 
Bradshaw, 1980; Schroeder et al., 1987). Patients on either no medication or 
a stable maintenance dose of 5­aminosalicylates (2.5 g/d) for the previous 3 mo 
were included. None of the patients had received corticosteroid, immunosup­
pressant, anti­TNF, or metronidazole therapy within 3 mo of enrollment. HC 
subjects approximately matched for age, sex, and smoking history were re­
cruited from the Department of Medicine, UCL. Written informed consent 
was obtained from all volunteers. No subject was studied more than once in 
each of the different experiments. Details of patients and HC subjects included 
in in vivo experiments are provided (Table S4). CD patients were genotyped 
for the three common polymorphisms in CARD15 as previously described 
(Table S4; Marks et al., 2006). In some studies, we compared the results ob­
tained from CD patients with ileal or colonic involvement, as there is evidence 
that different pathogenic mechanisms might operate in these regions of the 
bowel (Cuthbert et al., 2002). We excluded the 30% of CD patients with 
mixed ileocolonic disease to simplify phenotyping and analysis.
Neutrophil accumulation studies. Details of controls and patients are pro­
vided in Table S4. No patient had received corticosteroid, immunosuppressant, 
that CD results from a failure to digest and remove microbial 
and other foreign material.
Interestingly, there was no other direct relationship be­
tween the collections of genes identified in this study in mac­
rophages and the polymorphisms highlighted by the previous 
GWAS (Wellcome Trust Case Control Consortium, 2007; 
Barrett et al., 2008), with the exception of HLA­G and SPTLC2, 
which were up­regulated and down­regulated, respectively, 
in colonic CD (Table S3). This is not entirely unexpected 
because association studies interrogate the whole genome in 
a nonselective manner, whereas we have focused on RNA 
expression in a single cell type, which plays a pivotal role in 
inflammation, in resting cells and those after activation with 
a naturally occurring agonist.
Several microarray expression studies have previously been 
performed in CD and UC. However, their experimental ap­
proach differed greatly from ours, as did the results they ob­
tained. This is not surprising in view of the very diverse cell 
populations and variable states of stimulation in their samples. 
Those on blood cells were performed on freshly isolated un­
stimulated mixed cell populations consisting of lymphocytes 
and monocytes with granulocyte contamination (Mannick 
et al., 2004; Burczynski et al., 2006). The majority used bowel 
biopsies, in which a wide spectrum of cells is present in non­
inflamed tissue. These are further supplemented by innate 
and adaptive immune cells when inflammation is present 
(Lawrance et al., 2001; Costello et al., 2005; Hughes, 2005).
To understand the failure of macrophages to secrete nor­
mal quantities of proinflammatory cytokines in CD, we used 
TNF as a model, because this molecule has been extensively 
studied and experimental tools are readily available. We found 
that gene transcription and mRNA stability are normal in CD 
macrophages. Bref­A prevents vesicular movement between 
the ER and the Golgi, resulting in accumulation of proteins 
within the former. Stimulation in the presence of Bref­A 
revealed normal cytokine synthesis by CD macrophages. Normal 
synthesis coupled with deficient secretion and low intracellu­
lar levels of the cytokines indicate accelerated degradation. 
The accumulation of normal amounts of TNF and other pro­
inflammatory cytokines after the addition of lysosomal inhib­
itors to CD cells indicates that this aberrant breakdown occurs 
in the lysosomal compartment.
The observation that macrophage secretion of TNF in 
CD is abnormally low might at first seem paradoxical, given 
the therapeutic efficacy of TNF blockade in many of these 
patients (van Deventer, 1999). However, we are comparing 
two temporally distinct events, acute inflammation over a 
time course of hours with chronic inflammation over weeks 
to months. The acute inflammatory response, dependent on 
the acute release of proinflammatory cytokines, is important 
for the clearance of bacteria and fecal material from the tis­
sues, which takes place over a few hours. The lack of TNF after 
the administration of therapeutic antagonists for the treatment 
of other chronic inflammatory diseases has been reported to 
precipitate the development of CD (Charach et al., 2008; 
Yazisiz et al., 2008).
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If a biological half­life of 3 h was presumed, the absorbed dose was estimated 
at 0.5–10.0 mGy.
The threshold dose of 32P resulting in erythema after extravasation has 
been determined as 10 Gy (Castronovo et al., 1988). A dose of 1 kBq was 
therefore selected as producing sufficient emitted radioactivity to be record­
able at the skin surface but falling well within acceptable established safety 
limits and ensuring that inflammation generated was solely the result of the 
presence of bacteria rather than isotope.
Macrophage isolation and culture and stimulation. Peripheral venous 
blood was collected from subjects into syringes containing 5 U/ml heparin. 
Mononuclear cells were isolated by differential centrifugation (900 g for 30 min 
at 20°C) over Lymphoprep and washed twice with sterile PBS (Invitrogen) at 
300 g (5 min at 20°C). Cells were resuspended in 10 ml RPMI­1640 medium 
(Invitrogen) supplemented with 100 U/ml of penicillin (Invitrogen), 100 µg/ml 
streptomycin (Invitrogen), and 20 mM Hepes, pH 7.4 (Sigma­Aldrich) and 
plated at a density of 5 × 106 cells/ml in 8 cm2 Nunclon Surface tissue culture 
dishes (Nunc) at 37°C in 5% CO2. After 2 h, nonadherent cells were discarded 
and 10 ml of fresh RPMI supplemented with 10% FBS (Sigma­Aldrich) was 
added to each tissue culture dish. Cells were then cultured for 5 d at 37°C in 5% 
CO2, with the addition of a further 10 ml of fresh 10% FBS/RPMI after 24 h.
Adherent cells were scraped on day 5 and replated in 96­well culture 
plates (Nunc) at equal densities (105/well) in X­Vivo­15 medium (Cambrex). 
These primary monocyte­derived macrophages were incubated overnight at 
37°C in 5% CO2 to adhere and were then stimulated for up to 24 h, depend­
ing on the experiment, with 2.5 × 105 HkEc, prepared as previously de­
scribed (Marks et al., 2006), 2 µg/ml Pam3CSK4 (Enzo Biochem, Inc.), or 
200 ng/ml LPS (Enzo Biochem, Inc.).
Cytokine secretion assays. Macrophage supernatants were collected after 
24­h stimulation of primary monocyte­derived macrophages with HkEc as 
described in the preceding section. The expression profile of a panel of cyto­
kines in macrophage supernatants was measured using the Beadlyte Bio­Plex 
human cytokine assay (Bio­Rad Laboratories) according to the manufactur­
er’s instructions. Our assay was customized to detect and quantify IL­1Ra, 
IL­4, IL­5, IL­6, IL­10, IL­12, IL­13, IL­15, IL­17, G­CSF, GM­CSF, 
IFN­, IP­10, and MCP­1. IL­8 secretion was measured using an ELISA kit 
(R&D Systems). The assay was conducted according to the manufacturers’ 
instructions with recombinant human standards.
TNF release was measured using a cytotoxicity bioassay (obtained from 
B. Beutler, The Scripps Institute, La Jolla, CA) as previously described (Aggarwal 
et al., 1985). Mouse L929 fibroblast cells were grown in DME (Invitrogen), 
supplemented with 10% FBS (Sigma­ALdrich), 100 U/ml of penicillin (In­
vitrogen), and 100 µg/ml streptomycin (Invitrogen) at 37°C in 5% CO2. A 
confluent monolayer of mouse L929 fibroblasts was trypsinized and resus­
pended to 4 × 105 cells/ml in DME. L929 cells were seeded into 96­well flat 
bottomed tissue culture plates (4 × 104 cells/well) and incubated overnight 
at 37°C in 5% CO2. After overnight culture, the medium was discarded, re­
placed by 50 µl DME containing 0.04 mg/ml cyclohexamide, and incubated 
for 20 min at 37°C in 5% CO2. 50 µl of cell­free supernatant (diluted 1:50 in 
DME), collected from primary macrophages as already described, were added 
to individual wells. Serially diluted recombinant human TNF (100–0 pg/ml; 
R&D Systems) was used to determine the standard curve for the assay.
Cytokine release in culture supernatants was normalized for the numbers 
of viable cells in each well, ascertained with the MTT (3­[4,5­dimethylthiazol­
2­yl]­2,5­diphenyl tetrazolium bromide, tetrazolium salt) assay (Boehringer 
Ingelheim). 20 µl of 2.5 ng/ml MTT was added to each well and incubated for 
4 h at 37°C in 5% CO2. Supernatants were carefully discarded and 100 µl/well 
of lysis solution (90% isopropanol, 0.5% SDS, 0.04 N HCl, and 10% H2O) was 
added to each well for 1 h at room temperature. The absorbance was read at 
570 nm using a microplate reader (Anthos Labtec Instruments).
RNA purification. Total RNA was prepared from monocyte­derived 
macrophages, either unstimulated or stimulated for 4 h with HkEc, using the 
RNeasy Mini kit with RNase­free DNase treatment (QIAGEN). Optical 
anti­TNF, or nonsteroidal drug therapy within 3 mo of enrolling in the study, 
although patients on maintenance 5­aminosalicylates with no change in their 
dose in the previous 3 mo were included. Patients with a history of skin disease 
were not enrolled for any injection studies.
A fully antibiotic­sensitive clinical isolate of E. coli (NCTC 10418) was 
grown overnight at 37°C in DME (Sigma­ALdrich) and 1.25 g/liter sterile 
yeast extract (Oxoid). Bacteria were then killed by exposure to a UV source 
(ChemiDoc, trans­UV mode; Bio­Rad Laboratories) for 60 min, and washed 
multiple times in sterile saline. Bacterial concentrations were determined by 
optical density (OD600 = 0.365 equates to 108 E. coli/ml [Yourassowsky et al., 
1989]). Sterility of the final sample was confirmed by multiple cultures.
Peripheral venous blood was collected from subjects into syringes contain­
ing 5 U/ml heparin. Separate blood samples were taken for full blood count 
and routine serum biochemistry. Neutrophils were isolated by centrifugation 
through Lymphoprep (Axis Shield), and then erythrocytes were removed by 
sedimentation with 10% dextran followed by hypotonic lysis. The neutrophils 
were then washed once in sterile injection­grade normal saline and incubated 
with 6 MBq 111In­oxine (GE Healthcare) for 20 min at room temperature 
(Segal et al., 1981). A mean ± SEM of 3.40 ± 0.35 × 107 cells labeled with 
5.15 ± 0.17 MBq (n = 11) were resuspended in 5 ml of normal saline. These 
were injected intravenously through a cannula in a vein in the antecubital fossa, 
which was subsequently flushed with a further 10 ml of normal saline.
Immediately after neutrophil injection, 3 × 107 UV­killed E. coli sus­
pended in 100 µl of normal saline were injected subcutaneously into the volar 
aspect of each forearm. Radioactivity was counted using a  counter in scaler 
mode (RadEye B20; Thermo Fisher Scientific) over these injection sites at 
baseline and at 1, 4, and 24 h after injection. These sites were shielded from 
the remainder of the body during counting to avoid detection of label accu­
mulating in the liver or spleen. To control for background radioactivity, this 
was counted over a control site in the left calf and these counts were sub­
tracted from counts over the injection sites to obtain specific accumulations 
of radioactivity produced by the bacterial injections. The absolute radioactiv­
ity at the injection sites was determined by calibration of the meter against se­
rial dilutions of a sample of free 111In­oxine with known activity. The 24­h 
counts over the injection sites in the six HC subjects were 1,738 ± 98 cpm. 
We did not study control subjects with UC because we felt that the addi­
tional information we would obtain did not justify the theoretical risk of ad­
ministering radioactivity systemically to these subjects.
Bacterial clearance studies. Details of controls and patients included in each 
set of experiments are provided in Table S4. E. coli were grown, as before, 
overnight at 37°C in 9 ml of phosphate­free DME (Invitrogen) supplemented 
with 1 ml of phosphate­containing DME (Sigma­Aldrich), 1.25 g/liter of ster­
ile yeast extract, and 18.5 MBq 32P­orthophosphate PBS (GE Healthcare). This 
isotope was chosen because it is a  emitter with a short half­life (14.7 d) but 
of sufficient energy to emit through skin and readily and stably incorporate into 
bacteria (Jordan, 1970). Labeled bacteria were killed by UV exposure for 60 
min and washed multiple times in sterile saline to remove unbound radiolabel. 
A specific activity ± SEM of 6.39 ± 1.52 MBq per 108 bacteria was achieved. 
Unlabeled bacteria from the same reference sample were also grown and killed 
by UV exposure for 60 min, in the absence of radiolabel and in phosphate­
containing DME supplemented with sterile yeast extract.
A preparation of E. coli containing 1 kBq of radioactivity was mixed 
with unlabeled bacteria to produce a dose range of 105, 106, 107, 3 × 107, and 
108 bacteria in 100 µl of sterile saline for inoculation (different doses were 
used depending on the experiment) and injected into the volar aspect of 
both forearms. Surface radioactivity was counted over a 3­min period using 
a  counter in scaler mode (RadEye B203). Initial surface counts per minute 
at each site were 2,688 ± 160 (mean ± SEM). Counts were subsequently re­
peated at 4, 24, 48, and 72 h. Correlations between the readings in each arm 
were r2 = 0.67 (P < 0.005).
Radiation dose in bacterial clearance studies. Using values published 
for 32P in the MIRDOSE 3.1 spherical tumor model (Stabin, 1996), with a 
presumed tissue dispersion volume of 0.1–3.9 ml, a dose of 1 kBq was calcu­
lated to deliver an absorbed dose of 0.06–1.00 Gy if no clearance occurred. 
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GGGC­3). The final optimized concentrations for the forward and reverse 
primers plus the probe were 900 nmol/l, 900 nmol/liter and 100 nmol/liter, 
respectively. A standard curve was generated using human genomic DNA 
(Promega). PCR parameters were the following: 50°C for 2 min, 95°C for 
10 min, 40 cycles of 95°C for 15 s, and 60°C for 1 min. Data were acquired 
and processed with Sequence Detector 2.3 software (Applied Biosystems). A 
linear regression line calculated from the standard curves of serially diluted 
genomic DNA allowed relative transcript levels in RNA­derived cDNA 
samples to be calculated from the fluorescent signal in each run.
The data generated by the real­time PCR TaqMan were analyzed in 
Array Studio. The genes selected for RT­PCR were normalized using a co­
variate to account for any change in expression caused by RNA loading of the 
samples. This covariate was represented by the scores from the first principal 
component obtained from a PCA of the two housekeepers, ­actin and cy­
clophilin­, and 2­microglobulin (identified from the microarray data analy­
ses as having invariant expression across all samples). A general linear model 
was built to look at the comparisons of HCs versus each disease group by treat­
ment, and unstimulated versus stimulated samples by disease group. An FDR 
correction was applied using the Benjamini and Hochberg (1995) methods.
TNF reporter studies. Recombinant replication­deficient adenoviral con­
structs encoding pAdTrack­TNF 5 promoter­luciferase­3 UTR (AdTNF 
5/3) and pAdTrack­TRF 5 promoter­luciferase (AdTNF 5 only) were 
generated as previously described (Horwood et al., 2003). Macrophages 
were plated in 96­well plates (Nunc) at 105 cells/well and allowed to express 
adenoviral transgenes for 24 h before stimulation with HkEc for 4 h. Lucif­
erase reporter gene assays were performed as previously described (Palmer 
et al., 2008). Before lysis, viral infection rates were measured by GFP fluo­
rescence (excitation, 485 nm; emission, 520 nm) using a FLUOstar Omega 
machine (BMG LABTECH) and software according the manufacturer’s in­
structions, and luciferase activity was normalized to these levels.
mRNA stability. Macrophages were stimulated with HkEc for 4 h fol­
lowed by the addition of 2 µg/ml actinomycin D. Total RNA was purified 
as described in RNA purification at 0, 1, 2, and 4 h. TNF mRNA levels 
were determined by RT quantitative PCR and normalized to GAPDH and 
ribosomal 18S.
Cytokine protein arrays. 5 × 105 macrophages were incubated with 
HkEc alone or in combination with 2.5 µM Bref­A (Merck) or 2.5 µM mo­
nensin (Sigma­Aldrich) for 4 h. Cells were lysed in TBS containing 0.1% 
NP­40 and protease inhibitors, sonicated (3× 3­s bursts), and then interro­
gated with commercially available antibody arrays (Human Cytokine Array 
Panel A; R&D Systems), according to the manufacturer’s instructions. Pro­
cessed arrays were exposed to x­ray film, and the signal was determined and 
normalized to the internal positive control spots by densitometry using Im­
ageJ software (National Institutes of Health).
Lysosomal inhibition and cytokine production. 2 × 105 macrophages 
from patients with CD and HC subjects were prepared as previously de­
scribed and stimulated for 4 h with 5 × 105 HkEc plus either cell media, or 
media with 2.5 µM monensin, 10 mM NH4Cl, or 100 µM chloroquine. 
Macrophages were lysed and run on 10% tricine PAGE gel followed by 
Western blotting. Membranes were incubated with goat anti­TNF (R&D 
Systems) 1:1,500 overnight at 4°C. After washing, the membranes were in­
cubated with anti–goat­HRP (Vector Laboratories) at 1:2,000 for 1 h at room 
temperature, washed again, and then visualized with ECL plus detection re­
agent (GE Healthcare). All gels were subjected to ImageJ software analysis 
and normalized to actin.
Online supplemental material. Fig. S1 shows bacterial clearance in CD and 
HC subjects subdivided according to disease phenotype and CARD15 geno­
type. Fig. S2 shows macrophage cytokine release after 24­h stimulation with 
TLR2 and TLR4 ligands. Fig. S3 depicts macrophage phenotype analysis. 
Fig. S4 shows functional groupings of the most significantly up­regulated 
density readings were determined for OD260/OD280 and OD260/OD230 using 
a NanoDrop ND­1000 spectrophotometer (Thermo Fisher Scientific) to as­
sess protein and solvent contamination, respectively. Before GeneChip stud­
ies, RNA quality was further analyzed by assessing ribosomal RNA bands 
28S/18S ratios using a Bioanalyzer (Agilent Technologies) high resolution 
electrophoresis system.
Whole genome GeneChip expression analysis. RNA samples were an­
onymized and randomized by disease group, treatment, and gender into 
three balanced batches. Linear amplification of RNA samples was performed 
using the standard Ovation RNA Amplification System 2 (NuGEN) as one 
batch on two 96­well plates. Samples were then fragmented, biotin labeled, 
and hybridized in three separate batches to the human U133 plus 2 GeneChip 
(Affymetrix) for 16 h to generate the transcriptomic data. The microarrays 
were washed and scanned according to Affymetrix protocols. Quality was 
assessed using report files generated in GCOS (GeneChip Operating System; 
Affymetrix) and checked against in­house criteria (GlaxoSmithKline) for 
probe and hybridization quality by analysis of the data for background, per­
centage of present calls, background standard deviation, raw Q (noise), scal­
ing factor, GAPDH 3 to 5 ratio, and ­actin 3 to 5 ratio (Heber and Sick, 
2006). The data were assessed for homogeneity of quality control metrics by 
principal component analysis (PCA) of gene expression using Array Studio 
(OmicSoft Corporation). To ensure that all samples corresponded to the an­
notated gender, expression was analyzed for gender­specific genes (XIST 
and USP9Y). Data from a total of 66 microarrays were therefore analyzed: 
HC, 16 unstimulated and 12 HkEc; ileal CD, 9 unstimulated and 6 HkEC; 
and colonic CD, 13 unstimulated and 10 HkEc. Global gene expression of 
the normalized probe intensity data were initially analyzed using Array Stu­
dio for the visual assessment of key trends by PCA. Further analysis of the 
intensities used a General Linear Model (GLM) performed in Array Studio. 
The GLM was used to build comparisons of HCs versus each disease group 
by treatment. A second experiment was then performed in which compari­
sons were made between macrophages from HC (7 unstimulated and 
5 HkEc) and UC (19 unstimulated and 20 HkEc). Genes were considered to 
be differentially expressed between groups where P < 0.01, fold change was 
≥1.2, and expression level was greater than the median cut of 5.0 fluores­
cence units. Where appropriate, the p­value was corrected for multiple 
comparisons (FDR correction, Benjamini and Hochberg [1995] method). 
For the overlaps of the Venn diagrams where a significant result was ob­
tained independently in two separate experiments, the FDR correction was 
not applied; for assessment of the most significantly regulated genes, both 
raw p­value and FDR­corrected p­value are presented. Microarray data in 
MIAME format can be found at http://www.ebi.ac.uk/microarray­as/ae/ 
under accession nos. E­TABM­733 and E­TABM­734.
TaqMan protocol. Expression levels of selected genes found to be differ­
entially regulated by the transcriptomic array data were validated by real­time 
RT­PCR TaqMan analysis using the ABI Prism 7900 Sequence Detector 
System (Applied Biosystems). 200 ng of total RNA were reverse transcribed 
to complementary DNA (cDNA) using the High Capacity cDNA Reverse 
Transcription kit (Applied Biosystems) according to the standard protocol. 
The equivalent of 10 ng RNA per well was arrayed into 384­well plates using 
a Biomek FX robot (Beckman Coulter), and quantitative RT­PCR was 
performed using a 7900HT Sequence Detector System (Applied Biosystems) 
in a 10­µl reaction volume.
The following TaqMan primers and probes used: GMCSF (forward, 
5­AGCCTCACCAAGCTCAAGGG­3; reverse, 5­GGGTTGGAGG­
GCAGTGCT­3; probe, 5­CCCTTGACCATGATGGCCAGCC­3), 
IL6 (forward, 5­TGACCCAACCACAAATGCCA­3; reverse, 5­CAT­
GTCCTGCAGCCACTGG­3; probe, 5­CTGTGCCTGCAGCTTC­
GTCAGCA­3), IFN­ (forward, 5­CCAACGCAAAGCAATACAT­
GAAC­3; reverse, 5­ACCTCGAAACAGCATCTGACTCC­3; probe, 
5­TCATCCAAGTGATGGCTGAACTGTCGC­3), and TNF (forward, 
5­TCCTCTCTGCCATCAAGAGCC­3; reverse, 5­GTCGGTCACCC­
TTCTCCAGC­3; probe, 5­TGGAAGACCCCTCCCAGATAGAT­
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and down­regulated genes in macrophages stimulated with HkEc. Table S1 
shows cytokine mRNA levels after HkEc stimulation. Table S2 depicts dif­
ferentially expressed genes in ileal CD macrophages stimulated with HkEc. 
Table S3 depicts differentially expressed genes in colonic CD macrophages 
stimulated with HkEc. Table S4 provides demographics of subjects used in 
the injection studies. Online supplemental material is available at http://
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Abstract
Background: Crohn’s Disease (CD) is a chronic relapsing disorder characterized by granulomatous inflammation of the
gastrointestinal tract. Although its pathogenesis is complex, we have recently shown that CD patients have a systemic
defect in macrophage function, which results in the defective clearance of bacteria from inflammatory sites.
Methodology/Principal Findings: Here we have identified a number of additional macrophage defects in CD following
diacylglycerol (DAG) homolog phorbol-12-myristate-13-acetate (PMA) activation. We provide evidence for decreased DNA
fragmentation, reduced mitochondrial membrane depolarization, impaired reactive oxygen species production, diminished
cytochrome c release and increased IL-6 production compared to healthy subjects after PMA exposure. The observed
macrophage defects in CD were stimulus-specific, as normal responses were observed following p53 activation and
endoplasmic reticulum stress.
Conclusion: These findings add to a growing body of evidence highlighting disordered macrophage function in CD and,
given their pivotal role in orchestrating inflammatory responses, defective apoptosis could potentially contribute to the
pathogenesis of CD.
Citation: Palmer CD, Rahman FZ, Sewell GW, Ahmed A, Ashcroft M, et al. (2009) Diminished Macrophage Apoptosis and Reactive Oxygen Species Generation
after Phorbol Ester Stimulation in Crohn’s Disease. PLoS ONE 4(11): e7787. doi:10.1371/journal.pone.0007787
Editor: Stefan Bereswill, Charite´-Universita¨tsmedizin Berlin, Germany
Received October 12, 2009; Accepted October 16, 2009; Published November 12, 2009
Copyright:  2009 Palmer et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The work was funded by the Wellcome Trust (grant GHACB) (www.wellcome.ac.uk). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: andrew.m.smith@ucl.ac.uk
Introduction
Crohn’s disease (CD) is a chronic relapsing inflammatory disease
of the gastrointestinal tract associated with considerable lifelong
morbidity[1]. It is characterized by granulomatous inflammation
that most frequently affects the terminal ileum and colon. The
incidence of CD has risen dramatically since the latter part of the
20th century for reasons that remain poorly understood[2].
Despite tremendous advances in our understanding of the
immunology of the gastrointestinal tract, the pathogenesis of CD
remains elusive and highly contentious. Patient heterogeneity
supports the complex nature of this disease and is a major difficulty
in defining its cause. Various hypotheses concerning the
pathogenetic mechanisms have been proposed over the years[3].
Most implicate a dysregulated mucosal immune response to
intestinal luminal contents in those with a susceptible immuno-
logical background. The etiology of CD is almost certainly
multifactorial, with numerous genetic and environmental factors
that differ between individuals giving rise to a common syndrome.
We have previously shown a failure of acute inflammation in
CD that is systemic and operates at the level of the macro-
phage[4,5]. This defect results in diminished pro-inflammatory
cytokine release, reduced neutrophil recruitment and the persis-
tence of bacterial products within the tissue, which can potentially
drive chronic inflammation. Other groups have previously shown
abnormal apoptosis in both neutrophils and T-lymphocytes from
CD patients under a variety of conditions[6,7], and both anti-TNF
and 5-aminosalicylic acid (5-ASA) therapy have been shown to
induce apoptosis in leukocytes from CD patients[8–10]. These
observations lead us to investigate whether CD macrophages also
exhibit an apoptotic defect which may contribute to the immuno-
pathology of CD.
Apoptosis is a tightly-regulated mechanism in controlling tissue
homeostasis that can be initiated by a variety of signals and stress
factors; Its physiological and pathological importance is highlight-
ed by the fact that dysregulated apoptosis underlies many cancers
and malignancies[11]. Concurrently, it has been shown that CD
can predispose to an increased risk of developing colorectal
cancers[12]. Studies in mice showed that neutrophil and
macrophage apoptosis were characteristics of the resolving phase
of inflammation[13], suggesting an important role for apoptosis in
the resolution of inflammation, which is defective in many chronic
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7787
inflammatory diseases[14]. Induction of apoptosis can occur via
extrinsic factors (through death domain-containing receptors) or
via intrinsic factors such as activation of tumor suppressor protein
p53, which is activated in response to DNA damage, UV radiation
and a range of chemotherapeutic drugs, and induces apoptosis-
regulating pathways involving the mitochondria[15,16]. Such
intrinsic factors also include reactive oxygen species (ROS), which
was shown to induce apoptosis in RAW264.7 macrophages and
are posited to function via the mitochondria[17,18]. Furthermore,
studies in murine hepatocytes have shown that ROS-induced
apoptosis required mitochondrial involvement in a protein kinase
C (PKC)-dependent manner[19]. PKCs are a group of kinases that
have been widely associated with apoptotic signaling[20]. Studies
have shown that the regulation of PKC activity is highly complex,
involving both a variety of phosphorylation events at different
amino acid residues and conformational changes/cleavages
conveying different states of (de)activation, depending on isoform,
cell type and stimulus[21–23]. In particular, novel isoforms PKCd
and PKCe have been implicated in regulating cell survival and
apoptosis[22], by interacting with a variety of proteins from the
apoptotic machinery, including mitochondria-associated genes
and caspases during apoptotic signaling processes[24,25].
In this study, we demonstrate that stimulation with the DAG-
homologue PMA[22] induces an abnormal apoptotic response,
reduced NADPH oxidase activation and elevated IL-6 secretion in
macrophage from CD patients. These findings add to a growing
body of evidence highlighting disordered macrophage function
during the acute inflammatory response in CD, providing further
insight about the pathogenesis of this chronic disorder.
Materials and Methods
Ethics Statement
These studies were approved by the Joint UCL/UCLH
Committee for the Ethics of Human Research (project number
04/0324). Written informed consent was obtained from all
volunteers.
Patients
Patients with endoscopically- and histologically-proven CD
were identified through the gastroenterology outpatient clinics at
University College London Hospitals (UCLH). All patients had
quiescent disease at time of venesection (Harvey-Bradshaw
Activity #3). Healthy controls were identified through the
Department of Medicine, University College London (UCL). No
subject was studied more than once in each of the different sets of
experiments.
Macrophage Isolation, Culture and Stimulation
Peripheral venous blood was collected from subjects into
syringes containing 5 U/ml heparin. Mononuclear cells were
isolated by differential centrifugation (2000 rpm, 30 min) over
Lymphoprep (Axis-Shield, Oslo, Norway) and macrophages
differentiated as previously described[5]. Adherent cells were
scraped on day 5 and re-plated at densities (106 cells/ml) in X-
Vivo-15 medium (Cambrex, MD, USA). Plated macrophages
were incubated overnight at 37uC, 5% CO2, and then stimulated
as appropriate. Stimuli used were PMA at 1 mg/ml, 1 mM RITA
(2,5-bis (5-hydroxymethyl-2-thienyl) furan, obtained from the
National Cancer Centre, Drug Therapeutic Program, Frederick
MD (NSC-652287)), 1 mM Thapsigargin (Sigma-Aldrich, UK),
and 2.5 mM N-Acetyl-L-cysteine (NAC) (Sigma-Aldrich, UK),
heat-killed E. coli (HkEc), prepared as previously described (4) at a
ratio of 2.5 HkEc/macrophage, 2 mg/ml Pam3CSK4 (P3C) (Alexis
Biochemicals, San Diego), 200 ng/ml LPS (Alexis). 1 mg/ml
Infliximab (RemicadeH) anti-TNF neutralizing antibody, human
recombinant TNF at 25 ng/ml (Calbiochem, CA, USA), and
human recombinant IL-6 at 10 ng/ml (R&D Systems, Abingdon,
UK). Inhibitors used were 1 mM PKC inhibitor Bisindolylmalei-
mide I (BIM), (Calbiochem) and 25 mM topoisomerase II inhibitor
etoposide phosphate (Sigma-Aldrich, UK).
MTT Cell Viability Assay
Cell viability was ascertained by MTT assay (Boehringer
Ingelheim, Berkshire, UK). Briefly, 20 ml of 2.5 ng/ml MTT
were added to each well and incubated for 18 hours (h) at 37uC,
5% CO2. Supernatants were discarded and 100 ml/well of lysis
solution (90% Isopropanol, 0.5% sodium dodecyl sulphate (SDS),
0.04 M NH4Cl, 9.5% H20) added to each well for 1 h at room
temperature. The absorbance was read at 570 nm using a
FLUOstar OMEGA microplate reader and software (BMG
LABTECH Ltd., Aylesbury, UK).
DNA Fragmentation Assay
Macrophages were stimulated and cells permeabilized in 0.1%
Triton X-100/PBS with 2 mM propidium iodide (PI) (Sigma-
Aldrich, UK) for 1 h in the dark. DNA fragmentation was assessed
by flow cytometry as previously described [26] using a FACSCa-
libur flow cytometer (BD Biosciences, NJ, USA), and analysis
performed using the CellquestTM software. The proportion of
DNA giving fluorescence below the G1-0 peak (gated as M1) was
used as a measure of apoptosis.
Beadlyte Cytokine Secretion Assays
The expression profile of a panel of cytokines in macrophage
supernatants was measured using the Beadlyte Bio-PlexTM human
cytokine assay (Bio-Rad Laboratories, Hemel Hempstead, UK),
according to the manufacturer’s instructions. Our assay was
customized to detect and quantify IL-1ra, RANTES, IL-6, GM-
CSF and MCP-1.
ELISA
The concentrations of human IL-10 (PeproTech, Inc., NJ,
USA), IL6 (BD Biosciences) and IL-8 (PeproTech) were deter-
mined by ELISA according to the manufacturers’ instructions.
Cytochrome C concentrations in cell lysates were quantified using
the QuantikineH Human Cytochrome C Immunoassay (R&D
Systems) according to the manufacturer’s instructions. Absorbance
was read and analyzed at 450 nm on a FLUOstar OMEGA
microplate reader and software (BMG LABTECH Ltd., Ayles-
bury, UK).
TNF Bioassay
Release of bioactive TNF was measured using a cytotoxicity
bioassay (obtained from Prof. B. Beutler, The Scripps Institute,
CA, USA) as previously described[27]. Serially diluted rhTNF
(100–0 pg/ml) (Calbiochem) was used to determine the standard
curve for the assay.
AmplexH Red Reactive Oxygen Intermediate (ROI)
Release Assay
Release of H2O2 by PMA-stimulated HC and CD macrophages
was assessed by AmplexH Red fluorometric assay alongside a
standard curve. Cells were plated in a 96-well flat-bottomed plate
at a density of 105 cells/well. For inhibitor studies, cells were pre-
incubated with 1 mM inhibitor for 1 h. H2O2 production was
measured at 37uC in the presence of 4 mM AmplexH Red
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(Molecular Probes), 0.1 U/ml horseradish peroxidase (HRP)
(Sigma-Aldrich) and, where appropriate, 1 mg/ml PMA and
1 mM BIM in sterile PBS using the FLUOstar OMEGA
microplate reader (BMG LABTECH Ltd.). Excitation was set at
544 nm and emission was set at 590 nm, with measurements taken
at 30 sec intervals. Rate of H2O2 production per hour (nM/h) was
calculated over the first seven minutes (exponential phase) using
the FLUOstar OMEGA software (BMG LABTECH Ltd.).
Mitochondrial Membrane Potential Detection Assay
Loss of mitochondrial membrane potential in CD and HC
macrophages was measured by flow cytometry using the APO
LOGIXTM JC-1 kit (Peninsula Laboratories, LLC, CA, USA)
according to the manufacturer’s instructions. Fluorescence was
measured using FACSCalibur flow cytometer (BD Biosciences, NJ,
USA), and analysis performed using the CellquestTM software.
Statistical Analysis
Data were analyzed using paired or unpaired t-test using the
GraphPad Prism 5 software.
Results
Abnormal PMA-Induced Cell Death Is Associated with
Macrophages from CD Patients
Abnormal apoptosis has been previously described in neutro-
phils and T lymphocytes isolated from CD patients[6,7,28–30].
We wanted to investigate the affects of numerous apoptotic stimuli
on macrophages as these cells have been shown to be defective in
patients with CD[5,4]. Cell survival was determined by measuring
the amount of DNA fragmentation before and after stimulation. In
contrast to a published report on T lymphocytes apoptosis levels,
baseline rate of DNA fragmentation was not significantly different
between CD and HC macrophages (Figure 1). Macrophages were
stimulated for 24 h with an panel of apoptosis-inducing agents:
RITA (p53-activating small molecule)[31,32], PMA, etoposide
(topoisomerase II inhibitor), thapsigargin (sacro/endoplasmic
reticulum (ER) Ca2+ ATPase inhibitor, induces ER stress),
bacterial stimulation or TNF (Figure 1A). Increased DNA
fragmentation was observed after RITA, PMA and thapsigargin
stimulation in macrophages from HC and CD. Macrophages from
CD patients were more resistant to PMA-induced DNA
fragmentation (23.4610.7 %) compared to those from HC
(36.5611.6 %, p,0.0001) (Figure 1A and B). The addition of
TNF resulted in a moderate decrease in DNA fragmentation in
macrophages from CD subjects (1361.1 %) compared to
unstimulated cells (15.462 %, p,0.05) and TNF treated HC
macrophages (2063 %, p,0.05). Etoposide and bacteria exposure
had no effect on the level of DNA fragmentation compared to
unstimulated macrophages. Macrophages from CD patients
therefore undergo PMA-induced apoptosis, but the level of DNA
fragmentation is only 6464.4 % of that seen in HC. Decreased
rate of apoptosis in PMA-stimulated CD macrophages was
independent of disease phenotype (Figure S1), age (R2= 0.03)
and gender (p = 0.1399) (Table S1). These data show that the
induction of apoptosis via p53 and ER stress pathways are
unaffected in macrophages from CD patients. In contrast,
abnormal macrophage apoptosis levels are evident after stimula-
tion with PMA and to a lesser extent TNF.
In order to determine if decreased PMA-induced DNA
fragmentation in macrophages from CD patients was the result
of alterations in cell viability, a MTT assay was performed
(Figure 1C). Macrophage survival 24 h after PMA stimulation was
significantly higher in CD (99.263.4 %) than in HC (70.964.9 %,
p,0.0001). These data show that macrophages from CD patients
are much more resistant to PMA-induced apoptosis resulting in
increased survival compared to HC. These results contrast with
our findings in patients with chronic granulomatous disease
(CGD)[33], who show normal PMA-induced macrophage apo-
ptosis despite frequently presenting with granulomatous enteroco-
litis indistinguishable from CD [34,35]. In addition, macrophages
from patients with ulcerative colitis demonstrate a decrease in
viability after PMA exposure (78.8 64.6 %, n= 13) that was
equivalent to HC (p= 0.29) and significantly different to CD
(p= 0.018) (Figure S2). Defective macrophage viability after PMA
stimulation does not seem to be a consequence of general chronic
inflammation, but specific to patients with CD.
Loss of Mitochondrial Membrane Potential Is Impaired in
PMA-Stimulated CD Macrophages
Cell death via the apoptotic pathway results from a number of
key steps which include permeabilization of the mitochondrial
membrane and loss of membrane potential, cytochrome C release
and caspase 3 activation[36]. Ultimately these lead to DNA
fragmentation, membrane blebbing and apoptosis. Loss of
mitochondrial membrane potential in macrophages from CD
and HC following PMA stimulation for 24 h was measured
(Figure 2A and B). A significant loss of mitochondrial membrane
potential after PMA exposure was evident in both HC (p,0.001)
and CD (p,0.05) macrophages. The mean percentage of
macrophages demonstrating loss of mitochondrial membrane
potential was significantly lower in CD patients (10.362.2 %)
compared to HC (44.066.4, p,0.01) (Figure 2A and B).
Macrophages were incubated with RITA in order to investigate
p53 signaling which also results in loss of mitochondrial membrane
potential during the induction of apoptosis (Figure 2B)[31,15,32].
Stimulation with RITA induced a loss of mitochondrial membrane
potential in macrophages from both HC (p,0.01) and CD
(p,0.01), with no significant difference between the two groups
(p = 0.3553). These findings further supporting the concept that
the intrinsic apoptotic pathway downsteam of p53 is able to
operate normally in macrophage from CD patients. Loss of
mitochondrial membrane potential results in the release of
cytochrome C[16], which was measured after stimulation.
Intracellular cytochrome C levels in macrophages from CD were
significantly lower than those in HC macrophages after PMA
stimulation (p,0.01, Figure 2C). Resistance to apoptosis in
mucosal T lymphocytes from CD patients has previously been
shown to correlate with decreased Bax expression[24]. We
therefore assessed Bax mRNA levels in HC and CD macrophages
following PMA stimulation by quantitative PCR. PMA exposure
resulted in the upregulation of Bax in HC macrophages
(Figure 2D). The upregulation of Bax was significantly lower in
macrophages from CD patients after PMA stimulation compared
to HC subjects (Figure 2D). These results are consistent with the
diminished apoptosis observed thus far, and provide further
evidence for a general dysregulation of PMA-induced responses in
macrophages from CD patients.
Defective PMA-Induced Reactive Oxygen Species (ROS)
Production in CD Macrophages
In addition to an apoptotic response, PMA stimulation also
induces the production of ROS in macrophages through the
activation of the NADPH oxidase system[37]. PMA-induced
ROS production, determined by H2O2 generation, in HC and
CD macrophages was assessed (Figure 3A). The rate of H2O2
production was significantly decreased in CD macrophages
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(17.161.4 nM/h) compared to HC (23.761.9 nM/h, p,0.01).
In order to assess whether there was a causal link between
reduced H2O2 production and decreased apoptosis in macro-
phages from CD patients in response to PMA, cells were treated
with the antioxidant N-acetyl-L-cysteine (NAC). Macrophages
from HC pre-treated with NAC reduced the amount of free
H2O2 after PMA-stimulation by 46.7 %, which was even greater
than the 17% observed with macrophages from CD patients
(Figure 3B). However, reduced H2O2 levels in the presence of
NAC had no effect on PMA-induced DNA fragmentation
(Figure 3C) or mitochondrial membrane potential (Figure 3D).
This indicates that the decreased ROS levels observed in
macrophages from CD patients are not associated with, and
consequently not responsible for the resistance to PMA induced
loss in cell viability.
Macrophages from CD patients demonstrate two distinct
abnormalities after PMA stimulation: increased resistance to
apoptosis and diminished NADPH oxidase activity. These results
are in line with our previous findings showing normal levels of
PMA-induced apoptosis in macrophages from CGD patients who
generate no ROS due to a complete absence in NADPH oxidase
activity[33].
Figure 1. Defective apoptosis in macrophages from CD subjects. A Macrophages from HC and CD patients were untreated or stimulated
with 1 mg/ml PMA (HC n= 39, CD n=44), 1 mM RITA (HC n= 10, CD n= 7), 25 mM Etoposide (HC n=7, CD n=7), 1 mM Thapsigargin (HC n= 9, CD
n= 8) for 24 h, E. coli (HC n= 10, CD n= 12) or 25 ng/ml recombinant TNF. DNA fragmentation (events below the G1-0 peak) was assessed by flow
cytometry. Mean percentage6 SEM of apoptosis for HC (black bars) and CD (open bars) are shown (o significance between stimulated and untreated,
* between HC and CD). B Representative histograms for HC unstimulated (upper left panel), HC plus PMA 24 h (lower left), CD unstimulated (upper
right) and CD plus PMA 24 h (lower right). C Viability for CD and HC macrophages following stimulation with 1 mg/ml PMA for 24 h was assessed by
MTT assay. Data are presented as percent of untreated cells for HC (black squares, n = 24) and CD (open circles, n = 41) with group mean. Statistical
analysis: Paired or unpaired t-test. Symbols: p,0.05 (* or o), p,0.001 (*** or ooo).
doi:10.1371/journal.pone.0007787.g001
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Increased IL-6 Production in Macrophages from CD
Patients in Response to PMA
Previously, we have reported a defective acute inflammatory
response to microbial challenge associated with macrophages from
CD patients[5,4]. We were therefore interested in determining the
effects of chronic activation and reduced apoptosis with the DAG
homolog-PMA on cytokine generation by macrophages from CD
subjects. Analyses of cytokines produced in response to PMA did
not reveal the same dramatic difference in cytokine release seen
with bacterial and toll-like receptor stimulation [5]: TNF, MCP-1,
IL-8, IL-1Ra, IL-10, GM-CSF and RANTES were released at
levels not significantly different from HCmacrophages (Figure 4A).
Macrophages from CD patients produced significantly more IL-6
than HC at 24 h after PMA stimulation (Figure 4A, p,0.05).
Increased secretion of IL-6 by CD macrophages after PMA
stimulation is consistent with the elevated serum levels previously
reported for patients with active disease[38]. There is also a direct
correlation between IL-6 serum levels and disease severity[39]. IL-
6 has also been shown to produce anti-apoptotic effects via gp130
and the activation of the JAK/STAT3 pathway[40]. In order to
ascertain whether elevated IL-6 secretion exerted any effect on the
apoptotic response, HC and CD macrophages were stimulated
with recombinant IL-6 in the presence or absence of PMA.
Addition of IL-6 to HC and CD macrophages did not alter the
basal level of apoptosis seen in unstimulated cells (Figure 4B). As
shown previously, the macrophages from CD subjects were more
resistant to DNA fragmentation than HC after PMA activation.
The inclusion of IL-6 had no effect on the rate of DNA
fragmentation in either the HC or CD subjects with or without
PMA. STAT3 phosphorylation was also similar between the two
groups (data not shown). It therefore seems unlikely that the
elevation in IL-6 is responsible for the reduced apoptosis in
macrophages from CD patients.
PMA Induced Apoptosis and ROS Generation Signals
through a Bisindolylmaleimide Sensitive Pathway
PMA has been previously shown to activate a number of
intracellular signaling molecules which are sensitive to DAG
Figure 2. Mitochondrial membrane depolarization, cytochrome c and BAX expression are abnormal in CD macrophages after PMA
activation. Macrophages were stimulated with 1 mg/ml PMA for 24 h and the effects on mitochondrial membrane potential, cytochrome c and BAX
expression determined. A Representative histograms of macrophage population for HC unstimulated (upper left panel), HC PMA 24 h (lower left), CD
unstimulated (upper right) and CD PMA 24 h (lower right) are shown. Gated populations show cells with an intact mitochondrial membranes (M1)
and cells which have lost mitochondrial membrane integrity (M2). B Proportion of macrophages with mitochondrial membrane depolarization are
shown as mean percentage 6 SEM after either PMA (HC n=9, CD n= 10) or RITA (HC n= 5, CD n=5) stimulation. C Intracellular cytochrome C levels
in macrophages stimulated with 1 mg/ml PMA for 24 h were measured by ELISA. Cytochrome C production (ng/ml) at 24 h is shown for HC (n = 4,
black bars) and CD (n= 8, open bars). D Macrophages were stimulated with 1 mg/ml PMA for 4 h followed by total RNA isolation. Bax mRNA levels
were determined by qPCR and expressed as the change in expression compared to unstimulated cells. Statistical analysis: Paired or unpaired t-test.
Symbols: p,0.05 (*), p,0.01 (**), p,0.001 (***).
doi:10.1371/journal.pone.0007787.g002
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generation downstream of phospholipase C. These include the
classical and novel protein kinase C (PKC) family as well as a host
of other DAG responsive molecules[22]. The effects on apoptosis
and ROS generation in the presence of bisindolylmaleimide I
(BIM), a potent but none-selective inhibitor of PKC, were
assessed[41]. Pre-incubation with BIM significantly inhibits
PMA-induced DNA fragmentation (Figure 5A), mitochondrial
membrane depolarization (Figure 5B) and ROS generation
(Figure 5C) in macrophages from HC and from CD subjects.
The exact PMA sensitive molecules responsible for the abnormal-
ities are still unknown, but our findings suggest that the
abnormalities in macrophages from CD are downstream of a
BIM-sensitive PMA inducible pathway.
Discussion
This study identified several defects associated with macro-
phages from CD patients: 1) Macrophages show increased viability
and decreased apoptosis downstream of the DAG homolog PMA.
2) The impaired apoptotic response is PMA-specific, as activation
of apoptosis via p53 and ER stress are normal in CD
macrophages. 3) PMA-induced NADPH oxidase activity is also
impaired in CD macrophages. 4) PMA exposure also results in
elevated IL-6 release. In addition to these observations we have
recently described a major defect in the innate immune response
of CD patients in response to bacterial stimulation, which results in
impaired clearance as a consequence of defective cytokine
secretion from macrophages[5]. We therefore propose that
defective macrophage function plays a major role in the abnormal
acute inflammatory response and subsequent chronic granuloma-
tous inflammation in CD.
Studies investigating apoptosis in CD have thus far concentrat-
ed on lymphocytes and neutrophils[7,6,30,29,28], and this is the
first time that a defect in CD macrophage apoptosis has been
shown. Interestingly, aberrant apoptosis in T-lymphocytes was
observed in response to numerous apoptotic stimuli, including IL-
Figure 3. Decreased PMA-induced reactive oxygen species production in CD macrophages. NADPH oxidase activity was assessed by
measuring the generation of H2O2 by macrophages from HC and CD subjects after stimulation with 1 mg/ml PMA. A Production of H2O2 (nM/h) was
elevated after PMA stimulation in both HC (n = 29) and CD (n= 47) groups. Macrophages from CD patients demonstrated reduced H2O2 release than
HC. B H2O2 levels were determined after HC macrophages (n = 4) pre-incubated with 2.5 mM N-Acetyl-L-cysteine (NAC) for 1 h followed by PMA
stimulation. The presence of NAC resulted in reduced H2O2 levels. C DNA fragmentation and Dmitochondrial membrane potential were unaltered by
the presence of NAC. Statistical analysis: Paired or unpaired t-test. Symbols: p,0.05 (*), p,0.01 (**), p,0.001 (***), HC (black bars), CD (white bars).
doi:10.1371/journal.pone.0007787.g003
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2 deprivation, Fas ligand binding, and nitric oxide (NO) exposure,
as well as lower spontaneous apoptosis in CD biopsy tissue
explants[30]. These data contrast with our findings on several
accounts. Firstly, baseline (spontaneous) macrophage apoptosis
was comparable in HC and CD subjects. Secondly, apoptotic
responses following p53 activation and ER stress induction were
normal, suggesting a more specific defect in macrophages
compared to T lymphocytes in CD. These cell-type-specific
differences are further highlighted by the fact that CD neutrophils
exhibit delayed apoptosis in suspension and accelerated apoptosis
following adhesion to fibronectin[30], and support our hypothesis
of CD as a multi-factorial syndrome that has multiple interacting
cellular and tissue components[5,42].
PMA acts through the activation of DAG responsive proteins
and targets a number of potential pathways in human macro-
phages. Protein kinase C (PKC) family members are especially
sensitive to PMA activation and have been implicated in the
induction of both apoptosis as well as NADPH oxidase
activity[43,44]. The conventional or classical PKCs (a, bI, bII
and c) and the novel PKCs (d, e, g and h) are all activated by the
additional binding of DAG or its homologue PMA[44]. Due to
this complexity we were unable to identify abnormal PKC activity
using isotype specific activation antibodies, but the inclusion of
BIM, a non-selective PKC inhibitor provided some evidence to
support their involvement. Furthermore, abnormal PKC activity
has previously been identified in CD patients during acute
inflammation[45]. Defective apoptosis and NADPH oxidase
activity may result from abnormal PKC activity but equally it
may depend on downstream events. The fact that apoptosis occurs
normally when p53 and ER stress are activated directly suggest
that the machinery required for programmed cell death functions
normally in CD macrophages. Further work is needed to identify
the specific PMA inducible defects in macrophages from CD
patients.
We have previously shown that macrophages from CGD
patients that completely lack NADPH oxidase activity apoptose
normally after PMA activation[33]. The inclusion of the ROS
sequester NAC resulted in decreased levels of H2O2 but had no
apparent effect on the apoptotic response in macrophages from
HC. These observations suggest that reduced NADPH oxidase
activity does not confer protection against apoptosis after PMA
stimulation in primary human macrophages.
Figure 4. Dysregulated PMA-induced IL-6 production in CD macrophages. A Cytokine secretion from HC (n= 7) and CD (n= 10)
macrophages following stimulation with 1 mg/ml PMA for six hours was assessed. IL-6 production was significantly elevated in macrophages from CD
patients compared to HC subjects. B Measuring the effect of elevated IL-6 (1 ng/ml) on DNA fragmentation in the presence or absence of PMA
stimulation. DNA fragmentation was unaltered by the inclusion of IL-6 in both HC (n = 7) and CD (n= 7) macrophages. Statistical analysis: Paired or
unpaired t-test. Symbols: p,0.05 (*), p,0.01 (**), p,0.001 (***).
doi:10.1371/journal.pone.0007787.g004
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We have also shown dysregulation of PMA-induced secretion of
IL-6, a cytokine which has previously been associated with the
chronic phase of CD[38,46]. Macrophages are thought to be one
of the main cell types responsible for elevated intestinal IL-6
levels[47], and although our results show that IL-6 production
does not have an autocrine effect on macrophage apoptosis, it is
nonetheless possible that increased IL-6 levels in active CD
contributes to the pathogenesis. Current therapies for CD are
being developed that specifically target IL-6 and its receptor gp130
and the results from these studies will help to determine the precise
role IL-6 plays in the pathophysiology of CD[48]. Our previous
research has clearly shown that microbial stimulation resulted in
significantly reduced pro-inflammatory cytokine secretion, includ-
ing IL-6, in patients with CD[4,5]. This defect results in reduced
neutrophil recruitment and the retention of bacteria within the
tissue. It is plausible that chronic inflammation in CD is driven by
the residual bacteria/bowel content in combination with defective
macrophage apoptosis. This could result in the persistence of the
pro-inflammatory stimuli, prolonged cytokine secretion, a failure
in resolution, defective wound healing, granulomatous tissue
formation, angiogenesis, fibrosis and scar formation; all of which
are hallmarks of the chronic inflammatory phase in CD.
The precise mechanisms involved in acute inflammation and its
subsequent resolution remain poorly understood, although it has
become apparent that apoptosis plays an important role in the
resolution phase. Initial work identified neutrophil apoptosis as a
critical factor in switching off inflammation and inducing the
resolution phase[49]. More recently, a role for macrophage
apoptosis in the resolution phase of acute inflammation has been
described[13]. It now seems that the induction and subsequent
resolution of an acute inflammatory response require complex
coordinated phases with regards to cellular recruitment and
clearance of inflammatory cells. It is highly probable that defects
affecting these processes contribute to the onset of human
inflammatory diseases and specifically CD.
The importance of defective apoptosis in the immuno-pathology
of CD is further substantiated by evidence that several efficacious
CD therapies have the potential to induced apoptosis. Several
different TNF-antagonists show clinical efficacy in inflammatory
diseases[50]. These can broadly be divided into neutralizing
antibodies (infliximab and adalimumab) and recombinant recep-
tors (etanercept). Whilst both classes are equally clinically
efficacious in rheumatoid arthritis, the recombinant TNF
receptor/immunoglobulin G fusion protein etanercept is not
effective in CD[51]. Studies in peripheral and lamina propria T
lymphocytes have attributed this to the fact that, whilst both
classes therapeutics neutralize TNF in vitro, only the neutralizing
antibodies are capable of inducing apoptosis in these
cells[8,50,52]. It has thus been proposed that the beneficial effects
of anti-TNF therapies in active CD relate not to direct binding and
Figure 5. PMA induced apoptosis, NADPH oxidase activity and mitochondrial membrane depolarization are all inhibited by
Bisindolylmaleimide I. Macrophages from HC (n= 5–10) and CD (n= 5–10) were left untreated, or pre-incubated with 1 mM Bisindolylmaleimide I
(BIM) for 1 h followed by PMA stimulation. BIM significantly reduced A DNA fragmentation, B mitochondrial membrane depolarization and C H2O2
release in both HC and CD. Paired or unpaired t-test. Symbols: p,0.05 (*), p,0.01 (**), p,0.001 (***), HC (black bars), CD (white bars).
doi:10.1371/journal.pone.0007787.g005
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sequestering soluble TNF, but cross-linking of membrane-bound
forms and induction of leukocyte apoptosis[50]. Thiopurines and
methotrexate are immunosuppresants widely used in the treatment
of moderate to severe CD and other chronic inflammatory
conditions. Thiopurines have been shown to induce apoptosis via
induction of a mitochondrial pathway[53]. Methotrexate has been
shown to induce apoptosis as well as elevating ROS genera-
tion[54,55]. There is also evidence that 5-ASAs, another
commonly used group of drugs used in mild CD, may have the
ability to induced apoptosis in leukocytes[10,56,57]. Probiotics
have recently attracted much interest as a potential treatment for
CD. A recent study has shown that the administration of the
probiotic Lactobacillus casei resulted in an increase in the number of
intestinal lymphocytes undergoing apoptosis in active CD[58].
Collectively, these observations suggest that the clinical efficacy of
commonly used CD therapies might at least in part be due to
restoration of the apoptotic responses in macrophages and other
leukocytes. The association between therapeutic success in CD
and activation of apoptosis continue to increase and may be an
important consideration in future drug development for this
chronic inflammatory disease.
Supporting Information
Table S1 Patient demographics. All the CD patients used in this
study have been listed with gender, age, ethnicity, phenotype,
current treatment and smoking status if known. m = male, f =
female, TI = terminal ileal, MTX = methotrexate, * = data not
available.
Found at: doi:10.1371/journal.pone.0007787.s001 (0.01 MB
PDF)
Figure S1 Altered apoptotic response in CD macrophages is
independent of disease location. Data from CD macrophages
presented in Figure 1B are presented as percent of apoptotic cells
for each donor (HC n=39; CD n=44) sub-divided into disease
location: colonic disease (col) (n = 15), ileocolonic disease (I/C)
(n = 18) and terminal ileal disease (TI) (n = 11). Statistical analysis:
Unpaired t-test. Symbols: p,0.001 (***), HC (black squares), col
CD (open triangles), I/C CD (grey triangles) and TI CD (black
triangles).
Found at: doi:10.1371/journal.pone.0007787.s002 (1.29 MB EPS)
Figure S2 Abnormal macrophage response to PMA stimulation
is specific for CD patients. Viability assay for macrophages from
CD, HC and ulcerative colitis subjects following stimulation with
PMA for 24 h. Data are presented as percent of untreated cells for
CD (blue, n= 41), HC (red, n= 24) and UC (black, n= 13).
Statistical analysis: Unpaired t-test.
Found at: doi:10.1371/journal.pone.0007787.s003 (0.03 MB JPG)
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